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Background: Many deaths from cancer are caused by metastatic burden. Prognosis and survival rates vary,
but survival beyond 5 years of patients with untreated metastatic disease in the liver is rare. Treatment for
liver metastases has largely been surgical resection, but this is feasible in only approximately 20–30% of
people. Non-surgical alternatives to treat some liver metastases can include various forms of ablative
therapies and other targeted treatments.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of the different ablative and
minimally invasive therapies for treating liver metastases.
Data sources: Electronic databases including MEDLINE, EMBASE and The Cochrane Library were searched
from 1990 to September 2011. Experts were consulted and bibliographies checked.
Review methods: Systematic reviews of the literature were undertaken to appraise the clinical
effectiveness and cost-effectiveness of ablative therapies and minimally invasive therapies used
for people with liver metastases. Studies were any prospective study with sample size greater than
100 participants. A probabilistic model was developed for the economic evaluation of the technologies
where data permitted.
Results: The evidence assessing the clinical effectiveness and cost-effectiveness of ablative and other
minimally invasive therapies was limited. Nine studies of ablative therapies were included in the review;
each had methodological shortcomings and few had a comparator group. One randomised controlled trial
(RCT) of microwave ablation versus surgical resection was identiﬁed and showed no improvement invii
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ABSTRACT
viiioutcomes compared with resection. In two prospective case series studies that investigated the use of laser
ablation, mean survival ranged from 41 to 58 months. One cohort study compared radiofrequency
ablation with surgical resection and ﬁve case series studies also investigated the use of radiofrequency
ablation. Across these studies the median survival ranged from 44 to 52 months. Seven studies of
minimally invasive therapies were included in the review. Two RCTs compared chemoembolisation with
chemotherapy only. Overall survival was not compared between groups and methodological shortcomings
mean that conclusions are difﬁcult to make. Two case series studies of laser ablation following
chemoembolisation were also included; however, these provide little evidence of the use of these
technologies in combination. Three RCTs of radioembolisation were included. Signiﬁcant improvements in
tumour response and time to disease progression were demonstrated; however, beneﬁts in terms of
survival were equivocal. An exploratory survival model was developed using data from the review of clinical
effectiveness. The model includes separate analyses of microwave ablation compared with surgery and
radiofrequency ablation compared with surgery and one of radioembolisation in conjunction with hepatic
artery chemotherapy compared with hepatic artery chemotherapy alone. Microwave ablation was
associated with an incremental cost-effectiveness ratio (ICER) of £3664 per quality-adjusted life-year
(QALY) gained, with microwave ablation being associated with reduced cost but also with poorer outcome
than surgery. Radiofrequency ablation compared with surgical resection for solitary metastases < 3 cm
was associated with an ICER of –£266,767 per QALY gained, indicating that radiofrequency ablation
dominates surgical resection. Radiofrequency ablation compared with surgical resection for solitary
metastases ≥ 3 cm resulted in poorer outcomes at lower costs and a resultant ICER of £2538 per QALY
gained. Radioembolisation plus hepatic artery chemotherapy compared with hepatic artery chemotherapy
was associated with an ICER of £37,303 per QALY gained.
Conclusions: There is currently limited high-quality research evidence upon which to base any ﬁrm
decisions regarding ablative therapies for liver metastases. Further trials should compare ablative therapies
with surgery, in particular. A RCT would provide the most appropriate design for undertaking any further
evaluation and should include a full economic evaluation, but the group to be randomised needs
careful selection.
Source of funding: Funding for this study was provided by the Health Technology Assessment
programme of the National Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Despite advances in treatments for primary cancers, many deaths from cancer are caused by metastatic
burden. Survival rates vary, but survival beyond 5 years of patients with untreated metastatic disease in the
liver is rare. Prognosis can vary according to the extent of the disease in the liver, and according to the site
of the primary cancer. Treatment for liver metastases has largely been surgical resection, with 5-year
survival ﬁgures ranging from 25% to 39% for patients with liver metastases from colorectal cancer.
However, surgical resection is only feasible in approximately 20–30% of people. Non-surgical alternatives
have been developed in recent years to treat some liver metastases; these alternatives to surgery can
include various forms of ablative therapies and other targeted treatments.Objectives
1. To conduct a systematic review of the evidence on the clinical effectiveness and cost-effectiveness of
ablative therapies for liver metastases.
2. To adapt an existing or construct a de novo economic model to estimate the cost-effectiveness of
different approaches to treating liver metastases.
3. To identify deﬁciencies in current knowledge and to generate recommendations for future research.Methods
Fourteen electronic databases including MEDLINE, EMBASE and The Cochrane Library were searched from
1990 to September 2011. Experts were also consulted to identify additional studies and bibliographies of
relevant papers were checked.
Titles and abstracts were screened for eligibility and inclusion criteria were applied to the full text of
selected papers by two reviewers. Studies were included if they met prespeciﬁed criteria including any
ablative or minimally invasive technology (1) used in the UK for treating liver metastases; (2) reported in
comparative studies or a prospective cohort study with at least 100 participants; (3) where appropriate
compared with surgical resection, chemotherapy or best supportive care; and (4) including outcomes of
morbidity, mortality, survival, tumour ablation, local recurrence, or quality of life. Data extraction and
quality assessment were undertaken by one reviewer and checked by a second reviewer, with differences
resolved through discussion with a third reviewer. Studies were synthesised through a narrative review
with full tabulation of results.ResultsNumber and quality of studies
Searching identiﬁed 5381 references after deduplication, of which 16 met the inclusion criteria for the
systematic review of clinical effectiveness. The included studies were either randomised controlled trials
(RCTs) or prospective case series studies. Common reasons for exclusion were study design, including small
sample sizes of prospective case series studies, irrelevant participants, irrelevant interventions, and
irrelevant comparators. The overall quality of studies was weak and meta-analysis was not possible.xxiii
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SCIENTIFIC SUMMARY
xxivSummary of benefits and risks
Radio- or chemoembolisation
Seven studies provided evidence on the clinical effectiveness of radio- or chemoembolisation. Although
these interventions resulted in statistically signiﬁcant improvements in tumour response and time to disease
progression relative to their comparators, beneﬁts in terms of survival were equivocal. Radio- and
chemoembolisation were generally well tolerated.Microwave ablation
One RCT assessed a microwave ablation compared with surgical resection. It found no statistically
signiﬁcant difference between the interventions on measures of survival. Beneﬁts were shown in terms of
surgical invasiveness.Radiofrequency ablation
One non-randomised comparison study and ﬁve case series studies assessed radiofrequency ablation.
The non-randomised study reported few relevant data, and the case series studies differed such that
comparisons of the relative beneﬁts of radiofrequency ablation were not possible. Survival estimates
ranged from median survival of 24–32 months from treatment of liver metastases to 44–52 months from
diagnosis of liver metastases. Adverse events were generally mild to moderate only.Laser ablation
Two case series from the same centre were included, although the populations under study differed.
Estimates of overall survival were not reported consistently between the two studies meaning comparisons
are difﬁcult to make; however, survival rates at 5 years were in the region of 30–41%.Studies unpublished at the time of the review
Eight studies were identiﬁed in searches but were published as abstracts only, and ﬁve ongoing trials of
potential relevance to this review were identiﬁed.Systematic review of existing cost-effectiveness evidence
Searches for economic evaluations of ablative therapies for liver metastases identiﬁed 108 references, of
which two were included in the current review.
One economic evaluation compared radiofrequency ablation (with a range of treatment thresholds,
retreatment and follow-up options), surgical resection (with a range of treatment thresholds and follow-up
options) with no treatment in a population of people with surgically resectable or unresectable liver
metastases. Gazelle and colleagues used microsimulation in a state transition model. Model parameters
were derived from a range of studies. Strategies involving low treatment thresholds (fewer than three
metastases for radiofrequency ablation and fewer than six for surgical resection) were dominated
by strategies with higher thresholds, leading the authors to conclude that more aggressive
strategies – particularly for surgical resection – were likely to be more cost-effective. Radiofrequency
ablation was generally associated with lower quality-adjusted life-year (QALY) outcomes than surgical
resection – for example, at a treatment threshold of six metastases and follow-up at 12 months, quality-
adjusted life expectancy for a 65-year-old man with liver metastases undergoing radiofrequency ablation
was 1.36 and the corresponding ﬁgure for surgical resection was 3.39.
The other economic evaluation compared hepatic artery chemoembolisation with palliative care for people
with unresectable liver metastases. The absence of comparative studies demonstrating a survival beneﬁt for
hepatic artery chemoembolisation means that no ﬁrm conclusions can be drawn from the study – the
study is further weakened by the absence of any adjustment for quality of life in estimating the beneﬁts of
the technology.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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effectiveness (overall survival or quality-adjusted survival) from assumption or from microsimulation based
on the surrogate measure of proportion of liver replaced by tumour. These studies have limited relevance
to the NHS.Systematic review of health-related quality of life in subjects with
liver metastases
No comparative studies for the ablative therapies and the relevant comparators included in the current
study were identiﬁed. No evidence of the impact on patients’ health-related quality of life was found for
most of these interventions. One before-and-after study was found related to one of the included ablative
therapies and this reported no statistical signiﬁcant difference before and 1 week, 1 month and
6 months after initiation of laser ablation in people with progressive disease undertaking second- and
third-line chemotherapy.Southampton Health Technology Assessments Centre economic evaluation
A survival model was developed to estimate the cost of ablative therapies or other
non-invasive therapies in cohorts of adult patients with surgically resectable, or unresectable liver
metastases. Limitations in the evidence base (lack of comparative studies or limitations in reporting
survival outcomes) meant that not all identiﬁed therapies were included in the model.
The limitations of the evidence base need to be borne in mind when interpreting the results of the
economic evaluation. The model includes separate comparisons of two ablative therapies with surgery
(microwave ablation compared with surgery and radiofrequency ablation compared with surgery) and one
other non-invasive therapy (radioembolisation in conjunction with hepatic artery chemotherapy compared
with hepatic artery chemotherapy alone). Each of these comparisons is based on a single study.
Clinical effectiveness data in the model were based on overall survival and progression-free survival
functions estimated using linear regression on data extracted from survival plots reported in
included studies.
Health state utilities for stable disease and disease progression, derived in our review of published
quality-of-life studies, were applied in the model.
Resource use estimates were developed based on treatment intensity (number of treatments and length of
stay), on-treatment management and post-discharge monitoring reported in included studies. Unit costs
were derived from NHS reference costs – where these were inadequate, unit costs were sourced from a
local NHS provider.Radioembolisation plus hepatic artery chemotherapy compared with
hepatic artery chemotherapy
The analysis comparing radioembolisation plus hepatic artery chemotherapy with hepatic artery
chemotherapy alone showed improved outcomes (0.35 QALY gain) from radioembolisation plus hepatic
artery chemotherapy at an increased cost (incremental cost of £12,945), resulting in an incremental
cost-effectiveness ratio (ICER) of £37,303 per QALY gained. Although deterministic sensitivity analysis
showed that results were sensitive to variations in survival functions, utility estimates and costs of palliative
care, the ICER appeared fairly robust, varying between £34,000 and £40,000. Probabilistic sensitivity
analysis showed that radioembolisation plus hepatic artery chemotherapy had a probability of being
cost-effective of 0.1% at a willingness-to-pay threshold of £20,000 per QALY and 26% at a
willingness-to-pay threshold of £30,000 per QALY.xxv
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xxviMicrowave ablation compared with surgical resection
In the analysis comparing microwave ablation with surgical resection, the incremental cost is negative
(£327) – treatment of liver metastases with microwave ablation is slightly lower than treatment with
surgical resection – resulting in an ICER of £3664 per QALY gained. It should be noted that this positive
ICER is derived from negative incremental cost and incremental QALY values – that is to say, in this
analysis microwave ablation is associated with reduced cost but also poorer outcome than surgical
resection. The results appear to be most sensitive to variation in utility estimates applied in the model,
variation in values of parameters in the survival functions (for treatment effect on overall survival and all
parameters in the overall survival function), variation in procedure costs and to the cost of palliative care.
Probabilistic sensitivity analysis showed microwave ablation had a probability of being cost-effective of
31% at a willingness-to-pay threshold of £20,000 per QALY and 30% at a willingness-to-pay threshold of
£30,000 per QALY.Radiofrequency ablation compared with surgical resection for solitary
metastases < 3 cm
In the analysis comparing radiofrequency ablation with surgery for solitary metastases < 3 cm, the
incremental cost for radiofrequency ablation compared with surgical resection is negative (£6290) – a
reduction of around 25% in total costs. There is no difference in discounted life expectancy between
surgical resection and radiofrequency ablation for patients with solitary liver metastases of < 3 cm.
However, as surgical resection is associated with signiﬁcant reduction in quality of life for up to 6 months
post-operatively, surgical resection is associated with lower QALY outcome than radiofrequency ablation.
The estimated gain in discounted QALYs associated with radiofrequency ablation is 0.06. The ICER
is –£266,767 per QALY gained. In conventional terms this would indicate that radiofrequency ablation
dominates surgical resection for the treatment of (surgically resectable) small solitary liver metastases.
The cost-effectiveness results appear to be generally robust to variation in parameters included in the
deterministic sensitivity analysis. The results appear to be most sensitive to variation in values of parameters
in the survival functions (for treatment effect on overall survival and all parameters in the overall survival
function) and variation in the utility.Radiofrequency ablation compared with surgical resection for solitary
metastases ≥ 3 cm
The comparison of radiofrequency ablation with surgical resection for solitary metastases ≥ 3 cm showed
that radiofrequency ablation was associated with poorer outcomes, through a reduced life expectancy
(–1.43 years) and lower QALYs (–1.27 QALYs), and a lower incremental cost (–£3207). The reduced costs
and poorer outcome associated with radiofrequency ablation result in an ICER of £2538 per QALY.
Deterministic sensitivity analysis showed that the analysis was generally robust to variations in parameters,
with ICERs ranging from £2000 to £4000 per QALY. Probabilistic sensitivity analysis showed that
radiofrequency ablation has a probability of being cost-effective of 0% at willingness-to-pay thresholds of
£20,000 and £30,000 per QALY gained.Conclusions
The available evidence of effectiveness of ablative and minimally invasive technologies for treating liver
metastases was limited, with methodological weaknesses. As a consequence, it is difﬁcult to differentiate
between the different therapies. The analysis is therefore limited in its scope, with many uncertainties.
The results of radioembolisation and hepatic artery chemotherapy versus hepatic artery chemotherapy and
microwave ablation are presented; however, it is unclear whether or not these are currently relevant to
current management of liver metastases in the NHS.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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therapies for liver metastases. It is a rapidly developing ﬁeld and there is room for further trials comparing
ablative therapies with surgery, in particular. Any study should assess the clinical effectiveness and
cost-effectiveness of the different techniques, assessing measures of survival, response, recurrence, quality
of life, adverse events and costs. Outcomes should be reported separately for the different groups of
participants. A RCT would provide the most appropriate design for undertaking the evaluation and should
include a full economic evaluation, but the group to be randomised needs careful selection.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.xxvii
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This project will evaluate the clinical effectiveness and cost-effectiveness of the different ablative andminimally invasive therapies for treating liver metastases. It will review systematically the evidence on
those interventions that are currently available and used to treat liver metastases, including radiofrequency
ablation, microwave ablation, cryoablation, ethanol ablation, laser ablation, focused ultrasound, electrolytic
ablation, chemoembolisation and radioembolisation. These will be assessed separately and/or in sequence,
where possible and appropriate. If the systematic review of cost-effectiveness shows that there are no
appropriate good-quality economic evaluations, a new economic model relevant to the UK setting will be
developed. Deﬁciencies in current knowledge will be identiﬁed and recommendations for future
research generated.1
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Chapter 2 BackgroundDescription of underlying health problemMalignant neoplasms are, by deﬁnition, those that metastasise, although some do so only rarely.
Metastases (also known as secondary cancers or secondaries) are lesions that have separated from the
primary cancer and have disseminated to distant sites within the body.1 Metastases are very common in
the late stages of cancer, and tend to grow and multiply rapidly, and disseminated cancer accounts for
many deaths due to malignancy. The most common route of tumour spread comes via the blood vessels or
the lymphatic system. Malignant cells from the primary tumour proliferate to form new tumours in the
secondary site or sites.1 This is a complex process: for example, cells entering the liver may go down one of
several pathways. They may immediately be destroyed by local defence mechanisms, they may enter a
state of dormancy and never metastasise, they may initiate a short-lived process of proliferation that is
aborted before a metastasis is established or they may actively proliferate to form macrometastases.
Success or failure of the cells to produce a metastasis depends on their ability to induce stromal reaction
within the liver and to recruit host cells into the developing metastasis. Thus, although metastases are
initiated by abnormal cells from the primary cancer, not the host site, host cells play a major part in their
formation. Metastases in the liver that have come from breast cancer will be partly made up of abnormal
breast cancer cells, but most cells will be derived from the host tissue.
The liver is a common site of metastatic disease. It has a rich blood supply, which provides a suitable
environment for growth of metastases, and these metastases typically occur in the tissue close to blood
vessels. The liver is the ﬁrst capillary bed to be encountered by the circulating malignant cells of some
primary tumours.2 The liver has a dual blood supply, from the hepatic arteries and from the portal vein.
Supplying approximately three-quarters of the liver’s blood supply, the portal vein carries venous blood
drained from the spleen and gastrointestinal tract and its associated organs. The hepatic arteries,
stemming directly from the aorta, supply arterial blood to the liver, accounting for the remainder of its
blood ﬂow. The liver is thus an anatomically and physiologically obvious site for metastases to occur from
tumours of the colon and rectum, stomach, pancreas, biliary tree and small intestine. However, breast
cancer, lung cancer and melanoma also have a propensity to metastasise in the liver, but in these cases the
mechanism leading to the spread is less well understood.2 Blood supply is not the whole story, however;
other tissues with a very good blood supply do not characteristically develop metastases (e.g. heart,
skeletal muscle) and other factors must be involved. Recent evidence from Germany has shown that
approximately 59% of liver metastases were from colorectal cancer, 13% from pancreatic cancer, 13%
from breast cancer, 6% from gastric cancer, 4% from lung cancer, and 4% from oesophageal cancers.3
Liver metastases can grow as a mass or by spreading through the tissues. Most liver metastases are
multiple: in approximately 80% of cases more than one lobe of the liver is affected.4 Factors such as age,
sex, primary cancer site, histological type and duration of tumour inﬂuence the incidence and patterns of
liver metastases.4Epidemiology
Despite advances in treatments for primary cancers, many deaths from cancer are caused by metastatic
burden. Survival rates vary, but survival beyond 5 years of patients with untreated metastatic disease in the
liver is rare.5 In metastatic colorectal cancer the median survival without treatment is 8 months from
diagnosis of metastatic disease.6 Prognosis can vary according to the extent of the disease in the liver, and
according to the site of the primary cancer.7 Those with a limited number of metastases, or disease in one
lobe of the liver only, tend to survive longer,5 and those with colorectal liver metastases have a better
prognosis than those from most other primary cancers.73
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4Large-scale population-based assessments of the epidemiology of liver metastases are limited. This is
largely because of the fact that data in cancer registries are collected across primary cancer sites, and
therefore to gain full coverage for all people with liver metastases requires considerable resource.8 Studies
available have therefore tended to focus on colorectal liver metastases and as such are discussed here.
No recently undertaken studies identiﬁed on literature searches have a UK focus.
Leporrier and colleagues9 assessed 1325 people with colorectal carcinoma registered on the Digestive
Cancer Registry of Calvados, France, between January 1994 and December 1999. At a mean follow-up of
32 months, 358 (27%) individuals developed hepatic metastases. This equated to a rate of 19.5%
[95% conﬁdence interval (CI) 17.5% to 21.4%] at 1 year, 25.0% (95% CI 23.1% to 27.0%) at 2 years
and 29.3% (27.3% to 31.2%) at 3 years. These data include both synchronous (occurring at the time or
within 6 months of surgical resection of colorectal cancer) and metachronous (occurring subsequently) liver
metastases. For incidence data on these subgroups, see Table 1 below. Leporrier and colleagues9 also
present data on the characteristics of those with liver metastases and the actuarial survival estimates for
the group as a whole, which is not discussed here given the range of different treatments people received.
In a population-based cancer registry from Burgundy, France, Manfredi and colleagues8 studied 13,463
people diagnosed with a large bowel cancer between 1976 and 2000. Age-standardised incidence rates
of synchronous liver metastases, and actuarial incidence of metachronous liver metastases, can be seen
in Table 1.
Although comparisons between these two studies is difﬁcult owing to the different outcomes reported,
these results suggest that rates of synchronous liver metastases range from 14.5% to 18.9% of the total
populations. Where data are comparable (e.g. 1-year and 3-year data) similar values of actuarial incidenceTABLE 1 Estimated incidence rates of liver metastases in two population-based registry studies
Study All metastases
Synchronous
metastases
Metachronous
metastases rate
Leporrier et al.9
Registry study
Population: 1325 people with colorectal
cancer within the Calvados region of France
1994–1999
Actuarial incidence of liver metastases, % (95% CI)
1 year 19.5 (17.5 to 21.4) Not reported 4.0 (3.1 to 4.8)
2 year 25.0 (23.1 to 27.0) 8.7 (8.3 to 9.1)
3 year 29.3 (27.3 to 31.2) 13.5 (12.4 to 14.7)
Proportion with liver metastases during the study period (%)
27 18.9 8.1
Manfredi et al.8
Registry study
Population: 13,463 people with colorectal
cancer within the Burgundy region of France
1976–2000
Age-standardised incidence rate, per 100,000
Males 7.6
Females 3.7
Actuarial incidence of liver metastases (%)
1 year 4.3
3 year 12.0
5 year 14.5a
Proportion with liver metastases (%)
Not reported 14.5 12.8
a Text states 16.5%, table states 14.5%.
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that these rates are in line with earlier published estimates of the incidence of synchronous and
metachronous liver metastases.10,11
These estimates may be high, however. Recent data from a so far unpublished trial of intensive imaging in
colorectal cancer (the UK FACS Trial) show that of 1211 patients with curatively treated primary colorectal
cancer, all of whom had full evaluation by CT-CAP (computed tomography – chest/abdomen/pelvis) after
surgical resection or adjuvant chemotherapy if given and had a normal carcinoembryonic antigen (CEA)
prior to trial entry, only 174 (14.4%) had recurrences, with a median follow up of 54 months.12 These
results are derived from a randomised controlled trial (RCT), where experience has shown that patient
treatment is generally better than in ‘the real world’. They show, however, that if patients are fully staged
by computed tomography (CT) after treatment of the primary tumour and have a normal CEA, then the
relapse rate is low, suggesting that all metastases are synchronous and that those which appear to be
metachronous have been missed, or in some cases may not have been looked for.
Cancer statistics in the UK suggest that approximately 39,000 cases of colorectal cancer are diagnosed
each year.13 An estimate of the possible incident cases can be made by using the proportions seen to
develop liver metastases in the studies by Leporrier and colleagues9 and Manfredi and colleagues.8
If between 14% and 19% of people diagnosed with colorectal cancer had liver metastases at the time of
diagnosis, it would be expected that there would be in the region of between 5000 and 7000 cases in the
UK each year. Estimating the incidence of subsequent liver metastases is more difﬁcult from these data
sets as the rates of metachronous liver metastases relate to the proportions seen over the entire study
durations in both studies, and 1, 2 and 3 years in Leporrier and colleagues’,9 and 1, 3 and 5 years in
Manfredi and colleagues’ studies.8 Using 1-year rates of 4–4.3% would, however, suggest approximately
1500–1600 new cases per year. Taking these estimates together suggests that there may be somewhere in
the region of 7000–9000 incident cases of colorectal liver metastases in the UK each year. Corresponding
data are seen when estimating the rate by using the 1-year actuarial incidence (19.5%) of all metastases in
the Leporrier and colleagues’ study.9 An estimate of the likely number of people who will develop liver
metastases within 5 years of diagnosis can be made using the data from the Manfredi and colleagues8
study. This suggests that approximately 5000 individuals who did not have liver metastases at diagnosis
would be expected to develop liver metastases within 5 years of diagnosis.
These estimates relate only to those with colorectal cancer and only from data within 1 year of colorectal
diagnosis, and therefore the number of cases of liver metastases in the UK would be expected to be
higher than those shown here.
The prevalence of liver metastases is similarly difﬁcult to establish, with most evidence being based on
pathological case series reports rather than population-based studies. As such, reports give varying pictures
of the likely number of people with liver metastases. For example, autopsy studies suggest that somewhere
between 30% and 70% of people who have died from cancer had liver metastases. Precise estimates for
the numbers of people affected by liver metastases are therefore difﬁcult to establish.The impact of liver metastases
People with liver metastases may show relatively few symptoms and in many cases are symptom free.
However, for others, pain, weight loss, nausea and fevers are frequently experienced. A small group
of people develop jaundice or abdominal ascites (an accumulation of ﬂuid in the abdominal cavity) that
can be uncomfortable and painful. In addition, the psychological impact of having a life-limiting illness
is considerable.
In recent years, improvements in survival through cytoreductive therapies have led to an increased interest
in the use of local therapies for liver metastases. Local therapies have been shown to be effective in
eradicating early-stage primary liver tumours. However, the case for using such therapies in people with
liver metastases is less well established. With a higher likelihood of people surviving longer after effective5
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BACKGROUND
6systemic therapy, even if not cured, the eradication of residual metastases via local therapies may improve
prognosis and quality of life.14
The procedure of choice has been surgical resection, with 5-year survival ﬁgures ranging from 25% to
39%15,16 for liver metastases from colorectal cancer. However, surgical resection is feasible in only
approximately 20–30% of people.17 Non-surgical alternatives have been developed in recent years to treat
some liver metastases that are not suitable for surgical resection, and in some cases to be used as an
alternative to surgical resection. Minimally invasive treatments can include various forms of ablative
therapies and other targeted treatments.Current service provisionThe current service provision of ablation treatments for colorectal liver metastases in the UK is well
regulated within the various cancer plans of the four NHS health-care providers (England, Scotland, Wales
and Northern Ireland). Cancer networks covering populations of about 2 million within each provider have
designated tertiary specialised hepatobiliary centres to provide and be reimbursed for these treatments,
through network-designated Specialist Hepatobiliary Multidisciplinary Teams (SMDTs). Effectively this
means 18 such providers in England, three in Scotland, and one each in Wales and Northern Ireland.
Elsewhere in Europe, the provision of these services is more haphazard, being similar in Scandinavia and
the Netherlands, but fragmented in other health care economies including France and Germany.
The delivery of percutaneous image-guided (radiological) ablation of liver metastases is usually coterminous
with the provision of liver surgery, usually on the same hospital site, and certainly within the same
organisation. All decisions relating to whether or not to offer ablation therapy to a patient with colorectal
liver metastases are made through the hepatobiliary SMDT, although some latitude will be offered to an
operating surgeon who, at the time of surgery with the intention of resecting colorectal liver metastases,
may reconsider the operative strategy to include surgical resection plus ablation or ablation alone.
Cryotherapy, laser therapy and ethanol injection have largely been abandoned for the treatment of
colorectal liver metastases. Radiofrequency ablation, either percutaneous or operative, has been the
standard of care for the last decade; however, it is now being rapidly superseded in clinical practice by
microwave ablation. Microwave ablation has the advantage that it generates sufﬁcient energy to destroy
metastases in only 20% of the time required for similar tumour destruction using radiofrequency ablation,
yet has the same capital cost for the energy generator and single use disposable delivery probe as
radiofrequency ablation (and as such is considered more cost-effective). Present estimates are that about
2000 patients are being offered ablation therapies for colorectal liver metastases each year in England.Description of technology under assessment
Ablative therapies
Ablation is the localised destruction of abnormal tissue in situ.18 Tumour ablation is deﬁned as the direct
application of chemical or thermal therapies to a speciﬁc focal tumour or tumours in an attempt to achieve
eradication or substantial tumour destruction.19 The objectives of ablative therapy vary from complete
ablation of all lesions with curative intent to palliative debulking of the tumour load. A potentially curative
ablation aims to extend the area of treatment beyond the margins of the metastasis, whereas palliative
debulking aims to achieve maximum tumour necrosis while preserving adequate liver function and
patient well-being.20
Ablative therapies are a separate group of therapies to those that are delivered via a catheter
(transcatheter therapies such as embolisation, chemoembolisation and radioembolisation)20,21 (see Other
non-invasive therapies).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7There are two broad categories of ablative therapy: thermal ablation and chemical ablation.19,20 Different
terminology has been used in the literature to refer to some of these therapies, and so for consistency this
report uses recommended22 standard terms where possible, rather than necessarily those used by the
studies (Table 2).
Thermal ablation techniques
These techniques use a source of thermal energy to destroy a tumour either with heat (e.g. radiofrequency
ablation) or cold (e.g. cryoablation). Tumour cells are heated to a temperature that produces coagulative
necrosis or lesser degrees of cell death, either by prolonged heating of cells at 50–55 °C or short exposure
to temperatures above 60 °C.20
Each technique uses a different type of applicator to deliver the thermal energy: radiofrequency ablation
applicators are monopolar (single) or bipolar (two) electrodes; microwave applicators are radiating
antennas; laser applicators are light-emitting ﬁbres; and due to existing convention cryoablation applicators
are termed cryoprobes.19 Thermal ablation procedures may be carried out by open surgery, laparoscopically
or percutaneously.19,26,27
Blood ﬂow affects all of the thermal ablation methods by potentially removing heat before complete
tumour ablation is achieved (the heat sink effect refers to cooling by adjacent visible blood vessels) or
by prematurely warming tissue and limiting the effects of freezing. Parenchymal perfusion or
perfusion-mediated tissue cooling (or heating) also acts to diminish the overall ablation volume achieved.19
Strategies to overcome this include pharmacologically decreased blood ﬂow, hypotensive anaesthesia,
temporary vascular balloon occlusion of a speciﬁc vessel, intra-arterial embolisation and
chemoembolisation, and a Pringle manoeuvre (temporary hepatic arterial and portal venous occlusion
by means of direct compression of the vessels) during laparotomy.19TABLE 2 Ablative therapy types
Standard term used in report Alternative terminology
Thermal ablation techniques
Cryoablation19
Laser ablation Laser coagulation therapy
Laser interstitial tumour therapy
Laser-induced thermotherapy
Laser interstitial photocoagulation19
Laser-induced interstitial thermotherapy20
Microwave ablation19 Percutaneous microwave coagulation therapy
Microwave coagulation therapy
Radiofrequency ablation19,20,23
Ultrasound ablation19 Focused ultrasound
Chemical ablation techniques
Acetic acid ablation19 Percutaneous acetic acid injection23
Electrolytic ablation24,25 Electrolysis
Ethanol ablation Percutaneous ethanol instillation/injection
Percutaneous alcohol instillation19,20
7
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8Cryoablation
Cryoablation has a longer history than some other local ablative therapies, but there is controversy
regarding its use in the liver, including recent guidance suggesting that it be used in the context of clinical
trials only.28 Cryoablation destroys tissue by delivering tissue-lethal freeze–thaw cycles to the tissue via
cryoprobes through which a cryogen (liquid nitrogen or, more frequently, argon gas) is circulated.19,26,29
By insulating the probe shaft and delivery hoses, cooling is limited to the probe tip. Liquid nitrogen and
argon gas are capable of producing temperatures of at least –100 °C and cellular death results from direct
freezing of tissue between –20 and –40 °C.26,29 Freezing potentially produces large ablation zones and
allows clearer delineation of the margins around the metastases. The procedure has usually required
general anaesthesia and laparotomy for probe placement;29 however, cryoprobes small enough to be used
percutaneously have been developed in recent years.20 The efﬁcacy of liver cryoablation is unclear.28
Complications potentially include infections and haemorrhage, and perioperative mortality from myocardial
infarction, pulmonary embolus, respiratory failure and cryoshock syndrome (a systemic response consisting
of marked thrombocytopenia leading to coagulopathies, acute respiratory distress syndrome-like
syndrome and myoglobinuria).28Laser ablation
Laser ablation uses a laser source such as neodymium-doped yttrium aluminium garnet (Nd: YAG)19,29 to
deliver high-energy light (wavelength between 800 and 1064 nm) into the tumour. The optical ﬁbres are
placed into the tumour through a percutaneously located needle and the emitted photons travel up to
12 mm through soft tissue producing heating and cell death.20 The terms ‘direct’ or ‘interstitial’ are often
reported to clarify that optical ﬁbres are inserted directly into the tissue; however, it has been
recommended that ‘laser ablation’ replaces terms such as ‘laser interstitial tumour therapy’, ‘laser
coagulation therapy’ and ‘laser interstitial photocoagulation’.19
To enlarge the area of necrosis multiple ﬁbres can be inserted into the tumour at regularly spaced
intervals. This allows up to a 6–7-cm area of necrosis when the ﬁbres are simultaneously
energised. Adaptations have also been made to the ﬁbre tip to avoid localised overheating and charring
which decreases photon penetration, such as water-cooled ﬁbres.20,29 Treatment times vary but may
exceed 1 hour for a large (6–7 cm diameter) ablation.29
Smaller tumours show greater success30 and 5-year survival rates of 26% and median survival rates of
22–41 months have been reported across varying tumours.29,31–35 Complications include pain, segmental
infarction, abscess, pleural infusion and tumour seeding.29
It is thought that this technique has been largely replaced by others, although it may still be used outside
the UK.Microwave ablation
Microwave ablation refers to all electromagnetic methods of inducing tumour destruction by using devices
with frequencies from 30MHz to 30 GHz.19 As with radiofrequency ablation, microwave ablation involves
placement of an antenna directly into the target tumour, under imaging guidance. Thermal coagulation of
tissues is caused when microwaves (between 915MHz and 2.45 GHz) oscillate water molecules and impart
tissue heating through inefﬁciencies in this process.20,29 Dependent on frequency, and unlike
radiofrequency ablation, the zone of active heating around the probe feedpoint is approximately 2 cm
either side of the probe. Microwave ablation does not utilise retractable tines and the resulting ablation
tends to be slightly more elliptical.29 However, the treatment sessions are shorter than for radiofrequency
ablation with a 2-cm ablation zone produced in 60 seconds with microwave therapy. Multiple overlapping
ablations are used to treat larger volumes.20
Microwave ablation can be undertaken percutaneously, with imaging guidance and conﬁrmation of probe
positioning, or through open or laparoscopic surgery.36NIHR Journals Library www.journalslibrary.nihr.ac.uk
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tumour seeding, pleural effusion, and (rarely) bile duct injury. Theoretical complications might include
deterioration in liver function, and adjacent organ damage to the kidney, lung or heart.36
At present, most of the evidence for microwave ablation has been published in East Asia and concerns
hepatocellular carcinoma rather than metastatic disease.26 A recent study based on registry data from
18 international centres included 140 participants, 81% of whom were treated with microwave ablation
alone. This study suggests short times to achieve tumour ablation and low morbidity and mortality rates.37
Clinical experts have stated that microwave ablation using 2.45-GHz probes are being used in the UK and
appear to produce more rounded ablation zones with fewer issues of ‘reﬂected power’ and thinner
ablation zones than seen with devices at 915MHz.
Interventional procedure guidance issued in 2011 by the National Institute for Health and Care Excellence
(NICE) stated that ‘current evidence on microwave ablation for the treatment of liver metastases raises no
major safety concerns. The evidence on efﬁcacy is inadequate in quantity and quality. Therefore this
procedure should only be used with special arrangements for clinical governance, consent and audit or
research’.36 The cost-effectiveness of microwave ablation was not discussed in the NICE guideline.Radiofrequency ablation
The term radiofrequency ablation applies to coagulation induced from all electromagnetic energy sources
with frequencies less than 30MHz.19 An electrode is inserted into the tumour, usually assisted using some
form of image guidance.19,20 High-frequency alternating current (460 kHz)20,29 is transmitted from the tip of
the electrode into the immediate tissue, causing ionic agitation and subsequent frictional heating of
localised tissue to 100 °C, resulting in tissue death in an approximately spheroid volume of tissue.26,29,38
The zone of active heating is, however, within only a few millimetres of the probe tines and tissue
destruction is considerably reliant on conductive heating with its vagaries in the in vivo setting. A 2-cm
to 5-cm spherical thermal injury can be produced with each ablation, which takes in the region of
20 minutes.29
The needle tip has to be kept as cool as possible to prevent the adjacent tissue becoming charred, which
increases impedance and prevents conduction of current into the tumour beyond the zone of ablation.20
There are many electrode modiﬁcations available, and the type used inﬂuences the extent and
predictability of ablation. Multitined expandable electrodes have an array of multiple electrode tines that
expand from a central needle,19 allowing distribution of current distant from the needle tip.20 Internally
cooled electrodes are perfused with saline or water to prevent overheating of the needle tip. Perfusion
electrodes have small apertures at the active tip that allow saline to be infused or injected into the tissue
before, during or after ablation.19
Depending on the size, location and number of tumours, radiofrequency ablation can be undertaken
percutaneously, laparoscopically, or through open surgery (laparotomy).38 The percutaneous approach is
the least invasive and minimises morbidity. It is used for a limited number of small tumours usually remote
from hollow viscera. ‘Hydrodissection’ techniques can be utilised to displace adjacent thermally sensitive
organs, for small recurrences after prior surgical resection and for patients who are not candidates for
other approaches for anatomic or clinical reasons. The laparoscopic approach reduces access morbidity and
can permit some mobilisation of the liver, and detection of additional hepatic or extrahepatic disease. The
open laparotomy approach is the most invasive and can be performed alone or in conjunction with other
procedures such as surgical resection. It allows fuller mobilisation of the liver and use of the Pringle
manoeuvre, and is most often used for large tumours, larger number of tumour or tumours in
difﬁcult locations.38
A systematic review of complications of intraoperative radiofrequency ablation of liver metastases39
reported overall mortality ranging from 0% to 1.8% in studies of people undergoing radiofrequency
ablation without surgical resection, and morbidity rates ranging from 0% to 16%. The review reported9
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10rates of wound infection (0–1.8%), biliary complications (0–1.8%), pleural effusion (0–3.6%), liver failure
(0–1.8%), vascular complications (0%) and skin burns (0–1.8%). Complications speciﬁc to radiofrequency
ablation include hepatic abscesses, caused by infection of the necrotic tissue in the ablation site; biliary
stenosis, which appear after the ﬁbrous healing of biliary tract thermal damage; vascular thrombosis,
caused by thermal endothelial damage; and skin burns, which occur when the dispersion surface is
inadequate for the radiofrequency power.
Interventional procedure guidance issued in 2009 by NICE stated that ‘current evidence on the safety and
efﬁcacy of radiofrequency ablation for colorectal liver metastases is adequate to support the use of this
procedure in people unﬁt or otherwise unsuitable for surgical resection, or in those who have previously had
hepatic surgical resection, provided that normal arrangements are in place for clinical governance, consent
and audit’.40 The cost-effectiveness of radiofrequency ablation was not discussed in the NICE guideline.Ultrasound ablation (focused ultrasound)
High-frequency sound waves (ultrasound), which use energy levels of 30–100W, can heat tissue to over
90 °C and ablate liver metastases. Two methods of application of the ultrasound are currently used:
extracorporeal (or transcutaneous), and direct, for percutaneous application with a needle-like
applicator.19,41 In the former method, the ultrasound ablation is truly non-invasive. Most reports of the use
of ultrasound ablation to date relate to prostate, uterine ﬁbroids and hepatocellular carcinoma, but it can
be used in any solid tumour, including metastatic disease in the liver. Although early reports in hepatic
solid tumours indicated some promise,42 clinical experts advise that it is not widely used in the UK.Chemical ablation techniques
Acetic acid ablation
An alternative chemical agent which can be used for chemical ablation is acetic acid19 (alternative
descriptions include percutaneous acetic acid injection23). The procedure itself mirrors that of ablation with
ethanol. Most reports to date relate to its use in hepatocellular carcinoma rather than liver metastases and
clinical experts have indicated that it is not widely used in the UK.Electrolytic ablation (electrolysis)24,26Electrolytic ablation is performed by passing a direct current between two platinum electrodes. This creates
a change in the pH of the surrounding tissues, with an acidic environment around the anode and an
alkaline environment around the cathode.24,26 Chemical reactions then also cause the creation of toxic
products such as chlorine and hydrogen ions26 and these chemical changes result in tissue destruction in
the tumour. There is, at the present time, a lack of high-quality published data on the efﬁcacy of
electrolytic ablation in liver metastases.24 Clinical experts have stated that electrolytic ablation is not widely
used in the UK.Ethanol ablation
Percutaneous ethanol injection is the chemical ablative technique with the most extensive clinical
experience. Most reports to date relate to its use in hepatocellular carcinoma rather than liver metastases.
It is relatively simple to perform, quite inexpensive, and requires minimal equipment. Percutaneous ethanol
injection is performed by the injection of absolute alcohol through a needle placed percutaneously directly
into a tumour. The necrosis produced by ethanol injection results from cellular dehydration and tissue
ischaemia from vascular thrombosis. However, ethanol ablation is not as effective as thermal ablation
techniques for the treatment of metastases due to the limitations of adequate physical dispersal. For
appropriately sized tumours, ethanol ablation improves survival and compares favourably with surgical
resection for patients with hepatocellular carcinoma.43,44Other non-invasive therapies
Other forms of minimally invasive treatment involve the combination of various substances to block
the circulation through the hepatic artery (i.e. embolisation) and to introduce different chemo- orNIHR Journals Library www.journalslibrary.nihr.ac.uk
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used as cytostatic/cytoreductive interventions for managing liver metastases.Chemoembolisation
Transarterial chemoembolisation provides a treatment option that is minimally invasive as a cytoreductive
therapy. It is an alternative to systemic chemotherapy, surgical resection and non-surgical ablative
techniques to treat resectable and non-resectable tumours. This technique aims to selectively target the
liver metastases by delivering chemotherapy locally to the tumour via a hepatic arterial catheter combined
with embolisation of the blood ﬂow which acts both to prevent washout of the chemotherapeutic agent
into the general circulation and to cause selective tumour ischaemia,45 the aim being to improve the
pharmacodynamic availability of the delivered drug and reduce systemic toxicity. It is felt that liver
metastases are particularly amenable to chemoembolisation given their relative arterialisation against
background and the fact that the liver parenchyma receives two independent blood supplies, which serves
to minimise normal parenchymal injury. Commonly used chemotherapeutic agents include doxorubicin,
cisplatin and mitomycin (Mitomycin C Kyowa®, Kyowa Hakko) which may be used either singly or in
combination. The chemotherapeutic agent(s) may also be mixed with ethiodised oil (i.e. lipiodol), a viscous
material that was originally used as a contrast agent but which also helps to localise the chemotherapy
drugs inside the tumour cells.45,46 A variety of different agents have been used to achieve embolisation and
these agents have different properties. The properties of the particles that make up the embolic agent are
an important consideration as these factors determine whether the embolisation will be permanent or
transient, and what diameter of capillary will be occluded by the particles and the rate of drug elution
from the embolic material. Infusion rate and particle size, shape (spherical or non-spherical) and
concentration all affect the way that the particles penetrate the target tissue.45,46 New controlled-release
technologies in the form of drug-eluting beads provide a means to simultaneously deliver embolisation and
chemotherapy. Furthermore, drug-eluting beads release the chemotherapeutic agent that they are loaded
with in a more sustained manner for a prolonged period of time, thereby enhancing drug delivery to the
tumour and reducing systemic toxicity.45,46 In general, the systemic concentration of the chemotherapy
drug being delivered via drug-eluting beads is low, which helps to limit possible systemic side effects.
Treatment may be repeated for the same tumour to enhance the adequacy of treatment and may be
repeated in a staged approach in the contralateral lobe, for example, so as to reduce overall
hepatotoxicity. A recent non-systematic review46 cites RCTs which showed increased overall survival for
treating hepatocellular carcinoma. The evidence reported by this review indicates some beneﬁts when
treating hepatic metastases of breast, colorectal, and neuroendocrine primary tumours although none of
the studies cited appears to be a RCT in which overall survival is reported. As drug-eluting bead
transarterial chemoembolisation is a more recent technology, the evidence base is less mature;
nevertheless, a recent systematic review47 identiﬁed eight studies. Three of these are case series focusing
on liver metastases, which report response rates and procedure associated complications. No survival
outcomes are reported.Radioembolisation
Although radiotherapy is an important part of the treatment of most malignancies, its use in hepatic
cancers has been limited due to the low tolerance of the organ to radiation, the risk of radiation hepatitis
and damage to adjacent organs.20 Recent technological developments (e.g. co-axial microcatheters and the
development of embolic carrier particles of ∼30 μm) have, however, permitted targeted internal delivery of
radiotherapy to metastases while minimising background irradiation, a form of ‘microbrachytherapy’.48
As such, it relies on careful preparation of the liver to determine vascular anatomy and embolic exclusion
of potential extrahepatic collaterals so as to ensure appropriate deployment of the microembolic to the
target metastases. To ensure that no particles are able to travel to non-target sites, embolisation with
metal coils20,21 of vessels that feed tissue beyond the area to be treated may also be required before
treatment begins. The microspheres that act as the carrier particles may be made of glass, for example
TheraSpheres® (Nordion, Ottawa, ON, Canada) which are 20–30 μm in diameter,49 or resin, for
example SIR-Spheres® (Sirtex Medical Ltd, Sydney, NSW, Australia) which have diameters between 20 and11
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1260 microns.50 Both of the two commercially available microspheres contain the β-emitter yttrium-90 (90Y),
which has a maximum range of emissions in tissue of 11mm (mean 2.5 mm) and a half-life of
64 hours.49,50 Providing that the microspheres are correctly directed to the tumour, the short penetration
distance means that radiation doses above 120 Gy can be delivered to the tumour with tolerable levels of
radiation to the normal liver tissue.48 Radioembolisation has been used in the treatment of primary and
metastatic liver tumours. Unlike local ablation techniques, surgical resection and external beam radiation,
the scope of the therapy is not limited by the number, size or location of the tumours within the liver.20,48
However, there are some contraindications to treatment which include arterial-systemic shunting from liver
to lungs and major arterial reﬂux from the hepatic vasculature to arteries supplying the gastroduodenal
region. Radioembolisation is usually delivered with concomitant local or systemic chemotherapy. A recent
meta-analysis51 identiﬁed two RCTs in which resin microspheres were used to treat colorectal metastases
with the encouraging results of a survival beneﬁt for the radioembolisation arm.51 There is also evidence
showing beneﬁts in reducing liver metastases, allowing subsequent surgical resection. It is also thought to
increase time to progression, have limited adverse effects, be tolerable and maintain quality of life. This
study also included non-RCT data and studies focusing on hepatocellular carcinoma but a conclusion could
not be drawn from this larger pool of evidence about whether glass or resin microspheres were more
effective. Radioembolisation is relatively easy to deliver and can be undertaken as a day case or with a
one-night stay, but requires signiﬁcant angiographic work-up before administration.Relevant comparators
Surgical resection of metastases
The aim of surgical resection of liver metastases is to remove all macroscopic disease with clear margins
and leave sufﬁcient functioning liver.17 Five-year survival rates following the procedure range from
25% to 39%.15,16
Selection criteria for liver resection usually include controlled or controllable primary tumour, no
extrahepatic metastases detectable (or extrahepatic disease that can also be completely resected) and
surgical resection technically feasible with tumour-free margins. Surgical resection would not be
undertaken in people with such widespread hepatic involvement that residual liver function following
surgical resection would be inadequate. People should be ﬁt enough to tolerate general anaesthesia, have
no major comorbidity and ideally have normal liver function. People with extrahepatic disease that should
be considered for liver resection include resectable/ablatable pulmonary metastases; resectable/ablatable
isolated extrahepatic sites, for example spleen, adrenal, or resectable local recurrence; and local direct
extension of liver metastases to diaphragm/adrenal that can be resected.52 In the case of liver metastases
from colorectal cancer, approximately 20–30% of people may have disease that is potentially resectable.17
A further 20–30% of people with unresectable liver limited disease might be brought to surgical resection
with curative intent using induction systemic chemotherapy.53 In some people curative surgical resection is
aborted during surgery as metastases are unresectable.Chemotherapy
Chemotherapy provides a clinically effective option for treating liver metastases in people who are not
considered suitable for surgical resection.6,54 As well as having been shown to improve survival itself,
chemotherapy has resulted in the downsizing of tumours in cases where it was initially thought not
possible to resect due to their location or inadequate hepatic functional reserve.6,54,55 Where a
compromised hepatic function reserve is a concern,56 preoperative chemotherapy may reduce overt tumour
volume, so increasing the potential volume of future remnant liver.57 In some cases the use of
chemotherapy has allowed subsequent surgical resection or ablation, improving the chances of long-term
survival and the possibility of cure.58,59 Others have used a two-stage approach to surgical resection with
an initial non-curative surgical resection or ablation followed by chemotherapy and further surgical
resection to remove any remaining tumour.59,60 Consideration of such strategies is recommended to be
taken by a regional hepatobiliary unit.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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regimens and irinotecan-based regimen for people with non-resectable liver metastases.62 NICE have also
recognised the beneﬁts of the addition of therapies that target the epidermal growth factor receptor to
conventional cytotoxic chemotherapies, which are thought to improve the chances of surgical resection of
previously irresectable or suboptimally resectable tumours considerably, although they are of beneﬁt only
in patients who do not have activating mutations on the K-RAS gene. The addition of cetuximab (Erbitux,®
Merck Serono) to oxaliplatin-based regimens and irinotecan-based regimens (if unable to tolerate, or
contraindications to, oxaliplatin) has also been recommended by NICE for ﬁrst-line treatment of metastatic
colorectal cancer.61Best supportive care
Best supportive care (BSC) is often used as the comparator arm in cancer trials; however, it is usually not
well deﬁned and may be left open to local interpretation. A Cochrane systematic review of supportive care
for gastrointestinal cancer found that the descriptions of supportive care in the included studies were often
vague and heterogeneous, making direct comparisons difﬁcult.63 BSC may include antibiotics to control
infections, analgesics (including non-steroidal anti-inﬂammatory drugs and opioids), antiemetic drugs,
transfusions for anaemia, corticosteroids, nutritional support, localised radiation therapy to alleviate
symptoms such as pain, and psychosocial support. The European Organisation for Research and Treatment
of Cancer (EORTC) Pain and Symptom Control Task Force agreed on the following deﬁnition: ‘supportive
care for cancer patients is the multi professional attention to the individual’s overall physical, psychosocial,
spiritual and cultural needs, and should be available at all stages of the illness, for patients of all ages, and
regardless of the current intention of any anti-cancer treatment’.63 Chemotherapy can be administered as
a palliative treatment to people with unresectable metastatic disease. It can prolong both the time to
tumour progression and survival.6Place of the interventions in the treatment pathway
The clinical pathway for people with liver metastases depends in part upon the primary cancer the person
has when the metastases were diagnosed and the extent and location of the metastases. Although liver
metastases may originate from several primary sites, most research has been focused on colorectal liver
metastases as treatment has been noted to confer survival beneﬁt. As such, the clinical pathway outlined
reﬂects that recommended for people who have liver metastases from colorectal cancers.17,64
It is recognised that the management of people with liver metastases associated with colorectal cancer
should involve a hepatobiliary multidisciplinary team based in a cancer centre with responsibility for
colorectal cancer and, where available, for hepatobiliary cancer. Such teams would be likely to include
specialist surgeons trained and maintaining a special interest in liver resection, oncologists, diagnostic
and interventional radiologists with expertise in hepatobiliary disease, histopathologists and clinical
nurse specialists.17
The detection of liver metastases may occur at the point of ﬁrst presentation and diagnosis of the primary
cancer or subsequently during follow-up. Contrast CT scans of the abdomen are used to detect liver
metastases, although their sensitivity and speciﬁcity will vary depending on the equipment and contrast
enhancement used. Contrast enhanced magnetic resonance imaging (MRI) provides an alternative option
for assessing the liver for metastases and can be more effective than CT scans for small volume disease.
Ultrasound examination is thought not sufﬁciently sensitive to identify the presence of liver metastases.
CEA levels are thought to be elevated in up to 90% of people with liver metastases, although the point at
which these levels rise is less certain. Baseline measures should be undertaken, allowing assessment of
local or distant recurrence following initial treatment. The occurrence of isolated liver metastases should be
followed up with CT scans of the chest, abdomen and pelvis. Biopsy of the liver should not be performed
without discussion with the regional hepatobiliary unit, as there is the opportunity for dissemination of the
metastases. Fluorodeoxyglucose positron emission tomography (FDG-PET) may also be used to identify
hepatic colorectal metastases and extrahepatic disease that may have a bearing on treatment planning and
help with staging of the cancer.13
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14Surgical resection has been considered the primary treatment option for people with liver metastases.
The intention is to remove all macroscopic disease with clear (negative) margins, while leaving sufﬁcient
functioning liver. Candidates for surgical resection include people with solitary, multiple and bilobar
disease that have undergone, or who are able to undergo, radical treatment for the primary cancer. It can
be undertaken as a major or a staged process. Staged surgical resection may be undertaken where there is
a bulky bilateral lesion and it may be effective in sparing more normal liver than a major surgical resection
or in allowing surgical resection of metastases not normally included in a major surgical resection. The
selection criteria for people to undergo liver resection and the contraindications are outlined above.
Although the surgical resection of colorectal cancer and liver metastases would not normally be
undertaken simultaneously, this has occurred, and has been shown to be safe and efﬁcient when
undertaken in high-volume centres. Decisions concerning surgical resection and the patient’s suitability for
this should be discussed by the surgeon in consultation with a radiologist, an anaesthetist and the patient.
Recurrence occurs in 60% to 70% of people and follow-up should be continued for at least 5 years using
CT of the chest and liver and blood CEA.17
Of the people unable to undergo liver resection, those with isolated unresectable metastases and no
extrahepatic disease may be considered for ablative therapy. There are several ablative therapies which
may be curative for some people and offer the opportunity for improvements in symptoms and quality of
life more generally (see Chapter 5, Independent economic evaluation). The relative clinical effectiveness of
the different ablative therapies remains unclear and decisions concerning their use should be considered by
the surgeon, oncologist and interventional radiologist in consultation with the patient. For those people
not suitable for either liver resection or ablative therapy, referral should be made to the clinical and
medical oncologists for further management and supportive care.
Chemotherapy also has a role in managing people with liver metastases. People who have extensive
liver metastasises may receive systemic chemotherapy, hepatic artery catheter chemotherapy or
chemoembolisation. Systemic chemotherapy should be administered to people with extrahepatic disease.
It is thought that intra-arterial chemotherapy has consistently higher response rates compared with
systemic chemotherapy for people with liver metastases, due to the more direct delivery to the liver.
Hepatic artery chemoembolisation has developed to treat unresectable non-disseminated liver tumours,
increasing the response rates and decreasing tumour dissemination. Portal vein embolisation may be
used as an adjunctive technique to cause liver hypertrophy and extend the scope of liver resection.
On occasions, chemotherapy has been shown to reduce tumours to allow surgical resection. Selective
internal radiation therapy has been used for people with extensive liver disease without extrahepatic
metastases who have failed with 5-ﬂuorouracil (5-FU) and other cytotoxic treatments. However, the data
on the effectiveness of 5-FU administered via hepatic artery infusion provide no clear evidence to
support its use and combination chemotherapy may be equally or more effective. It is not used commonly
in the UK.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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clinical effectiveness and cost-effectiveness
The a priori methods for systematically reviewing the evidence of clinical effectiveness andcost-effectiveness are described in the research protocol (see Appendix 1), which was sent to experts
for comment. Although helpful comments were received relating to the general content of the research
protocol, there were none that identiﬁed speciﬁc problems with the methodology of the review. The
methods outlined in the protocol are brieﬂy summarised below. The systematic review followed the
general principles outlined in the Centre for Reviews and Dissemination (CRD) report ‘Undertaking
Systematic Reviews of Research of Effectiveness’ (third edition)65 and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement on the reporting of systematic reviews
and meta-analyses.66Identiﬁcation of studiesA comprehensive search strategy was developed, tested and reﬁned by an experienced information
scientist. Separate searches were conducted to identify studies of clinical effectiveness, cost-effectiveness,
quality of life, and epidemiology. Sources of information and search terms are provided in Appendix 2.
Searches were undertaken in March 2011 and updated in September 2011.
A total of 14 electronic resources were searched: 10 databases listing published papers and abstracts and
four databases listing ongoing studies. Searches were from 1990 to September 2011 with no language
restrictions. The following electronic databases were searched: MEDLINE (Ovid); MEDLINE In-Process &
Other Non-Indexed Citations (MEIP); EMBASE; The Cochrane Library including Central Register of
Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR); CRD including Health
Technology Assessment (HTA) Database, Database of Abstracts of Reviews of Effects (DARE) and NHS
Economic Evaluation Database (NHS EED); Science Citation Index and Conference Proceedings Citation
Index (Web of Science); Zetoc, The British Library; National Institute for Health Research Clinical Research
Network (NIHR CRN) Portfolio; Current Controlled Trials (CCT); Clinical trials.gov; and World Health
Organization (WHO) International Clinical Trials Registry Platform (ICTRP).
In addition, professional society websites and conferences were searched for recent abstracts and ongoing
studies (see Appendix 2). Bibliographies of included articles were checked for any additional references,
and our expert advisory group was contacted to identify additional published and unpublished studies.Study selection and data extractionStudies were selected for inclusion in the systematic review of clinical effectiveness through a two-stage
process using predeﬁned and explicit criteria. The full literature search results were independently screened
by two reviewers to identify all citations that possibly met the inclusion criteria. Full papers of relevant
studies were retrieved and assessed by one reviewer and checked by a second reviewer using a
standardised eligibility form. As far as possible, full papers or abstracts describing the same study were
linked together, with the article reporting key outcomes designated as the primary publication.
Data were extracted by one reviewer using a standard data extraction form (see Appendix 4) and checked
by a second reviewer. At each stage, any disagreements between reviewers were resolved by consensus or
if necessary by arbitration by a third reviewer.15
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METHODS FOR SYSTEMATIC REVIEW OF CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS
16Titles and abstracts identiﬁed by the search strategy for the systematic review of cost-effectiveness were
assessed for potential eligibility by two health economists using predetermined inclusion criteria.
Full papers were formally assessed for inclusion by one health economist with respect to their potential
relevance to the research question.Quality assessmentThe methodological quality and the quality of reporting of the included clinical effectiveness studies were
assessed using criteria based on those recommended by the CRD65 (see Appendix 3). Quality criteria were
applied by one reviewer and checked by a second reviewer, with any differences in opinion resolved by
consensus or by arbitration by a third reviewer.
Quality assessment for the systematic review of cost-effectiveness was based on a checklist for economic
evaluation publications67 and guidelines for good practice in decision-analytic modelling in health
technology assessment.68Inclusion and exclusion criteria
Intervention
All ablative therapies currently used in the UK, either alone or in sequence, including:
l radiofrequency ablation
l microwave ablation
l cryoablation
l ethanol ablation
l laser ablation
l focused ultrasound
l electrolytic ablation.
Other minimally invasive therapies currently used, speciﬁcally:
l chemoembolisation
l radioembolisation.Comparatorsl Surgical resection of metastases.
l Chemotherapy.
l BSC (as deﬁned by the included studies and including chemotherapy as part of BSC/palliative care).Participantsl People with liver metastases from any solid tumour primary site.Outcomesl Procedure-related morbidity, mortality and hospital stay.
l Rate of complete tumour ablation.
l Local recurrence rate.
l Progression-free survival.
l Overall survival.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7l Health-related quality of life.
l Costs and cost-effectiveness.Designl RCTs.
l Prospective non-randomised comparative studies.
l Prospective case series studies (sample size > n = 100).
l Economic evaluations (i.e. costs and consequences), including cost-effectiveness, cost–utility or
cost-beneﬁt analyses.
Systematic reviews identiﬁed by the search were used as a source for identifying primary studies
(see Appendix 1) and summarised (see Chapter 4, Existing systematic reviews).
Studies published as abstracts or conference presentations were included only if sufﬁcient details were
presented to allow an appraisal of the methodology and the assessment of results to be undertaken. Only
abstracts published from 2006 onwards were eligible for inclusion as it was expected that full publications
would be available for abstracts published before this time.
Where there was evidence from different types of study design for a speciﬁc intervention, only those
studies with the most rigorous designs were included and data extracted.
Studies that have assessed surgical resection of metastases have used several terms describing the
intervention and presenting results, including surgery, surgical resection and hepatectomy. Where
appropriate, these different terms have been changed to surgical resection to help clarity. The original
terms used have been kept in references, data extraction tables, where a speciﬁc description or reference
is made.Method of data synthesisStudies of clinical effectiveness and cost-effectiveness were synthesised through a narrative review with full
tabulation of the results of all included studies. It was considered inappropriate to combine the results of
the studies in a meta-analysis due to differences in the outcome measures and patient populations.
Within the clinical effectiveness section of this report, results are discussed according to the intervention to
aid interpretation.
Evidence from case series is generally considered to be very low quality.69 Thus, limited attention is given to
these studies to avoid undue weight being given to their results. The narrative synthesis of case series
studies focuses on the key outcomes for the whole study population (or participants eligible for inclusion in
the systematic review only, if reported separately) for survival, mortality, response rates and adverse events.
Where studies have reported outcomes for various subgroups this has been noted in the data extraction
forms (see Appendix 4). If the subgroups were speciﬁed a priori and appeared to be statistically powered,
they were discussed in the text.
The methods for the economic model are described in Chapter 5 (see Independent economic evaluation).17
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Chapter 4 Clinical effectivenessTotality of research availableSearching identiﬁed 5381 references after deduplication. The number of references excluded at each stage
of the systematic review is shown in Figure 1. References which were retrieved but later excluded are
listed in Appendix 5 with reasons for exclusion. Studies were often excluded for more than one reason;
the most common reason was study design, including small sample sizes of prospective case series studies
(121 studies), followed by irrelevant participants (34 studies), irrelevant intervention (21 studies), and
irrelevant comparator (four studies). Fourteen studies reported data only in abstracts and, as they did not
provide sufﬁcient information, were excluded. Two studies remain unclear on whether they are prospective
or retrospective despite review by three independent reviewers, and were therefore excluded. These are
listed in Appendix 5. Seventy-four potentially relevant non-English references were identiﬁed by the
searches and can be seen in Appendix 6. After examination of the titles and English abstracts
(where available) seven of these studies were retrieved for closer inspection. Three studies were excluded
at this stage, leaving four studies of possible relevance to the review. In view of the limited time and
resources, translation and full screening of the papers was not undertaken. These studies are listed in
Appendix 6. Searches identiﬁed 46 existing reviews or systematic reviews which were used as a source of
references. Finally, ﬁve potentially relevant ongoing studies were identiﬁed, and these are described in
Research in progress later in this chapter.
Twenty potentially eligible studies (in 23 publications) were identiﬁed. After selecting the highest level of
evidence available for each intervention, 16 studies (in 19 publications) were included in the systematic
review of clinical effectiveness. The included studies were either RCTs or prospective case series studies.
A summary of the highest level of evidence available for each intervention can be seen in Table 3, with
further details of these studies being reported in subsequent sections. The remaining four lower evidence
studies are listed in Appendix 5.
Laser ablationQuantity and quality of research
Two prospective case series70,71 describing laser ablation were included (Table 4). The narrative synthesis of
these data focuses on the key outcomes for survival, mortality, response rates and adverse events, as
described in Chapter 3 (see Method of data synthesis). Subgroups were reported in the studies; however,
these do not appear to have been speciﬁed a priori or be statistically powered and the results are therefore
not discussed here (see Appendix 4 for further details).
Both included case series were from the same institution in Germany, and some of the participants with
breast cancer may have been reported in both studies (see Table 4). The 2001 study by Mack and
colleagues70 presented combined data from participants with a variety of primary tumours, including
hepatocellular carcinoma, which were not eligible for inclusion in this systematic review. However, the
authors also presented data separately for participants with colorectal cancer and breast cancer, which are
reported here as per our inclusion criteria. However, caution is required as these data are subgroup
analyses (see Chapter 3, Method of data synthesis). The 2004 study by Mack and colleagues71 included
only women with liver metastases from breast cancer. Other eligibility criteria, such as the number and size
of metastases, were similar between studies. The 2001 study70 speciﬁed no extrahepatic spread, but in the
2004 study 31% of participants had bone metastases considered to be under control.71 The mean age of
participants was reported only for the colorectal cancer group in the 2001 study,70 and at 60.8 years this19
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Identified on searching
(after duplicate removal)
(n = 5381)
Titles and abstracts inspected
Full papers retrieved
(n = 219)
Full papers inspected
Potentially eligible
(n = 20) (in 23 publications)
Hierarchy of study design
examined
Included (n = 16)
(in 19 publications)
Excluded (n = 5088)
(of which 46 were reviews)
Potentially relevant 
non-English papers (n = 74)
Excluded (n = 196a)
Lower hierarchy excluded
(n = 4)
FIGURE 1 Flow chart of identification of studies. a, Two studies remain unclear on study design.
CLINICAL EFFECTIVENESS
20was slightly higher than for participants with breast cancer in the 2004 study (54.4 years).71 Other baseline
characteristics were not reported in the 2001 study.70 Participants in the 2004 study71 all had
chemotherapy prior to or after treatment of liver metastases and they had a mean of 2.5 (range 1–13) liver
metastases. The studies did not state whether intention of treatment was curative or palliative.
Case series provide very low-quality evidence69 and the quality of reporting of the two included case
series70,71 was poor (Table 5). Both studies speciﬁed patient selection criteria in advance, but neither study
completely described whether or not there were withdrawals and dropouts or reported if or how statistical
analysis accounted for missing data. Both studies failed to adequately describe blinding of participants to
the research question, although the importance of this is more relevant to subjective outcomes, such as
quality of life, than to objective outcomes, such as mortality. It was unclear whether or not authors
measured more outcomes than they reported, which can result in reporting bias.
Assessment of effectiveness: laser ablation
Mean survival of participants with liver metastases from colorectal cancer who had been treated with laser
ablation was 41.8 months (95% CI 37.3 months to 46.4 months) in the 2001 study by Mack and
colleagues,70 although it is not clear whether this is from diagnosis or treatment of liver metastases.
Among those with breast cancer liver metastases, mean survival was 51.6 months (95% CI 43.2 months to
60 months).70 In the 2004 study, mean survival of women with breast cancer was 58.8 months from
diagnosis of liver metastases [(95% CI 51.6 months to 64.8 months), median survival 51.6 months
(95% CI 40.8 months to 63.6 months)] and 50.4 months (95% CI 43.2 months to 57.6 months) from ﬁrst
treatment with laser ablation. However, the authors of the 2004 series note that the estimated mean
survival times are biased owing to the number of censored cases, that is to say if the event had not been
noted in the patient chart by the end of the observation period the cases were treated as if the event had
been reported at that time. Survival rates ranged from 85%71 to 97%70 at 1 year, and from 30%70 toNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 3 Summary of hierarchy of evidence identiﬁed, by intervention
First author Intervention Comparator Study design
Ablative technologies
Mack70 Laser ablation None Case series
Mack71 Laser ablation None Case series
Shibata72 MWA Surgical resection RCT
Kim73 RFA (1) Surgical resection Non-randomised comparison
(2) Surgical resection + RFA
Berber74,75 RFA None Case series
Gillams76,77 RFA None Case series
Siperstein78 RFA None Case series
Solbiati79 RFA None Case series
Sorensen80 RFA None Case series
Other non-invasive therapies
Taguchi81 Chemoembolisation Chemotherapy RCT
Agarwala82 Chemoembolisation Chemotherapy RCT
Vogl83 Chemoembolisation and laser ablation None Case series
Vogl84 Chemoembolisation and laser ablation None Case series
Gray85 Radioembolisation HAC RCT
Hendlisz86 Radioembolisation Chemotherapy RCT
Van Hazel87,88 Radioembolisation Chemotherapy RCT
HAC, hepatic artery chemotherapy; MWA, microwave ablation; RFA, radiofrequency ablation.
No studies of chemical (ethanol, acetic acid, electrolyte) ablation or focused ultrasound were identiﬁed.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 741%71 at 5 years (Table 6); however, comparison between studies is difﬁcult due to unclear reporting of,
and differences in, the calculation of survival.
The low quality of the evidence from these studies should be taken into consideration when interpreting
these results.Adverse events: laser ablation
Only one study71 reported adverse events from laser ablation (Table 7). No deaths occurred within 30 days
of treatment. The most common adverse event was non-symptomatic pleural effusion, which occurred 41
(9.1%) times in 452 treatments sessions. There were 20 (4.4%) events of small non-symptomatic
subscapular haematoma. Less frequent events also occurred (see Table 7).
Summary of clinical effectiveness: laser ablation
No comparative studies of laser ablation were identiﬁed. Two prospective case series, which provide very
low-quality evidence, were included from the same institution. One study reported data for people with
liver metastases from colorectal cancer and breast cancer separately, and the second study involved people
with breast cancer primary tumours only, although the eligibility criteria for the studies were similar.
Minimal baseline characteristics were provided for the breast and colorectal subgroups. The studies
provided estimates of overall survival for the study population, but comparisons are difﬁcult due to unclear
reporting of, and differences in, the calculation of survival. One study provided data on adverse events.21
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TABLE 5 Quality assessment: laser ablation (prospective case series)
Study
Patient criteria
speciﬁed a priori?
Blinding of
participants
to research
question?
Selective
outcome
reporting?
Withdrawals
described?
Missing data
accounted for
in analysis?
Mack et al., 200170 Yes NR Unclear NR NR
Mack et al., 200471 Yes NR Unclear NR NR
NR, not reported.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Microwave ablation
Quantity and quality of evidence available
One RCT72 that compared microwave ablation with surgical resection met the inclusion criteria (Table 8).
The RCT by Shibata and colleagues72 took place at a single centre in Japan and randomised 40 participants
whose primary cancer was colorectal. The intention of treatment with microwave ablation was not
explicitly stated but participants were potentially amenable to surgical resection and the aim of the study
was to compare the therapeutic efﬁcacy of microwave ablation in comparison with surgical resection.
Other key criteria for inclusion in the RCT were that there should be fewer than 10 liver metastases and
that the greatest dimension of the largest tumour should be < 80mm. The length of participant follow-up
after the intervention was not reported. For further details of the intervention see Appendix 4.
Although 40 participants were enrolled, only 30 participants were studied and reported on in the trial
publication (see paragraph below describing withdrawals). Slightly more than half of these 30 participants
were male, although in the microwave ablation arm females outnumbered males. The mean age of
participants was 61 years in each trial arm. The microwave ablation participants had a higher mean
number of liver metastases (4.1 vs. 3.0) with a slightly smaller mean size of the largest tumour than the
participants with surgical resection. Further details on baseline characteristics of the included participants
can be seen in Appendix 4.
Many of the methodological details needed to judge methodological validity were not reported (Table 9).
The authors reported an adequate method of generating the randomisation sequence, although it was not
reported whether or not any method was used to conceal intervention allocation. Without concealed
allocation there would be the possibility of selection bias. Shibata and colleagues72 did not report whether
or not those assessing patient outcomes were blind to intervention assignment. The outcome of overall
survival is not likely to be affected by blinding but there would be a risk of detection bias for the outcomes
of disease-free interval and adverse events if outcome assessors were not blind to the intervention received
by the patient.
Ten participants were withdrawn from the trial intraoperatively when additional tumours were found
either in the liver or elsewhere, which meant that these participants no longer met the inclusion criteria for
the trial. The group assignments and withdrawal reasons were provided for each of the 10 participants
and these were similar between the two arms of the trial. The paper does not report whether or not any
method was used to account for missing data; however, no further withdrawals were reported among the
30 participants who continued in the trial. The study did not undertake an intention-to-treat analysis and,
as noted above, other than the 10 participants who were withdrawn intraoperatively, there appeared to
be no other missing data to account for. It was not clear whether or not the authors had measured more
outcomes than they were reporting on in the trial publication. Overall, therefore, although 10 of the
initially randomised participants dropped out of the trial and an intention-to-treat analysis was not
conducted, the risk of measurement bias appears low because the reasons for participant dropout are
provided and appear balanced between the groups.23
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TABLE 7 Adverse events: laser ablation (prospective case series)
Study details
Total number of
complications Details
Mack et al., 2004;71 breast cancer primary,
n = 232; length of follow-up:
mean 1.8 years; 452 treatment sessions
68a 30-day mortality: 0
Pleural effusion: 4
Non-symptomatic pleural effusion: 41
Liver abscess: 2
Injury to bile duct: 1
Bronchial biliary ﬁstula: 0
Pneumothorax: 0
Small non-symptomatic subscapular haematoma: 20
a Total calculated by reviewer, assuming all adverse events had been reported in the paper.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Assessment of effectiveness: microwave ablation
Overall survival
Shibata and colleagues72 calculated overall survival (which was one of their two primary outcomes) from
the time of treatment to the end of the follow-up period (the length of this was not reported). During
follow-up nine of the microwave ablation group and 12 of the surgical resection group died (Table 10).
There was no statistically signiﬁcant difference in the estimated cumulative survival rates (p = 0.83). Mean
overall survival in the microwave ablation group was 27 months versus 25 months in the surgical resection
group. The estimated 1-, 2- and 3-year survival rates also indicated that therapeutic efﬁcacy was similar
between the two treatments (see Table 10).
Response
Response data were not reported by Shibata and colleagues.72Disease-free survival
Shibata and colleagues72 reported the outcome of disease-free survival but did not deﬁne this (Table 11).
There was no statistically signiﬁcant difference in the mean duration of disease-free survival between
microwave ablation and surgical resection groups (11.3 months vs. 13.3 months respectively, p = 0.47).
Indications of surgical invasiveness
Surgical invasiveness was the second of the study’s primary outcomes.72 Although there was no statistically
signiﬁcant difference between the two interventions for operation time or the length of hospitalisation
there was statistically signiﬁcantly less intraoperative blood loss in the microwave ablation group compared
with the surgical resection group {mean 360ml [standard deviation (SD) 230 ml] vs. 910ml [SD 490ml],
p = 0.027}. Furthermore, no participants in the microwave ablation group required a blood transfusion,
whereas six participants (38%) required a mean volume of 540ml of transfused blood in the surgical
resection group (Table 12).
Adverse events
Adverse events occurred in both trial arms with no statistically signiﬁcant difference between them (two
participants in the microwave ablation group vs. three participants in the surgical resection group,
p = 0.87). In the microwave ablation group one participant had a hepatic abscess and one had a bile duct
ﬁstula. A bile duct ﬁstula was also a complication for one participant in the surgical resection group, the
other adverse events in the surgical resection group being an intestinal obstruction and a wound
infection (Table 13).25
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TABLE 10 Overall survival: microwave ablation
Study details
Estimated overall survival calculated from treatment Mortality
Arm
Mean,
months
1 year
(%)
2 years
(%)
3 years
(%)
4 years
(%)
5 years
(%)
During
follow-up
Shibata et al., 2000;72
colorectal primary,
n = 40; follow-up:
not stated
MWA
(n = 14)
27 71 57 14 NR NR 9
Surgical
resection
(n = 16)
25 69 56 23 NR NR 12
p-value NR NR NR NR NR NR NR
MWA, microwave ablation; NR, not reported.
TABLE 11 Disease-free survival/time to progression: microwave ablation
Study details
Disease-free interval (months)
Arm Mean (months)
Shibata et al., 2000;72 colorectal primary,
n = 40; follow-up: not stated
MWA (n = 14) 11.3
Surgical resection (n = 16) 13.3
p-value 0.47
MWA, microwave ablation.
TABLE 12 Indications of surgical invasiveness: microwave ablation
Study details
Indications of surgical invasiveness, mean (SD) unless otherwise stated
Arm
Intraoperative
blood loss (ml)
Blood
transfusion
(ml)
Participants
requiring
blood
transfusion
Operation
time
(minutes)
Hospitalisation
(days)
Shibata et al., 2000;72
colorectal primary,
n=40; follow-up:
not stated
MWA
(n = 14)
360 (230) 0 (0) n = 0 (0%) 180 (20) 20 (7)
Surgical
resection
(n = 16)
910 (490) 540 (690) n = 6 (38%) 200 (50) 25 (12)
p-value 0.027 0.08 0.035 0.20 0.23
MWA, microwave ablation.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Summary
One RCT72 compared microwave ablation with surgical resection. The methodological quality of the RCT
appeared reasonable although some details needed to judge methodological quality were not reported.
No statistically signiﬁcant difference in the estimated cumulative survival, disease-free interval or incidence
of adverse events was found between the two groups. Measures of surgical invasiveness (blood loss,
requirement for and volume of blood transfusion) all showed a statistically signiﬁcant difference in favour
of the microwave ablation group. However, this did not lead to any shortening of the operation time or
length of hospital stay as there was no signiﬁcant difference in these two outcomes between the groups.27
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TABLE 13 Adverse events: microwave ablation
Study details
Adverse events, number (%) of participants
Total
frequency of
complicationsArm
Intra- or
post-
operative
deaths
Intestinal
obstruction
Bile
duct ﬁstula
Hepatic
abscess
Wound
infection
Shibata et al., 2000;72
colorectal primary,
n=40; follow-up:
not stated
MWA
(n = 14)
0 0 1 (7) 1 (7) 0 2 (14.3)
Surgical
resection
(n = 16)
0 1 (6) 1 (6) 0 1 (6) 3 (18.8)
p-value NR NR NR NR NR 0.87
MWA, microwave ablation; NR, not reported.
CLINICAL EFFECTIVENESS
28Radiofrequency ablation
Quantity and quality of evidence available
One prospective non-randomised comparison study73 and ﬁve prospective case series studies describing
radiofrequency ablation were included (Tables 14 and 15). The narrative synthesis of the data from the
case series studies focuses on the key outcomes for survival, mortality, response rates and adverse events,
as described in Chapter 3 (see Method of data synthesis). Subgroups were reported in some of these
studies, however these do not appear to have been speciﬁed a priori or be statistically powered and the
results are therefore not discussed here (see Appendix 4 for further details).
All participants in the non-randomised comparison study (Kim and colleagues)73 had colorectal liver
metastases. The participants were all reported to be eligible for surgical resection except those with
comorbidities, difﬁcult anatomical sites of metastases or more than four metastases. All ﬁve case series
studies included participants with colorectal liver metastases who were not candidates for surgical
resection due to various reasons (see Table 15). The study by Berber and colleagues74,75 was associated
with two publications which had overlapping recruitment dates. Although the 2008 paper75 reported that
intention of treatment was curative, this was not reported in the 2005 paper74 containing data relevant to
this systematic review. Intention of treatment was not reported by the other studies. The eligibility criteria,
such as the number and size of metastases and the presence of extrahepatic spread, varied between
studies. The mean age of participants ranged from 55 to 65 years, and 55% to 70% of the participants
were men. Participants had a mean of 1.573 to 476,77 liver metastases, although the number ranged up to
27 metastases in one of the studies.76,77 In one study that did not report mean number of metastases,
most (63%) participants had just one tumour. The mean size of the largest liver tumour was similar
between the case series studies reporting this, ranging from 3.279 to 4.1 cm.74 In the comparison study the
mean maximum size of liver tumour ranged from 2.1 to 2.6 cm across the three treatment groups.73 Some
of the participants had undergone previous liver resection in four of the studies,74,76,77,79,80 and
chemotherapy for liver metastases was also reported by four of the studies.74,78–80
The quality of reporting in the non-randomised comparative study was poor, with details lacking to assess
many aspects of the quality of the study and subsequent risk of bias (Table 16). This study therefore has
an uncertain risk of bias which should be noted when interpreting the results. Case series provide very
low-quality evidence69 and the quality of reporting of the ﬁve included case series was poor (Table 17).
One79 of the ﬁve included studies did not appear to specify patient selection criteria in advance, and
four74,76–79 of the studies did not completely describe whether or not they had any withdrawals and
dropouts. None of the studies reported if or how statistical analysis accounted for missing data. All studies
failed to adequately describe blinding of participants to the research question, although the importance ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7this is more relevant to subjective outcomes, such as quality of life, than to objective outcomes, such as
mortality. It was unclear whether or not authors measured more outcomes than they reported, which can
result in reporting bias.
Assessment of effectiveness: radiofrequency ablation
Four studies reported overall survival for all participants and these results are presented below (Table 18).
The non-randomised comparison study73 and one case series study76,77 reported survival for subgroups
only; these results are not discussed. Two studies74,80 calculated survival from both diagnosis of liver
metastases and radiofrequency ablation of liver metastases, one study from ablation only78 and one study
did not report how survival was calculated.79 Median overall survival after diagnosis of liver metastases was
reported as 44.6 months (measure of variation not reported)74 and 52 (95% CI 34 to 82) months.80 In the
same studies, median survival after radiofrequency ablation was 28.9 months74 and 32 (95% CI 24 to 45)
months.80 Median survival was 24 months (measure of variance not reported) in the third study reporting
survival from treatment.78 The remaining study reported median survival time of 36 (95% CI 28 to 52)
months,79 although it is unclear whether this is from diagnosis or ablation of liver metastases.
Survival rates at 1, 2, 3, 4 and 5 years were not consistently reported between the studies, making
comparison difﬁcult (see Table 18). Two studies79,80 reported estimated survival rates, one study78 reported
actual survival rates and one study74 did not report survival rates for the whole population. Estimated
1-year survival rates were 93% in the study that did not state the start point for the analysis,79 and 96%
(from diagnosis) or 87% (from radiofrequency ablation) in another study.80 The actual 5-year survival rate
was 18.4% (calculated from radiofrequency ablation) in the study by Siperstein and colleagues,78 and the
estimated 5-year survival rate was 44% (from diagnosis of liver metastases) in the study by Sorensen and
colleagues.80 The reason for the differences between studies is not clear, but may be due to differences in
inclusion criteria and methods of calculating survival.
One study reported recurrence rates. Solbiati and colleagues79 followed participants for 6 months to
52 months and found that 57% developed new metastases, which were detected after an estimated
median 12 (95% CI 10 to 18) months. At least one local recurrence was experienced by 54.7% of
participants. The estimated local recurrence rate at 18 months for all participants was 44%. One other
study76,77 provided data which may be indicative of the local recurrence rate; however, the data were
poorly deﬁned and it is therefore difﬁcult to establish the overall local recurrence rate. These data can be
found in Appendix 4.
The low quality of the evidence from these studies should be taken into consideration when interpreting
these results.Adverse events: radiofrequency ablation
Three studies76,77,79,80 reported data on adverse events from radiofrequency ablation (Table 19).
Twenty-nine (4.7%) major complications occurred in 617 treatment sessions in the study by Gillams and
Lees,76,77 comprising one anaesthetic, ﬁve systemic and 23 local complications. Sorensen and colleagues80
reported 12 (6.8%) major and seven (4%) minor complications occurring in 176 treatment sessions
(see Table 19). Just one (0.4%) severe complication (perforation of right colon) and one (0.4%) ‘other’
complication were reported by Solbiati and colleagues,79 occurring in 229 treatment sessions.
Summary of clinical effectiveness: radiofrequency ablation
One non-randomised comparative study and ﬁve prospective case series were included, which provide very
low-quality evidence. These studies involved participants with liver metastases from colorectal cancer,
although eligibility criteria for the studies differed. Four of the studies provided estimates of overall survival
for the study population, but comparisons are difﬁcult due to unclear reporting of, and differences in, the
calculation of survival. Major or severe complication rates were low.33
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TABLE 19 Adverse effects: radiofrequency ablation (prospective case series)
Study details
Total number of
complications Details
Gillams and Lees, 2009;76,77
colorectal primary, n = 309;
follow-up: NR;
617 treatment sessions
Major complicationsa 29 Systemic: 5
Anaesthetic: 1
Local: 23 [1 pneumothorax,
4 visceral thermal injuries, 6 abscesses,
4 jaundice (2 bile duct injury,
2 inadequate liver reserve),
7 haemorrhagic complications,
1 asymptomatic pseudoaneurysm]
Solbiati et al., 2001;79
colorectal primary, n = 117;
follow-up: 6–52 months;
229 treatment sessions
Severe complications 1 Perforation of right colon requiring
surgical repair
Other complications 1 Small intraperitoneal haemorrhage
Sorensen et al., 2007;80
colorectal primary, n = 102;
length of follow-up:
mean 23.6 (range 1–92) months;
176 treatment sessions
Major complicationsb 12 Abscesses requiring drainage:
hepatic, n = 2; subcutaneous, n = 1
Perforation of gastrointestinal wall:
gastric, n = 2; colonic, n = 1
Vascular: pseudoaneurysm of the
right hepatic artery, n = 1;
thrombosis of inferior caval vein, n = 1
Seeding, n = 1
Pneumothorax requiring drainage, n = 1
Perforation of the diaphragm, n = 1
Acalcular cholecystitis, n = 1
Minor complications 7 Hepatic abscesses not requiring
drainage, n = 2
Second-degree skin burn, n = 1
Subcapsular liver haematoma, n = 1
Subcutaneous haematoma, n = 1
Pleural effusion not requiring
drainage, n = 1
Fistula between RFA necrosis and
secondary biliary tract, n = 1
RFA, radiofrequency ablation.
a Requiring intervention or hospital stay beyond 72 hours.
b Threatening life, leading to substantial morbidity and disability or requiring prolonged hospitalisation.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Chemoembolisation
Quantity and quality of evidence available
Two RCTs81,82 in which the intervention was chemoembolisation met the inclusion criteria (Table 20). The
Taguchi and colleagues RCT81 was a Phase III study of intra-arterial chemotherapy with mitomycin C with
the addition of degradable starch microspheres to achieve chemoembolisation compared with intra-arterial
chemotherapy alone (no embolisation). The other RCT,82 by Agarwala and colleagues, was a Phase I/II
study of hepatic artery infusion with cisplatin plus polyvinyl sponge to achieve chemoembolisation or
hepatic artery infusion with cisplatin only (no embolisation). Neither study stated the intention of treatment
(e.g. curative, palliative) although the aim of Agarwala and colleagues82 was to identify the maximum35
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TA
B
LE
20
C
h
ar
ac
te
ri
st
ic
s
o
f
in
cl
u
d
ed
R
C
Ts
:c
h
em
o
em
b
o
lis
at
io
n
St
u
d
y
K
ey
in
cl
u
si
o
n
cr
it
er
ia
a
A
rm
n
A
g
e
(y
ea
rs
),
m
ea
n
Se
x,
(M
/F
)
N
o
.o
f
LM
Si
ze
o
f
LM
Pr
ev
io
u
s
tr
ea
tm
en
t
Ex
tr
ah
ep
at
ic
d
is
ea
se
(%
)
A
ga
rw
al
a
et
al
.,
20
04
;8
2
(U
SA
);
fo
llo
w
-u
p:
N
R
Pr
im
ar
y
tu
m
ou
r:
oc
ul
ar
m
el
an
om
a.
H
is
to
lo
gi
ca
lly
pr
ov
en
liv
er
m
et
as
ta
se
s,
ag
e
≥
18
ye
ar
s,
EC
O
G
pe
rf
or
m
an
ce
st
at
us
0–
2,
ad
eq
ua
te
he
pa
tic
,
re
na
l
an
d
ha
em
at
ol
og
ic
al
fu
nc
tio
n.
N
o
pe
rip
he
ra
l
va
sc
ul
ar
di
se
as
e
or
ot
he
r
co
nt
ra
in
di
ca
tio
n
to
fe
m
or
al
ar
te
ry
ca
th
et
er
is
at
io
n
C
is
pl
at
in
(1
00
m
g/
m
2
)
3
59
.7
(r
an
ge
36
–
81
)
9/
10
N
R
N
R
C
he
m
o,
n
=
2;
im
m
un
o,
n
=
3;
ta
m
ox
ife
n,
n
=
1
N
R
C
is
pl
at
in
(1
00
m
g/
m
2
)
pl
us
C
E
4
C
is
pl
at
in
(1
25
m
g/
m
2
)
6
C
is
pl
at
in
(1
25
m
g/
m
2
)
pl
us
C
E
6
Ta
gu
ch
ie
t
al
.,
19
92
;8
1
(J
ap
an
);
fo
llo
w
-u
p:
N
R
Pr
im
ar
y
tu
m
ou
r:
va
rio
us
in
cl
ud
in
g
co
lo
re
ct
al
(n
=
25
),
st
om
ac
h
(n
=
15
),
ga
ll
bl
ad
de
r
(n
=
1)
,
pa
nc
re
as
(n
=
1)
.b
N
on
-
re
se
ct
ab
le
,
w
ith
ou
t
de
m
on
st
ra
bl
e
tu
m
ou
rs
in
ot
he
r
or
ga
ns
;
re
se
ct
ed
pr
im
ar
y;
pa
te
nt
po
rt
al
ve
in
;
pe
rf
or
m
an
ce
st
at
us
0–
3;
he
pa
tic
ar
te
ry
an
at
om
y
su
ita
bl
e
fo
r
ca
th
et
er
is
at
io
n
In
tr
a-
ar
te
ria
lm
ito
m
yc
in
C
w
ith
D
SM
30
N
R
N
R
N
R
N
R
N
R
0c
In
tr
a-
ar
te
ria
lm
ito
m
yc
in
C
w
ith
ou
t
D
SM
30
N
R
N
R
N
R
N
R
N
R
0c
C
E,
ch
em
oe
m
bo
lis
at
io
n
(p
ol
yv
in
yl
sp
on
ge
);
ch
em
o,
ch
em
ot
he
ra
py
;
D
SM
,
de
gr
ad
ab
le
st
ar
ch
m
ic
ro
sp
he
re
s;
EC
O
G
,
Ea
st
er
n
C
oo
pe
ra
tio
n
O
nc
ol
og
y
G
ro
up
;
F,
fe
m
al
e;
im
m
un
o,
im
m
un
ot
he
ra
py
;
LM
,
liv
er
m
et
as
ta
se
s;
M
,
m
al
e;
N
R,
no
t
re
po
rt
ed
.
a
Fo
r
fu
rt
he
r
de
ta
ils
se
e
da
ta
ex
tr
ac
tio
n
fo
rm
s
in
A
p
p
en
d
ix
4
.
b
Pr
im
ar
y
tu
m
ou
r
ty
pe
s
w
er
e
on
ly
en
um
er
at
ed
fo
r
th
e
42
pa
rt
ic
ip
an
ts
ev
al
ua
bl
e
fo
r
ef
ﬁ
ca
cy
.
Th
es
e
da
ta
w
er
e
no
t
pr
ov
id
ed
fo
r
al
l6
0
pa
rt
ic
ip
an
ts
en
ro
lle
d
in
th
e
RC
T.
c
In
cl
ud
ed
pa
rt
ic
ip
an
ts
ha
d
to
be
w
ith
ou
t
de
m
on
st
ra
bl
e
m
al
ig
na
nc
ie
s
in
ot
he
r
or
ga
ns
;
th
er
ef
or
e,
it
is
as
su
m
ed
th
at
no
ne
ha
d
ex
tr
ah
ep
at
ic
di
se
as
e.
CLINICAL EFFECTIVENESS
36NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7tolerated dose of cisplatin and consequently statistical comparisons between cisplatin plus polyvinyl sponge
and cisplatin alone were not made. Taguchi and colleagues81 included 60 participants with non-resectable
liver metastases from a variety of primary tumour sites (colorectal, stomach, gall bladder and pancreas)
recruited from 11 hospital clinics in Japan. The primary tumour was an ocular melanoma in all
19 participants enrolled in the single-centre RCT by Agarwala and colleagues82 that took place in the USA.
The inclusion criteria of this study did not specify that liver metastases had to be non-resectable. Inclusion
criteria also required participants to have a performance status (not deﬁned) as 0–3 in the Taguchi and
colleagues’ study81 and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 in the
Agarwala and colleagues82 study. Neither study reported the length of their follow-up period. For further
details of the intervention see Appendix 4.
Participant characteristics were not reported by Taguchi and colleagues;81 however, it was stated that no
signiﬁcant differences existed between the two groups in terms of age, sex, performance status, site, stage
of tumours, numbers of tumours, maximal tumour size or preceding treatment. It was inferred from the
inclusion criteria that participants in this RCT81 did not have any extrahepatic disease. Agarwala and
colleagues82 reported participant characteristics for the overall group but not separately for each arm. The
mean age was 59.7 years, with almost equal numbers of male and female participants. Six participants
had received previous treatment for liver metastatic disease. Number and size of liver metastases treated
and proportion of participants with extrahepatic disease were not reported. Further details on baseline
characteristics of the included participants can be seen in Appendix 4.
Methodological details of the RCTs were poorly reported; therefore, most of the aspects of quality that
were assessed were judged as unclear (Table 21).
Although both studies were described as RCTs and Taguchi and colleagues81 stated that randomisation
charts had been used, neither study reported the method used to generate the randomisation sequence
and neither study reported whether or not intervention allocation had been concealed. Taguchi and
colleagues81 stated that there were no signiﬁcant differences between the groups for key variables at
baseline but did not present any data on this, and Agarwala and colleagues82 did not present baseline
data separately for each study arm. Consequently, the risk of selection bias in these trials is uncertain.
Neither RCT reported whether or not those assessing patient outcomes were blind to intervention
assignment. For the outcomes reported by these RCTs (response, toxicity/adverse events, and overall
survival) blinding of outcome assessors would have been feasible. However, as it is unknown whether or
not blinding occurred, the risks of detection bias and performance bias are uncertain.
Taguchi and colleagues81 indicated that fewer participants were evaluable for efﬁcacy (42 of the initial
60 participants) and safety outcomes (51 of 60 participants) than had been randomised. The numbers of
dropouts seem similar between the groups; however, reasons for participant drop-out are not provided
except that 10 withdrawals were due to adverse events. This study did not appear to undertake an
intention-to-treat analysis or account for the missing data in any way. These factors indicate an uncertain
risk of attrition bias. Agarwala and colleagues82 lost 2 of the 19 participants to follow-up with no other
dropouts reported. An intention-to-treat analysis was not undertaken and it is not clear how the missing
data were accounted for in the analysis of overall survival, and so the risk of attrition bias is also uncertain
in this study. It was not clear from either study whether other outcomes were assessed but not reported
on in the published paper (uncertain risk of reporting bias). Overall, the risk of bias in the two RCTs was
uncertain because many of the details needed to make a judgement were inadequately reported.Assessment of effectiveness: chemoembolisation
Overall survival
Taguchi and colleagues81 calculated overall survival in all randomised participants when the majority of the
participants in the treatment groups had died (number of deaths not reported). Although participants in37
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7the chemoembolisation arm (intra-arterial mitomycin C with degradable starch microspheres) had a longer
median survival time than those receiving intra-arterial mitomycin C only, the difference between the
groups was not statistically signiﬁcant (9.7 months vs. 7.6 months, no p-value reported) (Table 22).
Agarwala and colleagues82 reported that median overall survival for all treatment groups was 8.5 months
with no data presented for the separate arms of this study. Consideration should be given to the
uncertainties on key methodological attributes that were identiﬁed in the assessment of methodological
quality when interpreting these results.
Response
The two RCTs reported on the response of the tumour to treatment, but used slightly different criteria for
classifying response (see Appendix 7). Taguchi and colleagues81 reported that 42 of the 60 enrolled
participants could be evaluated for tumour response and found that the chemoembolisation group had a
higher response rate (complete response + partial response) than the group receiving intra-arterial
mitomycin C only (54.5% vs. 20%, p< 0.05). Results for response were also provided separately according
to primary tumour type (Table 23). In the RCT by Agarwala and colleagues,82 none of the participants
achieved a complete response, and only 3 of the 17 evaluable participants achieved a partial response. The
statistical comparisons carried out are not described in detail but the study authors state that there was no
statistically signiﬁcant difference in the response rates between the participants who received
chemoembolisation and those who did not, nor was there any difference between the two chemotherapy
dose tiers (p = 0.2769). When interpreting the results of these RCTs,81,82 consideration should be given to
the uncertainties on key methodological attributes that were identiﬁed in the assessment of
methodological quality.
Adverse events and toxicity
Pain, gastrointestinal disturbances and fever were experienced by a greater proportion of the participants
who were treated by Taguchi and colleagues81 with chemoembolisation than by those treated with
intra-arterial mitomycin C alone and the difference between the groups was statistically signiﬁcant for all
symptoms (Table 24). Five participants from each arm were withdrawn from the trial because of the
adverse events experienced. The participants withdrawn from the group receiving intra-arterial mitomycin
C alone were all withdrawn because of adverse results from clinical chemistry analysis. Two participants
were also withdrawn for this reason from the chemoembolisation group, and the other three participants
withdrawn from this group were withdrawn for subjective reasons (not further deﬁned). In addition to theTABLE 22 Overall survival: chemoembolisation
Study details
Estimated overall survivala
Arm Median, months (95% CI)
Agarwala et al., 2004;82
ocular melanoma primary,
n = 19; follow-up: NR
Cisplatin 100mg/m2 (n = 3) 8.5
Cisplatin 100mg/m2 plus PVS (n = 4)
Cisplatin 125mg/m2 (n = 6)
Cisplatin 125mg/m2 plus PVS (n = 6)
p-value NR
Taguchi et al., 1992;81
various primary cancers,
n = 60; follow-up: NR
Intra-arterial mitomycin C with DSM (n = 30) 9.7b
Intra-arterial mitomycin C without DSM (n = 30) 7.6b
p-value Not signiﬁcant
DSM, degradable starch microspheres; NR, not reported; PVS, polyvinyl sponge.
a Overall survival assumed to have been calculated from treatment as not reported in paper.
b Reported as number of days which has been divided by 30.4 to provide the estimated length in months. It has also been
assumed that n = 30 because paper states that survival was calculated on all randomised participants.
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TABLE 23 Tumour response: chemoembolisation
Study details Response (n)
Response
rate (%)
Arm CR PR StD PD NE
Agarwala et al.,
2004;82 ocular
melanoma primary,
n = 19;
follow-up: NR
Cisplatin 100mg/m2
(n = 3)
0 0 3 0 0
Cisplatin 100mg/m2
plus PVS (n = 4)
0 0 2 1 1
Cisplatin 125mg/m2
(n = 6)
0 1 5 0 0
Cisplatin 125mg/m2
plus PVS (n = 6)
0 2 3 0 1
p-valuec
Arm CR PR MR NC PD CR + PR
Taguchi et al.,
1992;81 various
primary cancers,
n = 60;
follow-up: NR
All
metastases
Intra-arterial mitomycin C
with DSM (n = 22)
1 11 0 6 4 54.5
Intra-arterial mitomycin C
without DSM (n = 20)
0 4 1a 7 8 20
p-value < 0.05
Colorectal
metastases
Intra-arterial mitomycin C
with DSM (n = 10)
1 3 5 1 40
Intra-arterial mitomycin C
without DSM (n = 15)
0 3 6a 6 20
p-value
Stomach
metastases
Intra-arterial mitomycin C
with DSM (n = 11)
0 8 0 3 72.7
Intra-arterial mitomycin C
without DSM (n = 4)
0 1 2a 1 25
p-value
Other
metastasesb
Intra-arterial mitomycin C
with DSM (n = 1)
0 0 1 0 0
Intra-arterial mitomycin C
without DSM (n = 1)
0 0 0 1 0
p-value
CR, complete response; DSM, degradable starch microspheres; MR, minimal response; NC, no change; NE, not evaluable
(two participants were lost to follow-up); NR, not reported (deﬁnitions are available in Appendix 7); PD, progressive disease;
PR, partial response; PVS, polyvinyl sponge; StD, stable disease.
a The participant with MR in the total group appears to have been classiﬁed as NC when data are presented by site of
primary tumour.
b Gall bladder (n = 1) and pancreas (n = 1).
c No statistically signiﬁcant difference in the response rates of the cisplatin plus PVS (chemoembolisation) or cisplatin only
(no embolisation) groups or the two dose tiers, p = 0.2769.
Blank cells indicate ‘not reported’.
CLINICAL EFFECTIVENESS
40data reported here, the Taguchi and colleagues study81 reported on hepatocellular carcinoma. These data
did not meet the inclusion criteria for the review. Taguchi and colleagues81 report two deaths that
occurred during their study, but it is not clear whether these deaths were of participants with liver
metastases or hepatocellular carcinoma.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 24 Adverse events: chemoembolisation
Study details Arm
Major adverse events (% participants)
Pain
Gastrointestinal
disturbances Fever
Taguchi et al., 1992;81
various primary cancers,
n = 60; follow-up: NR
Intra-arterial mitomycin C with
DSM (n = unclear)
59.3 48.1 40.7
Intra-arterial mitomycin C without
DSM (n = unclear)
16.7 12.5 8.3
p-value < 0.01 < 0.01 < 0.01
Participants withdrawn from trial due to
adverse reactions
Intra-arterial mitomycin C with
DSM (n = 30)
Subjective, 3; clinical chemistry, 2
Intra-arterial mitomycin C without
DSM (n = 30)
Subjective, 0; clinical chemistry, 5
Agarwala et al., 2004;82
ocular melanoma primary,
n = 19; follow-up: NR
Toxicity (number of participants)
Dose
limiting Grade 3 Grade 4
Cisplatin 100mg/m2 (n = 3) 0 2 0
Cisplatin 100mg/m2 plus PVS (n = 4) 0 1 2
Cisplatin 125mg/m2 (n = 6) 3a 3 3
Cisplatin 125mg/m2 plus PVS (n = 6) 3b 1 4
All doses Toxicity (grade as stated)
Transient alteration in liver
function tests (grades 1
and 2)
13/19
Dose reduction as result of
altered liver function
1/19
Haematological toxicity
Anaemia (grade 1–2) 2/19
Thrombocytopenia (grade 3) 2/19
DSM, Degradable starch microspheres; NR, not reported; PVS, polyvinyl sponge.
a Two of the dose-limiting toxicities were renal, the third was haematological.
b One of the dose-limiting toxicities was hepatic, one was haematological, and there was one death from
progressive tumour.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Toxicity was the primary outcome of the study by Agarwala and colleagues,82 which aimed to establish the
maximum tolerated dose of cisplatin with and without polyvinyl sponge. Dose-limiting toxicity did not
occur at the 100mg/m2 cisplatin dose tier, but half of the participants who received cisplatin (either with
or without polyvinyl sponge) at the 125mg/m2 dose tier experienced dose-limiting toxicity. A greater
number of grade 4 toxicities were also experienced by the participants at the 125mg/m2 dose tier than
participants at the 100mg/m2 dose tier. Across the whole study population the most common toxicity
during treatment was a transient alteration in liver function tests (grade 1 or 2), with only one participant
requiring dose reduction because of this. Haematological toxicity was less common than liver toxicity. Two
participants developed anaemia (grade 1–2) and two developed thrombocytopenia (grade 3). It is assumed
(although not clariﬁed in the paper) that the two occurrences of thrombocytopenia are included in the
earlier reporting of grade 3 toxicities. No statistical comparisons were reported between the groups but41
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CLINICAL EFFECTIVENESS
42this may have been due to the small numbers of participants in each study arm of this Phase I/II RCT.
The study authors concluded that their results indicated that the maximum tolerated dose of cisplatin for
hepatic artery infusion (either with or without polyvinyl sponge) was 125mg/m2. Agarwala and
colleagues82 noted that there were no complications related to the catheterisation procedure.Summary
Two RCTs81,82 compared chemoembolisation versus chemotherapy alone delivered directly via the hepatic
artery but only one compared overall survival. The methodological quality of the RCTs was uncertain
because the methodological details needed to judge different aspects of quality were poorly reported.
One RCT81 reported a statistically signiﬁcant difference in response rate that was in favour of
chemoembolisation treatment with mitomycin C and degradable starch microspheres. However, there
was no statistically signiﬁcant difference in overall survival. Furthermore, a greater proportion of the
chemoembolisation group experienced adverse events (statistically signiﬁcantly more pain, gastrointestinal
disturbances and fever). The chief aim of the other RCT82 was to establish the maximum tolerated dose of
cisplatin with and without polyvinyl sponge. Consequently toxicity was the primary outcome of the study
and the toxicity outcomes indicated that the maximum tolerated dose of cisplatin was 125mg/m2. Overall
survival was not compared between groups and the RCT did not ﬁnd a statistically signiﬁcant difference in
response between participants who received chemoembolisation and those receiving chemotherapy alone.
However, numbers were small in this study and it may not have been statistically powered.Chemoembolisation followed by laser ablation
Quantity and quality of research
Two prospective case series studies describing the combination of chemoembolisation and laser ablation
were included (Table 25).83,84 The narrative synthesis of these data focuses on the key outcomes of survival,
response rates (where reported) and adverse events, as described in Chapter 3 (see Method of data
analysis). Subgroups were reported in these case series studies; however, these do not appear to have
been speciﬁed a priori or be statistically powered and the results are therefore not discussed here (see
Appendix 4 for further details).
Both of these studies were undertaken in the same centre and by the same group. The premise of the
studies was to assess the use of chemoembolisation to ‘downstage’ liver metastases before laser ablation
treatment. The eligibility criteria varied between studies (see Table 25) and there is no evidence that
participants overlap. In the study by Vogl and colleagues84 all participants were women with metastatic
breast cancer who either were non-resectable, had recurrence after partial liver resection, or were
contraindicated or had refused surgical treatment. Participants were required to have ﬁve or fewer lesions
which were no larger than 5 cm in diameter. In the second study (Vogl and colleagues)83 participants had
various primary cancers with unresectable liver metastases that had shown no response to systemic
chemotherapy. Participants were required to have no more than four lesions, two of which could have a
diameter of 50–80mm but otherwise should be smaller than 50 mm. Participants with extrahepatic spread
were excluded. Across the two included studies the mean age of participants ranged from 57 to 62 years,
and in the study with various primary tumours 52% of the participants were men.83 All participants appear
to have received systemic chemotherapy for liver metastases in both studies, although this was not
explicitly reported in the more recent study.84
Case series provide very low-quality evidence69 and the quality of reporting of the two included case series
was poor (Table 26). Both included studies speciﬁed their patient selection criteria in advance, but both
failed to adequately describe blinding of participants to the research question, although the importance of
this is more relevant to subjective outcomes, such as quality of life, than to objective outcomes, such as
mortality. Neither study described completely whether or not they had any withdrawals and dropouts, and
it was also not reported if or how statistical analysis accounted for missing data. Finally, it was unclear
whether or not authors measured more outcomes than they reported, which can result in reporting bias.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 26 Quality assessment: chemoembolisation followed by laser ablation (prospective case series)
Study
Patient criteria
speciﬁed a priori?
Blinding of
participants to
research question?
Selective
outcome
reporting?
Withdrawals
described?
Missing data
accounted for
in analysis?
Vogl et al., 200383 Yes NR Unclear NR NR
Vogl et al., 201184 Yes NR Unclear NR NR
NR, not reported.
CLINICAL EFFECTIVENESS
44Results: chemoembolisation followed by laser ablationOverall survival
In both studies,83,84 survival was calculated from the commencement of the ﬁrst treatment with
chemoembolisation until death or last follow-up examination. In the study which included participants
with various primary cancers,83 the median survival was reported to be 26.2 months (Table 27). In the
study which included participants with metastatic breast cancer,84 the mean survival was reported to be
32.5 months (see Table 27). Survival rates at 1 2, 3 and 5 years were reported in one study only84 and
were 88.8%, 55.9%, 36.6% and 13.7%, respectively.
Response
Vogl and colleagues84 reported on the response of the tumour to treatment as measured by the Response
Evaluation in Solid Tumours (RECIST) criteria (see Appendix 7). The study reported the numbers of
participants fulﬁlling the criteria for each category of response and results showed that 62 (38.5%) of
participants had a complete response, 8 (5%) a partial response, 20 (12.4%) stable disease and 71
(44.1%) progressive disease. Of those with progressive disease, 64 (90%) underwent subsequent
chemoembolisation treatment. Vogl and colleagues84 also reported the mean time to progression as being
8.2 (SD 12.29) months and overall tumour control as 13.1 (SD 15.9) months. The study also reports the
proportion of participants with local recurrence of the lesion (see Appendix 4).Adverse events: chemoembolisation followed by laser ablation
Complications and side effects of treatments were reported in both studies (Table 28). These are reported
per participant, and show that adverse events varied, with many events being mild to moderate. Some
more marked complications were reported, including in one study where six events required further
intervention.84 No deaths occurred in the 2011 study,84 but one death occurred within 30 days in the
earlier Vogl and colleagues 200383 study.
The uncertain quality evidence from these studies should be taken into consideration when interpreting
the results discussed above.Summary of clinical effectiveness: chemoembolisation followed by
laser ablation
Two case series studies which provide data on participants who had chemoembolisation followed by laser
ablation were included.83,84 By their nature these studies provide very low-quality evidence. Eligibility
criteria differed between the two studies, but the general intention of treatment was to reduce tumours
by chemoembolisation so that they were suitable for treatment with laser ablation. Data for only the
combination treatment are presented here as higher-quality evidence on the effectiveness of
chemoembolisation therapy has been included elsewhere in this report. Survival rates were presented but
comparisons are difﬁcult owing to different calculations. Major or severe complication rates were low.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 28 Adverse effects: chemoembolisation followed by laser ablation (prospective case series)
Study details Total number of complications Details of participants (%)
Vogl et al., 2003;83
various tumours,
n = 82; follow-up: NR
‘No’ to ‘few’ symptoms:a
total n, not reported
Abdominal pain: 57.1%
Nausea: 82.2%
Fever:b 89.3%
Vomiting: 86.4%
Lethargy: 38.4%
‘Moderate’ to ‘marked’ symptoms:a
total n, not reported
Abdominal pain: 42.9%
Nausea: 17.8%
Fever:b 10.7%
Vomiting: 13.6%
Lethargy: 61.6%
Vogl et al., 2011;84
breast primary,
n = 161; follow-up:
mean 13.8 (SD 17.1)
months, max. 90 months
Complications requiring further
intervention: six (3.7%)
Four pleural effusions
Two biloma
Side effects of laser ablation:
100 (62.1%)c
57 (35.4%) reactive pleural effusion
(four reported above)
15 (9.3%) biloma (two reported above)
11 (6.8%) subcapsular haematoma
17 (10.6%) small basal lung atelectasis
0 deaths
0 seeding
max., maximum; NR, not reported.
a Also reports minor complications in seven (8.5%) and major complications in one (1.2%) which led to death (most likely
from sepsis) within 30 days of laser treatment.
b Fever indicated with a temperature of > 38.5 °C.
c Total calculated by reviewer.
CLINICAL EFFECTIVENESS
46Radioembolisation
Quantity and quality of evidence available
Three RCTs85–87 comparing radioembolisation with chemotherapy met the inclusion criteria (Table 29). In
two RCTs (Hendlisz and colleagues86 and Van Hazel and colleagues87) radioembolisation plus systemic
chemotherapy was compared with systemic chemotherapy only. In the RCT by Grey and colleagues85
radioembolisation with hepatic artery chemotherapy was compared with hepatic artery chemotherapy
alone. None of the included RCTs were undertaken in the UK, with two studies being carried out in
Australia85,87 and one in Belgium.86 Sample sizes were small; the largest sample was 70 participants in the
Grey and colleagues study of radioembolisation versus hepatic artery chemotherapy.85 Participant follow-up
was not reported in one study.87 In the other two RCTs follow-up was a minimum of 3.5 years from
randomisation in one85 and a median of 25 months in the other study.86 In this latter study seven
participants were alive at the time of analysis with a median follow-up of 10 months.86 In all three RCTs
the primary cancer site was colorectal (speciﬁed as colon only in one).85 The intention for treatment with
radioembolisation (i.e. curative, palliative, pre-surgical) was not explicitly stated in any of these studies;
however, eligible participants were required to have liver metastases that were unsuitable for surgical
resection in all three trials. Other key criteria for trial inclusion were a World Health Organization (WHO)
performance status of 0–2 in one RCT,85 and < 3 in one other RCT87 and an ECOG performance status of
0–2 in the remaining RCT.86NIHR Journals Library www.journalslibrary.nihr.ac.uk
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CLINICAL EFFECTIVENESS
48The majority of participants in each of the three RCTs were male, although in one arm of the Hendlisz and
colleagues RCT86 the ratio of male to female was approximately 50:50. Participant ages appear to be
similar across the three included RCTs, with mean or median ages being around 59–65 years. The
reporting of the number and size of liver metastases differed between the three studies. In the Grey and
colleagues85 RCT the number of liver metastases per participant were not reported. The study reports the
number of tumours sized as < 25%, 25–50% or > 50%, which relates to the proportion of liver
involvement. In this study the majority of participants were classiﬁed as having < 25% involvement.
In the Hendlisz and colleagues RCT,86 the number of metastases were presented per participant. In the
radioembolisation arm 10 participants had 2–4 metastases and eight participants had ﬁve or more
metastases. In the chemotherapy-alone arm, there were 10 participants with 2–4 metastases and 10 with
ﬁve or more metastases. In each arm, only one or two participants had a single metastasis or the number
of metastases could not be measured. The median sum of diameters of the metastases was reported to be
176.5 mm in the radioembolisation arm compared with 216mm in the chemotherapy-alone arm.86 The
third RCT, by Van Hazel and colleagues,87 reports that all participants had multiple liver metastases, but no
further details were provided. The size of metastases was reported as either < 25% or > 25% of liver
involvement, with the majority of cases meeting the < 25% category.
All participants had received previous chemotherapy treatment for their liver metastases in the Hendlisz
and colleagues RCT.86 In the RCT by Van Hazel and colleagues,87 this was not explicitly reported as a
baseline characteristic. It has been assumed that no participants received any treatment for their liver
metastases prior to randomisation because the participants would be excluded by the eligibility criteria if
they had received prior chemotherapy or radiotherapy. Finally, in the Grey and colleagues RCT85 14% of
participants receiving radioembolisation and 15% of participants receiving hepatic artery chemotherapy
were reported to have received prior treatment for their liver metastases before study entry.
Extrahepatic disease was apparent in 18% of the participants randomised to the radioembolisation arm,
and in 30% of participants randomised to the chemotherapy-only arm of the Van Hazel and colleagues
RCT.87 Participants were ineligible for study entry if they had evidence of extrahepatic metastatic disease in
the remaining two studies.85,86
Further details on baseline characteristics of the included participants can be seen in Appendix 4.
The three RCTs varied on a number of aspects of methodological quality and likelihood of bias (Table 30).
Only one RCT87 reported the information needed to assess the adequacy of the randomisation and
allocation processes. In this study87 there appeared to be a low risk of selection bias, the methods used to
generate random allocations were assessed as adequate, and the allocation was adequately concealed. In
the other two RCTs there is an uncertain risk of selection bias. Grey and colleagues85 state that participants
were randomised using a blinded envelope batch method, but no further details were provided. In the
Hendlisz and colleagues study86 randomisation was reported to use a minimisation technique, but no
further details were provided. These studies have therefore been classiﬁed as ‘unclear’ or ‘not reported’ on
questions relating to randomisation and allocation, which may suggest a possible risk of selection bias.
Study groups were reported to be well balanced on clinical criteria in all three studies. From the baseline
characteristics shown in Table 29, it would appear that there were some differences between groups in
terms of the gender ratio in the Hendlisz and colleagues study,86 and there was an apparent difference in
the proportion of participants with extrahepatic disease between arms in the study by Van Hazel and
colleagues.87 These largely similar groups may, however, indicate that the groups were well matched and
provide some indication that the randomisation schedules were reasonable (although assessed as unclear
based on the studies reporting).
Blinding of outcome assessors was assessed as being adequate in the Grey and colleagues85 study, only
partially adequate in the van Hazel and colleagues87 study (for some outcomes but not others), and not
undertaken in the Hendlisz and colleagues study.86 Therefore, there is some risk of detection bias in two of
the included RCTs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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CLINICAL EFFECTIVENESS
50All three RCTs were deemed to be at uncertain risk of reporting bias, as it was not clear whether or not
outcomes had been omitted from the study results. There were no unexpected imbalances in dropouts
between groups in any of the three included studies, which suggests low risk of attrition bias. Attrition
bias may, however, be a risk in the Hendlisz and colleagues study86 as there was no discussion of any
analysis by intention to treat, and missing data were not accounted for in the analyses. The study by van
Hazel and colleagues87 was assessed to be of low risk of bias on these factors, but it was not clear
whether or not missing data were accounted for in the study by Grey and colleagues.85
The methodological issues mentioned above for these three studies should be taken into account when
considering their results, presented subsequently.Treatment protocols
The treatment doses of yttrium-90 received by the participants in the radioembolisation arms of the three
included RCTs were presented in all three included studies, as were the doses of chemotherapy used in
both the radioembolisation arms and the chemotherapy arms. In addition, two studies reported data on
the number of cycles of chemotherapy received. These data can be seen in Table 31. For dose of
yttrium-90 received these were presented as mean doses in two studies,85,87 and median doses in the
remaining study.86 It would appear from the data that the doses used were similar across the three studies.
The chemotherapy agents used in the comparator arms of these three studies differed (see Table 31). With
regard to the dose of chemotherapy received, one study reported the mean dose,85 one reported the
median dose86 and the remaining study reported the dose intensity delivered. It is therefore difﬁcult to
compare doses between studies. However, the doses received did not appear to be different between the
treatment arms of each individual study. The total number of cycles delivered in the Van Hazel and
colleagues RCT87 did, however, appear to be different between the radioembolisation group and the
chemotherapy-only group.
Hendlisz and colleagues86 report details of additional therapies received by participants in both treatment
groups. Nine participants (of 21) in the radioembolisation arm received further therapy, seven received
chemotherapeutic agents (either alone or in combination with immunotherapy), one received radiotherapy
and in one further therapy was unspeciﬁed. In the chemotherapy-only arm, 16 of 23 participants received
further therapies; 10 crossed over to receive radioembolisation, and 6 received chemotherapeutic agents
(either alone or in combination with immunotherapy).Assessment of effectiveness: radioembolisation
Overall survival
Estimated median overall survival was reported in all three included RCTs,85–87 with the RCT by Grey and
colleagues85 also reporting estimated percentage survival at 1, 2, 3 and 5 years. In the two studies
comparing radioembolisation with systemic chemotherapy, participants in the radioembolisation arm had a
longer median survival than those receiving chemotherapy alone (Table 32). This difference was statistically
signiﬁcant in only one of these studies [hazard ratio (HR) 0.33; 95% CI 0.12 to 0.91; p = 0.025].87 In this
study87 overall survival was calculated in all randomised participants when the majority of the participants
in the treatment groups had died (with one participant in the radioembolisation group alive). This study
was rated on a number of methodological attributes to have a low risk of bias, although the sample
size was small and this should be considered when interpreting the results. In the Hendlisz and
colleagues study,86 which showed a non-statistically signiﬁcant trend for longer median survival in the
radioembolisation arm compared with the chemotherapy arm, the overall survival was calculated from time
of randomisation until death from any cause. Seven participants remained alive at the time of the analysis;
these participants had a median follow-up of 10 months, and this may in part account for the shorter
duration of estimated survival seen in this study compared with the other two RCTs.
In the RCT85 comparing radioembolisation with hepatic artery chemotherapy, survival rates were calculated
from the time of randomisation to death or last follow-up. In this study the majority of participants hadNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 31 Treatment doses received: radioembolisation
Study details
Treatment dosesa
Arm
Dose of
yttrium-90
received (GBq)
Number
cycles
chemotherapy
Dose,
chemotherapy
per patient (mg)
Grey et al., 2001;85
adenocarcinoma of
the colon primary,
n = 70; follow-up:
minimum of 3.5 years
from randomisation
Radioembolism + HAC,
n = 36
Meanb (SD): 2.156
(0.324)
Mean: 8.7
(SD 5.6)
per patient
Mean: 1863
(SD 1735)
HAC, n = 34 Not applicable Mean: 8.0
(SD 5.0)
per patient
Mean: 1822
(SD 1323)
Hendlisz et al., 2010;86
colorectal primary,
n = 46; follow-up:
median 24.8 months
(range 2–41). Seven
participants still alive
with a median
follow-up of 10 months
Radioembolisation +
systemic chemotherapy,
n = 21
Median (range):
1.79 (1.32–2.15);
3 (14%)
missing values
NR Median (range):
14,588 (4740–97,612);
1 missing value
Systemic chemotherapy
only, n = 23
Not applicable NR Median (range):
17,700 (3240–119,700);
3 (13%) missing values
Van Hazel et al.,
2004;87 colorectal
primary, n = 21;
follow-up: NR
Radioembolisation +
systemic chemotherapy,
n = 11
Mean: 2.25 Total number
of cycles:c 89d
Dose intensity: 85.4%
Systemic chemotherapy
only, n = 10
Not applicable Total number
of cycles:c 38
Dose intensity: 92%
HAC, hepatic artery chemotherapy; NR, not reported.
a Chemotherapeutic agents, cycle length and interval between cycles varied between the studies and full details are
available in Appendix 4.
b States that ﬁve participants received less and one participant more than the designated protocol amount of yttrium-90
activity, but all received within 90% of the 2–3 GBq required by the protocol.
c Assumed to be the sum of all cycles received by all participants in the trial.
d Apart from the two early deaths in the chemotherapy-only arm (received no chemotherapy), the reason number of
chemotherapy cycles was greater in the SIRT + chemotherapy group was because most participants had a prolonged
response and therefore continued to receive ongoing treatment. The slightly higher dose intensity in the chemotherapy
only group indicates that the lower response rate for participants in the control arm was not due to less intensive
chemotherapy. The last six participants whose yttrium-90 dose was individualised to BSA received from 1.5 to 2.1 GBq;
the initial ﬁve received a standard amount of 2.5-GBq yttrium-90 activity.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Tdied at the time of follow up (minimum of 3.5 years, at which time 65 of 70 participants had died).
Median survival was reported as being 17 months in the radioembolisation group compared with 15.9
months in the hepatic artery chemotherapy group (HR 1.41, 95% CI 0.86 to 2.34, p = 0.18). Survival to 1,
2, 3 and 5 years was achieved by a higher percentage of those in the radioembolisation group than of
those receiving hepatic artery chemotherapy alone (see Table 32). These differences were not statistically
different between the two groups (p-value not reported). The trial authors state that the HRs suggest that
those receiving hepatic artery chemotherapy alone had a 40% higher death rate than those receiving
radioembolisation. In addition, the study authors stated that Cox regression suggests those treated with
radioembolisation who survive more than 15 months experience a survival advantage compared with those
treated with hepatic artery chemotherapy alone (p = 0.06). However, these results should be treated
cautiously as it appears that this analysis was not deﬁned a priori.
The results of these studies are not directly comparable, and each has some methodological
shortcomings; however, results suggest that there may be a trend for a survival advantage following
treatment with radioembolisation.51
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The three included RCTs reported on the response of the tumour to treatment, but used slightly different
criteria for classifying responses seen (for further details, see Appendix 7). In addition, Grey and
colleagues85 measured response by two different means, by tumour area and by tumour volume, and
reported data for both of these measures, and Van Hazel and colleagues87 reported response data from
the ‘ﬁrst integrated response’ and the ‘best conﬁrmed response’. Grey and colleagues85 found that those
in the radioembolisation group had a higher response rate (complete response and partial response) than
the group receiving hepatic artery chemotherapy alone [44% vs. 18% (p = 0.01) when measured by
tumour area, and 50% vs. 24% (p = 0.03) when measured by tumour volume]. Hendlisz and colleagues86
reported disease control rates as partial response and stable disease (no complete responses occurred).
They found that the disease control rate in those in the radioembolisation group was higher than in those
in the chemotherapy alone group [86% vs. 35%, p = 0.001 (95% CI for the difference between
groups: 0.19 to 0.71)]. Both of these RCTs85,86 were rated as having a number of uncertainties on key
methodological attributes which should be considered in the interpretation of these results. Van Hazel and
colleagues87 did not report an overall estimate of tumour response rates in their study.87
As can be seen in Table 33, the studies reported the numbers of participants fulﬁlling the criteria for each
category of response. These were generally seen to be better in the radioembolisation arms compared with
the comparator arms, although statistical signiﬁcance testing was not undertaken in all cases. In the Grey and
colleagues RCT85 when response was measured by tumour area, two participants in the radioembolisation
arm achieved a complete response and 14 a partial response. In the hepatic artery chemotherapy arm there
were no complete responses and six partial responses. In terms of progressive disease, rates were lower in the
radioembolisation arm compared with the hepatic artery chemotherapy arm. Rates of participants with no
change in their tumour status were, however, the same across both arms. Overall the groups were reported
to be statistically signiﬁcantly different on all measures of response (p = 0.01). Similar patterns of response
were seen when measuring this outcome by tumour volume (see Table 33). The authors of this study also
reported that one participant in each arm had disease reduced to such an extent that they were subsequently
deemed surgically resectable and underwent surgical excision of metastases.
In the two studies comparing radioembolisation with systemic chemotherapy, similar patterns of response
occurred, although no complete responses were observed in either study. In the RCT by Hendlisz and
colleagues86 two participants achieved a partial response in the radioembolisation arm compared with no
participants in the chemotherapy-alone arm, but this difference was not statistically signiﬁcant (95% CI for the
difference between groups –0.10 to 0.32, p = 0.22). The number of participants with stable disease was higher
in the radioembolisation arm than in the chemotherapy arm, and the number of participants with progressive
disease was lower in the radioembolisation arm than in the chemotherapy arm.86 In the RCT by Van Hazel and
colleagues87 there were eight participants whose best conﬁrmed response was a partial response in the
radioembolisation group compared with no participants in the chemotherapy-alone group. Best conﬁrmed
responses of stable disease and progressive disease were fewer in the participants treated with radioembolisation
compared with those treated with chemotherapy (3 vs. 6 stable disease, and 0 vs. 4 progressive disease). Across
all categories of response the groups were reported to be statistically signiﬁcantly different (p = 0.001).
The results on response measures from the three studies are not directly comparable; however, they
suggest that radioembolisation treatment leads to better tumour response than systemic chemotherapy or
hepatic artery chemotherapy treatment alone.Time to progression
All three included RCTs reported outcomes related to time to disease progression. Grey and colleagues85
and Hendlisz and colleagues86 reported the median time to progression in the liver. Hendlisz and
colleagues86 additionally report the median time to progression (any), which is also reported as median
time to progressive disease in the Van Hazel and colleagues’ study.87 The study by Grey and colleagues8553
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TABLE 34 Time to disease progression: radioembolisation
Study details Arm
Median time to
progression in the
liver (months)a
Grey et al., 2001;85
adenocarcinoma of
the colon primary,
n = 70; follow up:
minimum of 3.5 years
from randomisation
By tumour area Radioembolism + HAC, n = 36 15.9
HAC, n = 34 9.7
p-value 0.001
By tumour volume Radioembolism + HAC, n = 36
12.0
HAC, n = 34 7.6
p-value 0.04
Arm
Median time to
liver progression
(months)
Hendlisz et al., 2010;86
colorectal primary,
n = 46; follow up:
median 24.8 months
(range 2–41). Seven
participants still alive
with a median follow-up
of 10 months
All progressions
considered as events
Radioembolisation + chemotherapy,
n = 18b
5.5
Chemotherapy only, n = 23 2.1
p-value HR 0.38; 95% CI 0.20
to 0.72; p = 0.003
Participants with
treatment change
censored at the time
of change
Radioembolisation + chemotherapy,
n = 18b
5.6 (15 events)
Chemotherapy only, n = 23 2.1 (22 events)
p-value HR 0.35; 95% CI 0.18
to 0.69; p = 0.002
Arm
Median time to
progression (months)
Radioembolisation + chemotherapy,
n = 21
4.5
Chemotherapy only, n = 23 2.1c
p-value HR 0.51; 95% CI 0.28
to 0.94; p = 0.03
Arm
Median time to
progressive disease
(months)
Van Hazel et al., 2004;87
colorectal primary,
n = 21; follow up: NR
Radioembolisation + systemic
chemotherapy, n = 11
18.6
Systemic chemotherapy only, n = 10 3.6
p-value < 0.0005
HAC, hepatic artery chemotherapy; NR, not reported.
a Time to progression presented in graphical form, data are available only in the abstract.
b Three participants in the radioembolisation arm were without documented progression and were censored at 4.3, 6.6,
and 26 months.
c All participants in the chemotherapy-only arm experienced disease progression ﬁrst in the liver. For these participants,
time to liver progression equals time to progression.
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56measured progression by two different means, by tumour area and by tumour volume, and reported data
for both of these measures, and Hendlisz and colleagues86 reported progression from ‘all progressions
considered as events’ and ‘patients with treatment change censored at the time of change’. The results,
seen in Table 34, are therefore not comparable, and for these studies results should also be interpreted in
the context of some uncertainties around the potential for bias and/or small sample sizes.
Median time to progression in the liver was reported to be statistically signiﬁcantly different between
radioembolisation and hepatic artery chemotherapy in the Grey and colleagues85 trial when measured by
either tumour area (15.9 months vs. 9.7 months, respectively, p = 0.001) or tumour volume (12 months vs.
7.6 months, respectively, p = 0.04). Radioembolisation also led to a longer time to progression in the liver
than chemotherapy alone in the Hendlisz and colleagues86 trial (all progressions considered an event:
5.5 months vs. 2.1 months for the two groups, respectively, p = 0.003). HRs can be seen in Table 34.
Hendlisz and colleagues86 report that local progression was documented in four participants (three
radioembolisation; one chemotherapy arm) after an unjustiﬁed change in the treatment allocated by
randomisation (no further details). Censoring these four participants does not change the median time to
liver progression (5.6 months vs. 2.1 months, respectively, p = 0.002).
Median time to progression at any site was also shown to be longer in the radioembolisation group
compared with the chemotherapy alone group in the Hendlisz and colleagues86 RCT (4.5 months vs.
2.1 months, respectively, p = 0.03). A similar pattern was seen in the study by Van Hazel and colleagues87
(radioembolisation 18.6 months vs. chemotherapy 3.6 months, p< 0.0005). This study also presents the
site of the ﬁrst disease progression. The most common site was the liver (eight participants in each
treatment arm). Other sites that showed progression in the radioembolisation group were the liver and
lung combined (n = 1), and the lung (n = 1) (one participant in this arm had died without progression).
In the chemotherapy-only group, the site of ﬁrst progression in the other two participants was the liver
and peritoneum combined in one, and bone in one other.
In these three studies radioembolisation led to more favourable results in terms of time before progressive
disease than chemotherapy alone.Quality of life
Two included RCTs assessed quality of life as an outcome.85,87 No numerical outcome data were reported
in either of these two studies. Grey and colleagues85 used a 13-point linear analogue self-assessment scale,
which was reported as validated. However, no further details of the measure or the validation were
provided. The study reports that there were no signiﬁcant differences between the treatment groups.
Sexual interest/ability deteriorated for both treatment groups over the 18-month period during which the
protocol treatments were delivered. For all other measures, there were trends towards improvement in
quality-of-life scores over the ﬁrst 18 months for both treatment groups.
Van Hazel and colleagues87 used the 23-point validated Functional Living Index – Cancer questionnaire.89
The authors state that, at 3 months, changes from baseline patient-rated quality of life were very similar
between both arms (p = 0.96). This was also the case for quality of life rated by the physician using the
Spitzer index (p = 0.98).90 The authors suggest that the lack of variation from baseline may have been
because most participants were still receiving chemotherapy during this time. In a more recently published
conference abstract,88 Van Hazel and colleagues state that at 3 months the radioembolisation group
showed a statistically signiﬁcant improvement in health-related quality of life compared with the
chemotherapy-only group (p = 0.03, 95% CI 1.4 to 27.6), but no statistically signiﬁcant differences
thereafter. This appears to be different from the result presented in the full publication; however, there is
limited detail reported in either publication and each may, in fact, be presenting different things. As in the
earlier publication, no outcome data were reported in the abstract.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 35 Adverse events (grade 3 or 4): radioembolisation
Study details Arm
Total number
complications Details
Grey et al., 2001;85
adenocarcinoma of
the colon primary,
n = 70; follow-up:
minimum of 3.5 years
from randomisation
Radioembolism + HAC,
n not reported
23a Bilirubin, n = 1 (grade 3)
Aspartate transaminase, n = 5 (grade 3);
n = 2 (grade 4)
Alkaline phosphatase, n = 14 (grade 3)
Nausea/vomiting, n = 1 (grade 3)
HAC, n not reported 23 Haemoglobin, n = 1 (grade 3)
Aspartate transaminase,
n = 12 (grade 3); n = 2 (grade 4)
Alkaline phosphatase, n = 5 (grade 3)
Nausea/vomiting, n = 2 (grade 3)
Diarrhoea, n = 1 (grade 3)
Hendlisz et al., 2010;86
colorectal primary,
n = 46; follow-up:
median 24.8 months
(range 2–41).
Seven participants
still alive with
median follow-up
10 months
Radioembolisation + systemic
chemotherapy, n = 21
1 Hand–foot syndrome, n = 1 (grade 3)
Systemic chemotherapy only,
n = 23
10 Stomatitis, n = 1 (grade 3)
Anorexia, n = 1 (grade 3)
Fatigue, n = 5 (grade 3)
Dyspnoea, n = 1 (grade 3)
Pulmonary, n = 1 (grade 3)
Allergy, n = 1 (grade 3)
Text states n = 6 participants with
grade 3 or 4 toxicity
p-value p = 0.10 (between number of
participants with grade 3/4 toxicity)
Van Hazel et al., 2004;87
colorectal primary,
n = 21; follow-up: NR
Radioembolisation + systemic
chemotherapy, n = 11
13 Granulocytopenia, n = 3
Nausea, vomiting, n = 1
Mucositis, n = 4
Gastritis, n = 1
Diarrhoea, n = 2
Cirrhosis, n = 1
Liver abscess, n = 1
Systemic chemotherapy only,
n = 10
5 Nausea, vomiting, n = 1
Mucositis, n = 1
Gastritis, n = 1
Diarrhoea, n = 1
Anorexia, n = 1
HAC, hepatic artery chemotherapy; NR, not reported.
a Text also reports a case of pancreatitis; however, it is not presented in the table.
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58Adverse events and toxicity
The total number of complications and toxicities graded 3 or 4 from the included studies can be seen in
Table 35. Two RCTs85,87 used the Union International Control Criteria (UICC) to deﬁne adverse events and
toxicity, and Hendlisz and colleagues86 used the Common Terminology Criteria for Adverse Events (CTCAE,
version 3). In the RCT comparing radioembolisation and hepatic artery chemotherapy with hepatic artery
chemotherapy, the total number of complications was the same in each of the two treatment groups.85 In
the two RCTs comparing radioembolisation with systemic chemotherapy, one found a greater number of
complications in the chemotherapy arm than in the radioembolisation arm,86 and the other found a greater
number of complications in the radioembolisation arm than in the chemotherapy arm.87 In terms of the
number of grade 3 or 4 complications, there appears to be no consistent ﬁnding across these three studies.
The types of complications and toxicities recorded in the three studies can also be seen in Table 35. These
are all those graded 3 or 4. One study86 also reported grade 1 and 2 complications and toxicities, which
can be seen in Appendix 4. Overall, the results suggest that radioembolisation is well tolerated, with the
occurrence of toxicities and adverse events not appearing to be particularly different from those with
hepatic artery chemotherapy or systemic chemotherapy. However, the methodological quality and sample
sizes of these included studies would indicate a need for caution in the interpretation of these results.Summary
Three RCTs85–87 compared radioembolisation with chemotherapy delivered either via the hepatic artery or
intravenously. The methodological quality of the RCTs was mixed, in many cases because the methodological
details needed to judge different aspects of quality were poorly reported. Two of the RCTs85,87 have an
uncertain risk of selection bias which should be considered in the interpretation of these results. The two
RCTs86,87 that compared radioembolisation with systemic chemotherapy compared overall survival between
the groups. Radioembolisation led to longer median survival in both of these studies; however, the
difference between groups was statistically signiﬁcant in only one study.87 The third RCT85 which compared
radioembolisation with hepatic artery chemotherapy reported median overall survival and estimates of
survival at 1, 2, 3 and 5 years but the difference between the groups was not statistically signiﬁcant.
All three RCTs reported tumour response to treatment but used slightly different criteria for classifying
response. Only two RCTs85,86 calculated an estimate of overall response and showed that those in the
radioembolisation group had statistically signiﬁcantly better response rates than their respective
comparator groups. The third RCT87 did not report an overall estimate of tumour response rate. Time to
progressive disease was reported in different ways in the three included RCTs, which all showed
favourable results in the radioembolisation groups when compared with their chemotherapy groups.
Quality of life was an outcome in two of the included studies; however, no data were presented. Adverse
events and toxicity occurred in all trial arms. In one RCT the adverse events were more numerous in the
radioembolisation arm,87 but this pattern was not seen in the other two RCTs.85,86Research in progressAs stated in Totality of research available, 14 publications were identiﬁed in searches but were excluded as
they were published as abstracts only. These 14 publications (eight studies) can be seen in Appendix 5.
Four of these were reported to be comparative studies (three RCTs, one non-randomised comparison) and
the abstracts were published between 2009 and 2010. As such these may be in the process of being
prepared for full publication at the time of writing. A summary of these four studies and the results from
their primary outcome is provided here for information.
Two studies assessed the use of radiofrequency ablation; one RCT compared radiofrequency ablation with
chemotherapy,91–94 and one non-randomised study compared radiofrequency ablation with surgical
resection.95 In a series of abstracts, Ruers and colleagues91–94 report on a RCT which compared overallNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7survival and safety outcomes in participants with up to nine unresectable colorectal liver metastases.
Participants were randomised to either systemic chemotherapy and radiofrequency ablation (n = 60) or
systemic chemotherapy alone (n = 59). Baseline characteristics were reported to be similar in the two arms.
The 30-month overall survival estimates were 61.7% (95% CI 48.21 to 73.93) in the radiofrequency and
chemotherapy arm and 57.6% (95% CI 44.0 to 70.39) in the chemotherapy arm. The study authors report
that the study design, however, did not allow for comparisons between treatment arms. Some participants
in the intervention arm did not receive the chemotherapy and some received surgical resection of their
metastases in addition to radiotherapy. Hirata and colleagues95 compared survival and complication rates
in participants with colorectal liver metastases having either radiofrequency ablation (n = 14) or surgical
resection (n = 35). Minimal baseline characteristics were provided; however, participants were
predominantly male and mean age was approximately 63 years. Study authors report no statistically
signiﬁcant differences in 5-year survival based on Kaplan–Meier estimates (34.2% in the radiofrequency
group vs. 30% in the surgical resection group).
One RCT assessed the use of radioembolisation compared with chemotherapy in participants with
colorectal liver metastases.96 The primary outcome for the study was time to liver progression; other
outcomes included overall survival and adverse events. Minimal baseline characteristics were reported in
the abstract but the authors state that they were well balanced in the two groups. Crossovers were
permitted after disease progression. Median time to liver progression was reported to be 24 weeks in the
radioembolisation arm (n = 21) and 9 weeks in the chemotherapy arm (n = 23) (HR 0.38; 95% CI 0.20 to
0.72, p = 0.003). An additional RCT compared chemoembolisation with systemic chemotherapy in those
with colorectal cancer liver metastases.97,98 Seventy-four participants were randomised and assessed for
median survival, progression-free survival, quality of life, response and safety. Median survival, assessed
with a median follow-up of 24 months, was 38% in the chemoembolisation group (n = 36) and 18% in
the chemotherapy group (n = 39).
In addition to these studies, our literature searches identiﬁed ﬁve ongoing trials of potential relevance to
this review. The FOXFIRE study is a UK-based open-label RCT of chemotherapy alone compared with
chemotherapy and radioembolisation. Adults with colorectal liver metastases are eligible for this ongoing
study, which has a primary outcome of overall survival. The study aims to recruit 490 participants and is
sponsored by the University of Oxford, UK, and funded by Cancer Research UK. A similar RCT is also being
undertaken currently in the Middle East and the USA (SIRFLOX).
Another open-label RCT evaluating the efﬁcacy of chemoembolisation in combination with chemotherapy
is currently ongoing in Germany (the DEBIRITUX study). This study is recruiting adults with unresectable
colorectal liver metastases. The primary outcome for the study is progression-free survival 6 months
following ﬁrst administration of study treatment. The study is sponsored by Martin Luther Universität,
Halle-Wittenberg, Germany, and Biocompatibles UK Ltd.
The DEBIRI study is an open-label RCT aiming to assess chemoembolisation for the treatment of
unresectable colorectal liver metastases. Participants with at least one measurable liver metastasis
(size > 1cm) will be randomised to receive either a combination of chemoembolisation plus chemotherapy
or chemotherapy alone. The study is sponsored by the University of Louisville, KY, and Biocompatibles UK
Ltd. The study details were last veriﬁed on ClinicalTrials.gov in November 2011, when the study status was
recorded as currently recruiting participants.
A RCT comparing transhepatic arterial chemotherapy with transcatheter arterial chemoembolisation plus
Folfox4 is currently ongoing in China. Participants with unresectable colorectal liver metastases are eligible
for this study, which has a primary outcome measure of overall survival. Follow-up is reported to be until
5 years post treatment. The study sponsor is the Fudan University, Shanghai, China. The recruitment status
of this study is unknown as the information on ClinicalTrials.gov was last updated in March 2009.59
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60Existing systematic reviewsForty-six review articles were identiﬁed on literature searches; 13 (in 15 publications) were assessed as
being systematic reviews. These 13 systematic reviews differed in terms of the interventions, participants,
and study designs eligible for inclusion. Many have included retrospective study designs and studies with
small sample sizes rather than exclude studies on the basis of quality. The comprehensiveness of the
literatures searches and the dates of searches also varied, with the most recently published systematic
review searching until January 2010. All 13 systematic reviews have been used as a source of potential
references and are brieﬂy described here. No systematic review of these reviews was undertaken.
One recently published systematic review (Pathak and colleagues)99,100 included all ablative therapies used
for those with colorectal liver metastases. All study designs were eligible for inclusion, including
retrospective studies, if they had a follow-up of at least 1 year and a sample size of at least 10 participants.
Searches were undertaken until January 2010 and the reviewers identiﬁed 75 studies; 26 cryoablation
studies, 13 microwave ablation studies and 36 radiofrequency ablation studies. The majority (50) of these
studies were retrospective in design; other studies had combination treatments or had samples of fewer
than 100 participants. Four of the included studies are included in the present review. Results were
discussed narratively, providing the ranges of estimates of the outcomes across the studies within each
ablative type. There was no discussion of the study validity or appropriateness of including all studies
together. No comparative data are presented except for one study of microwave ablation (included in the
present review); however, the review concludes that ablation offers a survival advantage compared with
chemotherapy alone, with acceptable complication rates. It is unclear where the data for this conclusion
come from as they do not appear in the publication.
Four systematic reviews (six publications) of radiofrequency ablation of liver metastases have been
identiﬁed on searches.38,39,101–104
The Australian Safety and Efﬁcacy Register of New Interventional Procedures group have published three
systematic reviews, each with slightly different inclusion criteria.101,102,104 Participants could include those
with colorectal liver metastases or hepatocellular carcinoma, and studies eligible were RCTs, quasi-RCTs,
and non-randomised comparative studies. In addition, case series studies (prospective or retrospective)
were eligible if they included consecutive participants and had a follow-up of at least 12 months. The
dates of searches varied but in the most recent publication the date given was April 2006. Twenty-six
studies were included, of which 13 were of participants with colorectal liver metastases. The review
conclusion was that there was not enough evidence to determine safety or efﬁcacy of radiofrequency
ablation in colorectal liver metastases.
Wong and colleagues38 also systematically reviewed the evidence for the use of radiofrequency ablation in
participants with colorectal liver metastases. Again, prospective and retrospective studies were eligible, and
these had to have a sample of 10 or more participants and a minimum length of follow-up of greater than
6 months. Searches were completed in April 2007. The review included 43 studies of various treatment
modalities (laparotomy, laparoscopy and open). Most of the studies were retrospective or small series
studies. The authors point out issues of many of the included studies, such as mixed populations, the risk
of selection bias, and inconsistency of reporting of outcomes. They concluded that survival and tumour
response to radiofrequency ablation varies widely between the included studies and that more research
is needed.
The third systematic review of radiofrequency ablation (Stang and colleagues)103 included studies of
radiofrequency ablation alone or combined with surgical resection or compared with surgical resection or
chemotherapy. Any study design was eligible for inclusion if there were at least 40 participants and a
median follow-up of 18 months or longer. In addition, the studies had to provide estimates of at least
3-year overall survival in those with colorectal liver metastases. Searches were of MEDLINE only up until
August 2008. Twenty-one studies were included: nine of radiofrequency ablation as a single therapy,NIHR Journals Library www.journalslibrary.nihr.ac.uk
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retrospective. Conclusions were that radiofrequency ablation offers a complementary option for the
treatment of limited colorectal liver metastases, but there were no data to support radiofrequency ablation
as an alternative in surgical candidates with resectable colorectal liver metastases. No validity assessment or
discussion of the limitations in study designs was provided.
Razaﬁndra and colleagues39 did not explicitly state their inclusion criteria but included those with
intraoperative radiofrequency ablation and excluded those with percutaneous radiofrequency ablation, and
those with only hepatocellular carcinoma. The review searched until December 2008 and reported only
complication rates. Thirty studies were included: most were small samples, most combined intraoperative
radiofrequency ablation with surgical resection, 13 included participants with hepatocellular carcinoma,
and all but one were retrospective studies. No validity assessment was undertaken. Conclusions were that
intraoperative radiofrequency ablation, which has different indications from percutaneous radiofrequency
ablation, has no speciﬁc complications associated with it, but that combining it with surgical resection may
lead to higher morbidity.
Two systematic reviews were identiﬁed which assessed radioembolisation.51,105 The Australian Medical
Services Advisory Committee105 reviewed the evidence from any study type in those with non-resectable
colorectal liver metastases. Sample sizes were required to be at least 10 participants. Searches were
undertaken until February 2001 and 11 studies were included. Two were RCTs and nine were case series
studies. Four studies met the inclusion criteria of the present review (two were below the threshold for the
hierarchy of evidence for radioembolisation), the others were either small sample, in primary liver cancers
or in mixed populations. The review concludes that radioembolisation may be more effective than
chemotherapy and that the treatment is reasonably safe. The second systematic review (Vente and
colleagues)51 included participants having radioembolisation for primary or secondary liver malignancies.
All study types were potentially eligible. The dates of the last search for literature were not reported.
The review included 30 articles, 19 on colorectal liver metastases. Of these, two were included in our
review; the others either were lower in the hierarchy of evidence or had small sample sizes. The review
concludes that radioembolisation is associated with high response rates, but the impact on survival is less
certain with the current evidence base.
Carter and Martin47 systematically reviewed the evidence for the use of chemoembolisation for liver
tumours (included hepatocellular carcinoma, liver metastases and cholangiocarcinoma). Searches were
undertaken until 2008 and eight studies were identiﬁed. Of these, only three were in populations with
liver metastases. Sample sizes of these three studies were fewer than 40. No overall conclusion for the use
of chemoembolisation in liver metastases was provided.
Interventions in the remaining ﬁve systematic reviews were not predominantly of ablative or cytoreductive
therapies but their respective inclusion criteria have the potential to include studies of these technologies.
Bergenfeldt and colleagues106 reviewed liver resection and local ablation (including radiofrequency ablation
and laser ablation) in those with breast cancer liver metastases. The review included 32 retrospective
studies, of which seven were of local ablation (six radiofrequency ablation; one laser ablation) and
concluded that local ablation has a favourable outcome on survival. Smith and McCall107 investigated
evidence for radical surgical resection and/or ablation in those with colorectal liver metastases. Forty-six
studies were included, seven with primarily participants undergoing ablative technologies (cryoablation,
radiofrequency ablation and laser ablation), with or without surgical resection. Six of these were excluded
from our review as either retrospective or small sample size, and one met the inclusion criteria of our
review. Results showed a range of survival estimates (all ablative therapies were taken together).
Gurusamy and colleagues’ systematic review of liver resection versus radiofrequency ablation or
cryoablation in participants with liver metastases from gastro-entero-pancreatic neuroendocrine tumours
found no studies that met the review inclusion criteria.108 Similarly, Gurusamy and colleagues109 found no
studies of surgical liver resection with lymphadenectomy versus other potentially curative (radiofrequency61
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62ablation) or palliative treatment in participants with colorectal liver metastases, who are found to have
hepatic node involvement. Both of these reviews were for the Cochrane database of systematic reviews of
effectiveness, and eligible studies would have been required to be RCTs.
Finally, Al-Asfoor and colleagues110 reviewed evidence of liver resection versus cryotherapy or
radiofrequency ablation in people who were candidates for liver resection or any other modalities of
intervention (i.e. cryosurgery and radiofrequency ablation as treatments for liver metastases) with colorectal
liver metastases. One RCT was identiﬁed which partially met the inclusion criteria. The study indicated a
5-year and 10-year survival rate of 44% and 19%, respectively, after cryosurgery. This study was excluded
from the present review as the intervention differed between participants in the cryosurgery arm (to
include 32% of participants having cryoresection).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The aim of this chapter is to assess the cost-effectiveness of ablative therapies for liver metastases,provided for treatment with curative or palliative intent. The economic analysis comprises:
l a systematic literature review of economic evaluations, health-related quality of life (HRQoL) and cost
studies of ablative therapies for the treatment of liver metastases
l the development of a de novo economic model and presentation of cost-effectiveness results.Systematic review of existing cost-effectiveness evidenceThe methods and inclusion criteria considered for this review of economic evaluations are presented
in Chapter 3 of this report. Searches for economic evaluations of ablative therapies for liver
metastases identiﬁed 108 studies that potentially met the inclusion criteria set out in Chapter 3 (see
Inclusion and exclusion criteria) of this report. From screening titles and abstracts, 102 studies were
excluded and six retrieved for full screening. Four of these studies did not meet the inclusion criteria as
they assessed a different population group from that speciﬁed in the research protocol111,112 or were found
not to be full economic evaluations.113,114 Hence, two economic evaluations were included in the current
review – Abramson and colleagues115 and Gazelle and colleagues116 (Figure 2 shows the ﬂow chart) – and
a summary of their characteristics in shown in Table 36.
Although both studies examined participants with liver metastases from colorectal carcinoma,
the populations may differ in characteristics that affect their eligibility for the different interventions
available. In fact, Abramson and colleagues115 analysed different interventions from the ones studied by
Gazelle and colleagues.116 Abramson and colleagues115 analysed the relative cost-effectiveness of hepatic
arterial chemoembolisation (HACE) and palliative care, in terms of US dollars (US$) per life-year gained
adopting a third-party payer perspective. Gazelle and colleagues116 conducted a cost–utility analysis of
radiofrequency ablation versus surgical resection according to a societal perspective.Critical appraisal of the studies
The economic evaluations included for this systematic review were assessed against a critical appraisal
checklist (Table 37) adapted from checklists by Philips and colleagues,68 Drummond and colleagues,67 and
the NICE reference case requirements.117
Both included economic evaluations concern a health-care system – Medicare, a US social insurance
programme designed speciﬁcally for citizens aged 65 or older – that is not comparable with the UK NHS,
which comprises the entire population. Though the patient groups of these studies are relevant for our
review in terms of pathology, they may differ signiﬁcantly from the population of interest for the UK NHS
in other characteristics due to the patient selection inherent in the different health-care systems. Also, even
if the settings in which the strategies took place were similar to the UK setting and thus the resource use
could be similar, the unit costs are likely to differ substantially from those for the UK.Modelling approach
Abramson and colleagues115 report the estimation of the incremental cost of hepatic artery
chemoembolisation versus palliative care and of the incremental cost-effectiveness ratios (ICERs) using a
range of hypothetical incremental survival estimates over 24 months. There is no description of a model
structure and its assumptions or any other indication of modelling the natural progression of the disease.
This approach is justiﬁed by the lack of evidence on the differential in survival beneﬁt between
interventions. However, Abramson and colleagues115 do not report their literature review as systematic.
The 11.1-month median survival reported by Stangl and colleagues57 for palliative care justiﬁed the use of
12 months of survival beneﬁt for the baseline.115 Yet details on the search conducted to identify this63
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and screening
(n = 6)
Titles and abstracts
inspected
Total identified from
searching (after
deduplication)
(n = 108)
Excluded
(n = 102)
Excluded
(N = 4; incorrect
population n = 3110,111
and study type n = 1)
Studies described in our review
(n = 2)
IGURE 2 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
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64Fpublication, and the reason for its choice and use of an approximate value is not provided. Results of the
case series reported by Abramson and colleagues115 substantiated the speculative range of values used for
the incremental survival of hepatic artery chemoembolisation versus palliative care (0–24 months). The
rationale for a 2-year model and discounting was not discussed.115 A lifetime horizon would have been
more appropriate;117 however, given the advanced stage of these patients’ disease, 2 years may be close
to their lifetime. The assumptions made adopting this type of analysis are not listed and the discussion of
them is very limited.
Gazelle and colleagues116 adapted an existing Markov state-transition microsimulation model118 to estimate
the relative cost-effectiveness of radiofrequency ablation and surgical resection and a variety of imaging
and treatment strategies in people with metastatic colorectal cancer. The modelling approach used is
appropriate and the model structure and its assumptions are described in detail. For each strategy, a
cohort of 10,000 patients with potential for treatment was simulated, having each individual moving from
the ‘alive_treat’ health state to the ‘alive no treat’ or to the ‘dead’ absorbing state, in monthly cycles.
Patients eligible for treatment stay in the ‘alive_treat’ health state until they die or become untreatable,
that is to say when they present more metastases than the treatment threshold or when they reach the
maximum number of interventions for the strategy being analysed. While patients are in the ‘alive_treat’
state, the model tracks metastases progression, diagnosis of the existing metastases (previously
undetected), the impact of diagnostic tests and of interventions and their complications.
For each cohort, only one imaging and treatment strategy is modelled by specifying parameters such as
the treatment threshold (1–6 metastases), follow-up interval (4, 6 or 12 months), and imaging test
sensitivity. For each simulated patient, the model tracks up to 15 individual hepatic metastases, specifying
and updating the location, size, rate of growth, detection, and removal/ablation of each metastasis. The
initial number, location and size of each metastasis are randomly drawn according to the distributions
assigned to each parameter. Over time, metastases grow, may be detected with imaging tests
(preoperatively or intraoperative), and may be removed. Each time a patient undergoes a diagnostic
imaging test, metastases may be independently detected or missed. Tumour detection is based on test
sensitivity, assuming that below a certain (deﬁnable) size threshold, all metastases are missed. The
authors116 assume that no new liver metastases develop over time.
This microsimulation model also accounted for patients’ quality of life, procedure-related adverse events,
and the impact of repeating the procedure. Patients’ baseline survival rates varied according to the
percentage of liver volume replaced by tumour (LVRT), but procedure-related morbidity and HRQoL were
assumed not to vary according to percentage of LVRT.116NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 36 Characteristics of economic evaluations
Characteristics
Author
Abramson et al.115 Gazelle et al.116
Publication year 2000 2004
Country USA USA
Funding source Harvard Medical School
(Department of Radiology,
Beth Israel Deaconess
Medical Center)
Institute for Technology Assessment and Department of
Radiology, Massachusetts General Hospital, Harvard Medical
School; Center for Risk Analysis and Department of Health
Policy and Management, Harvard School of Public Health; the
National Cancer Institute; and the US Department of the
Army
Study type Cost-effectiveness analysis Cost–utility analysis
Perspective Direct costs to the payer Societal perspective restricted to direct health and
productivity costs and beneﬁts
Study
population
Participants with liver metastases
of colorectal carcinoma
Participants with metachronous colorectal carcinoma liver
metastases
Intervention(s) HACE vs. palliative care Percutaneous RFA vs. surgical resection [consisting of surgical
resection (or metastasectomy) and laparotomy (for
unresectable metastases found at surgery)]
Intervention
effect
Range of speculative incremental
survival estimates (0–24 months)
Mortality: 5% (surgical resection), 1% (laparotomy),
0.3% (RFA)
Morbidity: 20% (surgical resection), 4% (laparotomy),
2% (RFA)
Length of hospital stay: 12 days (surgical resection),
5 days (laparotomy)
Additional LoS due to complications:
3 days (surgical resection, laparotomy, RFA)
QoL: 70% of pre-surgical value for 1 month; 95% x
pre-ablation value for 1 month
Probability of complete tumour necrosis with RFA: 0.784
(≤ 2.5 cm), 0.472 (> 2.5–4 cm), 0.316 (> 4–10 cm)a
Currency base 1998 US$ 1998 US$
Model type Simple calculation model State-transition Monte Carlo decision model
Time horizon 24 months Lifetime
Baseline cohort Participants with liver metastasis
of colorectal carcinoma
Simulated hypothetical cohort of 10,000 participants
Base-case
results
ICER ranges from $82,385/LY gained
with a 3-month survival beneﬁt to
$10,747/LY gained with 24 months’
survival beneﬁt
Permitting surgical resection vs. RFA up to six metastases with
CT follow-up every 12 months: 3.26 QALY gain, incremental
cost of $57,000, and ICER= $16,900 per QALY
Permitting surgical resection up to six metastases with CT
follow-up every 4 months vs. 12 months: 3.39 QALY gain,
incremental cost of $61,000, and ICER = $31,200 per QALY
Permitting surgical resection up to six metastases with
4 months’ follow-up vs. RFA up to six metastases with
12 months’ follow-up: ICER = $17,800 per QALY gain
ICER, incremental cost-effectiveness ratio; LoS, length of stay; LY, life-year; QALY, quality-adjusted life-year; QoL, quality of
life; RFA, radiofrequency ablation.
a Effectiveness estimates used by Gazelle et al.116 were derived from the literature or expert opinion; see Appendix 8b
for further details.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7
65
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ECONOMIC ANALYSIS
66Gazelle and colleagues116 described and justiﬁed the assumptions related to each of these parameters and
their sources (Appendix 8, data extraction form). However, their data were derived from a comprehensive
review of the literature, which was not reported as systematic and based on expert opinion. Limited detail
on parameter derivation is provided, as there is no explanation of the method used to pool estimates from
several sources, such as the hazard rates according to the percentage of LVRT. Most estimates used by
Gazelle and colleagues116 have come from different data sources and may not be representative of the
population of interest. Most input estimates used in the model were applied deterministically, apart from
the number of metastases per patient and the size of metastases (which were randomly drawn from a
population distribution), and some were subject to sensitivity analysis (further details are provided in
Appendix 8b).Estimation of quality-adjusted life-years
Patients’ HRQoL was accounted for only by Gazelle and colleagues,116 as Abramson and colleagues115 refer
to a cost-effectiveness analysis in which health beneﬁts are measured in life-years.
Gazelle and colleagues116 derived the HRQoL data used in their model from a review of the literature (not
reported as systematic and described with limited detail) and from expert opinion.116 According to Gazelle
and colleagues,116 the limited data available regarding quality of life in patients with metastatic colorectal
cancer suggest that the majority of survival is spent with a normal age-adjusted quality of life and that
patients’ quality of life seems to decline rapidly at the end of life. Thus, age- and sex-adjusted population
utilities reported by Fryback and colleagues119 [who used a preference measurement method, time
trade-off (TTO), to measure the utility for current health of the US general adult population] were
applied to survival without liver metastases. Based on evidence from studies120,121 conducted with
non-preference-based measures, the quality of life in the month prior to death was assumed to be 60% of
that for the control subjects, and a decrement was applied to reﬂect the impact of the interventions
(70% and 95% of the pre-intervention period for surgical resection and ablation respectively).120,121
None of the values assigned to the health states of patients with liver metastases were estimated through
the use of a standardised and validated instrument for HRQoL measurement.Estimation of costs
Abramson and colleagues115 described in detail the unit costs, resource use, and the sources of the
estimates used in their analysis – Abramson and colleagues’ case series data, assumptions, or referenced
sources. For instance, the probabilities of re-embolisation and of complications were estimated from the
case series reported by Abramson and colleagues.115 The perspective adopted was that of the third-party
payer using 1998 Medicare reimbursement rates as a proxy for inpatient hospitalisation, procedural, and
outpatient visit costs, and the Health Care Financing Administration Federal Upper Limit prices in 1998
were used for outpatient drug costs. The resource use considered comprises the initial evaluation of the
patient (including specialist visits, CT imaging and blood tests), resources related to the hepatic artery
chemoembolisation procedure (including a range of inpatient care accounting for several types of eventual
complications), follow-up costs, and iatrogenic symptom control. The costs of disease-related symptom
control were assumed to be nearly equal for both arms and therefore not included explicitly.
Gazelle and colleagues116 derived cost data from a non-systematic review of the literature and the
methods for their derivation were appropriately described. A societal perspective restricted to productivity
and direct medical costs and beneﬁts (including postoperative death costs) was adopted, and the unit costs
from the Medicare payment schedule were used for both tests and procedures. The cost of both technical
and professional resources for each intervention (liver resection, laparotomy and radiofrequency ablation)
and the costs of patient care per year (according to LVRT, derived from Taplin and colleagues122) were
included. Concerning radiofrequency ablation, it was assumed that up to three liver metastases could be
treated in 1 day and that two treatment sessions would be required for patients undergoing treatment for
four to six metastases; thus, the costs were adjusted accordingly, and the cost of repeat radiofrequency
ablation was assumed to be the same as the cost of initial therapy. Gazelle and colleagues116 also included
morbidity costs related to each intervention, deriving them from daily routine care costs among patientsNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7undergoing surgical resection. Complications from radiofrequency ablation were assumed to require 1-day
hospitalisation and the resource use involved would be similar to laparotomy-related complications.
The cost of preoperative diagnostic CT scans (assumed to be performed on an outpatient basis) and
intraoperative ultrasonography were also accounted for.Cost-effectiveness results
Abramson and colleagues115 estimated that a cost-effectiveness threshold of $50,000 per life-year gained
would require a survival beneﬁt for hepatic artery chemoembolisation of nearly 5 months more than
palliative care, and that the increment of 1 year in survival would be associated with an incremental cost of
$21,045. Statistical analysis of these results is not reported; however, deterministic one-way sensitivity
analyses are reported for the estimates of beneﬁt, resource use and unit costs of several components of
the strategies and it is stated that the results of the model were slightly inﬂuenced by changes in the cost
of chemoembolisation (varied by ± 25%), the mean number of re-embolisation procedures per patient
(1.0 or 2.0) and the schedule of follow-up visits after hepatic artery chemoembolisation (every 2 months or
every 6 months). Abramson and colleagues115 also state that the cost-effectiveness of hepatic artery
chemoembolisation varies considerably with expected survival beneﬁt, and that practitioners and payers
can generate preliminary cost-effectiveness estimates by using their own empirical assessments of the
survival beneﬁt of hepatic artery chemoembolisation. The authors115 acknowledge that a limitation of their
study is the lack of adjustment for quality of life, and that although hepatic artery chemoembolisation may
affect patients’ HRQoL positively due to the palliation of symptoms, there is potential for negative impact
on quality of life due to its morbidity and potential for complications.
Gazelle and colleagues’ results116 show that the incremental beneﬁts of surgical resection relative to
radiofrequency ablation seem to outweigh the incremental costs of surgical resection regardless of the
follow-up frequency. The ICER of a strategy of surgical resection of six or fewer metastases with a
12-month follow-up interval relative to the most effective non-dominated ablation strategy (i.e. ablation of
up to six metastases with 12-month follow-up as well) was $16,900 per quality-adjusted life-year (QALY)
gained. Increasing the frequency of follow-up for the up to six metastases surgical resection strategy
to a 4-month interval yields a similar ICER ($17,800 per QALY gained) relative to the most effective
non-dominated ablation strategy. Follow-up frequency had a greater impact on incremental
cost-effectiveness when both strategies of surgical resection of up to six metastases were compared – the
most effective surgical resection strategy of 4-month follow-up had an ICER of $31,200 per QALY gained
relative to the 12-month strategy.
Despite not reporting any statistical analysis for their results or probabilistic sensitivity analysis, Gazelle and
colleagues116 conducted sensitivity analyses and scenario analyses on two comparisons that differ from the
base-case analysis (which involved comparison of all non-dominated strategies, i.e. all strategies apart from
those that were more costly and less efﬁcient) – radiofrequency ablation of up to ﬁve metastases with
4-month follow-up versus a no-treat strategy and versus a surgical resection strategy of up to four
metastases with 6-month follow-up. The justiﬁcation for the choice of these comparisons of interest was
explained as due to their clinical relevance, but no further rationale was given. Sensitivity analysis was
performed with several parameters, such as diagnostic test sensitivity, tumour doubling time, and cost of
care. The number of metastases and the maximum tumour size treatable with radiofrequency ablation
were the parameters with greater impact on the ICER, which increased from $24,300 to $47,500 per
QALY when 10 metastases were considered, and to $88,300 per QALY if radiofrequency ablation is
conducted for tumours of up to 10 cm. No sensitivity analysis was performed on quality-of-life estimates,
such as the decrements applied to mimic the impact of surgical resection or ablation. The parameters for
which sensitivity analysis was performed were also tested under three scenarios of local control rates for
radiofrequency ablation: base case, improved radiofrequency ablation and perfect radiofrequency ablation.
The ‘perfect radiofrequency ablation’ scenario is intended to simulate the achievement of complete tumour
necrosis in all treated tumours, whereas in the ‘improved RFA’ scenario complete tumour necrosis is
assumed to be achieved in 100%, 75% and 50% of treated tumours ≤ 2.5 cm, > 2.5 cm and ≤ 4 cm,
and > 4 cm but ≤ 10 cm, respectively.67
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68Gazelle and colleagues116 state their results suggest that radiofrequency ablation of larger lesions should
be encouraged, even though local control rates diminish as the size of the target tumour increases. It is
important to keep in mind that these results were obtained for the comparison of radiofrequency ablation
of up to ﬁve metastases with 4-month follow-up versus a surgical resection strategy of up to four
metastases with 6-month follow-up. Gazelle and colleagues116 also state that across all scenarios, when all
possible radiofrequency ablation and surgical resection strategies were considered, more aggressive
surgical strategies (i.e., the treatment of patients with more tumours, more frequent post-treatment
follow-up regimens, and surgical resection rather than ablation) resulted in more QALYs gained than
radiofrequency ablation. In most cases, the ICERs of even the most aggressive surgical strategies were less
than $35,000 per QALY gained.Published economic evaluation – summary of methods
Table 37 below summarises the critical appraisal of the included economic evaluations.115,116TABLE 37 Critical appraisal checklist of economic evaluation
Item Abramson et al.115 Gazelle et al.116
1 Is there a clear statement of the decision problem? Yes Yes
2 Is the comparator routinely used in UK NHS? Yes Yes
3 Is the patient group in the study similar to those of interest
in UK NHS?
Yes Yes
4 Is the health care system comparable with UK? No No
5 Is the setting comparable with the UK? Yesa Yesa
6 Is the perspective of the model clearly stated? Yes Yes
7 Is the study type appropriate? Nob Yes
8 Is the modelling methodology appropriate? No Yes
9 Is the model structure described and does it reﬂect the
disease process?
No Yes
10 Are assumptions about model structure listed and justiﬁed? No Yes
11 Are the data inputs for the model described and justiﬁed? Yes Yes
12 Is the effectiveness of the intervention established based on a
systematic review?
No No
13 Are health beneﬁts measured in QALYs? No Yes
14 Are health beneﬁts measured using a standardised and validated
generic instrument?
No Noc
15 Are the resource costs described and justiﬁed? Yes Yes
16 Have the costs and outcomes been discounted? No Yes
17 Has uncertainty been assessed? Yes Yes
18 Has the model been validated? ? Yes
?, unclear.
a Secondary care setting appears to be comparable in terms of disease management and available resources (diagnostic,
resection/ablation and image guidance technology).
b Abramson et al. did not account for HRQoL (not a cost–utility analysis).
c Assumptions based on literature which had used Rotterdam Symptom Checklist, Hospital Anxiety and Depression Scale,
and Sickness Impact Proﬁle in 50 patients with colorectal liver metastases.121
Questions in this checklist based on Philips et al.68
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7None of the published studies addresses the decision problem of this report, as neither study concerns
a comparable health care system to the UK NHS, and therefore their resource use, costs and HRQoL
estimates are not appropriate for the UK setting. Moreover, none of the studies used effectiveness
estimates that had been found through a systematic review of the literature or report HRQoL estimates
from a standardised validated preference-based instrument, as per UK guidance for technology
appraisal.117
Abramson and colleagues115 offer limited data useful to the current decision problem as the modelling
approach adopted does not reﬂect the disease process and the estimation of health beneﬁts did not
consider patients’ HRQoL, hence a cost–utility analysis (standard method for UK technology appraisal)117
was not performed.
Gazelle and colleagues116 present an appropriate modelling approach for the current decision problem.
However, their cost–utility analysis does not follow UK standard methodology117 as the estimation of
health beneﬁts and the perspective adopted are inappropriate. HRQoL estimates used by Gazelle and
colleagues116 are assumptions based on Earlam and colleagues’ study,121 which had used several non-
preference-based instruments to measure the quality of life of patients with colorectal liver metastases.
Also, Gazelle and colleagues116 took on a societal perspective where productivity and postoperative death
costs are considered contrasting with the NHS and Personal Social Services (PSS) perspective.Systematic review of health-related quality-of-life evidenceA systematic review of the literature on the HRQoL of patients with liver metastases from any solid tumour
primary site was undertaken. The aim was to provide data to populate the economic model with utility
values appropriate to conduct a cost–utility analysis and to calculate the beneﬁts of interventions in QALYs.
The sources and search terms used are detailed in Appendix 9. Given the prospect that limited HRQoL data
would be available, the inclusion criteria were broadened to retrieve any primary or secondary research of
any design reporting HRQoL measures for patients with liver metastases at any stage of the disease,
irrespective of treatments received and of the HRQoL instrument(s) used.Results of the health-related quality-of-life systematic review
Searches for HRQoL data identiﬁed 535 studies that potentially met the inclusion criteria (Figure 3). From
screening titles and abstracts, 501 studies were excluded and 34 retrieved for full screening. Twelve of
these studies did not meet the inclusion criteria as they assessed a different population group from that
speciﬁed in the research protocol111,123–131 or were conference abstracts.132,133 Also the study by Lorenz and
colleagues134 was found irretrievable by the time of completion of the current report. From the updated
searches, 12 titles and abstracts were screened and no study was found to meet the inclusion criteria. One
of these was a conference abstract by Borrego-Estella and colleagues,135 which was excluded for not
providing sufﬁcient details.
From the 21 publications found to meet the inclusion criteria, three of them were reviews116,118,136 and 18
reported on 14 primary studies.14,120,121,137–150Primary research
The main characteristics of the included primary studies are brieﬂy presented in Table 38 – further details
on each study and their results are reported in Appendix 10.
Study purpose and design
Six of the 14 included studies14,120,121,140–142,144,145,149–151 are intervention studies encompassing the
assessment of patients’ HRQoL, and six studies137–139,146–148,151 were aimed speciﬁcally at studying the
quality of life of patients with liver metastases. One study143 was designed to investigate the clinical
outcomes and patient preferences at the end of life. Four RCTs are reported in eight included69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
References for retrieval
and screening
(n = 34)
Titles and abstracts
inspected
Total identified from
searching (after 
deduplication)
(n = 535)
Excluded
(n = 501)
Excluded
(N = 13; abstracts n = 2,a
incorrect
population n = 10 and
irretrievable n = 1)Studies described in our review
(n = 21)
FIGURE 3 Flow chart of identification of studies for inclusion in the HRQoL review. a, The abstracts provided
insufficient details of methods and results to allow inclusion in the systematic review.
ECONOMIC ANALYSIS
70publications;120,121,140–142,144,149,151 four publications report results from the same RCT.120,121,140,142 One
retrospective cohort study145 and nine prospective cohort studies14,137–139,143,146–148,150 were also included.Populations
Ten studies14,120,121,137,138,140,142–144,146,147,149–151 involved only participants with colorectal liver metastases.
One study139 also enrolled participants with primary liver tumours and benign hepatic lesions, whereas
another study148 included patients with liver metastases from other primary tumours (non-small cell lung,
pancreas, prostate, and stomach) besides those arising in the colorectum. There was one study on patients
with renal liver metastases,141 and another where patients’ primary tumours were not speciﬁed.145
The included studies differed in their participant inclusion criteria and therefore in participants’ prognostic
factors. Patients were enrolled in different stages of the disease (resectable,149,151 unresectable,120,121,140,142
unablatable,14 or resected),137 differing as well on the number or extent of metastases.120,121,140,142,144,149,151Interventions and comparators
No comparative evidence of the ablative interventions included in the review and the relevant comparators
were found. One before-and-after study was found of relevance to the present review – laser ablation.150
Comparative evidence is available for non-included interventions involving relevant comparators:
chemotherapy (hepatic artery chemotherapy and systemic) and BSC,120,121,140–142,144 surgical resection with
and without positron emission tomography (PET) imaging,149,151 surgical resection and BSC,138 and surgical
resection and/or ablation and BSC following exploratory laparotomy.14,146,147Health-related quality-of-life instruments
From the 14 primary studies found on HRQoL of patients with liver metastases, only three report the
use of a preference-based measure – the generic instrument European Quality of Life-5 Dimensions
(EQ-5D).146,147,149,151 All 14 studies report the use of a non-preference-based instrument, either
generic139,143–145,149,151 or condition-speciﬁc,137,138,148,150 or the use of both.14,120,121,140–142,146,147 No
publications involving a condition-speciﬁc preference-based measure were found.
The following generic non-preference-based instruments were used among the studies included: EQ visual
analogue scale (VAS),14,141,146,147,149,151 Short Form questionnaire-12 items (SF-12),139 Karnofsky Performance
Scale index,121,138,142,145 Sickness Impact Proﬁle (SIP),121,140,142 Hospital Anxiety and Depression Scale
(HADS),120,121,140,142 Rand 36-item health status proﬁle (RAND-36), Memorial Symptom Assessment Scale,NIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Medical Outcomes Study Sexual Functioning Scale,144 functional scale by Katz, quality of life (QoL)
Excellent–Poor scale and Proﬁle of Mood States (POMS).143
Nine of the 14 studies using non-preference-based measures used condition-speciﬁc measures. These were
the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire (EORTC
QLQ-C30),14,138,146–148,150 its liver metastases-speciﬁc questionnaire module EORTC QLQ-LMC21,138 the
Functional Assessment of Cancer Therapy – General scale (FACT-G) and its kidney-speciﬁc supplement the
Functional Assessment of Cancer Therapy – Kidney Symptom Index – Disease-Related Symptoms Subscale
(FKSI-DRS),141 the City of Hope QoL Scale/Cancer Patient Survey,137 and the Rotterdam Symptom Checklist
(RSC).120,121,140,142
One study using both condition-speciﬁc (EORTC QLQ-C30) and generic (EQ-VAS) non-preference-based
measures reports similar proﬁles of quality-of-life variation over time for both measures.153 Although some
evidence suggests that both preference- and non-preference-based instruments capture the variation of
people’s quality of life over time,146 results for patients with unresectable liver metastases suggest that
non-preference-based (generic and condition-speciﬁc) and preference-based measures are sensitive to
different aspects of quality of life over time.147 For resectable/ablatable patients, the condition-speciﬁc
measure appeared to be more sensitive to variations in patients’ quality of life.147 Despite the slight
discrepancies in results from studies with few participants, the EQ-5D seems to capture appropriately the
quality of life of patients with liver metastases, as its pattern of scores over time was similar to those
obtained with the non-preference-based EQ-5D VAS (generic) and EORTC QLQ-C30 (cancer-speciﬁc)
measures.146,147Preference-based measures
Three studies129,146,149,151 reported utility values for people with liver metastases. Each individual study
investigated the HRQoL of fewer than 100 patients with colorectal liver metastases. Two studies149,151
report results from one RCT151 to assess the added value of PET imaging that subsequently led to a
prospective cohort study of the total population,149 whereas the other two publications146,147 are
prospective cohort studies aimed speciﬁcally at the study of HRQoL in patients with liver metastases.
Table 39 shows a summary of the utility values reported in the primary research included in this review.
Wiering and colleagues149,151 provide EQ-5D utilities for resectable patients at baseline and after surgical
resection over 3 years in different health states: disease-free, non-curative, and recurrence (treated with
surgical resection or chemotherapy). Patients in the different health states had baseline scores crudely close
to 0.8 and a clear decrease 3 weeks after surgical resection,151 suggesting that patients with liver
metastases have similar HRQoL to that of the general population at that age. The Health Survey for
England (1996) reports the mean (± standard error) utilities for people living in private households in
England as 0.79 (± 0.006) for 55–64-year-olds and 0.78 (± 0.006) for 65- to 74-year-olds.154
Two other studies146,147 provide EQ-5D index scores over time for patients undergoing exploratory
laparotomy. The design of these studies146,147 does not allow the differentiation between surgical resection
and ablation in their impact on patients’ quality of life. Results for patients with unresectable liver
metastases (n = 20) suggest that non-preference-based (generic and condition-speciﬁc) and preference-
based measures are sensitive to different aspects of quality of life over time, as non-preference-based
scores presented deterioration of HRQoL at 6 months after enrolment, whereas EQ-5D utilities improved
slightly 2 weeks after enrolment but became comparable with baseline scores at 3 and 6 months.147 These
results should be considered with caution given that this is a prospective study of a small cohort.
Estimates for the unresectable/unablatable group reported by Langenhoff and colleagues147 are similar to
those obtained by Krabbe and colleagues.14673
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TABLE 39 Summary of utility values reported in original studies
Study health states Utility values, mean (SD)
Wiering et al.151
Resected
Disease free
Overalla 0.78 (0.23)
Baseline 0.82 (0.02)
2 weeks 0.65 (0.05)
3, 6 and 12 monthsb,c 0.80 (0.02), 0.83 (0.02), 0.83 (0.03)
24, 27 and 36 monthsb,c 0.81 (0.04), 0.83 (0.03), 0.76 (0.05)
Non-curative
Overalla 0.67 (0.31)
Baseline 0.78 (0.05)
3, 6 and 12 monthsb,c 0.67 (0.07), 0.60 (0.11), 0.64 (0.10)
Recurrence
Overalla 0.74 (0.25)
24, 27 and 36 monthsb,c 0.76 (0.04), 0.76 (0.04), 0.57 (0.07)
Recurrence treated with surgical resection
Overalla 0.82 (0.17)
12, 18 and 21 months 0.85 (0.02), 0.85 (0.02), 0.84 (0.03)
30 and 36 months 0.85 (0.03), 0.74 (0.08)
Recurrence treated with chemotherapy
Overalla 0.68 (0.28)
12, 18 and 21 months 0.75 (0.04), 0.68 (0.05), 0.70 (0.05)
30 and 36 months 0.70 (0.05), 0.45 (0.10)
Langenhoff et al.147
Inoperablec
Baseline 0.70 (0.07)
2 weeks 0.80 (0.02)
3 and 6 months 0.78 (0.02), 0.67 (0.11)
Resected or ablatedc,d
Baseline 0.86 (0.02)
2 weeks 0.70 (0.02)
3 and 6 months 0.78 (0.02), 0.85 (0.01)
Unresectable or unablatablec,d
Baseline 0.77 (0.06)
2 weeks 0.59 (0.09)
3 and 6 months 0.76 (0.04), 0.83 (0.02)
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TABLE 39 Summary of utility values reported in original studies (continued )
Study health states Utility values, mean (SD)
Krabbe et al.146
Overall baseline utilityd 0.84 (0.12)
Resected (± ablated)c,d
Baseline 0.85 (0.02)
2 weeks 0.68 (0.03)
3 and 6 months 0.74 (0.02), 0.83 (0.03)
Ablatedc,d
Baseline 0.90 (0.02)
2 weeks 0.81 (0.03)
3 and 6 months 0.90 (0.03), 0.90 (0.02)
Unresectable or unablatablec,d
Baseline 0.79 (0.05)
2 weeks 0.60 (0.08)
3 and 6 months 0.77 (0.07), 0.83 (0.03)
a Mean utility value over 3-year period.
b Months post-surgical resection showing statistically signiﬁcant effect.
c Extracted using Engauge (Engauge Digitizer: http://digitizer.sourceforge.net).
d Patients subject to exploratory laparotomy.
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Some evidence from generic non-preference-based measures suggests that liver metastases do not have
much impact on patients’ overall quality of life.121,137,142,143 This may be a result of the lack of sensitivity of
the instruments to the health domains affected by liver metastases. Condition-speciﬁc measure EORTC
QLQ-LMC21 symptom scales and single items indicate the main symptoms affecting patients with liver
metastases. There is evidence that patients with liver metastases on palliative care report signiﬁcant
deterioration over time of symptoms, such as taste problems, dry mouth, sore mouth, and peripheral
neuropathy.138 Patients with liver metastases show variation in quality of life according to the severity of
the disease (as different baseline EQ-5D and EORTC scores are shown in studies reporting results by
resectable/ablatable/unresectable subgroups),14,138,146,147 and to the recurrence of liver metastases.151
No signiﬁcant difference in functional improvement was shown between patients with ≥ 90% or < 90%
total liver tumour volume resected.145 Contrastingly, Earlam and colleagues121 showed a positive correlation
between percentage of hepatic replacement and RCS, SIP and HADS scores. There is also evidence that the
quality of life of patients with liver metastases is inﬂuenced by the percentage of hepatic replacement,121
and by the percentage of tumour removed (non-curative surgery).151 These results suggest that Karnofsky
Performance Scale145 is not sensitive to variations on quality of life of patients with liver metastases
according to hepatic volume replaced by tumour.
The quality of life of patients on symptom control seems to deteriorate late in the disease course (a
signiﬁcant decrement of quality of life is only seen 5 months to 1 month before death) and patients
receiving symptom control spent approximately 24% of their survival with normal RSC, SIP and HAD
scores.120,121 Unablatable patients had no clear variation of quality of life (EQ-VAS and EORTC QLQ-C30
scores) at 2 weeks and 3 months after enrolment, showing deterioration only at 6 months. However,
improvement of the EQ-5D index scores was seen 2 weeks after enrolment and these scores were75
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76comparable with baseline at 3 and 6 months.147 Unresectable patients had worse EORTC QLQ-LMC21
symptoms scores at 3 months (taste problems, dry mouth, sore mouth and peripheral neuropathy).138
The quality of life of patients with liver metastases appears to vary according to the stage of the disease
and prognostic factors, such as number and size of liver metastases (surrogate indicators: hepatic volume
replaced by tumour, eligibility for surgical resection/ablation), and seems to deteriorate slowly over time,
weakening severely at the end of life.Secondary research
The three reviews which met the inclusion criteria were economic evaluations using utility values to
calculate QALYs (Table 40).116,118,136 Two of these were conducted by Gazelle and colleagues,116,118 who
performed a cost–utility analysis to estimate the relative cost-effectiveness of radiofrequency ablation and
surgical resection (addressed also in Systematic review of existing cost-effectiveness evidence) through the
adaptation of the model they had previously used to study the cost-effectiveness of surgical resection
compared with no treatment.118 Gazelle and colleagues used the same rationale and HRQoL data sources
for the estimation of QALYs in both economic evaluations, based on published evidence119–121 and expert
opinion. From the Earlam and colleagues121 and Allen-Mersh and colleagues120 studies (both included in
the current review), Gazelle and colleagues116 inferred that the majority of survival of patients with
colorectal cancer liver metastases is spent with a normal age-adjusted quality of life. Thus, age- and
sex-adjusted population utilities119 were applied to survival without liver metastases (following surgical
resection/ablation). A decrement was applied to reﬂect the impact of the interventions (70%116,118 and
95%116 of the pre-intervention period for surgical resection and ablation, respectively). The quality of life of
patients with liver metastases in the month prior to death was also assumed to be 60% of that for the
control subjects. No sensitivity analyses were conducted on these estimates.
Karuna and colleagues136 conducted a cost–utility analysis of laparoscopy versus laparotomy for initial
surgical assessment and treatment of potentially resectable colorectal liver metastases. The utility weights
used for the estimation of QALYs were derived from the HRQoL study by Langenhoff and colleagues147
(included in the current review) and a HRQoL study in hepatocellular carcinoma patients155 (a different
population, hence not included in this review). Patients with immediate post-operative complications wereTABLE 40 Utility values used in previous economic evaluations
Study Health states Utility values Source
Gazelle et al.,116,118
2003, 2004 (USA)
With LM (pre intervention) Age- and sex-adjusted
population utilities
Fryback et al.119
Without LM (post intervention)
After surgical resection (ﬁrst month) 70% of pre-intervention utility Expert opinion based on
Earlam et al.121 and
Allen-Mersh120After RFA (ﬁrst month) 95% of pre-intervention utility
With LM (month prior to death) 60% of pre-intervention utility
Karuna et al.,136
2008 (USA)
Post resection without
morbidity/mortality
0.60, 0.74, 0.80a,b Langenhoff et al.147
Post laparoscopy, then laparotomy
without surgical resection
0.54, 0.67, 0.72a,b
Post resection with morbidity 0.57, 0.71, 0.78a Langenhoff et al.,147
Poon et al.155
Post-laparoscopy unresectable
disease
0.76, 0.72, 0.72a
LM, liver metastases; RFA, radiofrequency ablation.
a Two weeks, 3 months and 6 months post-exploratory laparotomy.
b These estimates differ from the ones extracted by the reviewer using Engauge (Engauge Digitizer: http://digitizer.
sourceforge.net) (see Table 39).
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7assigned a small decrement (0.02) in utility to account for the additional loss of quality of life. Patients’
quality of life was also assumed to be constant after 6 months post intervention, which was supported by
recent evidence that showed that quality of life is stable from 6 months post intervention until immediately
prior to death.119,147,155Summary and conclusions
The current review did not identify any comparative studies for the ablative therapies and the relevant
comparators included in the current study. No evidence of the impact on patients’ HRQoL was found for
most of these interventions. Only a before and after study was found related to one of the included
ablative therapies and this reported no statistical signiﬁcant difference before and 1 week, 1 month and
6 months after initiation of laser ablation in people with progressive disease undertaking second- and
third-line chemotherapy.150
Published research involving the comparators included in this study is very limited as it consists of studies
not involving comparisons of interest to our review120,121,140,142,144,146–149,151,153 and those assessing HRQoL
for a short follow-up period (3 or 6 months)138,146,147 or only at baseline.141 Part of the evidence identiﬁed
consists of prospective cohort studies where the impact of the intervention is assessed through comparison
of the cohort results before and after the intervention, and therefore without a control group.137,139,148,150
Several studies have enrolled fewer than 100 participants.137,145–151 Therefore, evidence of the impact of
ablative therapies is lacking.
Additionally, most of the evidence available has not been measured using a preference-based instrument
or non-preference-based measures that can be mapped to derive utilities.120,121,137,139–145
Moreover, there is little evidence of the variability of HRQoL of patients with liver metastases according to
the severity of the disease (indicated by prognostic factors such as the number and size of metastases, or
by surrogate indicators such as the proportion of total liver tumour volume resected or residual liver
volume), and the rate of tumour growth.Implications for future cost-effectiveness modelling
Modelling options are restricted by the little evidence available on HRQoL of patients with liver metastases.
The evidence available suggests near-normal quality-of-life levels at baseline, substantial decrement due to
the intervention followed by a quick recovery to baseline values138,146,147,149,151,153 and serious deterioration
of quality of life at the end of life,120,121,140,142 supporting the rationale taken on in previously published
economic evaluations.116,118,136 Evidence also suggests that patients’ eligibility to the interventions varies
according to disease severity (resectable, ablatable, inoperable).138,146,147 The quality of life of patients
treated by surgical resection or ablation does not deteriorate as much as that for patients found to be
unresectable/unablatable after exploratory laparotomy, and this latter group takes longer to regain its
baseline quality of life.147 Ablatable patients presented better scores than resectable/ablatable ones over
6 months, while those found to be unresectable at laparotomy reported worse scores over 6 months for
EQ-VAS, EORTC QLQ-C30, and EQ-5D index.146
Moreover, statistically signiﬁcant differences in quality of life over time were found between groups in
different health states (disease free, non-curative, and recurrence) indicating different quality of life for
progression-free survival and post-progression survival of resected patients and the impact of non-curative
interventions.151 Also, the RSC physical score was shown to be a predictor of survival for patients on
symptom control,121 and patients’ RAND-36 physical functioning was shown to vary over time as a
function of survival.144Implications for the independent survival model
In order to capture the most signiﬁcant variations of HRQoL of patients with liver metastases over time, the
independent survival-based model (further described in Independent economic evaluation) includes a77
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78number of health states. The impact of the interventions is captured by the resultant life expectancy in
each of the different utility-weighted health states.
The comparisons being analysed in the section of the report headed Independent economic evaluation
(regarding radioembolisation relative to hepatic arterial infusion, hepatic arterial infusion alone, microwave
ablation, radiofrequency ablation, and surgical resection) involve different subgroups of patients. The
comparison of radioembolisation associated to hepatic arterial infusion with hepatic arterial infusion alone
investigated unablatable patients (non-eligible to any sort of surgical or local ablative intervention);85
hence, the utility values reported for the inoperable group by Langenhoff and colleagues147 were assumed
to be generalisable to these patients. Both Shibata and colleagues72 and Kim and colleagues73 enrolled
resectable patients to compare an ablative intervention with surgical resection. Although patients’ inclusion
criteria (such as the maximum number of metastases) differ among studies, Wiering and colleagues’151
utility estimates seem generalisable to the surgical resection arms of the clinical effectiveness studies.72,73
Similarly, utilities from Krabbe and colleagues’146 ablatable group were used as estimates for the impact of
the ablative therapies on quality of life and for ablated patients with stable disease.
The following assumptions underlie the choice of the estimates presented in Table 41:
l Interventions’ impact measured 2 weeks after intervention is assumed to remain for a whole month as
it is applied to the ﬁrst cycle of the model.
l Given the lack of speciﬁc estimates, all ablative therapies are assumed to have the same impact on
patients’ quality of life.
l Ablated patients are assumed to reach stable disease at 6 months.
l Utility weight for resected patients with progressive disease assumed to be the same for ablated
patients in this health state, given the lack of particular evidence. This is thought to be a conservative
approach, as ablatable patients presented better scores than resectable/ablatable ones over 6 months
for EQ-VAS, EORTC QLQ-C30, and EQ-5D index.146TABLE 41 Utility weights used in the model
Utility values Health states, mean (SD)
Interventions Baseline Intervention impact Stable Progressive Terminal
HAC 0.70 (0.07)a 0.80 (0.02)b 0.78 (0.02)c 0.67 (0.11)d 0.45 (0.10)l
RE + HAC 0.70 (0.07)a 0.80 (0.02)b 0.78 (0.02)c 0.67 (0.11)d 0.45 (0.10)l
MWA 0.90 (0.02)e 0.81 (0.03)f 0.90 (0.02)g 0.74 (0.25)k 0.45 (0.10)l
RFA 0.90 (0.02)e 0.81 (0.03)f 0.90 (0.02)g 0.74 (0.25)k 0.45 (0.10)l
Surgical resection 0.82 (0.02)h 0.65 (0.05)i 0.78 (0.23)j 0.74 (0.25)k 0.45 (0.10)l
HAC, hepatic artery chemotherapy; MWA, microwave ablation; RE, radioembolisation; RFA, radiofrequency ablation.
a Inoperable group at baseline (Langenhoff et al.147).
b Inoperable group at 2 weeks (Langenhoff et al.147).
c Inoperable group at 3 months (Langenhoff et al.147).
d Inoperable group at 6 months (Langenhoff et al.147).
e Ablatable group at baseline (Krabbe et al.146).
f Ablatable group at 2 weeks (Krabbe et al.146).
g Ablatable group at 6 months (Krabbe et al.146).
h Disease-free group at baseline (Wiering et al.151).
i Disease-free group at 2 weeks (Wiering et al.151).
j Overall mean value (Wiering et al.151).
k Recurrence group overall mean value (Wiering et al.151).
l Recurrence treated with chemotherapy group at 36 months (Wiering et al.151).
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disease severity and the interventions they had undertaken. This is the estimate from the ﬁnal
measurement by Wiering and colleagues151 for their recurrence group with most advanced disease.
Conclusions
There is a lack of randomised comparative studies concerning ablative therapies and the relevant
comparators using a standardised, validated preference-based HRQoL instrument, such as the EQ-5D
(recommended for measuring and valuing health beneﬁts for health technology assessment in the UK).117
No evidence was found on condition-speciﬁc preference-based measures (expected to offer greater
resolution of patients’ HRQoL than a generic instrument such as the EQ-5D) either. At the time of writing,
the EORTC QLQ-LMC21 is the only instrument speciﬁc to liver metastases available; however, this is a
non-preference-based tool and no publications on its mapping into EQ-5D have been found.Independent economic evaluationA survival-based model was developed to estimate the cost-effectiveness of ablative therapies, or other
non-invasive therapies, in cohorts of adult patients with surgically resectable or unresectable liver
metastases. Due to data limitations identiﬁed in the clinical effectiveness review and discussed later in this
section of this report (primarily a lack of comparative studies, or limitations on the reporting of survival
outcomes in those comparative studies that were identiﬁed) the analysis does not include all therapies
identiﬁed (in Inclusion and exclusion criteria) as relevant to this review. The analysis for ablative therapies
was limited to comparisons of:
l microwave ablation versus surgical resection in surgically resectable patients
l radiofrequency ablation versus surgical resection in subgroups of surgically resectable patients.
The analysis for other non-invasive therapies was limited to a comparison of:
l radioembolisation (combined with hepatic arterial chemotherapy) versus hepatic arterial chemotherapy
alone for surgically unresectable patients.
The clinical effectiveness evidence used to populate the model was derived from studies with varying
designs (RCT72,85 and prospective cohort73) and varying risk of bias. The limitations of the evidence base
need to be borne in mind when interpreting the results of the modelled analyses.Methods for economic analysis
Model type and rationale for model structure
Figure 4 presents a schematic of the basic survival model which, in its simplest form, contains three
states – stable disease (i.e. patients’ state at entry to the trial), progressive disease and death.156,157
Movements between these states are usually permitted only in the progressive direction. This approach has
been adopted to model the cost-effectiveness of ablative therapies for liver metastases.Stable primary
tumour with liver
metastases
Progressive diseaseTTP OS-TTP
OS
Death
FIGURE 4 Schematic of the survival model adopted for the cost-effectiveness model. OS, mean overall survival;
OS-TTP, mean survival duration with progressive disease; TTP, mean time to progression.
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80An advantage of this approach is that the model is based on relevant ﬁnal outcomes (survival weighted by
quality of life) rather than using surrogate measures, such as tumour response or complete/partial resection
for which additional evidence would be required to establish the link to ﬁnal outcomes. Interpretation of
this basic model in the context of metastatic disease is slightly more complex than in the usual application,
where therapy is directed at the primary tumour. In this case patients’ primary tumour is assumed to be
stable and the intention of treatment is to remove the metastases (in the case of treatment with curative
intent) or to reduce the size of the metastases, improving quality of life and offering some increase in life
expectancy, in the case of treatment with palliative intent. Therefore, the stable disease state may include
quite different patients – those whose metastases have been completely removed and those with
remaining metastases. Quality of life for this group of patients is weighted to take account of those
metastases that are removed (equivalent to a complete response on standard chemotherapy outcome
scales) and those with remaining metastases (see later in this section). Including both groups of patients in
a single ‘stable’ health state in the survival model, rather than adopting a state transition model (explicitly
modelling response/removal of metastases), is a pragmatic decision based on the fact that studies have not
reported survival, duration of response or time to disease progression for these patient groups separately.
Patients enter the model with a stable primary tumour, with liver metastases and receive treatment with an
ablative therapy (with curative or palliative intent depending on the patient population in the included
study) or the relevant comparator treatment. Patients may experience disease progression or may die
without experiencing documented disease progression.
The model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Two versions
of the model were developed independently, using the same input parameters, and tested against each
other to ensure internal consistency. It is fully probabilistic to take into account parameter imprecision.
In addition, deterministic sensitivity analysis was used to explore different scenarios and assumptions in
the model.
The base-case analysis compares the mean overall survival with ablative therapy ð–OSAT Þ with the mean
overall survival for comparator ð–OSCÞ. The estimate of life-years gained with the ablative therapy, in
the base case, was calculated as:
LYGAT ¼ –OSAT− –OSC ð1Þ
To estimate the QALY gain associated with the ablative therapy (QALYGAT), response-speciﬁc utilities
[US for stable (which may be a weighted sum of the utility in patients whose metastases are removed
and those successfully treated but with residual metastases) and UP for disease progression, respectively],
derived in our review of quality-of-life studies (see Systematic review of health-related quality-of-life
evidence), were applied to the mean overall survival estimates, taking into account survival before
disease progression (mean time to progression,
–
TTPAT ) and post-progression survival ð
–
OSAT−
–
TTPAT Þ.
The quality-adjusted life expectancy gain was therefore calculated as:
QALYGAT ¼ –TTPAT  US þ ð–OSAT−
–
TTPAT Þ  UP−ð–TTPC  US þ ð–OSC−–TTPCÞ  UPÞ ð2ÞBaseline cohort
The population in the base-case analysis are adult patients with liver metastases. Patients receiving ablative
therapies, other non-invasive therapies or comparator treatments are assumed to have a stable primary
tumour and may be undergoing treatment of curative or of palliative intent.Perspective and time horizon
The perspective of the cost-effectiveness analysis is that of the NHS and PSS. A lifetime time horizon has
been adopted for the model.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Both costs and outcomes were discounted using a 3.5% discounting rate, as currently recommended by
the UK Treasury for public sector appraisal.158Assessment of uncertainty
The purpose of this analysis is to test the robustness of the cost-effectiveness results to variation in
structural assumptions and parameter inputs. Deterministic analyses were used to address particular areas
of uncertainty in the model. The uncertainties around the probability, resource use and cost estimates that
were expected, a priori, to have a disproportionate impact on the study results were investigated by
applying ranges around the point estimates used in the base-case analysis. Scenario analysis was used to
address the uncertainty associated with the choice of data source adopted for parameter values in the
base case and some aspects of the chosen structure of the model.
Parameter uncertainty was addressed using probabilistic sensitivity analysis (PSA). Probability distributions
were assigned to describe uncertainty around the point estimates used in the base-case analysis. Variables
included in the PSA, the sampling distribution and the parameterisation of the sampling distribution are
reported in Appendix 11. Each PSA is run for 1000 iterations.Data sources used in model
Figure 5 reports the ablative therapies and the number of studies identiﬁed in the clinical effectiveness
review. However, not all these studies provide robust data for the model or reported all relevant outcomes
in sufﬁcient detail to be included in the economic model.
One ablative therapy (laser ablation) was excluded from the model due to a lack of comparative studies.
Radiofrequency ablation was also initially excluded, due to a lack of comparative studies. However, one
non-randomised comparative study was subsequently identiﬁed in update searches,73 which compared
radiofrequency ablation with surgical resection and which reported overall survival and disease-free survival
for three subgroups of patients with liver metastases from colorectal cancer. The identiﬁed subgroups were
patients with solitary liver metastases of < 3 cm; patients with solitary liver metastases ≥ 3 cm; and patients
with multiple liver metastases. This was not a randomised study and patients undergoing each treatment
may not be directly comparable [e.g. mean age of patients undergoing surgical resection was youngerAblative therapies included in
review of clinical effectiveness
Laser ablation
n = 2
Microwave
ablation
n = 1
Radiofrequency
ablation
n = 5
n = 0 n = 1 n = 0 n = 1
n = 1 n = 1
n = 1 n = 1
Comparative studies
Report overall survival
Report Kaplan–Meier curve or
sufficient data to estimate
overall and progression-free
survival curves
Identified in
update search
FIGURE 5 Studies of ablative therapies providing sufficient data to model.
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82(57.1 years) than that of those undergoing radiofrequency ablation (60.4 years, reported p-value on
difference of 0.001)] and also appear to differ in terms of synchronicity (9.6% of surgically resected
patients had synchronous metastases and 90.4% had metachronous metastases, whereas 77% of
patients undergoing radiofrequency ablation had synchronous metastases and the remaining 23% had
metachronous metastases). The results from the modelled analysis based on this study should therefore be
treated with caution.
Figure 6 lists the other non-invasive therapies and the number of studies identiﬁed in the clinical
effectiveness review. While comparative studies of chemoembolisation were identiﬁed and included in the
systematic review of clinical effectiveness, the included studies did not report sufﬁcient detail on relevant
outcomes (overall survival and time to progression) to be included in the model. Two studies involving
radioembolisation also reported insufﬁcient detail on overall survival and time to progression to be
included in the model.
As a result three comparisons are included in the model – two ablative therapies compared with surgical
resection (microwave ablation compared with surgical resection based on the RCT reported by Shibata and
colleagues72 and radiofrequency ablation compared with surgical resection based on the cohort study
reported by Kim and colleagues73) and one other non-invasive therapy (radioembolisation in conjunction
with hepatic artery chemotherapy compared with hepatic artery chemotherapy alone, based on data
reported in the RCT by Grey and colleagues85). Each of these comparisons is based on a single study.
The following sections describe the data sources used to populate the model and any additional analyses
required to prepare the data for use in the model. There are three main subsections describing the
derivation of data for clinical effectiveness, quality of life and resource and cost. Where relevant these
subsections are further subdivided; for example, the resource and cost section is broken down to describe
costs applied at different phases of the patient care pathway, characterised as treatment/monitoring costs
and disease management costs.
The ﬁrst of the following subsections reports on the clinical effectiveness data included in the model
under the headings of overall survival, progression-free survival and adverse events. The derivation of data
used in the model is described under these headings for each of the therapies included in each analysis.Other non-invasive therapies
included in review of
clinical effectiveness
Chemoembolisation
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FIGURE 6 Studies of other non-invasive therapies providing sufficient data to model.
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disease state) applied in the model, based on the review of quality-of-life studies reported earlier (see
Systematic review of health-related quality-of-life evidence). The ﬁnal subsection reports the data
assumptions applied in the model for costing interventions and patient management – reported under
headings of treatment costs (including on-treatment management and post-discharge follow-up for
surgical resection); post-treatment monitoring (prior to disease progression); post-progression/palliative
care; and adverse events (if relevant).Clinical effectiveness
Statistical models were ﬁtted to data derived from survival plots reported in the included studies. Three
survival functions (exponential, Weibull and log-logistic) were ﬁtted in each case and the function offering
the best ﬁt was selected for the survival model. The three survival functions have different assumptions
regarding the hazard function: the exponential function assumes constant hazards over time; the Weibull
function assumes that hazard either increases or decreases monotonically with time; and the log-logistic
function has a hazard function with a single peak, thus the hazard may increase until time t and
decrease thereafter.
The exponential model has a very simple form and can be derived easily with minimal reported data (e.g.
from median survival),159 which may explain its popularity in many health economic models. However, the
constant hazard property may not be appropriate in many clinical settings. In contrast, the log-logistic
function, while having the ﬂexibility to capture monotonically declining rates as well as those that initially
increase and subsequently decline, can give rise to implausibly high maximum survival durations. As a rule,
the simplest form that is consistent with the observed data will be selected, which will, in many cases, be
the Weibull function.Overall survival – microwave ablation compared with surgical resection
Overall survival curves for patients undergoing surgical resection and microwave ablation, reported by
Shibata and colleagues,72 were scanned using Engauge software (Engauge Digitizer: http://digitizer.
sourceforge.net) and imported into Microsoft Excel. At the end of follow-up all patients with complete
follow-up in the trial had died [12 in the surgical resection arm (seven with hepatic failure) and nine in the
microwave ablation arm (six with hepatic failure)], with four patients in the surgical resection arm and ﬁve
in the microwave ablation arm censored at between 10 and 30 months of follow-up.
The extrapolated overall survival curves for the surgical resection arm, using different survival functions,
are given in Figure 7 along with Kaplan–Meier survival estimates from the trial report. The Weibull and
log-logistic survival functions appear to give the closest ﬁt to the overall survival curves.t (months)
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IGURE 7 Kaplan–Meier survival estimates from the Shibata and colleagues72 trial showing Weibull and alternativeF
model fit.
83
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ECONOMIC ANALYSIS
84The survival model was ﬁtted to the survival plots for both interventions simultaneously, using linear
regression, with surgical resection as the base intervention and estimating a HR for microwave ablation,
relative to surgical resection – full details on the method for transforming data for use in the linear
regression and for estimating the survival models are reported in Appendix 12.
Table 42 reports a comparison of observed survival at 1, 2 and 3 years against model predictions.
Data in Table 42 suggest that, while the exponential survival function is a particularly poor ﬁt for the
observed data, none of the survival functions provides good predictions of survival for the reported time
periods. Both the Weibull and log-logistic functions overestimate early survival (up to 1 year) and
underestimate later survival (from 2 years). The exponential and log-logistic functions estimate lower
survival with surgical resection at each reported time point, while the observed data has a higher survival
with surgical resection at 3 years.
Mean survival reported by Shibata and colleagues72 and from each of the modelled survival functions
(extrapolated to a maximum duration of 49 months for comparison with the area under the reported
Kaplan–Meier curve) are reported in Table 43.
Mean overall survival for the surgical resection arm estimated using the Weibull survival function is similar to
that estimated from the Kaplan–Meier curve and the value reported in the trial publication (24.7 estimated
from the Kaplan–Meier curve, 24.1 using the Weibull survival function and 25 months reported in the trial
publication). However, while mean survival estimated from the Kaplan–Meier curve for microwave ablation is
the same as for surgical resection (and in the trial publication is higher, at 27 months), mean overall survival
for microwave ablation, estimated using the Weibull survival function (22.9 months), is lower than for surgical
resection. The model using the exponential function appears to substantially underestimate overall survival
for both surgical resection and microwave ablation (with lower estimated survival for surgical resection
compared with microwave ablation). The log-logistic survival function also underestimates overall survival for
both surgical resection and microwave ablation (with lower estimated survival for surgical resection than for
microwave ablation), though the differences compared with the reported trial values are not as great.TABLE 42 Comparison of observed survival at 1, 2 and 3 years against model predictions
Year
Trial report Weibull model Exponential model Log-logistic model
MWA
Surgical
resection MWA
Surgical
resection MWA
Surgical
resection MWA
Surgical
resection
1 71% 69% 82% 83% 48% 40% 80% 78%
2 57% 56% 43% 47% 23% 16% 34% 31%
3 14% 23% 14% 18% 11% 8% 13% 12%
MWA, microwave ablation.
TABLE 43 Mean overall survival from Kaplan–Meier and modelled survival functions
Treatment arm
Mean overall survival (months)
Trial report Weibull Exponential Log-logistic
Surgical resection 24.7 24.1 12.7 21.1
MWA 24.8 22.9 15.4 21.7
MWA, microwave ablation.
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structural sensitivity analyses were included.Overall survival – radiofrequency ablation compared with surgical resection
Overall survival curves reported by Kim and colleagues73 were scanned using Engauge software and
imported into Microsoft Excel. The study reports survival curves for three groups of patients undergoing
surgical resection or radiofrequency ablation: those with solitary liver metastases with tumour size of
< 3 cm, those with solitary liver metastases of ≥ 3 cm and patients with multiple metastases. At the end
of follow-up (maximum of 72 months) the survival curves show a proportion of patients were still alive
(Table 44 shows 5-year survival reported in the study). The ﬁnal portions of the survival curves were
extrapolated using a regression analysis for each patient population separately. The survival model was
ﬁtted to data derived from the survival plots for both interventions simultaneously with surgical resection
as the base intervention and estimating a HR for radiofrequency ablation, relative to surgical resection.
Radiofrequency ablation compared with surgical resection for solitary
metastases < 3 cm
The extrapolated overall survival curves, for surgical resection, are given in Figure 8 along with Kaplan–
Meier survival estimates from the trial report. The Weibull and log-logistic survival functions appear to ﬁt
the overall survival curves reasonably well, although all of the modelled functions give lower predictions
than the Kaplan–Meier curves for survival over 5 years. The Weibull and log-logistic functions appear to
overestimate median survival [trial report = 59.6 months (this is not reported in the study, but has been
estimated from the Kaplan–Meier curve), Weibull = 52.9 months, log-logistic = 54.5 months] while the
exponential provides a closer estimate for median overall survival (61.2 months).TABLE 44 Five-year survival for patients with liver metastases from colorectal cancer treated with surgical resection
or radiofrequency ablation
Solitary
Multiple metastasesLess than 3 cm At least 3 cm
Surgical resection 51.2% 48%a 34.6%
RFA 51.1% 34%a 14.3%
RFA, radiofrequency ablation.
a Values not reported in paper, but estimated from Kaplan–Meier curve.
Data as reported by Kim and colleagues.73
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FIGURE 8 Kaplan–Meier survival estimates for resected patients with solitary metastases (< 3 cm) from the Kim and
colleagues73 study showing alternative model fit.
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86Table 45 reports a comparison of observed survival at 1, 2, 3 and 5 years against model predictions.
Data in Table 45 suggest that the exponential survival function is a poor ﬁt to the observed data over the
ﬁrst 24 months, while the Weibull and log-logistic functions both provide a reasonable ﬁt for early survival
(up to 3 years). Both functions seem to underestimate later survival with surgical resection and RFA. In
contrast the exponential function appears to give very close predictions for 3- and 5-year survival for
surgical resection.
Mean survivals derived from the study by Kim and colleagues73 and from each of the modelled survival
functions (extrapolated to a maximum duration of 72 months for comparison with the area under the
reported Kaplan–Meier curve) are reported in Table 46.
The exponential and Weibull give close predictions for mean overall survival, although the Weibull function
indicates no difference in survival between surgical resection and RFA, while the values read from the
Kaplan–Meier curve suggest that survival is slightly higher with surgical resection. The log-logistic function
slightly overestimates overall survival compared with the values read from the Kaplan–Meier curve and
suggests a slightly greater survival difference.
The Weibull model was adopted for the base-case analysis and the alternative survival functions in
structural sensitivity analyses were included.Radiofrequency ablation compared with surgical resection for solitary
metastases ≥ 3 cm
The extrapolated overall survival curves, for surgical resection, using different survival functions, are given
in Figure 9 along with Kaplan–Meier survival estimates from the trial report. The Weibull and log-logistic
survival functions appear to ﬁt the overall survival curves reasonably well, although all of the modelledTABLE 45 Comparison of observed survival at 1, 2, 3 and 5 years against model predictions in patients with solitary
metastases < 3 cm
Year
Study report Exponential model Weibull model Log-logistic model
Resect RFA Resect RFA Resect RFA Resect RFA
1 95% 95% 87% 87% 95% 95% 95% 95%
2 81% 85% 76% 75% 84% 83% 83% 83%
3 67% 63% 67% 65% 70% 69% 69% 69%
5 51.2% 51.1% 51% 49% 42% 42% 45% 45%
RFA, radiofrequency ablation.
TABLE 46 Mean overall survival from Kaplan–Meier and modelled survival functions
Treatment arm
Mean overall survival (months)
Study report Exponential Weibull Log-logistic
Surgical resection 49.7 49.2 49.5 50.2
RFA 49.5 48.5 49.5 49.9
Difference 0.2 0.7 0.0 0.3
RFA, radiofrequency ablation.
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FIGURE 9 Kaplan–Meier survival estimates for resected patients with solitary metastases (≥ 3 cm) from the Kim and
colleagues73 study showing alternative model fit.
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Kaplan–Meier curve vs. 43% for the exponential, 42% for Weibull and 43% for the log-logistic model).
Each of the modelled functions appears to overestimate median survival [trial report = 45.6 months
(this is not reported in the study, but has been estimated from the Kaplan–Meier curve),
exponential = 49.5 months, Weibull = 50.6 months, log-logistic = 50.2 months].
Table 47 reports a comparison of observed survival at 1, 2, 3 and 5 years against model predictions.
Data in Table 47 suggest that the exponential survival function underestimates early (up to 1 year) and late
(5 years) survival, while the Weibull and log-logistic functions both provide a reasonable ﬁt for early
survival (up to 2 years). Both functions seem to overestimate survival at 3 years and to underestimate
survival at 5 years.
Mean survival derived from the study by Kim and colleagues73 and from each of the modelled survival
functions (extrapolated to a maximum duration of 72 months for comparison with the area under the
reported Kaplan Meier curve) is reported in Table 48.
Mean overall survival for surgical resection estimated using the Weibull and log-logistic survival
functions is similar to that reported from the trial (47.2 months for the modelled functions compared with
47.4 months from the Kaplan–Meier curve). However, both functions estimate higher mean survival with
radiofrequency ablation (34.2 and 34.5 months for Weibull and log-logistic functions, respectively)TABLE 47 Comparison of observed survival at 1, 2, 3 and 5 years against model predictions in patients with solitary
metastases ≥ 3 cm
Year
Trial report Exponential model Weibull model Log-logistic model
Resect RFA Resect RFA Resect RFA Resect RFA
1 89% 77% 86% 86% 90% 82% 91% 79%
2 72% 56% 74% 74% 77% 60% 76% 56%
3 60% 34% 63% 64% 64% 42% 63% 40%
5 48% 34% 47% 47% 42% 18% 43% 23%
RFA, radiofrequency ablation.
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TABLE 48 Mean overall survival from Kaplan–Meier and modelled survival functions
Treatment arm
Mean overall survival (months)
Trial report Exponential Weibull Log-logistic
Surgical resection 47.4 47.2 47.2 47.2
RFA 32.9 47.4 34.2 34.5
Difference 14.5 0.2 13.0 12.7
RFA, radiofrequency ablation.
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88compared with the area under the Kaplan–Meier curve (32.9 months). The model using the exponential
function appears to provide a particularly poor ﬁt for both surgical resection and radiofrequency ablation.
The Weibull model was adopted for the base-case analysis and the alternative survival functions in
structural sensitivity analyses were included.Overall survival – radioembolisation plus hepatic artery chemotherapy
compared with hepatic artery chemotherapy alone
Overall survival curves reported by Grey and colleagues85 were scanned using Engauge software and
imported into Microsoft Excel. At the end of follow-up four patients included in the trial were still alive
(three in the radioembolisation plus hepatic artery chemotherapy arm and one in the control arm).
The ﬁnal portions of the survival curves were extrapolated using a regression analysis.
The extrapolated overall survival curves, for radioembolisation plus hepatic artery chemotherapy, using
different survival functions, are given in Figure 10 along with Kaplan–Meier survival estimates from the trial
report. The Weibull and log-logistic survival functions appear to ﬁt the overall survival curves reasonably
well, with the log-logistic survival function providing the closest ﬁt for median survival (trial report = 17
months, log-logistic = 18 months, Weibull = 20 months, exponential = 15.6 months).
Table 49 reports a comparison of observed survival at 1, 2, 3 and 5 years against model predictions.
Data in Table 49 suggest that the exponential survival function is a poor ﬁt to the observed data, while
the Weibull and log-logistic functions both provide a reasonable ﬁt for early survival (up to 2 years).t (months)
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FIGURE 10 Kaplan–Meier overall survival estimates for radioembolisation plus hepatic artery chemotherapy from the
Grey and colleagues85 trial showing alternative model fits. HAC, hepatic artery chemotherapy.
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TABLE 49 Comparison of observed survival at 1, 2, 3 and 5 years against model predictions
Year
Trial report Weibull model Exponential model Log-logistic model
HAC RE +HAC HAC RE +HAC HAC RE +HAC HAC RE +HAC
1 68% 72% 62% 72% 47% 59% 61% 71%
2 29% 39% 29% 41% 22% 34% 34% 36%
3 6% 17% 11% 21% 10% 20% 13% 19%
5 0% 4% 1% 4% 2% 7% 5% 7%
HAC, hepatic artery chemotherapy; RE, radioembolisation.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Both functions seem to overestimate survival with hepatic artery chemotherapy at 3 years, with the
log-logistic also overestimating survival for radioembolisation plus hepatic artery chemotherapy
and hepatic artery chemotherapy alone. In contrast, the Weibull function appears to give reasonable
predictions of 5-year survival for both treatment arms.
Mean survival reported by Grey and colleagues85 and from each of the modelled survival functions
(extrapolated to a maximum duration of 57 months for comparison with the area under the reported
Kaplan–Meier curve) is reported in Table 50.
Mean overall survival for radioembolisation plus hepatic artery chemotherapy and for hepatic artery
chemotherapy alone estimated using the Weibull survival function is very similar to that reported from the
trial (23.3 compared with 23.5 months and 18.6 compared 18.4 months, for radioembolisation plus
hepatic artery chemotherapy and for hepatic artery chemotherapy alone, respectively). The model using
the exponential function appears to underestimate overall survival for both radioembolisation plus hepatic
artery chemotherapy and for hepatic artery chemotherapy alone, and to overestimate the survival
difference when compared with the trial report. In contrast, while the log-logistic survival function gives
the closest ﬁt for median survival it appears to underestimate mean survival for radioembolisation plus
hepatic artery chemotherapy while overestimating for hepatic artery chemotherapy alone, hence
underestimating the survival difference compared with the trial report.
The Weibull model was adopted for the base-case analysis and the alternative survival functions in
structural sensitivity analyses were included.Progression-free survival – microwave ablation compared with
surgical resection
The trial report by Shibata and colleagues72 does not report Kaplan–Meier curves for progression-free
survival, or the proportion of patients remaining progression free at given time points. The only reportedTABLE 50 Mean overall survival from Kaplan–Meier and modelled survival functions for radioembolisation plus
hepatic artery chemotherapy and hepatic artery chemotherapy alone
Treatment arm
Mean overall survival (months)
Trial report Weibull Exponential Log-logistic
RE + HAC 23.5 23.3 20.7 22.7
HAC 18.4 18.6 15.5 19.0
Difference 5.1 4.7 5.2 3.7
HAC, hepatic artery chemotherapy; RE, radioembolisation.
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90information on time to disease progression reported in the trial publication is the mean disease-free
interval – no measures of variability (SDs or CIs) are reported. These mean values (Table 51) are used in the
model as estimates of progression-free survival – in the absence of any further indication an exponential
form for the survival function was assumed.
Progression-free survival – radiofrequency ablation compared with
surgical resection
Radiofrequency ablation compared with surgical resection for solitary
metastases < 3 cm
The extrapolated progression-free survival functions for surgical resection are given in Figure 11 along
with Kaplan–Meier estimates from the study publication. The Weibull and log-logistic survival functions
appear to ﬁt reasonably well for up to 12 months, but overestimate survival from 12 to 30 months.
All the parametric functions appear to overestimate median survival with the exponential function
(at approximately 30 months) giving the greatest discrepancy with the Kaplan–Meier estimate.
Mean times to progression from each of the modelled survival functions (truncated at 72 months for
comparison with the area under the reported Kaplan–Meier curve) are reported in Table 52.
Both the Weibull and log-logistic functions appear to underestimate mean progression-free survival,
and to slightly underestimate the difference between surgical resection and radiofrequency ablation.
The exponential function shows the greatest discrepancy with the values observed in the study.t (months)
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FIGURE 11 Kaplan–Meier progression-free survival estimates for resected patients with solitary liver metastases
(< 3 cm) from the Kim and colleagues73 study showing alternative model fit.
TABLE 51 Mean disease-free interval reported for surgical resection and microwave ablation
Treatment arm Mean disease-free interval (months)
Surgical resection 13.3
MWA 11.3
MWA, microwave ablation.
Data as reported by Shibata and colleagues.72
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TABLE 52 Mean progression-free survival from Kaplan–Meier and modelled survival functions for patients with
solitary liver metastases (< 3 cm)
Treatment arm
Mean progression-free survival (months)
Study report Exponential Weibull Log-logistic
Surgical resection 30.0 34.3 27.8 29.2
RFA 31.6 34.4 29.0 30.5
Difference 1.6 0.1 1.2 1.3
RFA, radiofrequency ablation.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7The Weibull model was adopted for the base-case analysis and the alternative survival functions in
structural sensitivity analyses were included.Radiofrequency ablation compared with surgical resection for solitary
metastases ≥ 3 cm
The extrapolated progression-free survival curves, for surgical resection, using different survival functions,
are given in Figure 12 along with Kaplan–Meier survival estimates from the trial report. The Weibull and
log-logistic survival functions appear to ﬁt the progression-free survival curves reasonably well, although all
the modelled functions give lower predictions than the Kaplan–Meier curves for survival over 5 years. Each
of the modelled functions appears to overestimate progression-free survival [trial report = 24.9 months (this
is not reported in the study, but has been estimated from the Kaplan–Meier curve), exponential =
37.1 months, Weibull = 32 months, log-logistic = 30 months].
Mean progression-free survival derived from the study by Kim and colleagues73 and from each of the
modelled survival functions (extrapolated to a maximum duration of 72 months for comparison with the
area under the reported Kaplan–Meier curve) is reported in Table 53.
The Weibull model was adopted for the base-case analysis and the alternative survival functions in
structural sensitivity analyses were included.t (months)
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FIGURE 12 Kaplan–Meier progression-free survival estimates for surgical resection in patients with solitary
metastases (≥ 3 cm) from the Kim and colleagues73 study showing alternative model fit.
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TABLE 53 Mean progression-free survival from Kaplan–Meier and modelled survival functions for patients with
solitary metastases (≥ 3 cm)
Treatment arm
Mean overall survival (months)
Study report Exponential Weibull Log-logistic
Surgical resection 35.5 39.1 37.0 36.7
RFA 20.1 39.3 17.1 18.5
Difference 15.1 0.2 19.9 18.3
RFA, radiofrequency ablation.
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92Progression-free survival – radioembolisation plus hepatic artery chemotherapy
compared with hepatic artery chemotherapy alone
Kaplan–Meier estimates for time to disease progression (by tumour area and by tumour volume) reported
by Grey and colleagues85 were scanned using Engauge software and imported into Microsoft Excel.
The extrapolated survival functions for time to disease progression for radioembolisation plus hepatic artery
chemotherapy are given in Figure 13 along with Kaplan–Meier survival estimates from the trial report.
The Weibull and log-logistic survival functions appear to ﬁt reasonably well, with both survival functions
providing close ﬁts for median time to disease progression (trial report = 15.9 months, Weibull =
15.7 months, log-logistic = 15.4 months, exponential = 14.9 months).
Mean times to progression from each of the modelled survival functions (truncated at 24 months for
comparison to the area under the reported Kaplan–Meier curve) are reported in Table 54.
Mean progression-free survival for radioembolisation plus hepatic artery chemotherapy and for hepatic
artery chemotherapy alone estimated using the Weibull survival function is the same as the value
estimated from the Kaplan–Meier curves reported from the trial (15.2 months compared with 15.2 months
and 9.8 months compared with 9.8 months, for radioembolisation plus hepatic artery chemotherapy and
for hepatic artery chemotherapy alone, respectively), with similar estimates of the difference. The model
using the exponential function appears to underestimate progression-free survival for radioembolisation
plus hepatic artery chemotherapy but overestimate for hepatic artery chemotherapy alone, leading to an
underestimate of the difference in progression-free survival when compared with the trial report and the
Weibull survival model. In contrast, while the log-logistic survival function appears to give a similar ﬁt to
the Weibull function (see Figure 13), it underestimates progression-free survival for both radioembolisation
plus hepatic artery chemotherapy and for hepatic artery chemotherapy alone, and appears to overestimate
the survival difference compared with the trial report and the Weibull survival model.t (months)
S(
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FIGURE 13 Kaplan–Meier time to progression estimates from the Grey and colleagues85 trial showing Weibull and
alternative model fit. HAC, hepatic artery chemotherapy; RE, radioembolisation.
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TABLE 54 Mean progression-free survival from Kaplan–Meier and modelled survival functions
Treatment arm
Mean progression-free survival (months)
Trial report Weibull Exponential Log-logistic
RE + HAC 15.2 15.2 14.9 14.9
HAC 9.8 9.8 11.6 9.1
Difference 5.4 5.3 3.3 5.8
HAC, hepatic artery chemotherapy; RE, radioembolisation.
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structural sensitivity analyses were included.Adverse events – microwave ablation compared with surgical resection
Adverse events for patients in the study by Shibata and colleagues72 are reported in Table 13 in the clinical
effectiveness section of this report (see Chapter 4, Microwave ablation).Adverse events – radiofrequency ablation compared with surgical resection
The study by Kim and colleagues73 reports that there was no treatment-related mortality in the
radiofrequency ablation or surgical resection groups, but that treatment-related morbidity was statistically
signiﬁcantly higher in the surgical resection group [11/177 (6.2%) of the radiofrequency ablation group
compared with 59/278 (21.2%) of the surgical resection group, p< 0.001]. The number and proportion of
patients in each group experiencing treatment-related morbidity, by cause, is reported in Table 55.
Adverse events – radioembolisation plus hepatic artery chemotherapy
compared with hepatic artery chemotherapy alone
Adverse events for patients in the study by Grey and colleagues85 are reported in Table 35 in the clinical
effectiveness section of this report (see Chapter 4, Radioembolisation).Quality of life
Utility weights currently applied in the model are reported in Table 56 and were derived from our
systematic review of quality-of-life studies in patients with liver metastases (see Systematic review of
health-related quality-of-life evidence). The utility value for stable disease (with or without liver metastases)
is based on the baseline value reported by Wiering and colleagues.151 The effect of treatment on quality of
life is based on the proportionate reduction for treated patients at 2 weeks reported for ablated patients
by Krabbe and colleagues146 (mean utility reduced from 0.90 to 0.81 at 2 weeks, a 10% reduction) and byTABLE 55 Adverse events for RFA compared with surgical resection
Adverse event RFA, n = 177 Surgical resection, n = 278
Bleeding (transfusion) 2 (1.1) 13 (4.7)
Abscess 8 (4.5) 17 (6.1)
Wound infection 0 (0.0) 10 (3.6)
Transient respiratory failure 1 (0.6) 18 (2.9)
Ileus 0 (0.0) 11 (4.0)
Total 11 (6.2) 59 (21.2)
RFA, radiofrequency ablation.
Data as reported by Kim et al.73
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TABLE 56 Utility weights applied to states in the model
Health state in model Utility weight Source
Stable disease, with residual metastases 0.82 Wiering et al.151
Up to 6 months post surgical resection 0.65a Wiering et al.,151 Krabbe et al.146
Up to 3 months post ablation 0.74b Krabbe et al.146
Disease progression 0.62c Tappenden et al.,160 Petrou and Campbell161
Terminal (month before death in progressive disease) 0.45 Wiering et al.151
a Assuming a 21% reduction in quality of life associated with surgical resection: 0.82 0.79 = 0.65.
b Assuming a 10% reduction in quality of life associated with ablation: 0.82 0.90 = 0.74.
c The utility value for progressive disease is derived from the value for stable disease. A relative weighting of 0.75 was
applied for quality of life following disease progression: 0.82 0.75 = 0.62.
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94Wiering and colleagues151 for surgical patients (mean utility reduced from 0.82 to 0.65 at 2 weeks, a 21%
reduction). The reduction in quality of life resulting from surgical resection is applied for 6 months, based
on proﬁles reported by Wiering and colleagues151 and Krabbe and colleagues,146 while the quality-of-life
reduction resulting from ablation is applied for 3 months, based on proﬁles reported by Krabbe and
colleagues.146 A relative weighting of 0.75 for disease progression is applied in the model, based on an
estimate reported by Tappenden and colleagues,160 derived from Petrou and Campbell161 which was
identiﬁed in a systematic review of studies reporting utility values for health states relevant for patients
with metastatic colorectal cancer (not speciﬁc to people with liver metastases).
Resource use and cost
The groups of health care costs included in the base-case health economic model are treatment costs
[including cost of interventions, costs of intervention administration, on-treatment monitoring and costs of
post-discharge follow-up (where relevant)], post-treatment monitoring and palliative care costs.Treatment costs: microwave ablation compared with surgical resection
In the trial reported by Shibata and colleagues,72 microwave ablation was performed after laparotomy and
consisted of a series of 10–30 second coagulation periods, followed by a 10-second coagulation-free
period, for each tumour (up to total coagulation period of between 2 and 20 minutes). The average
reported operation time was 180 minutes, with total hospitalisation period of 20 days (SD 7 days). Five of
the 14 patients undergoing microwave ablation for liver metastases (36%) in the trial were reported to
receive a second round of treatment. Microwave ablation procedure costs can be seen in Table 57.TABLE 57 Microwave ablation procedure costs
Item Cost (£)
MWA procedurea 3866
Additional bed-daysb 4436
Total 8302
MWA, microwave ablation.
a NHS Reference Costs 2009–10.162 Hepatobiliary procedures category 3 without complications and comorbidities.
HRG code GA07B.
b Average length of stay for HRG GA07B is 3.75 days. Average length of stay for MWA in trial by Shibata and colleagues73
was 20 days. Additional days are costed at inpatient excess bed-day cost of £273 per day.
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1 month after discharge from hospital.
The average total cost for patients undergoing microwave ablation, including outpatient follow-up at
1 month post discharge and allowing for repeat procedures in 36% of patients, was estimated as £11,613.
In the trial reported by Shibata and colleagues,72 hepatectomy (referred to here as surgical resection) was
deﬁned as lobectomy, segmentectomy, subsegmentectomy and/or wedge resection depending on the
number, location and size of tumours. The trial report does not indicate the relative frequency of each of
these procedures. It was assumed that all procedures were performed as wedge resection (HRG code
GA05B, Hepatobiliary Procedures category 5). The impact of this assumption is explored in sensitivity
analyses applying lower unit costs for less resource intensive procedures, and higher unit costs for more
resource intensive procedures.
It was assumed that all patients admitted for surgical resection would require follow-up as outpatients
1 month after discharge from hospital, as for those undergoing microwave ablation (Table 58). The
average total cost for patients undergoing surgical resection, including outpatient follow-up at 1 month
post discharge, was estimated as £12,173 (Table 59).Treatment costs: radiofrequency ablation compared with surgical resection
In the trial reported by Kim and colleagues,73 radiofrequency ablation was performed percutaneously
under local anaesthetic using ultrasound guidance to ensure a 1-cm ablation margin around the tumour.
A single electrode, with 3-cm exposed tip, was used for small tumours and a triple-cluster electrode with
2.5-cm exposed tip was used for larger tumours, at the discretion of the radiologist. Radiofrequency
current was emitted for 10–15 minutes with the generator set to deliver maximum power impedance
in impedance control mode. Destruction of liver metastases was conﬁrmed by follow-up CT and
ultrasound the next day. Mean duration of hospitalisation was 4.2 days (SD = 2.8 days, with a range of
1–32 days). The study does not report whether or not patients underwent repeat treatment with
radiofrequency ablation.
It was assumed that all patients undergoing radiofrequency ablation would require follow-up as
outpatients 1 month after discharge from hospital.
The average total cost for patients undergoing microwave ablation was estimated as £3628 (Table 60).TABLE 58 Resource use and unit costs for post-discharge follow-up of surgical patients
Item Frequency of use Unit cost (£)
Outpatient attendancea Once, at 1 month post discharge 128.13
Full blood countb Once, at 1 month post discharge 0.50
Liver function testsb Once, at 1 month post discharge 0.38
CEAb Once, at 1 month post discharge 1.74
Abdominal CTc Once, at 1 month post discharge 100.65
Total 236.81
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 105
hepatobiliary and pancreatic surgery.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
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TABLE 59 Surgical resection procedure costs
Item Cost (£)
Surgical resection procedurea 6629
Additional bed-daysb 5308
Total 11,937
a NHS Reference Costs 2009–10.162 Hepatobiliary procedures category 5 without CC. HRG code GA05B.
b Average length of stay for HRG GA05B is 5.7 days. Average length of stay for surgical resection in trial by Shibata and
colleagues72 was 25 days. Additional days are costed at inpatient excess bed-day cost of £275 per day.
TABLE 60 Radiofrequency ablation procedure costs
Item Cost (£)
RFA procedurea 3391
Additional bed-daysb 0
Total 3391
RFA, radiofrequency ablation.
a NHS Reference Costs 2009–10.162 Endoscopic/radiology category 4. HRG code GB01Z.
b Average length of stay for HRG GB01Z is 4.6 days. Average length of stay for RFA in study by Kim and colleagues73 was
4.2 days.
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underwent lobectomy, 15% (42/278) segmentectomy and 80% (222/278) subsegmentectomy. Surgical
resection of a liver segment and wedge resection of the liver are both classiﬁed under ‘Hepatobiliary
procedures – category 5’ (a relatively resource intensive grouping) for NHS Reference Costs, while
hemi-hepatectomy is classiﬁed under ‘Hepatobiliary procedures – category 6’ (a more resource-intensive
grouping). It was assumed that the majority of procedures would be classiﬁed as category 5 – equivalent
to segmentectomy or subsegmentectomy – and the relevant NHS Reference Costs have been applied
(Table 61). The impact of this assumption is explored in sensitivity analyses applying lower unit costs, for
less resource-intensive procedures, and higher unit costs, for more resource-intensive procedures.
The mean duration of hospitalisation for resected patients was 13.4 days (SD = 4.5, with a range
from 7 to 42 days).
It was assumed that all patients undergoing surgical resection would require follow-up as outpatients
1 month after discharge from hospital, as for those undergoing radiofrequency ablation (Table 62).
The average total cost for patients undergoing surgical resection, including outpatient follow-up at
1 month post discharge, was estimated as £8983.Treatment costs: radioembolisation plus hepatic artery chemotherapy
compared with hepatic artery chemotherapy alone
In the trial reported by Grey and colleagues,85 hepatic artery chemotherapy consisted of the administration
of ﬂoxuridine (FUDR) at 0.3 mg/kg of body weight per day (in 12-day cycles). The chemotherapy was
administered via a hepatic artery port inserted during a laparotomy procedure. The laparotomy was also
used to conﬁrm that patients did not have existing, non-excisable, extrahepatic disease. ChemotherapyNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 61 Surgical resection procedure costs
Item Cost (£)
Surgical resection procedurea 6629
Additional bed-daysb 2118
Total 8747
a NHS Reference Costs 2009–10.162 Hepatobiliary procedures category 5 without CC. HRG code GA05B.
b Average length of stay for HRG GA05B is 5.7 days. Average length of stay for surgically resected patients in the
study reported by Kim and colleagues73 was 13.4 days. Additional days are costed at Inpatient excess bed-day cost
of £275 per day.
ABLE 62 Resource use and unit costs for post-discharge follow-up of patients with liver metastases treated with
adiofrequency ablation
Item Frequency of use Unit cost (£)
Outpatient attendancea Once, at 1 month post discharge 128.13
Full blood countb Once, at 1 month post discharge 0.50
Liver function testsb Once, at 1 month post discharge 0.38
CEAb Once, at 1 month post discharge 1.74
Abdominal CTc Once, at 1 month post discharge 100.65
Total 236.81
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 105
hepatobiliary and pancreatic surgery.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
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rwas discontinued on evidence of tumour progression within the liver, extrahepatic disease requiring
change to systemic chemotherapy, unacceptable toxicity, at patient request or at a maximum of 18 cycles.
As the laparotomy procedure and hepatic artery chemotherapy were common treatments in both trial
arms, and hepatic artery chemotherapy dosing appears to have been similar in both arms (mean number
of cycles was 8.0 and 8.7, amount of protocol chemotherapy per patient 1822 and 1863 for hepatic artery
chemotherapy and radioembolisation plus hepatic artery chemotherapy, respectively), this cost is not
included in the model as it would not inﬂuence the calculation of incremental cost for radioembolisation
plus hepatic artery chemotherapy.
Radioembolisation, in the trial reported by Grey and colleagues,85 consisted of the administration of
SIR-Spheres,® at a dosage dependent on the size of tumour. Patients with a tumour < 25% of liver volume
received a dose equivalent to 2 GBq, those with tumour volume of 25–50% received equivalent to
2.5 GBq and those with tumours > 50% of liver volume received equivalent to 3 GBq. The trial protocol
allowed for dose reduction in patients who experienced greater than 10% lung–liver breakthrough
(reducing the yttrium-90 by 2% for every 1% of lung–liver breakthrough in excess of 10%). Estimating
the average dose, based on the distribution of tumour size across patients in the radioembolisation plus
hepatic artery chemotherapy arm of trial, yields an average dose of 2.21 GBq (Table 63). This differs
slightly from the mean delivered dose of 2.156 GBq (SD = 0.324) in the trial report, due to ﬁve patients
receiving less and one patient receiving more than the protocol-speciﬁed dose (although these dose97
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TABLE 63 Estimated average dose of yttrium-90 activity
Tumour size (percentage of liver involved with tumour) Number of patients (%) Dose
< 25% 24 (67) 2.0 GBq
25–50% 9 (25) 2.5 GBq
> 50% 3 (8) 3.0 GBq
Average for patient group 2.2 GBq
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98variations do not appear to be due to lung–liver breakthrough as the trial reported that no patient
experienced a greater than 10% breakthrough).
Average costs for radioembolisation using SIR-Spheres® are reported in Table 64.
Administration and on-treatment monitoring
All patients eligible for treatment with hepatic artery chemotherapy or radioembolisation plus hepatic
artery chemotherapy undergo laparotomy by a surgical oncologist to conﬁrm non-resectable status of
metastases, to look for evidence of intra-abdominal spread of the tumour and insertion of a permanent
hepatic artery catheter connected to a subcutaneous access port (for delivery of hepatic artery
chemotherapy and for insertion of SIR-Spheres® for radioembolisation). As indicated, this procedure is
common to both intervention and comparator and is not included in the costing.
Patients undergoing radioembolisation require a nuclear medicine scan to determine the amount of
SIR-Spheres® that would pass through the liver and lodge in the lungs [macroaggregated albumin (MAA)
shunt study and breakthrough study] and will be admitted as inpatients for the radioembolisation
procedure (Table 65 shows estimated costs).TABLE 64 Unit costs for radioembolisation consumables
Item Cost (£)
Average consumables costs for SIR (parts 1 and 2) 2861
SIR-Spheres® yttrium-90 therapy 8050
Total cost 10,911
Source: Julie Thomas, University Hospital Southampton NHS Foundation Trust, 2012, personal communication.
TABLE 65 Radioembolisation procedure costs
Item Cost (£)
MAA shunt studya 500
Breakthrough studya 500
Radioembolisation procedureb 2305
Total 3305
a Julie Thomas, University Hospital Southampton NHS Foundation Trust, 2012, personal communication.
b NHS Reference Costs 2009–10.162 Endoscopic/radiology category 3 without complications and comorbidities.
HRG code GB02C.
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to receive hepatic artery chemotherapy. The full package of on-treatment monitoring is listed in Table 66
and consists of an outpatient visit (with full blood count, liver function tests and serum CEA test) every
4 weeks as well as an abdominal CT every 3 months (to identify disease progression) and a alpha-
fetoprotein test every 3 months.
Follow-up costs: microwave ablation compared with surgical resection
Following the end of treatment, and prior to disease progression, patients are assumed to attend as
outpatients (with full blood count, liver function tests and serum CEA test) and to have an abdominal CT
(Table 67).
Follow-up costs: radiofrequency ablation compared with surgical resection
Following the end of treatment, and prior to disease progression, patients are assumed to attend as
outpatients every 3 months (with full blood count, liver function tests and serum CEA test) and to have an
abdominal CT (Table 68).TABLE 66 Resource use for on-treatment monitoring
Item Frequency of use Unit cost (£)
Outpatient attendancea Every 4 weeks 98.25
Full blood countb Every 4 weeks 0.50
Liver function testsb Every 4 weeks 0.38
CEA testb Every 4 weeks 1.74
Abdominal CTc Every 3 months 100.65
Alpha-fetoprotein testb Every 3 months 1.82
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 301S.
Surgical gastroenterology.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
TABLE 67 Resource use for microwave ablation/surgical resection patients – post-treatment monitoring
(for patients whose disease has not progressed)
Item Frequency of use Unit cost (£)
Outpatient attendancea Every 3 months 128.13
Full blood countb Every 3 months 0.50
Liver function testsb Every 3 months 0.38
CEAb Every 3 months 1.74
Abdominal CTc Every 3 months 100.65
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 105
hepatobiliary and pancreatic surgery.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
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TABLE 68 Resource use for patients treated with radiofrequency ablation or surgical resection – post-treatment
monitoring (for patients whose disease has not progressed)
Item Frequency of use Unit cost (£)
Outpatient attendancea Every 3 months 128.13
Full blood countb Every 3 months 0.50
Liver function testsb Every 3 months 0.38
CEAb Every 3 months 1.74
Abdominal CTc Every 3 months 100.65
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 105
hepatobiliary and pancreatic surgery.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
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100Follow-up costs: radioembolisation plus hepatic artery chemotherapy
compared with hepatic artery chemotherapy alone
Following the end of treatment, and prior to disease progression, patients are assumed to attend as
outpatients every 3 months (with full blood count, liver function tests and serum CEA test) and to have an
abdominal CT (Table 69).
Palliative care costs
Palliative care costs in the model are estimated at £600 per month and are based on those adopted by
Tappenden and colleagues,160 derived from Remak and Brazil.163 These costs are applied for the remaining
life expectancy of patients who experience disease progression, irrespective of their initial treatment.Results of independent economic analysis
Microwave ablation compared with surgical resection
This section reports cost-effectiveness results for a cohort of patients with resectable liver metastases
undergoing either microwave ablation or surgical resection, based on the trial report by Shibata and
colleagues.72 Discounted costs (identifying the contribution of procedure costs, surgical follow-up,
monitoring prior to disease progression and palliative care) are presented alongside the life expectancy
and quality-adjusted life expectancy for patients in the cohort. The results are presented as incremental
cost per life-year gained and incremental cost per QALY gained.TABLE 69 Resource use for post-treatment monitoring (for patients whose disease has not progressed)
Item Frequency of use Unit cost (£)
Outpatient attendancea Every 3 months 98.25
Full blood countb Every 3 months 0.50
Liver function testsb Every 3 months 0.38
CEAb Every 3 months 1.74
Abdominal CTc Every 3 months 100.65
a NHS Reference Costs 2009–10.162 Consultant-led: follow-up attendance non-admitted face to face. Code 301S.
Surgical gastroenterology.
b Southampton University Hospitals NHS Trust (marginal costs including stafﬁng, reagents and overheads).
c NHS Reference Costs 2009–10.162 Computerised tomography scan, one area, no contrast. HRG code RA08Z.
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surgical resection are presented in Table 70. Costs and health outcomes in the table have been discounted
at 3.5%.
The estimated gain in discounted life expectancy associated with microwave ablation is negative –
microwave ablation is associated with a reduction of 0.10 years (5.2 weeks) when compared with surgical
resection. The equivalent undiscounted values are 0.11 years (5.7 weeks). The estimated reduction in
discounted QALYs, associated with microwave ablation, is 0.09. The equivalent undiscounted value is
0.10 QALYs.
The incremental cost associated with microwave ablation is also negative (£327), indicating that treatment
of liver metastases with microwave ablation is slightly lower cost than treatment with surgical resection.
Table 71 reports a breakdown of treatment costs, by phase of treatment, for each cohort.
In this analysis, microwave ablation as a treatment for patients with resectable liver is associated with both
reduced outcomes (in terms of life expectancy and quality-adjusted life expectancy) and reduced costs,
resulting in an ICER of £3664 per QALY gained. However, it should be noted that this positive ICER is
derived from negative incremental cost and incremental QALY values – in this analysis microwave ablation
is associated with reduced cost but also poorer outcome than surgical resection, requiring a judgement on
whether or not the savings can justify the poorer outcome.Deterministic sensitivity analysis
A sensitivity analysis was conducted to consider the effect of uncertainty around the model structure and
for variation in certain key parameters that were expected, a priori, to be inﬂuential on the cost-
effectiveness results. The method adopted in most cases was univariate sensitivity analysis; that is, varying
one parameter at a time, leaving all other variables unchanged. This is to highlight the impact, if any, ofTABLE 70 Base-case analysis for microwave ablation and surgical resection
Treatment Costs (£) Life-years
Incremental cost per
life-year gained (£) QALYs
Incremental cost per
QALY gained (£)
Surgical resection 20,152 1.94 1.38
MWA 19,825 1.84 3293 1.29 3664
MWA, microwave ablation.
TABLE 71 Treatment costs by phase of treatment for microwave ablation and surgical resection
Phase of treatment MWA (£) Surgical resection (£)
Active treatment Procedure cost 11,291 11,937
Surgical follow-up 322 237
Non-progressive disease monitoring 1487 1606
Palliative care 6726 6373
Total 19,825 20,152
MWA, microwave ablation.
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102each selected parameter alone on the cost-effectiveness results. In some situations (such as the analysis of
alternative parametric forms for the survival function, or the analysis using the upper conﬁdence limits for
all parameters in survival model) a set of related parameters are varied simultaneously. The effects of
uncertainty in multiple parameters were addressed using PSA, which is reported later in the section.
Table 72 reports the results of the sensitivity analysis. Except for the sensitivity analysis with respect to time
horizon, all analyses were conducted using a 5-year time horizon. The table is divided to distinguish
between analyses undertaken due to uncertainties over structural assumptions in the model,
methodological uncertainties (in this case related to the discount rates applied in the model) and
uncertainty over parameter values. Where unit costs have been taken from NHS Reference Costs, the
upper and lower quartiles have been used in the sensitivity analysis. In all other cases unit costs have been
varied by plus or minus 20%.TABLE 72 Deterministic sensitivity analysis – microwave ablation and surgical resection for resectable
liver metastases
Incremental
cost (£)
Life-years
gained
QALYs
gained
ICER (£ per
QALY gained)
Base case –327 –0.10 –0.09 3664
Structural assumptions
Truncate survival at maximum follow-up for trial –325 –0.09 –0.08 3866
Extrapolate overall survival up to 10 years –328 –0.10 –0.09 3634
Exponential overall survival modela 1869 0.22 0.11 17,007
Log-logistic overall survival modela 767 0.05 0.00 648,069
Methodological assumptions
Discount rates (0% for both costs and outcomes) –329 –0.11 –0.10 3409
Discount (6% for costs and 1.5% for outcomes) –326 –0.10 –0.09 3496
Parameter uncertainty
Lower 95% CI for treatment effect –5239 –0.78 –0.50 10,526
Upper 95% CI for treatment effect 3194 0.44 0.24 13,035
Lower 95% CI for all parameters in overall survival model –819 –0.17 –0.13 6348
Upper 95% CI for all parameters in overall survival model –175 0.12 0.09 –1979
Exclude palliative care costs –680 –0.10 –0.09 7618
Upper limit for utility values –327 –0.10 –0.08 4116
Lower limit for utility values –327 –0.10 –0.11 2951
Procedure cost: lower quartile 534 –0.10 –0.09 –5976
Procedure cost: upper quartile 1008 –0.10 –0.09 –11,292
Cost of palliative care reduced by 20% –398 –0.10 –0.09 4455
Cost of palliative care increased by 20% –257 –0.10 –0.09 2873
Cost of outpatient visit for monitoring: lower quartile –312 –0.10 –0.09 3494
Cost of outpatient visit for monitoring: upper quartile –343 –0.10 –0.09 3842
a The trial reported insufﬁcient detail to model alternative parametric forms for progression-free survival – as a result an
exponential function has been used for progression-free survival in all analyses, including the base case.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7The cost-effectiveness results appear to be generally within the range of £2800 to £5000. However, it
should be noted that the majority of these positive ICERs are the result of negative incremental cost and
incremental QALY values – that is to say, in this analysis microwave ablation is associated with reduced
cost but also poorer outcome than surgical resection. In this context the conventional interpretation of
cost-effectiveness as being below a given acceptable threshold is reversed. Rather than balancing any
increased cost against gains in outcome (as would be typical for interpreting cost-effectiveness results) the
decision framework in this case would be to consider whether or not the size of savings (indicated by the
lower incremental cost) can justify the reduced outcome.
Among the structural sensitivity analyses the results appear to be most sensitive to assumptions over the
functional form for the survival functions. In terms of parameter inputs, the results appear to be most
sensitive to variation in utility estimates applied in the model, variation in values of parameters in the
survival functions (for treatment effect on overall survival and all parameters in the overall survival
function), variation in procedure costs, and the cost of palliative care.
Time horizon for the model appears to have a limited impact on the cost-effectiveness estimates.
Truncating survival at the maximum duration observed for each arm reported in the RCT by Shibata and
colleagues72 leaves both incremental cost and incremental QALYs almost unchanged, while increasing the
maximum survival duration to 10 years leads to a slight increase in incremental cost and incremental
QALYs. Adopting alternative parametric forms for the overall survival functions leads to large changes in
the incremental cost and incremental QALYs, and hence the ICER. Adopting an exponential form for the
overall survival function results in positive incremental cost of £1869 and also results in a positive QALY
gain, unlike the base-case analysis. Adopting a log-logistic form also results in a positive incremental cost,
but produces a QALY gain close to zero and results in a high-value ICER. However, it should be borne in
mind that these functional forms did not ﬁt the observed data as closely as did the Weibull form adopted
in the base case.
Varying the discount rates applied has comparatively little effect. Zero discount rates for costs and
outcomes result in a slight increase in incremental cost and a slight increase in incremental QALYs
compared with baseline values. Applying discount rates of 6% for costs and 1.5% for outcomes leads
to a slight reduction in incremental cost and leaves incremental QALYs almost unchanged.
Varying the value of the treatment effect parameter in the overall survival model, between its upper and
lower conﬁdence limits, has a large effect on both incremental cost and incremental outcome. At the
lower limit of the treatment effect parameter, incremental costs increase to –£5239 and incremental
QALYs increase to –0.50, causing the ICER to increase to £10,526. At the upper limit of the treatment
effect parameter, the incremental cost and incremental QALYs become positive, the QALY gain changing
from a small negative number (–0.09) to 0.24 and incremental cost rising to approximately £3200. At the
lower limit of all the parameters in the overall survival model the proportionate increase in incremental cost
is greater than the proportionate increase in incremental QALYs, leading to an increase in ICER. At the
upper limit for all the parameters in the overall survival model the incremental cost remains negative while
the incremental QALYs becomes positive – in this case microwave ablation would be dominant (providing
better outcomes at lower cost).
Variation in procedure costs (between the upper and lower quartiles reported for the NHS Reference
Costs) appears to have a large inﬂuence on the results. Incremental costs are positive at the upper and
lower limits for procedure cost so that, given that outcomes are slightly poorer for microwave ablation
than for surgical resection, microwave ablation is dominated (providing poorer outcomes at higher cost) in
this analysis. The cost-effectiveness results also appear to be sensitive to variation in palliative care costs. If
palliative care costs are reduced, or removed, incremental cost increases up to a maximum of –£680 (when
palliative care costs are removed from the model).103
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104Probabilistic analysis
In a PSA, where the parameters of the survival models (both overall and progression-free survival), health
state utility values, treatment cost, cost of outpatient attendances and patient monitoring, as well as costs
of managing adverse events and palliative care were sampled probabilistically, microwave ablation is
associated with reduced costs in 56% of simulations (with a range from –£10,866 to £8606) and lower
QALYs in 68% of simulations (with a range of –0.80 to 0.54) when compared with surgical resection
(Figure 14 shows this and also shows the 95% conﬁdence ellipse).
The probabilistic analysis generated cost and QALY estimates for each intervention that were greater than
those for the base-case analysis (see Table 71 for the base-case analysis). However, the mean incremental
cost and mean QALY gain were similar (–£327 and –0.09 QALYs compared with –£377 and –0.07 QALYs
for the deterministic base case and PSA respectively). Table 73 reports the mean costs and outcomes from
the probabilistic analysis (including the 2.5th and 97.5th percentiles to give an indication of the range of
the simulated values) and the ICER for microwave ablation compared with surgical resection, based on the
mean values generated in the probabilistic analysis.10,000
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FIGURE 14 Cost-effectiveness plane – incremental cost and incremental QALYs for microwave ablation compared
with surgical resection.
TABLE 73 Costs and outcomes from probabilistic analysis for microwave ablation and surgical resection
Procedure
Discounted costs (£) Discounted QALYs
ICER (£)Mean
2.5th
percentile
97.5th
percentile Mean
2.5th
percentile
97.5th
percentile
Surgical resection 21,578 13,298 35,722 1.44 0.59 2.61
MWA 21,160 13,091 35,529 1.37 0.61 2.55 5428
MWA, microwave ablation.
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cost-effectiveness acceptability curve was derived, representing the proportion of simulations where
microwave ablation is cost-effective for a range of willingness-to-pay thresholds, up to £100,000
(Figure 15). In this analysis microwave ablation had a probability of being cost-effective of 31% at
a willingness-to-pay threshold of £20,000 per QALY and 30% at a willingness-to-pay threshold
of £30,000 per QALY.
Radiofrequency ablation compared with surgical resection
This section reports cost-effectiveness results for a cohort of patients with resectable liver metastases
(small or large solitary liver metastases) undergoing either radiofrequency ablation or surgical resection,
based on data reported by Kim and colleagues.73 The analyses are conducted separately for each patient
population, those with:
l solitary metastases < 3 cm
l solitary metastases ≥ 3 cm.
Discounted costs (identifying the contribution of procedure costs, surgical follow-up, monitoring prior to
disease progression and palliative care) are presented alongside the life expectancy and quality-adjusted
life expectancy for patients in the cohort. The results are presented as incremental cost per life-year gained
and incremental cost per QALY gained.Radiofrequency ablation compared with surgical resection for solitary
metastases < 3 cm
Costs and outcomes modelled for cohorts of patients receiving treatment of radiofrequency ablation or
surgical resection are presented in Table 74. Costs and health outcomes in the table have been discounted
at 3.5%.1.00
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FIGURE 15 Cost-effectiveness acceptability curve for microwave ablation.
TABLE 74 Base-case analysis for radiofrequency ablation and surgical resection for patients with (resectable) liver
metastases < 3 cm
Treatment Costs (£) Life-years
Incremental cost per
life-year gained (£) QALYs
Incremental cost per
QALY gained (£)
Surgical resection 25,612 4.28
Not applicablea
2.99
RFA 19,322 4.28 3.05 –98,998
RFA, radiofrequency ablation.
a Not calculated: no difference in life expectancy.
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106The incremental cost associated with radiofrequency ablation, compared with surgical resection, is
negative (£6290) indicating that costs of treatment for small solitary liver metastases with radiofrequency
ablation are lower than for surgical resection. Table 75 reports a breakdown of treatment costs, by phase
of treatment, for each cohort.
There is no difference in discounted life expectancy between surgical resection and RFA for patients with
solitary liver metastases of < 3 cm. This reﬂects the non-signiﬁcant differences in overall survival shown in
Table 44 (under Clinical effectiveness: overall survival earlier in this section) – the HR for overall survival for
RFA compared with surgical resection estimated in the linear regression used to derive the survival model
was 1.00 indicating no difference. However, as surgical resection is associated with signiﬁcant reduction
in quality of life for up to 6 months post-operatively, surgical resection is associated with lower QALY
outcome than radiofrequency ablation. The estimated gain in discounted QALYs associated with
radiofrequency ablation is 0.06.
In this analysis, radiofrequency ablation as a treatment for patients with (surgically resectable) small solitary
liver metastases is associated with similar outcomes (in terms of life expectancy and quality-adjusted life
expectancy) and reduced costs (compared with surgical resection), resulting in an ICER of –£266,767 per
QALY gained. In conventional terms this would indicate that radiofrequency ablation dominates surgical
resection for the treatment of (surgically resectable) small solitary liver metastases.Deterministic sensitivity analysis
Table 76 reports the results of the sensitivity analysis. Except for the sensitivity analysis with respect to
time horizon, all analyses were conducted using a 10-year time horizon. The table is divided to
distinguish between analyses undertaken due to uncertainties over structural assumptions in the model,
methodological uncertainties (in this case related to the discount rates applied in the model) and
uncertainty over parameter values. Where unit costs have been taken from NHS Reference Costs, the
upper and lower quartiles have been used in the sensitivity analysis. In all other cases unit costs have been
varied by ± 20%.
The cost-effectiveness results appear to be generally robust to variation in parameters included in the
deterministic sensitivity analysis, with the majority of ICERs (for radiofrequency ablation compared with
surgical resection) remaining negative. In this case negative ICERs indicate reduced costs for radiofrequency
ablation compared with surgical resection and small gains in QALY outcomes. In general there are no
differences in expected survival (no life-years gained or lost) between radiofrequency ablation and surgical
resection, except in the structural sensitivity analysis adopting alternative forms for the survival function
and the parameter sensitivity analysis on parameter values in the survival function. Variation in values of
parameters in the overall survival function would be expected to have some impact on life expectancyTABLE 75 Treatment costs by phase of treatment for radiofrequency ablation and surgical resection for patients
with (resectable) liver metastases < 3 cm
Phase of treatment RFA (£) Surgical resection (£)
Active treatment Procedure cost 3391 8747
Surgical follow-up 237 237
Adverse event costs 50 251
Non-progressive disease monitoring 2344 2232
Palliative care 13,301 14,145
Total 19,322 25,612
RFA, radiofrequency ablation.
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TABLE 76 Deterministic sensitivity analysis – radiofrequency ablation and surgical resection for (resectable) liver
metastases < 3 cm
Incremental
cost (£)
Life-years
gained
QALYs
gained
ICER (£ per
QALY gained)
Base case –6290 0.00 0.06 –98,998
Structural assumptions
Truncate survival at maximum follow-up for trial –6127 0.00 0.06 –105,296
Extrapolate overall survival up to 15 years –6342 0.00 0.07 –97,208
Exponential overall survival and progression-free
survival model
–8385 –0.09 0.05 –158,041
Log-logistic survival and progression-free survival model –6618 –0.03 0.05 –142,645
Methodological assumptions
Discount rates (0% for both costs and outcomes) –6407 0.00 0.07 –95,021
Discount (6% for costs and 1.5% for outcomes) –6220 0.00 0.07 –94,716
Parameter uncertainty
Lower 95% CI for treatment effect –4506 0.25 0.21 –21,275
Upper 95% CI for treatment effect –8046 –0.24 –0.08 97,599
Lower 95% CI for all parameters in survival model –4729 0.22 0.19 –24,517
Upper 95% CI for all parameters in overall survival model –7541 –0.17 –0.04 185,312
Lower 95% CI for all parameters in progression-free
survival model
–8907 0.00 0.15 –60,483
Upper 95% CI for all parameters in progression-free
survival model
–4772 0.00 0.01 –327,301
Exclude palliative care costs –5446 0.00 0.06 –85,709
Upper limit for utility values –6290 0.00 0.00 –41,012,309
Lower limit for utility values –6290 0.00 0.20 –30,988
Procedure cost: lower quartile –5805 0.00 0.06 –91,365
Procedure cost: upper quartile –7175 0.00 0.06 –112,926
Cost of palliative care reduced by 20% –6121 0.00 0.06 –96,340
Cost of palliative care increased by 20% –6459 0.00 0.06 –101,656
Cost of outpatient visit for monitoring: lower quartile –6307 0.00 0.06 –99,254
Cost of outpatient visit for monitoring: upper quartile –6273 0.00 0.06 –98,730
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7estimates, whereas variation in values of parameters in the progression-free survival function would be
expected to impact on the QALY estimates (given the difference in utility for stable and progressive
disease states).
Among the structural sensitivity analyses the results appear to be most sensitive to assumptions over the
functional form for the survival functions. The exponential and log-logistic functions are associated with
slightly poorer survival with radiofrequency ablation, hence a slightly reduced QALY gain compared with
the base case. However, the cost reduction, with RFA compared with surgical resection, is also greater
when using the exponential and log-logistic functions of the survival function. In terms of parameter
inputs, the results appear to be most sensitive to variation in values of parameters in the survival functions107
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108(for treatment effect on overall survival and all parameters in the overall survival function) and variation in
the utility estimates applied in the model. The results appear to be relatively insensitive to variation in
costs, time horizon and discount rates.Probabilistic analysis
In a PSA, where the parameters of the survival models (both overall and progression-free survival), health
state utility values, treatment cost, cost of outpatient attendances and patient monitoring, as well as costs
of managing adverse events and palliative care were sampled probabilistically, radiofrequency ablation is
associated with reduced costs (with a range from –£11,189 to –£1369) in all simulations and increased
QALYs for the majority of simulations when compared with surgical resection (Figure 16 shows this and
also shows the 95% conﬁdence ellipse). However, radiofrequency ablation is associated with lower QALYs
in 23% of simulations (with an overall range of –0.21 to 0.07).
The probabilistic analysis generated cost and QALY estimates for each intervention that were similar to
those for the base-case analysis (see Table 74 for the base-case analysis). Table 77 reports the mean costs
and outcomes from the probabilistic analysis (including the 2.5th and 97.5th percentiles to give an
indication of the range of the simulated values) and the ICER for radiofrequency ablation compared with
surgical resection, based on the mean values generated in the probabilistic analysis.TABLE 77 Costs and outcomes from probabilistic analysis for radiofrequency ablation and surgical resection for
(resectable) liver metastases < 3 cm
Procedure
Discounted costs (£) Discounted QALYs
ICER (£)Mean
2.5th
percentile
97.5th
percentile Mean
2.5th
percentile
97.5th
percentile
Surgical resection 25,521 16,749 35,217 3.00 2.32 3.82
RFA 19,192 9,767 28,751 3.07 2.36 3.85 –102,415
RFA, radiofrequency ablation.
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FIGURE 16 Cost-effectiveness plane – incremental cost and incremental QALYs for RFA and surgical resection for
(resectable) liver metastases < 3 cm.
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7In addition to graphing the incremental cost and incremental QALYs for radiofrequency ablation, a
cost-effectiveness acceptability curve was derived, representing the proportion of simulations where
radiofrequency ablation is cost-effective for a range of willingness-to-pay thresholds, up to £100,000
(Figure 17). In this analysis radiofrequency ablation had a probability of being cost-effective of 100% at a
willingness-to-pay threshold of £20,000 per QALY and 100% at a willingness-to-pay threshold of £30,000
per QALY.
Radiofrequency ablation compared with surgical resection for
solitary metastases ≥ 3 cm
Costs and outcomes modelled for cohorts of patients receiving treatment radiofrequency ablation or
surgical resection are presented in Table 78. Costs and health outcomes in the table have been discounted
at 3.5%.
Radiofrequency ablation for patients with solitary liver metastases of ≥ 3 cm is associated with signiﬁcantly
poorer outcome – reduced life expectancy and poorer QALY outcomes – than for surgical resection. The
incremental cost associated with radiofrequency ablation, compared with surgical resection, is negative
(£3207) indicating that costs of treatment for larger solitary liver metastases with radiofrequency ablation
are lower than for surgical resection. Table 79 reports a breakdown of treatment costs, by phase of
treatment, for each cohort.
In this analysis, radiofrequency ablation as a treatment for patients with (surgically resectable)
larger solitary liver metastases is associated with poorer outcomes (in terms of life expectancy and
quality-adjusted life expectancy) and reduced costs (compared with surgical resection), resulting in an ICER
of £2538 per QALY gained. This positive ICER is the result of negative incremental cost and incremental
QALY values – that is to say, in this analysis RFA is associated with reduced cost but also poorer
outcome than surgical resection, requiring a judgement on whether or not the savings can justify the
reduced outcome.1.00
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FIGURE 17 Cost-effectiveness acceptability curve for radiofrequency ablation for (resectable) liver metastases < 3 cm.
TABLE 78 Base-case analysis for radiofrequency ablation and surgical resection for patients with solitary liver
metastases ≥ 3 cm
Treatment Costs (£) Life-years
Incremental cost per
life-year gained (£) QALYs
Incremental cost per
QALY gained (£)
Surgical resection 18,527 4.24 3.24
RFA 15,050 2.81 2241 1.97 2538
RFA, radiofrequency ablation.
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TABLE 79 Treatment costs by phase of treatment for radiofrequency ablation and surgical resection for patients
with solitary liver metastases ≥ 3 cm
Phase of treatment RFA (£) Surgical resection (£)
Active treatment Procedure cost 3391 8747
Surgical follow-up 237 237
Adverse event costs 50 251
Non-progressive disease monitoring 1392 3312
Palliative care 9981 5711
Total 15,050 18,257
RFA, radiofrequency ablation.
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110Deterministic sensitivity analysis
Table 80 reports the results of the sensitivity analysis. Except for the sensitivity analysis with respect to time
horizon, all analyses were conducted using a 10-year time horizon. The table is divided to distinguish
between analyses undertaken due to uncertainties over structural assumptions in the model,
methodological uncertainties (in this case related to the discount rates applied in the model) and
uncertainty over parameter values. Where unit costs have been taken from NHS Reference Costs, the
upper and lower quartiles have been used in the sensitivity analysis. In all other cases unit costs have been
varied by plus or minus 20%.
The cost-effectiveness results appear to be generally robust to variation in parameters included in the
deterministic sensitivity analysis, with the majority of ICERs (for radiofrequency ablation compared with
surgical resection) varying between £2000 and £4000. However, it should be noted that these positive
ICERs are the result of negative incremental cost and incremental QALY values – that is to say, in this
analysis radiofrequency ablation is associated with reduced cost but also poorer outcome than surgical
resection. As noted earlier, the decision framework in this situation involves a judgement on whether or
not the size of savings (indicated by the lower incremental cost) can justify the reduced outcome.
The results appear relatively insensitive to structural or methodological assumptions. Adopting the
exponential overall survival and progression-free survival model reduces the difference in life expectancy
and the QALY loss for radiofrequency ablation compared with surgical resection, but also reduces the cost
reduction. Adopting the log-logistic overall survival and progression-free survival model gives results closer
to the base case. However, it should be borne in mind that these functional forms did not ﬁt the observed
data as closely as did the Weibull form adopted in the base case.
In terms of parameter inputs, the results appear to be most sensitive to variation in values of parameters in
the survival functions (for treatment effect on overall survival and all parameters in the overall survival
function). The results appear to be relatively insensitive to variation in costs other than palliative care costs,
where reduction in palliative care costs is associated with an increase in the difference in costs between
radiofrequency ablation and surgical resection. However, even at the extreme value (where palliative care
costs are excluded from the model), the cost reduction with RFA does not appear to be large enough to
make the associated QALY loss, when compared with surgical resection, acceptable for patients with
larger solitary liver metastases.Probabilistic analysis
In a PSA, where the parameters of the survival models (both overall and progression-free survival), health
state utility values, treatment cost, cost of outpatient attendances and patient monitoring, as well as costs
of managing adverse events and palliative care were sampled probabilistically, radiofrequency ablation forNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 80 Deterministic sensitivity analysis – radiofrequency ablation and surgical resection for patients with
solitary liver metastases ≥ 3 cm
Incremental
cost (£)
Life-years
gained
QALYs
gained
ICER (£ per
QALY gained)
Base case –3207 –1.43 –1.26 2538
Structural assumptions
Truncate survival at maximum follow-up for trial –3069 –0.95 –0.87 3534
Extrapolate overall survival up to 10 years –3373 –1.61 –1.41 2399
Exponential overall survival and progression-free
survival model
–2790 –0.84 –0.79 3543
Log-logistic overall survival and progression-free
survival model
–3655 –1.37 –1.20 3057
Methodological assumptions
Discount rates (0% for both costs and outcomes) –3130 –1.71 –1.50 2093
Discount (6% for costs and 1.5% for outcomes) –3265 –1.58 –1.39 2349
Parameter uncertainty
Lower 95% CI for treatment effect –750 –1.09 –1.06 709
Upper 95% CI for treatment effect –5414 –1.74 –1.45 3725
Lower 95% CI for all parameters in the overall
survival model
114 –1.03 –1.04 –110
Upper 95% CI for all parameters in the overall
survival model
–5673 –1.11 –0.92 6184
Lower 95% CI for all parameters in progression-free
survival model
–6374 –1.43 –1.16 5484
Upper 95% CI for all parameters in progression-free
survival model
–7329 –1.43 –1.13 6474
Exclude palliative care costs –7477 –1.43 –1.26 5918
Upper limit for utility values –3207 –1.43 –1.14 2801
Lower limit for utility values –3207 –1.43 –1.52 2104
Procedure cost: lower quartile –2722 –1.43 –1.26 2154
Procedure cost: upper quartile –4092 –1.43 –1.26 3238
Cost of palliative care reduced by 20% –4061 –1.43 –1.26 3214
Cost of palliative care increased by 20% –2353 –1.43 –1.26 1862
Cost of outpatient visit for monitoring: lower quartile –2926 –1.43 –1.26 2316
Cost of outpatient visit for monitoring: upper quartile –3501 –1.43 –1.26 2771
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7patients with solitary liver metastases ≥ 3 cm is associated with reduced costs for the majority (97%) of
simulations (with an overall range from –£10,721 to £4591) and reduced QALYs for all of the simulations
(with a range of –1.63 to –0.63) when compared with surgical resection (Figure 18 shows this and also
shows the 95% conﬁdence ellipse).
The probabilistic analysis generated cost and QALY estimates for each intervention that were similar to
those for the base-case analysis (see Table 78 for the base-case analysis). Table 81 reports the mean costs
and outcomes from the probabilistic analysis (including the 2.5th and 97.5th percentiles to give an111
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
6000
4000
2000
– 2000
– 4000
– 6000
– 8000
– 10,000
– 12,000
– 1.8 – 1.6 – 1.4 – 1.2
Incremental QALYs
In
cr
em
en
ta
l c
o
st
s 
(£
)
– 1.0 – 0.8 – 0.6
0
FIGURE 18 Cost-effectiveness plane – incremental cost and incremental QALYs for radiofrequency ablation and
surgical resection for (resectable) liver metastases ≥ 3 cm.
TABLE 81 Costs and outcomes from probabilistic analysis for radiofrequency ablation and surgical resection for
(resectable) liver metastases ≥ 3 cm
Procedure
Discounted costs (£) Discounted QALYs
ICER (£)Mean
2.5th
percentile
97.5th
percentile Mean
2.5th
percentile
97.5th
percentile
Surgical resection 19,267 13,464 29,456 3.23 2.36 4.11
RFA 15,307 8306 25,301 2.02 1.35 2.82 3259
RFA, radiofrequency ablation.
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112indication of the range of the simulated values) and the ICER for radiofrequency ablation compared with
surgical resection, based on the mean values generated in the probabilistic analysis.
In addition to graphing the incremental cost and incremental QALYs for radiofrequency ablation, a
cost-effectiveness acceptability curve was derived, representing the proportion of simulations where
radiofrequency ablation is cost-effective for a range of willingness-to-pay thresholds, up to £100,000
(Figure 19). In this analysis, radiofrequency ablation had a probability of being cost-effective of 0% at all
willingness-to-pay thresholds of above £9000 per QALY.
Radioembolisation plus hepatic artery chemotherapy compared with hepatic
artery chemotherapy alone
This section reports cost-effectiveness results for a cohort of patients with non-resectable liver metastases
from adenocarcinoma of the large bowel receiving either radioembolisation plus hepatic artery
chemotherapy or hepatic artery chemotherapy alone, based on the trial report by Grey and colleagues.85
Discounted costs (identifying the contribution of radioembolisation consumables, administration of
treatment and monitoring while on treatment, management of adverse events, monitoring prior to disease
progression and palliative care) are presented alongside the life expectancy and quality-adjusted life
expectancy for patients in the cohort. The results are presented as incremental cost per life-year gained
and incremental cost per QALY gained.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 19 Cost-effectiveness acceptability curve for radiofrequency ablation for (resectable) liver metastases ≥ 3 cm.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Costs and outcomes modelled for cohorts of patients receiving treatment with radioembolisation plus
hepatic artery chemotherapy and hepatic artery chemotherapy alone are presented in Table 82. Costs and
health outcomes in the table have been discounted at 3.5%.
The estimated gain in discounted life expectancy, associated with the addition of radioembolisation to
hepatic artery chemotherapy, is 0.37 years (19 weeks). The equivalent undiscounted values are 0.40 years
(21 weeks). The estimated gain in discounted QALYs, associated with the addition of radioembolisation to
hepatic artery chemotherapy, is 0.35. The equivalent undiscounted value is 0.37 QALYs.
The incremental cost, associated with the addition of radioembolisation to hepatic artery chemotherapy,
is £12,945. Table 83 reports a breakdown of treatment costs, by phase of treatment, for each cohort.TABLE 82 Base-case analysis for patients receiving treatment with radioembolisation plus hepatic artery
chemotherapy and hepatic artery chemotherapy alone
Treatment Costs (£) Life-years
Incremental cost per
life-year gained (£) QALYs
Incremental cost per
QALY gained (£)
HAC 6010 1.49 1.06
RE + HAC 18,955 1.86 35,225 1.41 37,303
HAC, hepatic artery chemotherapy; RE, radioembolisation.
TABLE 83 Treatment costs by phase of treatment for patients receiving treatment with radioembolisation plus
hepatic artery chemotherapy and hepatic artery chemotherapy alone
Phase of treatment RE +HAC (£) HAC (£)
Active treatment Radioembolisation consumables 10,911
Radioembolisation administration 3305
On-treatment monitoring 1122 267
Non-progressive disease monitoring 686 909
Palliative care 2930 4834
Total 18,955 6010
HAC, hepatic artery chemotherapy; RE, radioembolisation.
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114For patients receiving hepatic artery chemotherapy alone, the costs fall under the heading of monitoring
(both on-treatment monitoring and post-treatment monitoring for disease progression) and palliative care,
with palliative care constituting the largest component of total costs (80% total costs) for this cohort.
In contrast, for patients receiving treatment with radioembolisation plus hepatic artery chemotherapy,
while palliative care remains a costly phase of care, this has reduced to 15% of total costs for this cohort.
Active treatment with radioembolisation (including radioembolisation administration and on-treatment
monitoring in addition to the costs of the intervention itself) represents 81% of total costs for this cohort,
with radioembolisation consumables constituting 71% of total treatment costs. Monitoring for disease
progression in patients following cessation of treatment makes a relatively small contribution to total costs
in this cohort of patients (4% of total costs).
Radioembolisation, in addition to hepatic artery chemotherapy, as a treatment for patients with
non-resectable liver metastases from adenocarcinoma of the large bowel, is associated with both improved
outcomes (in terms of life expectancy and quality-adjusted life expectancy) and increased costs. QALY
outcomes have increased by approximately 33% while costs have approximately trebled, yielding an ICER
for the addition of radioembolisation to hepatic artery chemotherapy of £37,303 per QALY gained.Deterministic sensitivity analysis
A sensitivity analysis was conducted to consider the effect of uncertainty around the model structure
and for variation in certain key parameters that were expected, a priori, to be inﬂuential on the
cost-effectiveness results. The method adopted in most cases was univariate sensitivity analysis; that is,
varying one parameter at a time, leaving all other variables unchanged. This is to highlight the impact, if
any, of each selected parameter alone on the cost-effectiveness results. In some situations (such as the
analysis of alternative parametric forms for the survival function, or the analysis using the upper conﬁdence
limits for all parameters in survival model) a set of related parameters are varied simultaneously. The effects
of uncertainty in multiple parameters were addressed using PSA, which is reported later in the section.
Table 84 reports the results of the sensitivity analysis. Except for the sensitivity analysis with respect to time
horizon, all analyses were conducted using a 5-year time horizon. The table is divided to distinguish
between analyses undertaken due to uncertainties over structural assumptions in the model,
methodological uncertainties (in this case related to the discount rates applied in the model) and
uncertainty over parameter values. Where unit costs have been taken from NHS Reference Costs, the
upper and lower quartiles have been used in the sensitivity analysis. In all other cases unit costs have been
varied by plus or minus 20%.
The cost-effectiveness results appear to be generally robust to variation in the parameters included in the
deterministic sensitivity analysis, with ICERs varying between approximately £34,000 and £40,000 per
QALY gained. Among the structural sensitivity analyses, the results appear to be most sensitive to
assumptions over the functional form for the survival functions. In terms of parameter inputs, the results
appear to be most sensitive to variation in utility estimates applied in the model, variation in values of
parameters in the survival functions (for treatment effect on overall survival and all parameters in the
overall survival function) and to the cost of palliative care.
Time horizon for the model appears to have a limited impact on the cost-effectiveness estimates.
Truncating survival at the maximum duration observed for each arm reported in the RCT by Grey and
colleagues85 reduces the QALY gain by 0.005 and costs by £38. The proportionate reduction in outcome
(1.3%) is greater than the proportionate reduction in costs (0.3%), hence the ICER increases, but only by a
small amount. Increasing the maximum survival duration to 10 years has the opposite effect – a slight
increase in QALY gain and a slight increase in costs, with the proportionate change in QALYs being
greater than the proportionate increase in costs, leading to a small reduction in the ICER. Adopting an
alternative (log-logistic) parametric form for the overall survival and progression-free survival functions has
more effect, resulting in an 8.4% reduction in QALY gain, a 8.6% reduction in cost, and a small reduction
in the ICER to £37,198. In contrast, with the exponential form of the overall survival and progression-freeNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 84 Deterministic sensitivity analysis
Incremental
cost (£)
Life-years
gained
QALYs
gained
ICER (£ per
QALY gained)
Base case 12,945 0.37 0.35 37,303
Structural assumptions
Truncate survival at maximum follow-up for trial 12,907 0.36 0.34 37,697
Extrapolate overall survival up to 10 years 13,118 0.37 0.37 35,935
Exponential overall survival and progression-free
survival model
13,938 0.41 0.38 36,782
Log-logistic overall survival and progression-free
survival model
11,826 0.29 0.32 37,198
Methodological assumptions
Discount rates (0% for both costs and outcomes) 12,930 0.40 0.37 34,562
Discount (6% for costs and 1.5% for outcomes) 12,958 0.39 0.36 35,778
Parameter uncertainty
Lower 95% CI for treatment effect 16,085 0.80 0.61 26,436
Upper 95% CI for treatment effect 9023 –0.18 0.02 423,802
Lower 95% CI for all parameters in survival model 16,871 0.91 0.67 25,067
Upper 95% CI for all parameters in survival model 9143 –0.16 0.03 294,208
Lower 95% CI for all parameters in progression-free
survival model
12,449 0.37 0.36 34,377
Upper 95% CI for all parameters in progression-free
survival model
13,447 0.37 0.33 40,536
Exclude palliative care costs 14,848 0.37 0.35 42,788
Upper limit for utility values 12,945 0.37 0.29 44,032
Lower limit for utility values 12,945 0.37 0.46 27,917
Procedure cost: lower quartile 11,830 0.37 0.46 34,090
Procedure cost: upper quartile 13,565 0.37 0.46 39,089
Cost of palliative care reduced by 20% 13,946 0.37 0.35 40,186
Cost of palliative care increased by 20% 12,564 0.37 0.35 36,206
Cost of outpatient visit for monitoring: lower quartile 12,891 0.37 0.35 37,147
Cost of outpatient visit for monitoring: upper quartile 13,018 0.37 0.35 37,515
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7survival functions, the QALY gain increases by 9.2% and incremental cost by 7.7%, leading to a slightly
larger reduction in the ICER (to £36,782).
Varying the discount rates applied has comparatively little effect. Zero discount rates for costs and
outcomes result in a slight reduction in incremental cost and a slight increase in incremental QALYs
compared with baseline values. Applying discount rates of 6% for costs and 1.5% for outcomes leads to a
slight increase in incremental cost and incremental QALYs. The resulting ICER is slightly lower than in the
base case.115
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116Varying the value of the treatment effect parameter in the overall survival model, between its upper and
lower conﬁdence limits, has a greater effect on outcomes than on cost. In the model, variation in survival
(unless it is assumed to be associated with variation in progression-free survival) has an impact only on the
duration of post-progression survival, and therefore will affect only the estimate of palliative care costs.
A similar situation applies to QALY outcomes where it is assumed that all gains or losses of life expectancy
associated with variation in the treatment effect parameter are weighted by post-progression utility values.
This explains why the proportionate variation in QALY gains is less than the variation in life-years gained.
The cost-effectiveness results are less variable if all parameters in the survival models are included (at the
95% conﬁdence limits) in the sensitivity analysis, rather than just the treatment effect estimated in the
overall survival model, with ICERs varying between approximately £25,000 and £294,200 per QALY
gained. Variation in the parameters of the progression-free survival model had less impact on the results.
The next greatest variation in cost-effectiveness results, associated with parameter inputs, is related to
deterioration in quality of life related to disease progression. Assuming no quality-of-life impact from
disease progression (the upper limit of the relative effect, i.e. 1) leads to a reduction of 0.05 (15%) in the
QALY gain associated with radioembolisation plus hepatic artery chemotherapy. As a result the ICER
increases to £44,032 per QALY gained. In contrast, assuming a much greater reduction in quality of life
due to disease progression (using the lower limit of the relative effect, i.e. 0.20) leads to an increase of
0.12 (34%) in the QALY gain associated with radioembolisation plus hepatic artery chemotherapy, with
the ICER reducing to £27,917 per QALY gained.
In terms of cost parameters, the model results appear to be most sensitive to variation in the cost of
palliative care.Probabilistic analysis
In a PSA, where the parameters of the survival models (both overall and progression-free survival), health state
utility values, treatment cost, cost of outpatient attendances and patient monitoring, as well as costs of
managing adverse events and palliative care were sampled probabilistically, radioembolisation plus hepatic
artery chemotherapy is associated with increased costs (from £469 to £21,241) in all simulations and
increased QALYs for the majority of simulations when compared with hepatic artery chemotherapy alone
(Figure 20 shows this and also shows the 95% conﬁdence ellipse). However, radioembolisation plus hepatic
artery chemotherapy is associated with lower QALYs in 8% of simulations (with a range of –0.44 to 0.88).– 0.6
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FIGURE 20 Cost-effectiveness plane – incremental cost and incremental QALYs for radioembolisation plus hepatic
artery chemotherapy compared with hepatic artery chemotherapy alone.
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those for the base-case analysis (see Table 82 for the base-case analysis). Table 85 reports the mean costs
and outcomes from the probabilistic analysis (including the 2.5th and 97.5th percentiles to give an
indication of the range of the simulated values) and the ICER for radioembolisation plus hepatic artery
chemotherapy compared with hepatic artery chemotherapy alone, based on the mean values generated in
the probabilistic analysis.
In addition to graphing the incremental cost and incremental QALYs for radioembolisation plus hepatic
artery chemotherapy, a cost-effectiveness acceptability curve was derived, representing the proportion of
simulations where radioembolisation plus hepatic artery chemotherapy is cost-effective for a range of
willingness-to-pay thresholds, up to £100,000 (Figure 21). In this analysis radioembolisation plus hepatic
artery chemotherapy had a probability of being cost-effective of 0.1% at a willingness-to-pay threshold of
£20,000 per QALY, 26% at a willingness-to-pay threshold of £30,000 per QALY and 68% at a
willingness-to-pay threshold of £50,000 per QALY.
Summary of economic analysis
There is a very limited evidence base for conducting economic analysis of ablative therapies and other non-
invasive therapies for the treatment of patients with surgically resectable, or unresectable, liver metastases.
There is a limited number of comparative studies reporting ﬁnal outcomes for ablative therapies or other
non-invasive therapies, although the comparator (in some cases) or patterns of care may be of limited
relevance to current UK clinical practice, the study designs may be prone to bias or study publications may
not include sufﬁcient detail to allow robust economic analysis.
Three comparative studies were identiﬁed that reported sufﬁcient data to model two ablative therapies
(microwave ablation and radiofrequency ablation) and one non-invasive therapy (radioembolisation).TABLE 85 Costs and outcomes from probabilistic analysis for radioembolisation plus hepatic artery chemotherapy
and hepatic artery chemotherapy alone
Procedure
Discounted costs (£) Discounted QALYs
ICER (£)Mean
2.5th
percentile
97.5th
percentile Mean
2.5th
percentile
97.5th
percentile
HAC 6262 1624 12,880 1.08 0.69 1.58
RE + HAC 18,954 15,676 22,734 1.41 1.28 1.55 38,944
HAC, hepatic artery chemotherapy; RE, radioembolisation.
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FIGURE 21 Cost-effectiveness acceptability curve for radioembolisation plus hepatic artery chemotherapy.
117
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ECONOMIC ANALYSIS
118Ablative or other non-invasive therapies may be less costly than surgical resection, as a result of shorter
lengths of hospital stay and reduced complication rates. The analysis suggests that, where ablative
therapies or other non-invasive therapies can achieve similar overall and progression-free survival, they may
result in improved outcomes for patients (in terms of QALY gains) by avoiding short- to medium-term
reduction in quality of life associated with surgical resection. In this situation, ablative or other non-invasive
therapies may dominate surgical resection (by providing a QALY gain at reduced cost) or may offer a
cost-saving option (by providing equivalent outcomes at reduced cost). In contrast, in situations where
ablative or other non-invasive therapies are associated with inferior survival, the lower short to medium
quality-of-life reduction associated with these therapies is not sufﬁcient to yield improved overall outcomes
compared with surgical resection. If ablative or other non-invasive therapies are associated with a QALY
loss, the potential cost savings, compared with surgical resection, are unlikely to be sufﬁcient to make such
treatment acceptable, in cost-effectiveness terms.
The results of the economic analysis are subject to a high degree of uncertainty, given the limited data
available and the comparatively small size of the majority of included studies. Additional – higher quality –
research on outcomes for patients with liver metastases, treated with ablative or other non-invasive
therapies and comparator treatments, is required for robust cost-effectiveness modelling to be undertaken.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Clinical effectiveness
Ablative therapies
Nine studies assessing ablative therapies for treating liver metastases were included in the systematic
review.70–80 One RCT compared microwave ablation with surgical resection,72 two case series assessed laser
ablation70,71 and one non-randomised comparison73 and ﬁve cases series assessed radiofrequency
ablation.74–80 Although the people included in the RCT assessing microwave ablation72 and the non-
randomised comparison assessing radiofrequency ablation73 were amenable to surgical resection, those
undergoing either laser surgery or radiofrequency ablation in the seven case series were not considered to
be candidates for surgical resection.70,71,74–80 The studies tended to focus on people diagnosed with
colorectal carcinoma as the primary cancer,72–80 although one study included women with metastatic
breast cancer71 and another study assessed people with primary cancers from several sites.70 People
included in most studies were similar in terms of age (mean age ranged from 55 to 65 years), sex (male
55–70%), previous treatment (received chemotherapy and/or liver resection), and extent of metastases
(mean number of metastases 1.5–4; mean size of metastases 2–4 cm).72–80 One case series differed,
focusing on younger women with breast cancer as the primary site (mean age 54.4 years)71 and another
provided limited details about the participants.70 Although the methodological quality of the RCT was
considered moderate,72 the quality of reporting of the methodology used in the non-randomised
comparison73 and the case series was poor and, as a consequence, their methodological quality was
uncertain.70,73–80 All studies were at risk of bias.
The RCT comparing microwave ablation with surgical resection found no statistically signiﬁcant difference
between the interventions on estimated cumulative survival rates (p = 0.83). Limited differences were also
reported in mean overall survival (27 months vs. 25 months respectively), survival at 1, 2 or 3 years (1 year
71% vs. 69%, 2 years 57% vs. 56%, 3 years 14% vs. 23%), mean disease-free survival (11.3 months vs.
13.3 months, p = 0.47) or adverse events.72 Microwave ablation did result in statistically signiﬁcant beneﬁts
in terms of measures of surgical invasiveness compared with surgical resection, with people experiencing
lower blood loss and having less need for blood transfusions. In contrast, there was no statistically
signiﬁcant difference in operation times or days the participants stayed in hospital.
The case series studies assessing the effects of laser-induced70,71 and radiofrequency ablative
therapies74,75,78–80 reported median or mean survival, survival to 5 years’ follow-up and mortality.
Laser-induced ablation resulted in a mean survival of between 50.4 to 58.8 months for women with
metastatic breast cancer and 41.8 months for people with metastatic colorectal cancer.70,71 Five-year
survival varied from 34% to 41% for women with metastatic breast cancer and 30% for people with
metastatic colorectal cancer.70,71 People with metastatic colorectal cancer who underwent radiofrequency
ablation had median survival from diagnosis ranging from 44.6 months to 52 months and from treatment
from 24 months to 32 months.74,75,78–80 Three-year survival from treatment ranged from 20% to 46% and
5-year survival was reported as 18%.78–80 A non-randomised comparison study73 and a case series76,77
assessing radiofrequency ablation reported survival for subgroups only; these results were not discussed.
Mortality among people with liver metastases following colorectal cancer who had undergone
radiofrequency ablation ranged from 31% to 63%, reﬂecting in part the difference in the follow-up period
of the studies.78–80 Adverse events were reported and, although major or severe events were evident, rates
were thought to be relatively low.71,76,77,79,80119
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120Other minimally invasive techniques
Five RCTs assessing the clinical effectiveness of other minimally invasive techniques were included in the
systematic review.81,82,85–88 Three RCTs compared the use of radioembolisation plus either hepatic artery
chemotherapy or systemic chemotherapy with chemotherapy alone85–88 and two RCTs compared the use
of different types of chemotherapy with and without embolisation (i.e. degradable starch microspheres or
polyvinyl sponge).81,82 People included in the three RCTs assessing the use of radioembolisation had
metastatic colorectal cancer and were not amenable to curative surgical resection, local ablation and, in
some instances, to standard chemotherapy.85–88 The two RCTs comparing chemoembolisation with
chemotherapy alone included people with ocular melanoma or various tumours as the primary cancer
site.81,82 Although people recruited to one RCT assessing chemoembolisation were not candidates
for surgical resection,81 it was unclear if this was so in the other RCT.82 In two RCTs assessing
radioembolisation, the people randomised to the different arms appeared similar in terms of age (mean
age 59–65 years), sex (male 76% to 91%) and the number, size and extent of liver metastases.85,87,88 The
third RCT of radioembolisation had arms that differed in terms of the sex of the participants and the size
of the liver metastases.86 Limited information was presented on the characteristics of the participants in the
two RCTs assessing chemoembolisation.81,82 Although the methodological quality of the ﬁve RCTs varied,
many lacked information on key methodological criteria making the quality uncertain and the studies
prone to a risk of bias.
The three RCTs of radioembolisation plus chemotherapy and the two RCTs of chemoembolisation showed
some beneﬁt when compared with chemotherapy alone on measures of survival, response, time to
progression and adverse events, although differences were not always statistically signiﬁcant.81,82,85–88
Estimated overall survival for people receiving radioembolisation plus systemic chemotherapy was
longer, signiﬁcantly so in one RCT (p = 0.025),87,88 than that experienced by people receiving systemic
chemotherapy alone (10 vs. 7.3 months;86 29.4 vs. 12.8 months).87,89 Survival rates up to 5 years’
follow-up were higher for people receiving radioembolisation plus chemotherapy than for those receiving
chemotherapy alone (1 year 72% vs. 68%, 2 years 39% vs. 29%, 3 years 17% vs. 6%, 5 years 3.5% vs.
0%), though differences were not statistically signiﬁcant.85 Estimated overall survival was reported in one
RCT comparing chemotherapy with and without embolisation, ﬁnding a non-statistically signiﬁcant beneﬁt
for chemoembolisation (9.7 months vs. 7.6 months).81
Radioembolisation and chemoembolisation were shown to improve tumour response compared with
chemotherapy alone. Radioembolisation plus chemotherapy led to statistically signiﬁcant beneﬁt on all
categories of response compared with chemotherapy alone (p< 0.05) in two RCTs.85,87,88 It also resulted in
statistically signiﬁcant improvement on response rates in one RCT (complete plus partial response: 44% vs.
18%, p = 0.01)85 and disease control rates (partial response plus stable disease: 86% vs. 35%, p = 0.001)86
in another RCT. Improvements in tumour response were shown for chemoembolisation compared with
chemotherapy alone on the different categories of response and a summary response measure (complete
plus partial response: 54.5% vs. 20%, p< 0.05).81 Time to disease progression was assessed in the
three RCTs comparing radioembolisation plus chemotherapy with chemotherapy alone.85–88 Despite
using different measures, it was evident that people receiving radioembolisation plus chemotherapy
had signiﬁcantly longer median times to disease progression than those receiving chemotherapy
only (p< 0.05).
Adverse events and toxicity were reported by all ﬁve RCTs comparing radioembolisation or
chemoembolisation with chemotherapy alone.81,82,85–88 Although the three RCTs comparing
radioembolisation plus chemotherapy with chemotherapy presented differing ﬁndings, overall it appeared
that both interventions were reasonably well tolerated.85–88 In contrast, one RCT reported signiﬁcantly
(p< 0.01) higher rates of pain, gastrointestinal disturbance and fever following chemoembolisation
compared with chemotherapy.81 Another RCT comparing chemoembolisation with chemotherapy assessed
toxicity associated with different doses, ﬁnding limited difference between the comparators.82NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Two prospective case series assessed the use of chemoembolisation to ‘downstage’ liver metastases prior
to laser thermotherapy.83,84 Although the participants included in the studies differed in the site of their
primary cancers, speciﬁcally women with breast cancer84 and people with various primary tumours,83 both
groups were of similar age (mean 61.8 years83 vs. 57 years84), considered to have unresectable liver
metastases and had had no response to previous systemic chemotherapy for liver metastases. The quality
of reporting of the methodology used in the case series was poor and, as a result, their methodological
quality was uncertain. All studies were at risk of bias.
Survival from ﬁrst chemoembolisation treatment ranged from a median survival of 26.2 months for those
with various primary tumours83 to a mean survival of 32.5 months for women with metastatic breast
cancer.84 Survival rates at 1, 3 and 5 years for women with metastatic breast cancer were 88.8%, 36.6%
and 13.7% respectively.84 Tumour response for women with metastatic breast cancer showed that 38.5%
had complete response, 5% partial response, 12.4% stable disease and 44.1% progressive disease.84
Time to progression was reported as 8.2 months and overall tumour control 13.1 months for women with
metastatic breast cancer.84 Adverse events varied between the studies, with the majority being considered
mild to moderate.83,84 The case series of women with metastatic breast cancer reported that six people had
complications requiring further intervention.84Summary
The search strategy identiﬁed 16 studies for inclusion in the systematic review. Five RCTs provided
comparative evidence on the clinical effectiveness of the addition of radioembolisation or
chemoembolisation to chemotherapy when compared with chemotherapy alone. All ﬁve RCTS did not
clearly state the intention for treatment (i.e. pre-surgical, curative or palliative); however, none was in
people thought to be amenable to surgical resection. Although these interventions resulted in statistically
signiﬁcant improvements in tumour response and time to disease progression relative to their comparators,
beneﬁts in terms of survival were equivocal. Radioembolisation and chemoembolisation were thought to
be as well tolerated as their comparators in terms of adverse events, although one study reported
signiﬁcant pain, gastrointestinal disturbance and fever following chemoembolisation. The evidence
provided by the nine studies on the clinical effectiveness of ablative therapies was limited. Only one RCT
was identiﬁed that assessed an ablative therapy, speciﬁcally comparing microwave ablation with surgical
resection. It found no statistically signiﬁcant difference between the interventions on measures of survival.
Beneﬁts following microwave ablation were shown in terms of surgical invasiveness (i.e. intraoperative
blood loss and blood transfusions). A non-randomised comparison study assessing radiofrequency ablation
reported survival for subgroups only and the results were not reported. All the other studies assessing
ablative therapies, whether separately or in combination with other non-invasive therapies, which
presented results for relevant groups, were case series. These studies focused on people who were
considered not to be candidates for surgical resection. Differences in the studies preclude any sensible
comparison of the relative beneﬁts of the different ablative therapies other than against no treatment.
Unsurprisingly, when compared with the natural history of the condition, ablative therapies provide
improved survival (mean survival 8 months vs. 26 to 60 months respectively; 5-year survival 0% vs. 13% to
41%, respectively). Assessment of the adverse events reported by the case series indicates that the
different ablative therapies have limited serious adverse events.Cost-effectiveness
Systematic review of published economic evaluations
Two full economic evaluations of ablative therapies or other non-invasive therapies for the treatment of
liver metastases were included in the systematic review.115,116 One of the economic evaluations compared
radiofrequency ablation (with a range of treatment thresholds, retreatment and follow-up options),
surgical resection (with a range of treatment thresholds and follow-up options) with no treatment in a
population of people with surgically resectable or unresectable liver metastases.116 In this study
resectability was deﬁned only in terms of the total number of metastases (with treatment threshold varying121
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122from 1 to 6). The other economic evaluation compared hepatic artery chemoembolisation with palliative
care for people with unresectable liver metastases.115 Both studies were conducted in the USA and both
were modelling studies, deriving estimates of effectiveness (overall survival115 or quality-adjusted survival116)
from assumption115 or from microsimulation based on the surrogate measure of proportion of liver
replaced by tumour.
Abramson and colleagues115 present a simple spreadsheet model which estimated costs, based on
assumption and (for complication rates) on a small, unpublished case series of 21 people in one institution.
The incremental costs of hepatic artery chemoembolisation, above standard palliative care, were estimated
over a range of potential survival beneﬁts – from 0 to 24 months. Cost-effectiveness was estimated by
dividing the estimated incremental cost by the assumed survival beneﬁt. The study is explicit in its
assumptions and clear on the absence of empirical data to support the assumed survival beneﬁts. The
absence of comparative studies demonstrating a survival beneﬁt for hepatic artery chemoembolisation
means that no ﬁrm conclusions can be drawn from the study – the study is further weakened by the
absence of any adjustment for quality of life in estimating the beneﬁts of the technology.
Gazelle and colleagues116 used microsimulation in a state transition model to estimate the effectiveness of
radiofrequency ablation and surgical resection in reducing (or eliminating) the proportion of liver replaced
by tumour and thereby reducing patients’ risk of death. Model parameters (such as number, size and
rate of growth of liver metastases, risk of death associated with increasing proportion of liver volume
replaced by tumour and effectiveness of radiofrequency ablation in achieving tumour necrosis) were
derived from a range of studies. Simulated patients had a mean number of six metastases, up to a
maximum of 15, with the number, size and location determined by random draws from probability
distributions. Patients undergoing surgical resection were allowed one reoperation, whereas those
undergoing radiofrequency ablation were permitted a larger number of repeat procedures. The key
determinant of patient survival in the model was the proportion of liver volume replaced by tumour,
although this was not modelled as having any impact on quality of life – age- and sex-speciﬁc utility values
for the general population were applied to patients with liver metastases. Patients whose liver metastases
were successfully resected or ablated were assumed to face general population age- and sex-speciﬁc
mortality risks. Gazelle and colleagues116 modelled a number of treatment thresholds (1–6 metastases) and
follow-up intervals (4, 6 and 12 months) yielding a large number of potential strategies. Strategies
involving low treatment thresholds (fewer than three metastases for radiofrequency ablation and fewer
than six for surgical resection) were dominated by strategies with higher thresholds, leading the authors to
conclude that more aggressive strategies – particularly for surgical resection – were likely to be more cost-
effective. Radiofrequency ablation was generally associated with lower QALY outcomes than surgical
resection – for example, at a treatment threshold of six metastases and follow-up at 12 months, quality-
adjusted life expectancy for a 65-year-old man with liver metastases undergoing radiofrequency ablation
was 1.36 and the corresponding ﬁgure for surgical resection was 3.39.
Both of the identiﬁed economic evaluations have limited relevance to the NHS as both were conducted in
the USA, and while both attempt to overcome the absence of comparative evidence to support their
analyses the credibility of their results depends on an evaluation of the assumptions regarding the survival
advantage with hepatic artery chemoembolisation, over palliative care, in the study by Abramson and
colleagues115 and the key assumption on quality of life and adequacy of the proportion of liver volume
replaced by tumour to predict mortality in the study by Gazelle and colleagues.116Southampton Health Technology Assessments Centre
economic evaluation
A survival model was developed to estimate the cost of ablative therapies or other non-invasive therapies
in cohorts of adult patients with surgically resectable, or unresectable, liver metastases. Limitations in the
evidence base (lack of comparative studies or limitations in reporting survival outcomes) meant that not all
identiﬁed therapies were included in the model.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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and risk of bias. Some of the comparisons in the model use data from studies with small numbers of
participants. The limitations of the evidence base need to be borne in mind when interpreting the results
of the economic evaluation. The model includes separate comparisons of two ablative therapies with
surgical resection (microwave ablation compared with surgical resection and radiofrequency ablation
compared with surgical resection) and one other non-invasive therapy (radioembolisation in conjunction
with hepatic artery chemotherapy compared with hepatic artery chemotherapy alone). Each of these
comparisons is based on a single study.
Clinical effectiveness data in the model were based on overall survival and progression-free survival
functions estimated using linear regression on data extracted from survival plots reported in included
studies. Three parametric survival functions were ﬁt to the observed data and the best-ﬁtting function was
selected on the basis of a visual inspection of the model ﬁt and comparison of predictions of median
survival period (1, 2, 3 or 5 years) with values reported in included studies. The exponential function
generally gave a poor ﬁt to the observed data, while the Weibull and log-logistic functions typically
provided reasonable ﬁts to the observed data. Where the Weibull and log-logistic appeared to provide
equally good ﬁt to the observed data, the Weibull function was selected as it was less prone to give large
maximum survival durations.
Health state utilities, for stable disease and disease progression, derived in our review of published
quality-of-life studies were applied in the model. Additional quality-of-life adjustments were incorporated
into the model in recognition of a short- to medium-term impact of treatment on quality of life.
Resource use estimates were developed based on treatment intensity (number of treatments and length of
stay), on-treatment management and post-discharge monitoring reported in included studies. Unit costs
were derived from NHS Reference Costs – where these were inadequate unit costs were sourced from a
local NHS provider (University Hospital Southampton NHS Foundation Trust).Microwave ablation compared with surgical resection
In the analysis comparing microwave ablation with surgical resection, total costs for surgical resection were
£20,152 with outcomes of 1.94 life-years and 1.38 QALYs, while for microwave ablation the total costs
were £19,825 and outcomes were 1.84 life-years and 1.29 QALYs. Microwave ablation is associated with
a reduction of 0.10 years (5.2 weeks), which translates to a QALY reduction of 0.09. The incremental cost
associated with microwave ablation is also negative (£327) – treatment cost of liver metastases with
microwave ablation is slightly lower than treatment with surgical resection – resulting in an ICER of £3664
per QALY gained. It should be noted that this positive ICER is derived from negative incremental cost and
incremental QALY values – that is to say, in this analysis microwave ablation is associated with reduced
cost but also poorer outcome than surgical resection so that the decision framework in this case would be
to consider whether or not the extent of savings (indicated by the negative incremental cost) can justify the
reduced outcome.
In deterministic sensitivity analyses the ICER generally remained within the range of £2800 to £5000,
where microwave ablation was associated with a small reduction in QALY and slightly lower costs. Among
the structural sensitivity analyses, the results appear to be most sensitive to assumptions over the
functional form for the survival functions. In terms of parameter inputs, the results appear to be most
sensitive to variation in utility estimates applied in the model, variation in values of parameters in the
survival functions (for treatment effect on overall survival and all parameters in the overall survival
function), variation in procedure costs and to the cost of palliative care.
In a PSA microwave ablation is associated with reduced costs in around half of all simulations and lower
QALYs in 68% of simulations when compared with surgical resection. Microwave ablation had a
probability of being cost-effective of 31% at a willingness-to-pay threshold of £20,000 per QALY and
30% at a willingness-to-pay threshold of £30,000 per QALY.123
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124Radiofrequency ablation compared with surgical resection for solitary
metastases < 3 cm
In the analysis comparing radiofrequency ablation with surgical resection for solitary metastases < 3 cm,
total costs for surgical resection were £25,612 with outcomes of 4.28 life-years and 2.99 QALYs, while for
radiofrequency ablation the total costs were £19,322 and outcomes were 4.28 life-years and 3.05 QALYs.
The incremental cost for radiofrequency ablation compared with surgical resection is negative (£6290) – a
reduction of around 25% in total costs. There is no difference in discounted life expectancy between
surgical resection and radiofrequency ablation for patients with solitary liver metastases of < 3 cm.
However, as surgical resection is associated with signiﬁcant reduction in quality of life for up to 6 months
post-operatively, surgical resection is associated with lower QALY outcome than radiofrequency ablation.
The estimated gain in discounted QALYs associated with radiofrequency ablation is 0.06. The ICER is
–£266,767 per QALY gained. In conventional terms this would indicate that radiofrequency ablation
dominates surgical resection for the treatment of (surgically resectable) small solitary liver metastases.
The cost-effectiveness results appear to be generally robust to variation in parameters included in the
deterministic sensitivity analysis, with the majority of ICERs (for radiofrequency ablation compared with
surgical resection) remaining negative. In this case negative ICERs indicate reduced costs for radiofrequency
ablation compared with surgical resection and small gains in QALY outcomes. In general there are no
differences in expected survival (no life-years gained or lost) between radiofrequency ablation and surgical
resection, except in the structural sensitivity analysis adopting alternative forms for the survival function
and the parameter sensitivity analysis on parameter values in the survival function. The exponential and
log-logistic functions are associated with slightly poorer survival with radiofrequency ablation, hence
a slightly reduced QALY gain compared with the base case. However, the cost reduction, with
radiofrequency ablation compared with surgical resection, is also greater when using the exponential and
log-logistic functions of the survival function. In terms of parameter inputs, the results appear to be most
sensitive to variation in values of parameters in the survival functions (for treatment effect on overall
survival and all parameters in the overall survival function) and variation in the utility estimates applied in
the model. The results appear to be relatively insensitive to variation in costs, time horizon and
discount rates.
In a PSA radiofrequency ablation is associated with reduced costs in all simulations and increased QALYs
for the majority of simulations when compared with surgical resection. Radiofrequency ablation had a
probability of being cost-effective of 100% at willingness-to-pay thresholds of £20,000 and £30,000 per
QALY gained.Radiofrequency ablation compared with surgical resection for solitary
metastases ≥ 3 cm
Total costs for surgical resection were £18,527 with outcomes of 4.24 life-years and 3.24 QALYs, while for
radiofrequency ablation the total costs were £15,050 and outcomes were 2.81 life-years and 1.97 QALYs.
The incremental cost for radiofrequency ablation compared with surgical resection is negative (£3207) – a
reduction of around 17% in total costs. However, radiofrequency is also associated with signiﬁcantly
poorer outcome – reduced life expectancy and poorer QALY outcomes – than for surgical resection
resulting in an ICER of £2538 per QALY gained. However, it should be noted that these positive ICERs are
the result of negative incremental cost and incremental QALY values – that is to say, in this analysis
radiofrequency ablation is associated with reduced cost but also poorer outcome than surgical resection.
In this context the conventional interpretation of cost-effectiveness as being below a given acceptable
threshold is reversed. Rather than balancing any increased cost against gains in outcome (as would be
typical for interpreting cost-effectiveness results) the decision framework in this case would be to
consider whether or not the size of savings (indicated by the lower incremental cost) can justify the
reduced outcome.
The cost-effectiveness results appear to be generally robust to variation in parameters included in the
deterministic sensitivity analysis, with the majority of ICERs varying between £2000 and £4000. The resultsNIHR Journals Library www.journalslibrary.nihr.ac.uk
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results were most sensitive to variation in values of parameters in the survival functions (for treatment
effect on overall survival and all parameters in the overall survival function). The results were relatively
insensitive to variation in costs other than palliative care costs, where reduction in palliative care costs is
associated with an increase in the difference in costs between radiofrequency ablation and surgical
resection. However, even at the extreme value (where palliative care costs are excluded from the model)
the cost reduction with radiofrequency ablation does not appear to be large enough to make the
associated QALY loss, when compared with surgical resection, acceptable for patients with larger solitary
liver metastases.
In a PSA, radiofrequency ablation is associated with reduced costs for the vast majority of simulations and
reduced QALYs for all of the simulations when compared with surgical resection. Radiofrequency ablation
had a probability of being cost-effective of 0% at willingness-to-pay thresholds of £20,000 and £30,000
per QALY gained.Radioembolisation plus hepatic artery chemotherapy compared with hepatic
artery chemotherapy alone
Total costs of hepatic artery chemotherapy alone were £6010 with outcomes of 1.49 life-years and 1.06
QALYs, while for radioembolisation plus hepatic artery chemotherapy the total costs were £18,955 and
outcomes were 1.86 life-years and 1.41 QALYs. The incremental cost for radioembolisation plus hepatic
artery chemotherapy compared with hepatic artery chemotherapy alone is £12,945 – an increase of
around 215% in total costs. Radioembolisation plus hepatic artery chemotherapy is also associated with
improved outcomes (0.35 QALY gain) resulting in an ICER of £37,303 per QALY gained.
The cost-effectiveness results appear to be generally robust to variation in the parameters included in the
deterministic sensitivity analysis, with ICERs varying between approximately £34,000 and £40,000 per
QALY gained. Among the structural sensitivity analyses, the results appear to be most sensitive to
assumptions over the functional form for the survival functions. In terms of parameter inputs, the results
appear to be most sensitive to variation in utility estimates applied in the model, variation in values of
parameters in the survival functions (for treatment effect on overall survival and all parameters in the
overall survival function) and to the cost of palliative care.
In a PSA, radioembolisation plus hepatic artery chemotherapy is associated with increased costs in all
simulations and increased QALYs for the majority of simulations when compared with hepatic artery
chemotherapy alone. In this analysis radioembolisation plus hepatic artery chemotherapy had a probability
of being cost-effective of 0.1% at a willingness-to-pay threshold of £20,000 per QALY, 26% at a
willingness-to-pay threshold of £30,000 per QALY and 68% at a willingness-to-pay threshold of
£50,000 per QALY.Summary of Southampton Health Technology Assessments Centre
economic evaluation
There is a very limited evidence base for conducting economic analysis of ablative therapies and other
non-invasive therapies for the treatment of patients with surgically resectable, or unresectable, liver
metastases. There is a limited number of comparative studies reporting ﬁnal outcomes for ablative
therapies or other non-invasive therapies, although the comparator (in some cases) or patterns of care may
be of limited relevance to current UK clinical practice, the study designs may be prone to bias or study
publications may not include sufﬁcient detail to allow robust economic analysis.
Three comparative studies were identiﬁed that reported sufﬁcient data to model two ablative therapies
(microwave ablation and radiofrequency ablation) and one non-invasive therapy (radioembolisation).
Ablative or other non-invasive therapies may be less costly than surgical resection, as a result of shorter
lengths of hospital stay and reduced complication rates. The analysis suggests that, where ablative
therapies or other non-invasive therapies can achieve similar survival to surgery, they may result in125
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126improved outcomes for patients (in terms of QALY gains) by avoiding short- to medium-term reduction in
quality of life associated with surgical resection. In this situation, ablative or other non-invasive therapies
may dominate surgical resection (by providing a QALY gain at reduced cost) or may offer a cost-saving
option (by providing equivalent outcomes at reduced cost). In contrast, where ablative or other
non-invasive therapies provide inferior survival, the lower short-term quality-of-life reduction associated
with such therapies is not sufﬁcient to yield improved overall outcomes compared with surgical resection.
If ablative or other non-invasive therapies are associated with a QALY loss, the potential cost savings,
compared with surgical resection, are unlikely to be sufﬁcient to make such treatment acceptable, in
cost-effectiveness terms.Strengths and limitations of the assessmentThe evidence synthesis has the following strengths:
l It is independent of vested interests.
l It has been undertaken following the principles for conducting systematic reviews and economic
evaluations. The methods were set out in a research protocol (see Appendix 1), which deﬁned the
research question, study selection criteria, quality assessment criteria, data extraction process and the
process by which the methods will be employed at different stages in the systematic review and
economic evaluations.
l An advisory group has informed the evidence synthesis from its initiation. The research protocol and a
copy of the draft ﬁnal report were sent to the advisory group for review and comment.
l The systematic review brings together the evidence for the clinical effectiveness and cost-effectiveness
of ablative and other minimally invasive therapies for treating people with liver metastases. This
evidence has been critically appraised and presented in a consistent and transparent manner.
l A new economic model has been developed following recognised guidelines and systematic searches
have been conducted to identify data to populate the different parameters. The main results have been
summarised and presented.
In contrast, the evidence synthesis has certain limitations:
l Despite conducting a wide-ranging and systematic search of the literature, it was evident that the
evidence assessing the clinical effectiveness and cost-effectiveness of ablative and other minimally
invasive therapies was limited. Although a large number of case series studies were identiﬁed, they
tended to be retrospective, involve small numbers of participants and present limited details of their
methods and results. As a consequence, the evidence synthesis focused on experimental studies and
prospective case series involving 100 participants or more. Unfortunately, these studies were often
poorly reported in terms of their methods and results.
l Although non-English-language studies were identiﬁed in the searches, translation and full screening
of the papers was not undertaken. These studies are listed in Appendix 6.
l Authors of primary studies were not contacted to request additional information. Although this may
have provided helpful data to clarify study selection, assessment of the quality of studies and additional
outcome data, it was felt that the considerable information that could be requested would not be
feasible within the time constraints of the project.
l With limited comparative studies identiﬁed by the evidence synthesis, the interventions included may
not be those currently relevant to current management in the NHS. The six RCTs included in the
evidence synthesis compared ablative and other minimally invasive therapies with surgical resection,
hepatic arterial chemotherapy and local or systemic chemotherapy.
l The lack of high-quality comparative evidence on the clinical effectiveness of the different ablative and
other minimally invasive techniques limited the opportunities for developing an economic evaluation.
As a consequence, the models were limited to a comparison of radioembolisation plus hepatic artery
chemotherapy with hepatic artery chemotherapy, radiofrequency ablation compared with surgicalNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7resection and microwave ablation compared with surgical resection. These may not be the most
appropriate comparisons.Other relevant factorsl Given the heterogeneous nature of the studies included in the systematic review of clinical
effectiveness, synthesis of the results was difﬁcult. With few comparative studies, differences in
participants, outcomes assessed and the interventions used meant that meta-analysis was considered
inappropriate. As a result, studies were synthesised narratively with limited conclusions drawn about
the clinical effectiveness of the different interventions.
l It is thought that ablative and other minimally invasive therapies are a possible treatment option for
people with liver metastases who currently (i) would undergo surgical resection with curative intent,
(ii) are not candidates for surgical resection but would receive chemotherapy or (iii) are receiving
palliative treatment with chemotherapy. Unfortunately, the limited extent of the evidence has meant
that the majority of the evidence has focused on people who are not candidates for surgical resection.
l Outcomes reported by the studies assessing clinical effectiveness varied. Although survival was
reported by studies, it differed in terms of the measure reported (i.e. mean or median, estimated or
actual, overall or disease-free survival), period covered (i.e. from diagnosis or treatment) and the groups
of participants included (i.e. all people or subgroups). Measures of recurrence, response, time to
progression, quality of life and surgical invasiveness are reported by a limited number of studies,
limiting the extent of comparisons that can be made.127
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Chapter 7 ConclusionsImplications for service provisionClearly, although much has been deﬁned by this analysis, much remains unresolved and worthy of further
investigation (see Suggested research priorities, below). Bearing in mind the increasing incidence of
primary hepatocellular carcinoma, which is also treated by surgical resection and liver ablation therapies,
and the widening indications for repeated and multiple ablation treatments of colorectal cancer metastases
in the liver and at other sites (most notably lung), there may be an increasing unmet demand for the
different treatment options assessed in this report. There are only ﬁnite numbers of trained hepatobiliary
surgeons and interventional radiologists experienced and competent to deliver these treatments, and so it
is imperative to anticipate these demands and match them to training and accreditation in these
disciplines. Inevitably, the extent and nature of the development of the service will depend on further
clariﬁcation of the needs for treatment and the comparative effectiveness of the options available for the
different patient groups. As this is new and previously undelivered activity, any increase in provision will
have a signiﬁcant ﬁnancial impact on the demands for NHS resources and time, at a time of increasing
austerity within the health care budget.
These are technically challenging and complex technologies, frequently integrated into complex long-term
multidisciplinary treatment strategies, and should not be considered as stand-alone ‘one-off’ interventions
administered in isolation. Given the specialist nature of these services, it seems appropriate for the
provision of ablative therapies to continue through the current cancer network-determined SMDTs and
service providers at the designated tertiary hepatobiliary centres across the NHS. The development of the
service will need continued review to ensure that the extent and quality of provision is appropriate to the
needs identiﬁed.Suggested research prioritiesThe systematic review has shown limited good-quality evidence assessing the clinical effectiveness and the
cost-effectiveness of the different ablative and other minimally invasive therapies for treating liver
metastases. As a consequence, it has proved difﬁcult to differentiate between the different therapies in
their ability to improve survival, time to progression, response to treatment, recurrence rates, quality of life,
and adverse events. Although comparative evidence has shown some beneﬁt from radioembolisation and
chemoembolisation when compared with different forms of chemotherapy on measures of survival,
response and quality of life, results were not unequivocal. Similarly, the experimental and observational
evidence on the ablative therapies provides limited evidence to judge the effectiveness of these
technologies relative to other options. Studies focused on people who were not deemed suitable
candidates for surgical resection. The studies did not consider other groups, such as people suitable for
surgical resection or people with disease progression following conventional management. Furthermore,
there is little upon which to base a judgement of the effectiveness of ablative therapies on metastases
arising from different primary cancers, despite it being thought that different cancers, and even different
subtypes of the same cancer, have different patterns of metastasis. Lastly, as with all emerging
technologies, analysis of published literature can report only work that has been completed, and will
under-report ongoing research and that which is still in its planning stages.
The lack of evidence on the beneﬁts and costs of the different ablative and minimally invasive therapies
rendered the economic evaluation limited in its scope and speculative, with many uncertainties remaining.
Although results for the comparison of radioembolisation plus hepatic artery chemotherapy with hepatic
artery chemotherapy (£37,303 per QALY) and microwave ablation compared with surgical resection129
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130(£4681 per QALY) are presented, it is unclear whether or not these are entirely relevant to the NHS.
The limited evidence base and the assumptions required mean that the analysis should be considered
illustrative. It does not provide evidence for recommendations for future practice.
The evidence synthesis has revealed the limited evidence available to assess the clinical effectiveness and
cost-effectiveness of the different ablative and other minimally invasive technologies. It will be important to
undertake further primary research to provide comparative evidence on the different interventions that
provide alternative treatment options for people at various stages in the management of their
liver metastases.
Given the lack of an ideal preference-based measure for this population and the limited evidence for
mapping the cancer-speciﬁc, non-preference based EORTC QLQ-C30 into the generic preference-based
EQ-5D, both tools (EQ-5D and EORTC QLQ-C30, supplemented with EORTC QLQ-LMC21, preferably)
should be used in future studies. Using both tools would enable capturing clinically relevant outcomes as
well as those relevant to subsequent economic evaluations in a UK context.
Further evidence on the variation of quality of life of patients with liver metastases along disease
progression and according to different prognostic factors (such as number and size of metastases or
hepatic volume replaced by tumour, and percentage of tumour removed) could enable the assessment of
the cost-effectiveness of ablative therapies for relevant patient subgroups, provided that effectiveness
estimates for those subgroups were available as well.
Although studies could include those who would undergo such procedures as part of their palliative care,
it would appear more beneﬁcial to focus on people who are receiving treatment with curative intent. This
would include people who are and are not suitable for surgical resection. With most studies included in
this evidence synthesis being non-comparative studies of people who are not candidates for surgical
resection and only one comparative study of a microwave ablation compared with surgical resection, both
treatments require further research. Criteria for suitability for inclusion in a trial would also include number
of lesions identiﬁed. A local recurrence rate of 6–7% following surgical resection will stay the same
regardless of whether there is one lesion or three separate lesions (provided, of course, that all three are in
one lobe of the liver), whereas for radiofrequency ablation there would be a degree of multiplication of
risk of local recurrence by the number of lesions treated.
Several interventions could be included in any study undertaken, but they should be those that are
considered most relevant to the NHS in the UK. Of the different ablative and minimally invasive techniques
considered by this evidence synthesis, radiofrequency ablation, microwave ablation, chemoembolisation
and radioembolisation appear to have received most research and to be considered relevant. Inevitably,
opinions may differ as to which of these interventions or the other options available should be prioritised
for further research. Although all four could be studied, comparative experimental evidence assessing
chemoembolisation and radioembolisation has been published, and there are ongoing studies of
chemoembolisation (e.g. the FOXFIRE trial). However, limited evidence is available on radiofrequency,
microwave or other forms of ablative therapy. Ideally, given the uncertainty that remains as regards their
effectiveness in treating people who are and are not candidates for surgical resection, both groups should
be included and the comparator technologies should include surgical resection and chemotherapy.
However, pragmatic thought should be applied to issues arising from study design, including the ability of
a trial to recruit subjects.
Liver resection is an effective treatment for localised colorectal liver metastases.15 Liver resection is also now
a very safe procedure with perioperative mortalities of around 1%, and indeed in patients with limited
disease (those also most suitable for ablation) the risks may be even lower. The advent of laparoscopic
resection further increases the acceptability of surgical resection over other modalities. It thus becomes
difﬁcult to argue ethically that a trial of liver resection versus an alternative technique is needed in most
patients, and it would be difﬁcult in patients with a certain level of ﬁtness to recruit any to a trial withoutNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7concealing some of the facts regarding liver resection. Certainly this is the situation in colorectal cancer,
although the situation in other cancers (e.g. breast) may be different.
There is a group of patients, however, in whom the risk and beneﬁts are less clear. These patients are
elderly or they have signiﬁcant comorbidities which pose signiﬁcant risk from a surgical procedure. This is a
group in which there is equipoise regarding treatment and many such patients may already be offered
ablation rather than surgical resection.SummaryAny study should assess the clinical effectiveness and cost-effectiveness of the different techniques,
assessing measures of survival, response, recurrence, quality of life, adverse events, and costs. Outcomes
should be reported separately for the different groups of participants. A RCT would provide the most
appropriate design for undertaking the evaluation and should include a full economic evaluation, but the
group to be randomised needs careful selection.131
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Research aim
The research will undertake an evidence synthesis to assess the clinical and cost effectiveness of ablative
therapies for treating liver metastases.Objectives1. To conduct a systematic review of the evidence on the clinical and cost effectiveness of ablative
therapies for liver metastases.
2. To adapt an existing or construct a de novo economic model to estimate the cost effectiveness of
different approaches to treating liver metastases.
3. To identify deﬁciencies in current knowledge and to generate recommendations for future research.Methods for synthesis of evidence of clinical effectiveness
A systematic review of the evidence for clinical effectiveness will be undertaken following the general
principles outlined in Centre for Reviews and Dissemination (CRD) report ‘Undertaking Systematic Reviews
of Research on Effectiveness’ (Third edition)65 and the PRISMA statement on the reporting of systematic
reviews and meta-analyses.66Search strategy
A systematic search will be conducted to identify relevant studies assessing the use of ablative therapies for
treating liver metastases. Several sources will be used including electronic databases, bibliographies of
articles, grey literature and consultation with experts. A comprehensive database of relevant published and
unpublished articles will be constructed using the Reference Manager software package. The searches
carried out will include:
l General health and biomedical databases: MEDLINE (Ovid), EMBASE (Ovid), and the Science
Citation Index.
l Specialist electronic databases: The Cochrane Library (Wiley), NHS Centre for Reviews and
Dissemination HTA database.
l Research in progress: Current controlled trials metaRegister, ISRCTN database, WHO ICTRP Portal and
ClinicalTrials.gov.
l WWW: Subject speciﬁc internet sites or relevant associations (e.g. ASGBI).
l Grey literature, specialist abstract and conference proceeding resources (The British Library’s ZETOC
and ISI Proceedings).
l Checking of reference lists of included studies.
l Hand searching of journals relevant to the topic (previous 2 years only).
l Consultation with experts in the ﬁeld.
All databases will be searched from 1990 to the current date. Searches will be conducted with no
language restriction, with non-English-language articles placed in a separate database. Articles in French,
Spanish, Italian or German that have an abstract in English will be considered in the selection process
along with English language articles, if resources are available.Study Selection
Studies will be selected for inclusion in the systematic review through a two-stage process using
predeﬁned and explicit criteria (see Table 86). The full literature search results will be screened by two
reviewers to identify all citations that may meet the inclusion criteria. Full manuscripts of all selected147
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TABLE 86 Inclusion criteria for the systematic review
Intervention All ablative therapies currently used in the UK, including:
Radio-frequency ablation (RFA);
Microwave Ablation;
Cryoablation;
Ethanol Ablation;
Laser Ablation;
Focused Ultrasound;
Electrolytic Ablation.
Other minimally-invasive therapies currently used, speciﬁcally:
Chemoembolisation;
Radioembolisation.
These will be assessed separately and/or in sequence, where possible and appropriate.
Comparators Surgical resection of metastases;
Chemotherapy;
BSC (as deﬁned by the included studies and including chemotherapy as part of
BSC/palliative care).
Population People with liver metastases from any solid tumour primary site
Outcomes Procedure-related morbidity, mortality and hospital stay;
Rate of complete tumour ablation;
Local recurrence rate;
Progression-free survival;
Overall survival;
Health related quality of life;
Costs and cost effectiveness.
Study Design Randomised controlled trials;
Prospective non-randomised comparative studies;
Prospective case series studies (sample size >n=100);
Economic evaluations.
Systematic reviews identiﬁed by the search will be used as a source for identifying
primary studies.
Studies published as abstracts or conference presentations will only be included if sufﬁcient
details are presented to allow an appraisal of the methodology and the assessment of results
to be undertaken. Only abstracts published from 2006 onwards will be eligible for inclusion.
Where there is evidence from different types of study design for a speciﬁc intervention,
only those studies with the most rigorous designs will be included and data extracted.
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piloted on a sample of papers. Any disagreements over study inclusion will be resolved by consensus or if
necessary by arbitration involving a third reviewer.
Studies including patients with primary hepatocellular carcinoma, cholangio-carcinoma, lymphomas, focal
nodular hyperplasias and liver cell adenomas will be excluded. Case control studies and qualitative studies
will also not be included.Data extraction
The extraction of studies’ characteristics, methods and ﬁndings will be conducted by one reviewer, and
checked by a second reviewer, using a standardised pre-piloted data extraction form. Any disagreements
between reviewers will be resolved by discussion or, if necessary, by arbitration by a third reviewer.Quality assessment
The methodological quality of all included studies will be appraised using formal quality assessment
criteria. Studies assessing clinical effectiveness will be assessed using criteria recommended by CRD65 and
Cochrane Collaboration.69 Cost effectiveness studies will be assessed using an adapted set of criteria based
on those recommended by Drummond and colleagues67 and Philips and colleagues.68 Two reviewers will
assess all studies included in the review for quality with any disagreements between reviewers being
resolved by discussion with a third reviewer.Data synthesis
The results of included studies will be tabulated and summarised in a narrative review. The methods of
data synthesis will be determined by the nature of the studies identiﬁed through searches and included in
the review. Quantitative synthesis of results will be considered if there are several high-quality studies of
the same design, but speciﬁc details are not possible until the data has been obtained. Sources of
heterogeneity will be investigated using appropriate methods.Methods for synthesis of evidence of cost effectiveness
The cost effectiveness of ablative therapies for liver metastases will be assessed through a systematic
review and, where appropriate, the development of an economic model. The systematic review of cost
effectiveness will focus on full economic evaluations (i.e. costs and consequences) and will follow the
methods outlined in section 5.3. The inclusion criteria will be the same as for the clinical effectiveness
review apart from study design (cost effectiveness, cost utility or cost beneﬁt analyses). The quality of the
included economic evaluations will be assessed using a critical appraisal checklist based upon that
proposed by Drummond and colleagues67 and Philips and colleagues.68 The data from any included studies
will be tabulated and discussed in a narrative review. Published studies carried out from the UK NHS and
Personal Social Services (PSS) perspective will be examined in more detail. Any economic models identiﬁed
will be considered for further development for the current evaluation. If no relevant high quality economic
evaluations are identiﬁed, a de novo economic model will be developed.
The type and structure of any economic model will be informed by several sources including previous
models identiﬁed in the systematic review of cost effectiveness, evidence on the epidemiology, natural
history of the condition and through discussions with relevant clinical experts. The model structure will be
validated through discussion with expert advisors. The model will compare those interventions considered
effective in the systematic review of clinical effectiveness (see Table 1) with the standard comparators of
surgical resection of metastases and, where this is not appropriate, either chemotherapy or best supportive
care. The analysis will be from an NHS and PSS perspective and adopt a lifetime horizon. Future costs and
beneﬁts will be discounted at an annual rate of 3.5%. The economic evaluation will adhere to best
practice for developing economic models as outlined in the current NICE methodological guidance117 and
by Philips and colleagues.68149
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APPENDIX 1
150Data to populate the model parameters will be derived from best available evidence and will originate
from several sources. The systematic reviews of clinical and cost effectiveness will be used to provide data
inputs for the measures of clinical effectiveness and will also provide information on adverse events and
complications associated with included interventions. Where suitable, studies included in the systematic
reviews of clinical and cost effectiveness will be used to provide data on resources use, costs and quality of
life. Additional targeted searches will be conducted to identify other relevant studies reporting resource
use, quality of life or utility values, and cost data for relevant patient groups. Data on unit costs will be
obtained from published sources where available (e.g. NHS Reference Costs,164 Unit Costs for Health and
Social Care165) and/or developed from a collaboration with the costing unit at Southampton University
Hospitals NHS Trust. Costs will be inﬂated to current prices as necessary. Where data are limited, possibly
on quality of life and resource use, judgements will be made in consultation with clinical and other experts
as to the input values for these parameters. In all instances, the model description will clearly indicate the
place in the evidence hierarchy for data entering the model,166 particularly as evidence of effectiveness may
come from studies with a range of designs.
The modelled population will be deﬁned based on the published evidence about the characteristics of UK
population of patients with liver metastases of any solid tumour primary site, and the populations for
which good quality clinical effectiveness evidence is available. Where evidence is available patient
subgroups will be analysed separately. The results of the economic model will be presented as the
incremental cost effectiveness of each ablative therapy in comparison with the other ablative therapies and
the speciﬁed comparators (i.e. surgical resection of metastases, chemotherapy or best supportive care,
where appropriate). Cost effectiveness will be estimated in terms of incremental cost per quality-adjusted
life-year (QALY) gained. Uncertainty will be investigated through deterministic and probabilistic sensitivity
analysis and scenario analysis. Deterministic sensitivity analysis will be used to address particular areas of
uncertainty in the model relating to the model structure, methodological assumptions and parameters
around which there is considerable uncertainty or which may be expected, a priori, to have a
disproportionate effect on study results. Parameter uncertainty will be more generally addressed using
probabilistic sensitivity analysis, with probability distributions assigned to point estimates used in the
base-case analysis. Results will be presented using appropriate methods including plots in the cost
effectiveness plane, cost effectiveness acceptability curves and, if relevant, the cost effectiveness
acceptability frontier.
Quality assurance of the economic model will be undertaken through several different stages. The
structure of the model will be discussed with expert clinical advisors to assess clinical relevance and
plausibility. The model will be subjected to logic checks to assure internal consistency. Validation will also
include dual development (development in two packages, for example MS Excel and TreeAge, using
identical parameter inputs). External validation will be based on comparison of model outputs with
available clinical data and against outputs from similar models.Advisory group
An advisory group to inform the project will be recruited. The advisory group will be representative of
potential users of the review from different professional backgrounds and opinions. These will include
academics and clinicians, and a health economist/methodologist. A patient group representative will also
be recruited to the advisory group. The advisory group provide expert advice to support the project,
provide comments on a version of the protocol and of the ﬁnal report, as well as advising on the
identiﬁcation of relevant evidence. All members of the advisory group will be asked to register competing
interests and to keep the details of the report conﬁdential.Competing interests of authors
None declared.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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All databases searched for the systematic review are presented below. Searches were updated on13 September 2011.Database searched
Clinical effectiveness
searches
Cost-effectiveness and
quality-of-life searches
Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library)
All available years All available years
Cochrane Database of Systematic Reviews
(CDSR, The Cochrane Library)
All available years All available years
Database of Abstracts of Reviews of Effects
(DARE, Centre for Reviews and Dissemination)
All available years All available years
EMBASE 1990–2011 1990–2011
Health Technology Assessment Database
(Centre for Reviews and Dissemination)
All available years All available years
MEDLINE (Ovid) 1990–2011 1990–2011
MEDLINE In-Process & Other Non-Indexed Citations (MEIP) Searched 12 April 2011
National Health Service Economic Evaluation Database
(NHS EED, CRD)
All available years All available years
Web of Knowledge (Science Citation Index and
Conference Proceedings)
1990–2011 1990–2011
Zetoc, The British Library 1990–2011
Searched for ongoing trials
National Institute for Health Research Clinical Research Network (NIHR CRN Portfolio, formally UKCRN website)
Current Controlled Trials (CCT)
Clinical trials.govThe MEDLINE search strategy (presented below) for the systematic review of clinical effectiveness was
adjusted as necessary for other electronic databases for both clinical effectiveness and cost-effectiveness
(including quality-of-life information) searches. Search strategies for the systematic review are available
from the authors on request. Citations identiﬁed by the searches were added to a Reference Manager
(Thomson ResearchSoft, San Francisco, CA, USA) database.151
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APPENDIX 2
152MEDLINE search strategyNIHR1. exp Liver Neoplasms/sc [Secondary] (22,058)
2. exp Neoplasm Metastasis/ (133,433)
3. exp liver neoplasms/ (106,857)
4. 2 and 3 (9386)
5. (liver adj5 (secondar* or metasta* or micro-metasta* or micrometasta*)).tw. (21,489)
6. (hepat* adj5 (secondar* or metasta* or micro-metasta* or micrometasta*)).tw. (12,239)
7. 1 or 4 or 5 or 6 (40,827)
8. exp catheter ablation/ or exp ablation techniques/ (75,978)
9. exp Laser Therapy/ (43,645)
10. Cryosurgery/ (10,032)
11. Electrocoagulation/ (9522)
12. Electrolysis/ (1849)
13. Microwaves/ (10,483)
14. High-Intensity Focused Ultrasound Ablation/ (110)
15. Chemoembolization, therapeutic/ (2561)
16. electrochemotherapy/ (158)
17. (chemoemboli?ation or radioemboli?ation).tw. (2897)
18. ("chemo-emboli*" or "radio-emboli*").tw. (223)
19. (ablat* or photoablat* or cautery or electrocautery or electrolysis or electrolytic or diathermy or laser*
or microwave* or radiofrequency or "radio frequency" or cryosurg* or cryoablat* or cryotherap* or
thermoablati* or "thermo destruc*" or "thermo coag*" or "thermal coag*" or "thermometry" or
"transarterial emboli*" or "transarterial emboli*" or electrocoagulation* or "bead emboli*").tw.
(192,928)
20. (RFA or HIFU or IGA or "DEBs" or SIRT or TACE or PAAI or T or PEIT).tw. (44,547)
21. "drug eluting bead*".tw. (50)
22. (focus* adj5 ultrasound).tw. (1939)
23. (microsphere* adj2 inject*).tw. (1193)
24. (ethanol adj2 inject*).tw. (2467)
25. ("acetic acid" adj2 inject*).tw. (261)
26. acetic acid/ad, tu (363)
27. or/8-26 (263,845)
28. 7 and 27 (3215)
29. limit 28 to yr="1990 -Current" (3034)
30. limit 29 to humans (2877)
31. (editorial or comment or letter).pt. (1,052,888)
32. 30 not 31 (2766)Reference listsThe reference lists of retrieved articles were examined for additional studies.Other searchesThe experts advisory group were contacted in order to obtain information about additional references and
any ongoing studies.Journals Library www.journalslibrary.nihr.ac.uk
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American Society of Clinical Oncology (ASCO).
Association of Surgeons of Great Britain and Ireland (ASGBI).
Society of Academic and Research Surgery (SARS).
UK Clinical Research Collaboration (UKCRC).
Journal of One Day Surgery.153
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Appendix 3 Quality assessmentQuality assessment for randomised controlled trials
(answer yes/no/not reported/unclear)1. Was the method used to generate random allocations adequate?
2. Was the allocation adequately concealed?
3. Were the groups similar at the outset of the study in terms of prognostic factors, e.g. severity of disease/size, number of
tumours, performance status, and extrahepatic disease?
4. Were outcome assessors blinded to the treatment allocation?
5. (i) Were there any unexpected imbalances in dropouts between groups? (ii) If so, were they explained or adjusted for?
6. Is there any evidence to suggest that the authors measured more outcomes than they reported?
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned?
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate?
Note: only answer part (ii) of a question if the answer to part (i) is yes.Quality assessment for non-randomised comparisons
(answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori?
2. Was the allocation to study groups adequately concealed?
3. Were the groups comparable on key prognostic factors?
4. Were outcome assessors blinded to the treatment allocation?
5. Is there any evidence to suggest that the authors measured more outcomes than they reported?
6. Were withdrawals and dropouts completely described?
7. (i) Were there any unexpected imbalances in dropouts between groups? (ii) If so, were they explained or adjusted for?
8. Did the analyses include an intention-to-treat analysis?Quality assessment for case series studies
(answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori?
2. Was the participant blinded to the research question?
3. Is there any evidence to suggest that the authors measured more outcomes than they reported?
4. Were withdrawals and dropouts completely described?
5 (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate?
Note: only answer part (ii) of a question if the answer to part (i) is yes.155
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Mack et al., 200170Study and intervention details Participants Outcome measures
Country: Germany
Funding: not reported
Intervention: laser ablation
Number of centres: one
Indication for treatment: liver metastases
from a mix of primary tumour types
Intention of treatment: not stated
Number of participants: overall 705
(outcomes not data extracted as contains
5% hepatocellular carcinoma, 20% other
primary tumours without separate
outcome data). Data extracted: 393
participants with colorectal cancer primary;
127 participants with breast cancer primary
Sample attrition/dropout: not reported
Inclusion criteria: patients who developed
metastases in remaining liver after
hepatectomy; patients who had metastases
in both liver lobes; patients with
contraindications for surgery or
unresectable lesions, patients refusing
hepatic surgery
Exclusion criteria: patients with more than
ﬁve metastases, metastases larger than
5 cm in greatest diameter, extrahepatic
tumour spread
Outcomes: rate of complications and
side effects; local tumour control
rate, overall survival. Only overall
survival data extracted for the groups
of interest (see below)
Method of assessing outcomes:
survival by Kaplan–Meier, no further
details reported
Length of follow-up: not reported
Participant
characteristics
Laser ablation (n = 705 overall;a 393 colorectal cancer primary; 127 breast
cancer primary)
Age (years), mean (range) Overall: 59 (24–89)a
Colorectal primary: 60.8 (range not reported)
Breast cancer primary – age not reported
Male/female, n (%) Overall 385/320 (55/45)a
Primary cancer site Colorectal cancer 57%, 393 participantsb
Breast cancer 18%, 127 participants
Hepatocellular carcinoma 5%, number not reported
Other tumours 20%, number not reported
Number of liver metastases Not reported per patient
Size of metastases Not reported per patient
Previous treatments for liver
metastases
Not reported
a The overall group includes 5% participants with hepatocellular carcinoma.
b Likely that either the number or percentage of participants is incorrect because 393 participants is not 57% of
705 participants (it is 56%). Per cent male/female calculated by reviewer.
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158ResultsOutcomes Laser ablation
Comments: reported for the overall group and not data extracted: rate of complications and side effects; local tumour
control rate, overall survival. States that survival did not differ signiﬁcantly (p > 0.05) between male and female patients or
between patients with colorectal metastases and those with metastases from other tumour types
Patients with unresectable colorectal liver metastases (n = 393)
Overall survival, mean (95% CI) months 41.8 (37.3 to 46.4)
1-year survival rate 93%
2-year survival rate 74%
3-year survival rate 50%
5-year survival rate 30%
Overall survival of patients with one or two initial liver metastases, mean (95% CI) 50.4 months (44.4 to 56.4)
Overall survival of patients with three or more initial liver metastases, mean (95% CI) 34.8 months (31.2 to 38.4)
Comments: differences between overall survival of patients with one or two initial metastases versus those with three or
more initial metastases were assessed with the log-rank test and the Tarone–Ware test and were shown to be not
statistically signiﬁcant
Kaplan–Meier plot of overall survival presented but not data extracted
Patients with breast cancer liver metastases (n = 127)
Overall survival, mean (95% CI) years 4.3 (3.6 to 5.0)
1-year survival rate 97%
2-year survival rate 75%
3-year survival rate 65%
5-year survival rate 34%
Comments: there may be some overlap between these breast cancer liver metastases patients and those reported in
another paper by the same author (Mack et al., 200471)
Kaplan–Meier plots of overall survival presented but not data extracted
General comments
Generalisability: difﬁcult to determine due to very limited baseline characteristics
Outcome measures: for the groups of interest only overall survival was reported
Inter-centre variability: not applicable, only one centre
Conﬂict of interests: not reportedQuality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
4. Were withdrawals and dropouts completely described? Not reported
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Mack et al., 200471Study and intervention details Participants Outcome measures
Country: Germany
Funding: not stated
Intervention: laser ablation
NB: Ten patients treated with
non-irrigated laser application
system, the remainder (n = 222)
with an internally cooled laser
applicator system with the ﬁrst
38 of these patients treated
less aggressively than the
remaining 184
Number of centres: one
Indication for treatment: breast cancer liver
metastases
Intention of treatment: not stated
Number of participants: 232
Sample attrition/dropout: not reported
Inclusion criteria: recurrent liver metastases
after partial liver resection (n = 19, 8.2%);
metastases in both liver lobes (n = 105,
45.2%); locally non-resectable tumours
(n = 44, 19%); general contraindications
for surgery (n = 6, 2.6%); refusal of
surgical resection (n = 58, 25%)
Exclusion criteria: more than ﬁve tumours,
tumour larger than 5 cm at greatest
diameter, known extrahepatic spread
(lymph node metastases resected at the
time of primary breast cancer resection
were not considered extrahepatic spread).
Bone metastases that were under control
(by systemic treatments and/or radiation
therapy) were not a contraindication to
laser ablation
Outcomes: ablation volume,
adverse events, local tumour control
rate, overall survival
Method of assessing outcomes:
local tumour control – evaluated
only for metastases treated with the
irrigated power laser applications
system with at least a 6-month
follow-up. Enhanced and
unenhanced magnetic resonance
images obtained before and after
laser treatment were compared
with each other and those obtained
at 3, 6 and 12 months’ follow-up.
Areas that did not enhance with
contrast medium were considered
to represent necrotic tissue.
Recurrent tumour at ablation site
deﬁned as volume of lesion
increased compared with that at
the examination 3 months earlier
and parts of the lesions showing a
bulge consisting of solid material
with contrast enhancement
Tumour volume and volume of
necrosis calculated using the three
greatest dimensions of the tumour
(x, y and z) as [(4π/3)(x/2)(y/2)(z/2)]
All evaluations performed by two
radiologists and decision made by
consensus
Length of follow-up: mean
follow-up after the ﬁrst treatment
was 1.8 years (maximum 7.7 years,
median 1.6 years)
Participant characteristics Laser ablation (n = 232)
Age (years), mean (SD) years 54.4 (9.9) range 27–79
Male/female 100% female
Primary cancer site Breast
Number of liver metastases, mean (range) 2.5 (1–13)
Size of metastases, n/N metastases (% of metastases)
< 2 cm 251/578 (43.4)
2–3 cm diameter 191/578 (33.0)
3–4 cm diameter 75/578 (13.0)
4–5 cm diameter 61/578 (10.6)
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Participant characteristics Laser ablation (n = 232)
Previous treatments for liver metastases States all patients receiving
chemotherapeutic regimens
of choice prior to or after
laser treatment
Bone metastases that were considered to be under control 72/232 (31%)
Comments: it is not clear whether or not the maximum number of liver metastases (n = 13) is above the threshold of ﬁve
(as per exclusion criteria) because of additional metastases found during the ﬁrst round of treatment that had not been
visible at the time of inclusion, or whether or not the number of liver metastases includes new metastases which were
detected during follow-up after the ﬁrst round of treatment
Baseline data reported but not extracted: tumour location by liver segment; percentage known bone metastases considered
under control; proportion of metasynchronous and synchronous metastases; mean time between diagnosis of primary
tumour and diagnosis of metastases
APPENDIX 4
160ResultsOutcomes Laser ablation (n = 232)
Mean survival from date of diagnosis of metastases 4.9 years (95% CI 4.3 to 5.4)
Median survival from date of diagnosis of metastases 4.3 years (95% CI 3.4 to 5.3)
1-year survival rate metastases diagnosis 96% (198 patients)
2-year survival rate metastases diagnosis 80% (133 patients)
3-year survival rate metastases diagnosis 63% (68 patients)
5-year survival rate metastases diagnosis 41% (23 patients)
Mean survival after ﬁrst laser treatment 4.2 years (95% CI 3.6 to 4.8)
1-year survival rate after ﬁrst laser treatment 85% (154 patients)
2-year survival rate after ﬁrst laser treatment 66% (86 patients)
3-year survival rate after ﬁrst laser treatment 51% (34 patients)
5-year survival rate after ﬁrst laser treatment 38% (12 patients)
Comments: states that estimated mean survival times are biased due to the number of censored cases. If the event had
not been noted in the patient chart by the end of the observation period the cases were treated as if the event had been
noted at that time. The proportion of participants surviving at 1, 2, 3, and 5 years is also reported but has not been
data extracted. Kaplan–Meier plots for survival from data of metastases diagnosis and survival after ﬁrst laser treatment
are presented in the paper but have not been data extracted
Subgroup analyses of survival by number of metastases, patient treatment group, indications for laser therapy, lymph node
stage, metasynchronous or synchronous metastases, timing of development of metastases after diagnosis of primary
tumour, size of metastases, and presence or absence of controlled bone metastases are presented but have not been
data extracted
Local tumour recurrence rate at 6 months (n/N metastases) reported according to size of metastases. Data are also provided
for recurrence at 3 months; it is not clear in the paper whether or not these 6-month data include the recurrences noted at
3 months’ follow-upNIHR Journals Library www.journalslibrary.nihr.ac.uk
(continued )
Outcomes Laser ablation (n =
Incomplete ablation, n metastases 2
Adverse events, n/N treatment sessions
Pleural effusion 4/452
Non-symptomatic pleural effusion 41/452
Liver abscess 2/452
Injury to bile duct 1/452
Bronchial biliary ﬁstula None
Thirty-day mortality None
Pneumothorax None
Small non-symptomatic subscapular haematoma 20/452
Comments: note that a treatment session could include the treatment of more than one metastasis
Number of treatment sessions per patient, mean (range) 2.0 (1.0–8.0)
Comments: data on number of laser applicators per metastasis, number of laser applicators per patient, and
treatment rounds not data extracted (all treatment sessions necessary to ablate all metastases visible were su
one treatment round)
General comments
l Generalisability: due to limited baseline characteristics the generalisability of this study is uncertain
l Outcome measures: appear appropriate for the study
l Inter-centre variability: not applicable, single centre
l Conﬂict of interests: authors stated no ﬁnancial relationship to disclose
1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured
more outcomes than they reported?
Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the
methods appropriate?
Not reported
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162Microwave ablation
Shibata et al., 200072Study details Participants Outcome measures
Country: Japan
Design: RCT
Number of centres: one
Funding: not reported
Intervention:
1. microwave ablation;
2. hepatic resection
Indication for treatment: multiple
metastatic colorectal carcinoma in liver
Intention of treatment (curative/
palliative/pre-resection/not stated):
not stated
Number of participants:
Number randomised: (1) microwave,
n = 20; (2) hepatectomy, n = 20
Number studied: (1) microwave,
n = 14; (2) hepatectomy, n = 16
Sample attrition/dropout: 10 excluded
intraoperatively
Inclusion criteria: participants were
potentially amenable to hepatic
resection
Primary colorectal carcinoma conﬁrmed
histologically, multiple but < 10
metastatic tumours in liver, at least one
liver tumour characterised histologically
by ultrasound-guided needle biopsy,
largest tumour had greatest dimension
< 80mm by contrast-enhanced CT, no
evidence of periportal lymph node,
coeliac lymph node or extrahepatic
distant metastases, or ascites, no liver
cirrhosis or chronic hepatitis
Primary outcomes:
survival rate; surgical
invasiveness
Secondary outcomes:
adverse events
Method of assessing
outcomes: serum CEA
was measured 4 weeks
before and 4 weeks
after treatment.
CT, ultrasonography
and chest radiography
performed every
3 months
Length of follow-up: not
reported
Participant characteristics
Microwave ablation
(n = 14)
Hepatectomy
(n = 16) p-value
Age, years, mean (SD) 61 (10) 61 (9) p = 1.0
Male/female 6/8 10/6
Primary cancer site Colorectal 100% Colorectal 100%
Number of liver metastases,
mean (SD)
4.1 (2.1) 3.0 (1.0) p = 0.10
Distribution of liver metastases
Size of metastases: greatest
dimension of largest liver
tumour, mm, mean (SD)
27 (11) 34 (17) p = 0.21
Previous treatments for primary
cancer
NR NR
Time from primary treatment NR NR
Previous treatment for liver
metastases
NR NR
Time from previous liver
metastases treatment
NR NR
Comorbidities (including other
metastases)
NR NR
NR; not reported.
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Microwave ablation
(n = 14)
Hepatectomy
(n = 16) p-value
Cumulative survival rate p = 0.83
Mean duration of survival, months 27 25
Estimated survival, %
1 year 71 69
2 year 57 56
3 yeara 14 23
Deaths during follow-up 9 12
Disease-free interval (months), mean 11.3 13.3 p = 0.47
a The statistical power calculated for the 3-year survival rates with a one-sided signiﬁcance level of 0.05 was 0.65
Legend to ﬁgure 3 indicates that survival was measured from time of treatment
As 9 out of 14 patients in the microwave group died during follow-up and 12 out of 16 died in the hepatectomy group
there may be an error in ﬁgure 3 of the paper (Kaplan–Meier chart of overall survival). Although the ﬁgure is a small size it
appears to show tick marks, the typical indicator for censored data, e.g. due to participants still being alive at the time of
analysis. However, there seem to be four tick marks on the microwave survival line (when ﬁve might be expected) and
conversely ﬁve tick marks on the hepatectomy line (when four might be expected). Furthermore, checking the plot using
digitising software also suggests the survival plot lines have been mislabelled
Adverse events
Intraoperative or postoperative deaths 0 0
Intestinal obstruction 0 1 (6%)
Bile duct ﬁstula 1 (7%) 1 (6%)
Hepatic abscess 1 (7%) 0
Wound infection 0 1 (6%)
Total frequency of complications 2 (14.3%) 3 (18.8%) p = 0.87
Indications of surgical invasiveness
Intraoperative blood loss (ml), mean (SD) 360 (230) 910 (490) p = 0.027
Blood transfusion (ml), mean (SD) 0 (0) 540 (690) p = 0.08
No. of patients requiring blood transfusion (%) 0 (0) 6 (38) p = 0.035
Operation time (minimum), mean (SD) 180 (20) 200 (50) p = 0.2
Period of hospitalisation (days), means (SD) 20 (7) 25 (12) p = 0.23
Intervention details
1. Microwave ablation performed after laparotomy using microwave tissue coagulator HSD-20M (Azwell, Osaka, Japan) for
total period of 2–20 minutes. Superﬁcial tumours were treated at output of 100watts, 2-cm-long needle electrode
(0.7mm diameter, TM-20, Azwell). Deep-seated tumours were treated at 60 watts, 20-cm needle electrode (1.6mm
diameter, TMD-16CBL, Azwell). Needle electrode inserted several tines into each target tumour guided by
ultrasonography. One course of ablation of each tumour consisted of a series of 10–30-second ablation periods
followed by a 10-second ablation-free period
2. Hepatic resection performed according to a standard method (references provided), lobectomy, segmentectomy,
subsegmentectomy and/or wedge resection depending on number, location or size of tumourscontinued163
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Details of post-intervention treatments
1. Five patients had a second round of microwave ablation therapy
Methodological comments
l Allocation to treatment groups: randomised without stratiﬁcation according to a computer generated 1 : 1
randomisation list
l Blinding: not reported, assume none
l Comparability of treatment groups: similar in age, number of tumours and size of greatest tumour. Other baseline
characteristics not reported
l Method of data analysis: cumulative survival rate calculated using Kaplan–Meier method, in which the difference
between the treatment groups was evaluated using a log-rank test. For other data, groups compared using two-tailed,
non-paired Student t-test or a chi-square with Yates’ correction. Signiﬁcant if p< 0.05
l Sample size/power calculation: number required (n = 40) calculated with a signiﬁcance level of 0.05 and power of
0.9 based on the assumption that microwave ablation increased the 3-year survival by 50% above that of hepatic
resection for multiple colorectal metastases (18%)
l Attrition/dropout: 10 patients dropped out intraoperatively due to metastases in periportal and/or coeliac lymph nodes
(one microwave, two hepatectomy), ≥ 10 tumours in liver (three microwave, two hepatectomy), peritoneal
dissemination (2 microwave). Of these 10, seven were treated as planned and treatment abandoned in three
(peritoneal dissemination in two, portal/coeliac lymph node metastases in one)
General comments
l Generalisability: patients with multiple liver metastases from colorectal carcinoma
l Outcome measures: length of follow-up not reported
l Inter-centre variability: not applicable
l Conﬂict of interests: not reported
l Other: high dropout rate (10 of 40 patients excluded intraoperatively)
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164Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Not reported
3. Were the groups similar at the outset of the study in terms of prognostic factors,
e.g. severity of disease/size, number of tumours, performance status, extrahepatic disease
Yes
4. Were outcome assessors blinded to the treatment allocation? Not reported
5. (i) Were there any unexpected imbalances in dropouts between groups? (ii) If so, were they
explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned? No
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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Non-randomised comparison study
Kim et al., 201173Study and intervention details Participants Outcome measures
Country: Republic of Korea
Funding: not stated
Intervention: radiofrequency ablation
Comparators:
(1) hepatic resection;
(2) combination radiofrequency
ablation and resection
Number of centres: one
Indication for treatment:
colorectal liver metastases
Intention of treatment:
not explicitly stated
Number of participants:
482: RFA 177; resection 278;
combination 27
Sample attrition/dropout:
not stated
Inclusion criteria: not stated
as such. All patients were
initially considered for
resection, except for those
with surgery-prohibitive
comorbidities, difﬁcult
anatomical site, and more
than four metastases:
these were considered
for RFA. No details of how
the other participants were
allocated to groups
Exclusion criteria: extrahepatic
metastases excluded at onset
of treatment
Outcomes: recurrence,
disease-free survival, overall survival
Method of assessing outcomes:
not stated
Length of follow-up: states carried
out every 3–6 months, unclear on
duration
Participant characteristics RFA (n = 177) Resection (n = 278)
RFA + resection
(n = 27)
Age (years), mean (SD) 60.4 (10.7) 57.1 (10.9) 55.7 (11.1)
Male/female (%) 121/56 (68.4/31.6) 168/110 (60.4/39.6) 15/12 (55.6/44.4)
Primary cancer site Colorectal Colorectal Colorectal
Number of liver metastases,
mean (SD)
1.6 (0.9) 1.5 (0.8) 3.1 (1.6)
Size of metastases, maximum,
mean (SD)
2.1 (1.0) 2.6 (2.0) 2.1 (1.4)
Previous treatments for
liver metastases
Not stated Not stated Not stated
Comments: the RFA group had more participants with metachronous liver metastases than the resection group
(RFA 90.4%; resection 23.1%; combination group 0%)
RFA, radiofrequency ablation.
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166ResultsOutcomes RFA (n = 177) Resection (n = 278)
RFA + resection
(n = 27)
Survival Not reported Not reported Not reported
Mortality (treatment related) 0 0 0
Comments: presents data for subgroups with solitary metastases < 3 cm and ≥ 3 cm but not extracted as not a pre-deﬁned
subgroup. Also presents univariate and multivariate analyses of factors associated with overall survival and disease-free
survival (age, sex, type of treatment, number of metastases, maximum tumour size, synchronicity, location and
chemotherapy after treatment), but not extracted here. Also reports overall survival and disease-free survival rates in a
subgroup who had multiple liver metastases across the three treatments (presented graphically), but not extracted here as
not a predeﬁned subgroup
General comments
l Generalisability: study undertaken in Korea, which may limit generalisability of results to the UK population
l Outcome measures: do not present data for entire group on any outcome measure
l Inter-centre variability: not applicable
l Conﬂict of interests: states none
RFA, radiofrequency ablation.Quality assessment for non-randomised comparisons (answer yes/no/not
reported/unclear)1. Were the patient selection criteria speciﬁed a priori? No
2. Was the allocation to study groups adequately concealed? Unclear
3. Were the groups comparable on key prognostic factors? No
4. Were outcome assessors blinded to the treatment allocation? Not reported
5. Is there any evidence to suggest that the authors measured more
outcomes than they reported?
Unclear
6. Were withdrawals and dropouts completely described? Not reported
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Not reported
8. Did the analyses include an intention-to-treat analysis? Not reported
9. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reportedNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Case series studies
Berber et al., 2005,74 200875Study and intervention details Participants Outcome measures
Country: USA
Funding: not reported
Intervention: radiofrequency ablation
(laparoscopic)
Number of centres: one
Indication for treatment: colorectal
liver metastases
Intention of treatment: not stated in
2005 paper.74 States curative intent
in 2008 paper75
Number of participants: 135
Sample attrition/dropout: not stated
Inclusion criteria: unresectable liver
disease, predominant liver disease
(minor extrahepatic disease allowed),
enlarging metastases, worsening
symptoms, failure to respond to
other treatments, fewer than eight
metastases on preoperative CT scan
(if identiﬁed during treatment to
have more not excluded), < 20%
total liver volume replaced with
tumour, normal biliary duct
diameters
Exclusion criteria: not stated
Outcomes: survival, progression-free
survival
Method of assessing outcomes: not
stated
Length of follow-up: between 1 and
52 months depending on how long
since RFA procedure at the time of
the analysis
Participant characteristics Radiofrequency ablation (n = 135)
Age (years), mean (SEM) 62 (1)
Male/female (%) 85/50 (63/37)
Primary cancer site Colorectal
Number of liver metastases ablated, mean (SEM) 3.2 (0.2)
Largest liver metastases, size, mean (SEM) 4.1 (0.4)
Previous chemotherapy for liver metastases 80%
Previous liver resection 14%
Extrahepatic disease 40 (30%)
Comments: none
SEM, standard error of the mean.167
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168ResultsOutcomes Radiofrequency ablation (n = 135)
Median Kaplan–Meier survival post radiofrequency ablation 28.9 months
Median Kaplan–Meier survival after diagnosis liver metastases 44.6 months
Comments: purpose of study was to identify predictors of survival and therefore presents data for a range of subgroups
of potential relevance to survival, and a number of prognostic factors. Report sex, age, primary tumour, node status,
location of liver metastases, type of metastases, number of metastases, largest size of metastases, extrahepatic disease,
pre-RFA chemotherapy and carcinoembryonic agent. Data not extracted
Also present median progression-free survival for those participants who did not have extrahepatic disease at time of the
ablation, not extracted here
Also reports cause of death and site of initial recurrence of disease
Kaplan–Meier curves presented in paper
The recruitment dates of the 2005 and 2008 publications overlap but do not have the same starting point
The 2008 publication76 aimed to identify factors that predict local recurrence following radiofrequency ablation. Primary
and metastatic liver tumours were included. Data are presented per tumour and the paper does not report the number of
participants with colorectal tumours or any baseline data
Presents Kaplan–Meier curve (analysed on a per-lesion basis) of local tumour control separately for colorectal metastases
Local recurrence was identiﬁed in at least one liver tumour in 46% of patients with colorectal cancer
No other relevant data to extract
General comments
l Generalisability: reasonable sample size of colorectal cancer participants; however, limited baseline characteristics
presented
l Outcome measures: appear reasonable. Follow-up likely to be short for some patients, unclear what impact this would
have on the survival curve data
l Inter-centre variability: not applicable
l Conﬂict of interests: states authors indicated no potential conﬂicts of interest
RFA, radiofrequency ablation.Quality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Gillams and Lees, 2009,77 200476Study and intervention details Participants Outcome measures
Country: UK
Funding: not reported
Intervention: radiofrequency ablation
Number of centres: one
Indication for treatment: colorectal
liver metastases
Intention of treatment: not stated
Number of participants: n = 309
Sample attrition/dropout: not
stated. Some baseline
characteristics not known for
some patients, numbers reported
Inclusion criteria: all patients
treated with radiofrequency
ablation since 1997. Acceptance
criteria: inoperable due to number
or distribution of tumours resulting
in inadequate residual liver
volume, inability to achieve
margins because of tumour
location adjacent to the vena cava
and hepatic conﬂuence, or
presence of extrahepatic disease
or concomitant morbidity. Five or
fewer tumours of 5 cm or less in
diameter, or up to nine tumours
with a maximum diameter of 4 or
4.5 cm, or a solitary tumour less
than 7 cm in diameter.
Extrahepatic disease if stable on
treatment. Ablation of larger
tumours performed later in study
period due to evolving ablation
technology. More extensive
disease sometimes treated due to
progression between referral and
ablation and cross-sectional
imaging underestimating extent of
disease
Outcomes: survival; complications
Method of assessing outcomes: CT
scan prior to discharge (baseline for
comparison) and at 3-month
intervals
Complications assessed using
Society of Interventional Radiology
guidelines
Length of follow-up: not reported in
the 2009 publication
Participant characteristics Radiofrequency ablation (n = 309)
Age (years), mean (range) 64 (24–92)
Male/female 198/111
Primary cancer site Left colon: 118/285 (41%)
Right colon: 51/285 (18%)
Rectum: 95/285 (33%)
Multiple: 12/285 (4%)
Unspeciﬁed colonic: 9/285 (3%)
Number of liver metastases, mean (median, range) 4 (3, 1–27)
Size of largest metastasis (cm), mean (median, range) 3.7 (3.5, 0.9–12)
Previous treatments for liver metastases Liver resection: 48/309 (16%)
Extrahepatic disease 115/309 (37%)
Data on chemotherapy received incomplete and no data extracted
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170ResultsOutcomes Radiofrequency ablation (n = 309)
Overall survival Not reported for whole group. Univariate and multivariate
survival analysis presented for a number of variables
Procedure related mortality 0
Number of major complications (requiring intervention or
hospital stay beyond 72 hours)
29 (617 treatment sessions)
Systemic 5
Anaesthetic 1
Local 23 (3.7%) [one pneumothorax, four visceral thermal
injuries, six abscesses, four jaundice (two bile duct
injuries, two inadequate liver reserve), seven
haemorrhagic complications and one asymptomatic
pseudoaneurysm]
Developed new liver metastases 72 (50%), of whom 23 had recurrence adjacent to
ablated lesions
Developed new sites or progression of extrahepatic
metastases
71 (49%), of whom 19 had local liver recurrence
Developed local liver recurrence without evidence of
disease elsewhere
30
Survival curves presented for those with and without extrahepatic disease, and comparing different liver tumour volumes in
patients without extrahepatic disease. Overall survival presented for 167 patients reported the 2004 paper76
General comments
l Generalisability: patients with inoperable colorectal liver metastases. Changes in techniques and other treatment during
period of study
l Outcome measures: survival reported for subgroups only
l Inter-centre variability: not applicable
l Conﬂict of interests: not reportedQuality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5 (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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Country: USA
Funding: not reported
Intervention: radiofrequency
ablation
Number of centres: two
Indication for treatment: colorectal
liver metastases
Intention of treatment: not stated
Number of participants: 234
Sample attrition/dropout: not
reported
Inclusion criteria: not candidates for
resection and/or failed chemotherapy,
presence of extrahepatic spread, up to
12 hepatic lesions with a maximal
dominant lesion size of 10 cm
Exclusion criteria: not reported
Outcomes: progression of ablated
disease; evidence of new hepatic disease
or extrahepatic disease, overall survival
Method of assessing outcomes: data
collected 1 week post ablation, at
1 month, and then every 3 months.
CT scans and laboratory data used to
identify the presence or recurrence of
metastatic disease
Survival calculated from treatment of
liver metastases
Length of follow-up: median
24 months (range 1 to 94) from time of
ablation to death or data analysis
Participant characteristics Radiofrequency ablation (n = 234)
Age (years), mean (SEM) 62 (1)
Male/female, n (%) 153/81 (65/35)
Primary cancer site Colorectal
Number of liver metastases, mean (SEM) 2.8 (0.14), range 1–12
Largest tumour size, mean (SEM), cm 3.9 (0.2), range 1.1–10.2
Previous chemotherapy for liver metastases ‘Majority’
Extrahepatic disease, n/N (%) 55/234 (23.5)
Comments: indicates that chemotherapy received by participants differed across the course of the 10-year study
SEM, standard error of the mean.ResultsOutcomes Radiofrequency ablation (n = 234)
Actuarial median survival 24 months
Actual 3-year survival 20.2%
Actual 5-year survival 18.4%
Deaths during study period 148/234
Comments: survival in a range of subgroups also presented to assess factors affecting long-term survival (number of lesions,
lesion size, chorioembryonic antigen levels, presence of extrahepatic disease, stage of disease at presentation) with survival
curves presented. Also present median progression-free survival for those participants who did not have extrahepatic
disease at time of the ablation, not extracted here
General comments
l Generalisability: consecutive patients accrued from two locations over a 10-year period (May 1997 to March 2007) but
limited baseline characteristics. Patients either had non-resectable disease or were not able to undergo resections due
to comorbidities
l Outcome measures: appear reasonable
l Inter-centre variability: not known
l Conﬂict of interests: not stated
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172Quality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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Country: Italy
Funding: not reported
Intervention: radiofrequency
ablation
Number of centres: two
Indication for treatment:
colorectal liver metastases
Intention of treatment: not
stated
Number of participants: 117
Sample attrition/dropout: of
117 patients, status
determinable in 96 (82%)
at 12 months; 64 (55%) at
24 months; 45 (38%) at
36 months; and 38 (32%)
at 48 months
Inclusion criteria: patients not
considered for surgical
metastasectomy due to
extrahepatic metastases, prior
hepatic metastasectomy, age,
disease extent and/or
comorbidity; refusal to
consent to surgery
Exclusion criteria: not stated
Outcomes: time to death, time to new
metastases, time to tumour recurrence,
complications
Method of assessing outcomes:
post-treatment CT scans obtained
7–14 days following ablation, with
additional follow-up scans at 3–4 months
following therapy and thereafter at 4- to
6-month intervals. Each image was
compared with baseline studies. Scans
were interpreted by a total of four
investigators: two from each institution.
No more than two were involved in the
treatment of any one patient. A consensus
of the readers was used to judge
treatment effectiveness
Technical success deﬁned as no detectable
tumour 7–14 days after treatment
Length of follow-up: 6 to 52 months
Participant characteristics Radiofrequency ablation (n = 117)
Age (years), mean (SD) 64.8 (10.8)
Male/female, n (%) 81/36 (69.2/30.8)
Primary cancer site Colorectum
Number of liver metastases, n (%)
One 74 (63.2)
Two 29 (24.8)
Three 9 (7.7)
Four 5 (4.3)
Diameter of metastases (cm), mean (SD); median (range) 2.8 (1.2); 2.6 (0.6–9.6)
Largest metastasis (cm), mean (SD); median (range) 3.2 (1.3); 3.0 (0.7–9.6)
Previous liver resection, n (%) 24
Systemic chemotherapy only prior to ablation, n (%) 20 (17)
Systemic chemotherapy prior to and following ablation, n (%) 84 (72)
No systemic chemotherapy, n (%) 13 (11)
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174ResultsOutcomes Radiofrequency ablation (n = 117)
Technical success, n/N (%) tumours treated 176/179 (98)
Incomplete initial therapy, n patients (%) 3 (2.6)
Deaths, n (%) 36 (31)
Estimated median survival, months 36 (95% CI 28 to 52 months)
Estimated 1-year survival 93%
Estimated 2-year survival 69%
Estimated 3-year survival 46%
New metastases developed during follow up, n/N (%) patients 67/117 (57)
Median time to detection of new metastases, months 12 (95% CI 10 to 18 months)
Local recurrence, n/N (%) lesions 70/179 (39.1)
Estimated local recurrence rate at 18 months for all patients 44%
Patients with at least one local recurrence, n (%) 64 (54.7)
Comments: time to death is reported by number of metastases but has not been data-extracted. Median time to local
recurrence not estimable due to small number of events. Time to new metastases also reported by number of metastases
but not data extracted. Data on retreatments not data extracted. Kaplan–Meier curves presented
Severe complications n = 1 (perforation of right colon,
required surgical repair)
Other complications n = 1 (small intraperitoneal haemorrhage,
stabilised without treatment)
Comments: 229 treatment sessions
General comments
l Generalisability: took place at two tertiary referral centres with consecutive participants recruited over a 4-year period
(July 1995 to October 1999)
l Outcome measures: appear appropriate
l Inter-centre variability: not reported
l Conﬂict of interests: not reportedQuality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? No
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Sorensen et al., 200780Study and intervention details Participants Outcome measures
Country: Denmark
Funding: not reported
Intervention: radiofrequency
ablation
Number of centres: one
Indication for treatment: colorectal
liver metastases.
Intention of treatment: not stated
Number of participants: 102
consecutive patients
Sample attrition/dropout: two
participants excluded from follow-up
evaluation. One RFA was to reduce
tumour prior to surgery, one resulted
in a ﬁstula and the whole liver
segment was resected
Inclusion criteria: inoperability due to
prior hepatic resection or comorbidity
(n = 100), or refused surgery (n = 2).
Four or fewer tumours with a
maximum diameter of 4 cm (based on
contrast-enhanced CT diagnosis)
Exclusion criteria: known extrahepatic
spread, uncontrolled coagulopathy, or
tumours situated less than 1 cm from
the gall bladder, central biliary
structures, or bowel
Outcomes: survival; complications
Method of assessing outcomes: survival
estimated using Kaplan–Meier method
and deﬁned as the time between
diagnosis of liver metastases and death
or the end of the follow-up period, or
the time between the ﬁrst RFA
treatment and death or the end of the
follow-up period
Complications were classiﬁed in
accordance with the deﬁnitions of the
Society for Cardiovascular and
Interventional Radiology (reference
provided). Complications threatening
life, leading to substantial morbidity
and disability or requiring prolonged
hospitalisation were considered major
complications. All others were
considered minor complications
Length of follow-up: mean follow-up
was 23.6 months (range 1–92 months)
Participant characteristics Radiofrequency ablation (n = 102)
Age (years), mean (range) 64 (33–84)
Male/female 61/41
Primary cancer site Rectum 35 (34%)
Colon 67 (66%)
Number of liver metastases, mean (range) per participant 3.3 (1–17)
Size of metastases, mean (range) 2.2 (0.5–6.5)
Previous treatments for metastases 26 participants (25%) were
down-staged with chemotherapy prior
to RFA 25 (25%) had undergone
resection of liver metastases prior
to RFA
Presentation of liver metastases Synchronous: 27 (26%) = diagnosed
< 12 months following primary resection
Metachronous: 75 (74%)
Comments: RFA was performed with or without resection. Six participants (6%) received chemotherapy during RFA
treatment and one (1%) was treated with a combination of stereotactic radiation therapy and RFA
RFA, radiofrequency ablation.175
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176ResultsOutcomes Radiofrequency ablation (n = 102)
Median survival, from diagnosis 52 months (95% CI 34 to 82)
Estimated survival from diagnosis
1-year survival 96%
2-year survival 79%
3-year survival 64%
4-year survival 52%
5-year survival 44%
Median survival from ﬁrst RFA treatment 32 months (95% CI 24 to 45)
Estimated survival from ﬁrst RFA treatment
1-year survival 87%
2-year survival 62%
3-year survival 46%
4-year survival 26%
Mortality rate during follow-up 35 (35%)
Comments
Major complications Total number of major complications: n = 12
Abscesses requiring drainage: hepatic n = 2, subcutaneous n = 1
Perforation of gastrointestinal wall: gastric n = 2, colonic n = 1
Vascular: pseudoaneurysm of the right hepatic artery n = 1,
thrombosis of inferior caval vein n = 1
Seeding n = 1
Pneumothorax requiring drainage n = 1
Perforation of the diaphragm n = 1
Acalcular cholecystitis n = 1
Minor complications Total number of minor complications, n = 7
Hepatic abscesses not requiring drainage, n = 2
Second-degree skin burn, n = 1
Subcapsular liver haematoma, n = 1
Subcutaneous haematoma, n = 1
Pleural effusion not requiring drainage, n = 1
Fistula between RFA necrosis and secondary biliary tract, n = 1
Comments: complication rates based on number of treatments (n = 176)
General comments
l Generalisability: some participants underwent simultaneous resection, number not reported. The electrodes used
differed [single 78 (44%) versus cluster, 87 (49%) treatments] depending on tumour size
l Outcome measures: appropriate
l Inter-centre variability: not applicable
l Conﬂict of interests: not reported
RFA, radiofrequency ablation.
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Quality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Yes
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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APPENDIX 4
178Chemoembolisation
Agarwala et al., 200482Study and intervention details Participants Outcome measures
Country: USA
Design: RCT (dose escalation trial)
Number of centres: one
Funding: not reported
Intervention:
(1) chemotherapy (100mg/m2);
(2) chemotherapy (100mg/m2)
plus chemoembolisation;
(3) chemotherapy (125mg/m2);
(4) chemotherapy (125mg/m2)
plus chemoembolisation
See below for intervention details
Indication for treatment: ocular
melanoma liver metastases
Intention of treatment (curative/
palliative/pre-resection/not stated):
not stated
Number of participants:
randomised n = 19; assessable for
response n = 17
(1) cisplatin 100mg/m2, n = 3
(2) cisplatin 100mg/m2 plus
polyvinyl sponge, n = 4
(3) cisplatin 125mg/m2 n = 6
(4) cisalpin 125mg/m2 plus
polyvinyl sponge, n = 6
Sample attrition/dropout: n = 2
Complete history and physical
examination performed
before study entry. Laboratory
studies listed
Inclusion criteria: history of ocular
melanoma, histologically proven
liver metastases measured by CT or
ultrasound. Age at least 18 years,
ECOG performance status of 0–2,
adequate hepatic (bilirubin
< 3 normal), renal (creatinine
< 2.0mg%, creatinine clearance
> 50ml/min) and haematological
(white blood cell count
> 4000/mm3, platelet count
> 100,000/mm3) function
Exclusion criteria: peripheral
vascular disease or any other
contraindication to femoral artery
catheterisation. Pregnancy (use of
acceptable form of contraception
for duration of study required). Any
prior systemic antineoplastic
therapy had to be discontinued at
least 4 weeks (6 weeks for
nitrosoureas) before study
Primary outcomes: toxicity
(establishing maximum tolerated dose)
Secondary outcomes: response;
median survival
Method of assessing outcomes:
baseline tumour evaluations obtained
by CT scans no longer than 6 weeks
before ﬁrst treatment.
Daily blood tests during therapy
(hospitalised for treatment). After
discharge, pre-treatment blood studies
repeated weekly for 4 weeks
Response assessed 4 weeks after
treatment by abdominal CT scan
Tumour response assessed via
standard response criteria
(no reference given)
Complete response deﬁned as
complete radiographic disappearance
of evident hepatic disease for at least
4 weeks
Partial response deﬁned as a 50% or
greater decrease in the sum of the
products of the perpendicular
diameters of all measurable hepatic
lesions lasting at least 4 weeks
without increase in size of existing
lesions or appearance of new lesions
Stable disease deﬁned as less than
25% increase or less than 50%
decrease in all measurable lesions
Progressive disease deﬁned as a
greater than 25% increase in liver
lesions or appearance of any new
lesions in liver or elsewhere
Toxicities graded according to National
Cancer Institute Common Toxicity
Criteria
‘Dose-limiting toxicity’ deﬁned as
occurrence of grade 3 or higher
toxicities in 2 of 6 patients treated at
any dose tier. Death from any cause
on study was considered to be a dose
limiting toxicity
‘Maximum tolerated dose, determined
to be the tier below “dose-limiting
toxicity”’
Length of follow-up: not stated
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Participant characteristics Total (n = 19)
Age (years), mean (range) 59.7 (36–81)
Male/female 9/10
Primary cancer site Ocular melanoma 100%
Number of liver metastases Not stated
Distribution of liver metastases Not stated
Size of metastases Not stated
Previous treatments for primary cancer Enucleation, n = 18
Local radiation, n = 7
Time from primary treatment Not stated
Previous treatment for liver metastases Chemotherapy, n = 2
Immunotherapy, n = 3
Tamoxifen, n = 1
Time from previous liver mets treatment Not stated
Comorbidities (including other metastases) Not stated
ECOG performance status of 0 or 1 17
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7ResultsOutcomes Total (not clear if n = 19 or n = 17)
Median survival 8.5 months
Kaplan–Meier survival curve with 95% CIs presented
Clinical response
Cisplatin
100mg/m2
(n = 3)
Cisplatin
100mg/m2
plus polyvinyl
sponge (n = 4)
Cisplatin
125mg/m2
(n = 6)
Cisplatin
125mg/m2
plus polyvinyl
sponge (n = 6)
Complete response 0 0 0 0
Partial response 0 0 1 2
Stable disease 3 2 5 3
Progressive disease 0 1 0 0
Not evaluable 0 1 0 1
States no statistically signiﬁcant difference in the response rates between patients who did or did not receive polyvinyl
sponge or between the two dose tiers (p = 0.2769)
Toxicity
Cisplatin
100mg/m2
(n = 3)
Cisplatin
100mg/m2
plus polyvinyl
sponge (n = 4)
Cisplatin
125mg/m2
(n = 6)
Cisplatin
125mg/m2
plus polyvinyl
sponge (n = 6)
Dose limiting toxicity 0 0 3 (renal 2,
haematological 1)
3 (hepatic 1, haematological 1,
death from progressive tumour)
Grade 3 toxicity 2 1 3 1
Grade 4 toxicity 0 2 3 4
125mg/m2 was determined to be the maximum tolerated dose. Twelve of 19 participants went on to receive cycle 2.
One patient each received ﬁve, six and seven cycles of therapy
continued
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Total (n = 19)
Transient alteration in
liver function tests
(grade 1 and 2)
13 of 19
Dose reduction as result of
altered liver function
1 of 19
Haematological toxicity
Anaemia (grade 1–2) 2
Thrombocytopenia
(grade 3)
2
No complications related to catheterisation procedure
Intervention details
Hospitalised for treatment
Intrahepatic arterial infusions chemotherapy with cisplatin and chemoembolisation with polyvinyl sponge: polyvinyl sponge
administered at a ﬁxed dose of 15ml and mixed with increasing doses of cisplatin. Total dose of cisplatin administered in
two portions during cycle 1. All patients ﬁrst received cisplatin 50mg mixed with 5ml of polyvinyl sponge suspension
(10mg/ml of 150 nm polyvinyl solution premixed with water-based radio-opaque contrast material) in bolus aliquots over
an average of 30 minutes, followed by the balance of the total dose of cisplatin administered as a 1mg/ml solution into the
same hepatic artery over 30 minutes. This was followed by administration of sufﬁcient volume of polyvinyl sponge
suspension (without cisplatin) to achieve slowing of arterial blood ﬂow to tumour as identiﬁed by ﬂuoroscopy. Additional
cycles of chemoembolisation were administered to same hepatic arterial branch pending re-evaluation by arteriography.
Cycle 2 administered same as cycle 1. If 50mg cisplatin with 5-ml polyvinyl sponge could not be completely administered
due to slowing of blood ﬂow from previous treatment, polyvinyl sponge administration was stopped and cisplatin solution
administered. If arterial blood ﬂow was allowed, the remaining mixture was administered. If as a result of previous
treatment no amount if cisplatin/polyvinyl sponge could be administered without completely occluding the artery, the
treatment order was reversed, i.e. cisplatin solution over 30 minutes followed cisplatin 50mg with 5-ml polyvinyl sponge
suspension. Cycle 3 and 4 administered as cycle 1 and 2, but previously untreated metastases were targeted
Intrahepatic arterial infusions chemotherapy with cisplatin alone: prepared as an admixture of cisplatin powder
reconstituted with sterile water to yield volume of 150ml consistent with solubility. Mixture administered as a1-mg/ml
solution (total dose 15ml) infused over 30 minutes into hepatic artery branch supplying tumour
Cisplatin dose escalation: planned in ﬁve tiers of three patients each (100mg/m2, 125mg/m2, 156mg/m2, 195mg/m2, and
245mg/m2), reﬂecting a 25% increase in dosage per tier. If three patients treated at a particular dose tier of a given
treatment arm did not experience any grade 3 or higher toxicity, then the cisplatin dosage was escalated by 25% for the
next patient. If one of these did experience a grade 3 or higher toxicity, another three patients were treated at that same
dose and treatment arm. Patients not entered onto higher dose tier until at least 4 weeks after last patient treated on
previous dose tier
Patients who demonstrated stable or responding disease were eligible to receive additional cycles of therapy at the same
dose (no intrapatient dose escalation was permitted). Therapy was repeated for up to a maximum of 10 cycles unless a
dose-limiting toxicity intervened
Pre and concomitant medications: to decrease risk of renal tubular injury from cisplatin: prior to treatment patients
hydrated overnight with 0.5 normal saline and 20mEq KCl/l at rate of 125ml per hour. This was increased to 250ml per
hour during and after treatment to maintain urine output of 100ml per hour. To prevent nausea and vomiting: patients
premedicated with ondansetron 10mg intravenously every 4 hours for four doses, and a single dose of lorazepam
1mg intravenous with the ﬁrst ondansetron dose. Narcotic analgesics for pain control as required
Methodological comments
l Allocation to treatment groups: states randomised, no further details
l Blinding: not reported
l Comparability of treatment groups: baseline characteristics reported for whole sample only, groups cannot be compared
l Method of data analysis: groups not compared statistically. Kaplan–Meier survival curve presented for whole group only
l Sample size/power calculation: states at least three patients were to be assigned to each treatment arm at each dose
of cisplatin. No rationale provided
l Attrition/dropout: 17 of 19 patients were evaluable for a response. Two assigned to polyvinyl sponge arm (one from
each cisplatin dose) were lost to follow-up
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General comments
l Generalisability: patients with ocular melanoma metastatic to the liver. Limited baseline characteristics presented so
generalisability unclear. Small dose escalation trial at a single centre
l Outcome measures: response and toxicity reported for each group, measures seem appropriate. Survival not reported
for each group (but sample sizes very small)
l Inter-centre variability: not applicable
l Conﬂict of interests: not reported
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors, e.g. severity of
disease/size, number of tumours, performance status, extrahepatic disease
Unclear
4. Were outcome assessors blinded to the treatment allocation? Unclear
5. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned? No
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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APPENDIX 4
182Taguchi et al., 199281Study and intervention details Participants Outcome measures
Country: Japan
Design: RCT
Number of centres: 11 hospital
clinics
Funding: not stated
Intervention: (1) intra-arterial
mitomycin C with degradable
starch microspheres (DSM);
(2) intra-arterial mitomycin C
without DSM
See below for intervention details
Indication for treatment:
metastatic liver cancer
Intention of treatment (curative/
palliative/pre-resection/not
stated): not stated
Number of participants:
(1) intra-arterial mitomycin C
with DSM, n = 30;
(2) intra-arterial mitomycin C
without DSM, n = 30
Sample attrition/dropout: not
stated; however, 18 (intervention
1, n = 8; intervention 2, n = 10)
and 9 patients were not
evaluable for efﬁcacy and safety
respectively. No reasons
provided. Five in each group
withdrawn due to
adverse events
Inclusion criteria: non-resectable
liver cancer without
demonstrable malignancies in
other organs; a resected primary;
a patent portal vein;
performance status of 0–3; a
hepatic artery anatomy suitable
for catheterisation
Exclusion criteria: patients had
received chemotherapy,
radiotherapy or immunotherapy
in preceding month, were
suffering from severe cardiac or
pulmonary disease, had a
serum bilirubin count more than
twice the normal level, had a
white blood count below
3000/mm3 or a platelet count
below 50,000/mm3
Primary and secondary outcomes:
tumour response; adverse events;
overall survival
Method of assessing outcomes:
Complete response deﬁned as
disappearance of all measurable
lesions, evaluable lesions as well as
non-quantiﬁable malignant
lesions, and no appearance of
new lesions, determined by two
observations not less than
4 weeks apart
Partial response deﬁned by
decrease of 50% or more in
lesions that can be measured in
two directions without
deterioration of any evaluable or
other lesion, and no appearance
of new lesions, determined by two
observations not less than
4 weeks apart
No change deﬁned by decrease of
25% in lesions that can be
measured in two directions, less
than 30% in lesions that can be
measured in one direction, to an
increase of less than 25% in such
lesions without deterioration in
other lesions, with no appearances
of new lesions, determined by
two observations not less than
4 weeks apart
Progressive disease deﬁned as an
increase of 25% or more in the
product of the sum of diameters
of measurable lesions, or
deterioration in other lesions or
appearance of new lesions
Minimal response deﬁned as a
condition between no change and
partial response
Adverse events noted by patient or
clinician were rated on a scale 0–4
by the clinician and followed to
normalisation. Clinical blood
proﬁle undertaken at start and
two weekly, including blood cell
count, blood analyses, urinalyses,
tumour markers
Length of follow-up: not stated
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Participant characteristics
Intra-arterial
mitomycin C
with DSM
Intra-arterial
mitomycin C
without DSM p-value
Age (years) Not stated Not stated Not stated
Male/female Not stated Not stated Not stated
Primary cancer site Not stated
Colorectal 10/22 15/20
Stomach 11/22 4/20
Gall bladder 1/22 0/20
Pancreas 0 1/20
Number of liver metastases Not stated Not stated Not stated
Distribution of liver
metastases
Not stated Not stated Not stated
Size of metastases Not stated Not stated Not stated
Previous treatments for
primary cancer
Not stated Not stated Not stated
Time from primary treatment Not stated Not stated Not stated
Previous treatment for
liver metastases
Not stated Not stated Not stated
Time from previous liver
mets treatment
Not stated Not stated Not stated
Comorbidities (including other
metastases)
Not stated Not stated Not stated
Comments: patient characteristics are not reported separately for the different indications or treatment groups. Study states
that no signiﬁcant differences existed in age, sex, performance status, site, stage of tumours, numbers of tumours or
maximal tumour size and preceding treatment between patients
DSM, degradable starch microspheres.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7ResultsOutcomes
Intra-arterial
mitomycin C with
DSM (n = 22)
Intra-arterial
mitomycin C without
DSM (n = 20) p-value
Tumour response rates
Complete response 1 0 Not stated
Partial response 11 4 Not stated
Minimal response 0 1 Not stated
No change 6 7 Not stated
Progressive disease 4 8 Not stated
Total 22 20 Not stated
Response rate, % (CR + PR) 54.5 20 p< 0.05
CommentscontinuedCR, complete response; DSM, degradable starch microspheres; PR, partial response.183
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(continued )
Outcomes
Intra-arterial
mitomycin C with
DSM (n = 22)
Intra-arterial
mitomycin C without
DSM (n = 20) p-value
Tumour response rates by primary tumour site
Colorectum
Complete response 1 0 Not stated
Partial response 3 3 Not stated
No change 5 6 Not stated
Progressive disease 1 6 Not stated
Total 10 15 Not stated
Response rate, % (CR + PR) 40 20 Not stated
Comments
Stomach
Complete response 0 0 Not stated
Partial response 8 1 Not stated
No change 0 2 Not stated
Progressive disease 3 1 Not stated
Total 11 4 Not stated
Response rate, % (CR + PR) 72.7 25 Not stated
Comments
Others (gall bladder and pancreas)
Complete response 0 0 Not stated
Partial response 0 0 Not stated
No change 1 0 Not stated
Progressive disease 0 1 Not stated
Total 1 1 Not stated
Response rate, % (CR + PR) 0 0 Not stated
Comments
Patients withdrawn from trial
due to adverse reactions
Intra-arterial
mitomycin C with
DSM (n = 30)
Intra-arterial
mitomycin C without
DSM (n = 30)
Subjective 3 0 Not stated
Clinical chemistry 3 5 Not stated
Comments
Major adverse events
(% patients)
Intra-arterial
mitomycin C with
DSM (n = unclear)
Intra-arterial
mitomycin C without
DSM (n = unclear)
Pain 59.3 16.7 p< 0.01
Gastrointestinal disturbances 48.1 12.5 p< 0.01
Fever 40.7 8.3 p< 0.01
Comments: two patients died; however, it is unclear whether they were from the patients with hepatocellular carcinoma or
metastatic liver cancer. One died from a high dose of mitomycin C and in the other the cause remains uncertain
CR, complete response; DSM, degradable starch microspheres; PR, partial response.
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Major adverse events
(% patients)
Intra-arterial
mitomycin C with
DSM (n = unclear)
Intra-arterial
mitomycin C without
DSM (n = unclear)
Other outcomes
n = 30 n = 30
Median survival times (days) 294 231 Not signiﬁcant
Comments: haematological measures were reported; however, these have not been extracted. Overall, 21% (9/44) patients
died of extrahepatic malignant disease
Intervention details
The study included people with hepatocellular carcinoma or metastatic liver cancer; only information for people with
metastatic liver cancer was extracted
Intra-arterial mitomycin C (< 8mg/m2 body surface area), with DSM every second week. Mean DSM dose levels were
569.8mg ± 173.6 mg
Intra-arterial mitomycin C without DSM
Treatment was administered through a catheter and port implanted. Prophylactic cholecystectomy was performed on most
patients. Dose of DSM was individually established for each patient by angiography prior to ﬁrst administration and was
achieved through incremental injections of 300mg DSM 1 minute apart. When arterial occlusion was achieved without
back ﬂow or pain, the appropriate dose was identiﬁed. If severe pain occurred, dosage was reduced by 150mg
subsequently. Treatment was given over a 17-week period and comprised three sessions. Each session consisted of three
treatment occasions every second week making a total of nine treatments. Treatment was terminated if no response to
therapy after the ﬁrst session (three treatments) – classiﬁed as a progression of disease
Methodological comments
l Allocation to treatment groups: randomisation charts, no other details
l Blinding: not stated
l Comparability of treatment groups: states that there were no signiﬁcant differences on key variables, no data presented
l Method of data analysis: tumour responses rates were compared using Mann–Whitney U-test, variation in survival time
was determined by log-rank test, difference in rate of adverse events by Fisher’s direct method and a chi-squared test
l Sample size/power calculation: not stated
l Attrition/dropout: provides indication of the numbers of evaluable patients for different outcomes, no reasons provided,
although 10 withdrawn due to adverse events
General comments
l Generalisability: unclear due to the limited data provided, although patients likely to be aged 15–75 years and to have
had primary colorectal or stomach tumour
l Outcome measures: clearly deﬁned and appropriate
l Inter-centre variability: not stated
l Conﬂict of interests: not stated
DSM, degradable starch microspheres.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors ,e.g. severity of
disease/size, number of tumours, performance status, extrahepatic disease
Yes
4. Were outcome assessors blinded to the treatment allocation? Unclear
5. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned? No
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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APPENDIX 4
186Chemoembolisation combined with laser ablation
Vogl et al., 201184Study and intervention details Participants Outcome measures
Country: Germany
Funding: not stated
Intervention: chemoembolisation
followed by laser ablation
NB: twenty-one participants were
eligible for laser ablation at baseline,
and only underwent one or two
sessions of chemoembolisation ﬁrst.
The other participants had at least
three sessions
Number of centres: not stated
Indication for treatment: breast
cancer
Intention of treatment: not stated
Number of participants: 314
chemoembolisation, of whom 161
underwent laser ablation
(reported here)
Sample attrition/dropout: not stated
Inclusion criteria: metastatic lesions
of breast cancer, either in both liver
lobes, locally non-resectable, or
recurrent after partial liver resection.
Those with existing contraindication
to surgery, refused surgical
treatment, had adverse reactions or
no response to systemic
chemotherapy also included. Five or
fewer lesions, none larger than 5 cm
in diameter
Exclusion criteria: poor general
condition (Karnofsky rating < 70%);
presence of ascites, partial or
complete thrombosis of the portal
vein, poor hepatic synthesis (serum
albumin < 2mg/dl), high serum
bilirubin (> 3mg/dl), renal
insufﬁciency (serum creatinine
> 2mg/dl) and respiratory or
cardiovascular failure
Outcomes: survival, response, time to
progression, local tumour control rate,
complications and adverse events
Method of assessing outcomes: survival
period deﬁned as starting with the
ﬁrst chemoembolisation treatment and
ending with death or last follow-up
examination. Survival rate measured
with the Kaplan–Meier method
Response to combination treatment
was evaluated using the Response
Evaluation in Solid Tumours (RECIST)
criteria
Time to progression and the period for
local tumour control rate were deﬁned
as starting as of completion of the last
laser treatment and ending with
progression or local recurrence. For
those without progression or local
recurrence, the end point was the last
follow-up examination of the study.
Time to progression included
development of de novo metastasis
and local intrahepatic recurrence.
The local tumour control rate referred
only to local recurrence in previously
ablated areas
Complications and adverse events
obtained from imaging studies and
from clinical and laboratory data, blood
test results, ultrasound tests
Length of follow-up: a mean of
13.8 (SD 17.1) months,
maximum 90 months
Participant characteristics
Chemoembolisation + laser ablation
(n = 161)
Age (years), mean 57 (SD 1.3), range 31–83
Male/female All female
Primary cancer site Breast
Number of liver metastases Not stated
Size of metastases Mean diameter 3.36 (SD 1.94),
range 0.6–12.5 cm
Previous treatments for liver metastases All had systemic chemotherapy,
unclear if for metastatic disease
Mitomycin C alone: 53
Mitomycin C and gemcitabine: 108
Comments
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7ResultsOutcomes Chemoembolisation + laser ablation (n = 161)
Mean survival period 32.5 (SD 21.6) months, range 5–101 months
Estimated survival
1 year 88.8%
2 years 55.9%
3 years 36.6%
5 years 13.7%
Comments: paper reports mean survival period for those who did or did not have progressive disease, not reported here.
Also reports survival by those treated with mitomycin alone or mitomycin with gemcitabine, not reported here
Response
Complete 62 (38.5%)
Partial 8 (5%)
Stable disease 20 (12.4%)
Progressive disease 71 (44.1%)
Comments: 64 of those with progressive disease underwent additional chemoembolisation treatment
Overall local tumour control 13.1 (SD 15.9) months
Mean time to progression 8.2 (SD 12.29) months, range 0–69 months
Local recurrence 3 (1.9%)
Complications requiring further intervention
(aspiration or drainage)
6 (3.7%)
4 pleural effusions
2 biloma
Side effects of laser ablation 57 (35.4%) reactive pleural effusion (4 reported above)
15 (9.3%) biloma (2 reported above)
11 (6.8%) subcapsular haematoma
17 (10.6%) small basal lung atelectasis
0 deaths
0 seeding
Comments
General comments
l Generalisability: minimal baseline characteristics reported to assess generalisability
l Outcome measures: appear reasonable, unclear what follow-up period used
l Inter-centre variability: not applicable
l Conﬂict of interests: not reported187
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188Quality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Vogl et al., 200383Study and intervention details Participants Outcome measures
Country: Germany
Funding: not stated
Intervention: chemoembolisation
followed by laser ablation. Also
reports case series data on those just
receiving chemoembolisation,
not reported here
Number of centres: not stated
Indication for treatment: various
primary cancers (see below). Patients
had systemic chemotherapy and
either developed progressive disease
or had not responded; surgical
resection of primary tumour,
unresectable synchronous or
metachronous liver metastases
Intention of treatment: not stated
Number of participants: 162
chemoembolisation, of which,
82 underwent laser ablation
(reported here)
Sample attrition/dropout: not stated
Inclusion criteria: unresectable liver
metastases that showed no response
to systemic chemotherapy, as seen at
contrast material-enhanced MRI, no
more than four metastases, and no
extra-hepatic spread. Two of the four
metastases were allowed to have a
diameter between 50 and 80mm,
but the other had to be smaller than
50mm. Those between 50 and
80mm were targeted with
chemoembolisation
Exclusion criteria: poor performance
status (Karnofsky status ≤ 70%),
nutritional impairment, presence of
neoplastic ascites, high serum total
bilirubin (> 3mg/dl), poor
hepatic synthesis (serum albumin
< 2.0mg/dl), renal failure (serum
creatinine > 2mg/dl), partial or
complete thrombosis of the portal
vein, cardiovascular or respiratory
failure, poor mental state, unable to
provide consent
Outcomes: treatment success, survival,
side effects and complications
Method of assessing outcomes:
tumour volume calculated from
magnetic resonance images.
Treatment success deﬁned as
achievement of shrinkage of target
lesions to a diameter of less than
50mm so that local ablation was
possible. Stable disease deﬁned as no
substantial change in size during the
chemoembolisation treatment.
Progressive disease deﬁned as an
increase in size of a target lesion
during chemoembolisation or newly
developing lesions in the liver (these
outcomes were used to determine
which participants would receive laser
treatment)
Survival calculated from
commencement of the ﬁrst
chemoembolisation treatment by using
Kaplan–Meier method
Complications and side effects by
questionnaire where symptoms were
rated as ‘none’, score 1; ‘few’,
score 2; ‘moderate’, score 3;
‘marked’, score 4
Length of follow-up: not stated
Participant characteristics Chemoembolisation + laser ablation (n = 82)
Age (years) Total group only reported, n = 162. Mean age 61.8 (range 23.2–88.3)
Male/female 43/39
Primary cancer site Colorectal: 62; breast: 14; other: 6
Number of liver metastases Average of 1.2 lesions per participant
Size of metastases Unclear, only those > 50mm or larger recorded
Previous treatments for liver
metastases
All had systemic chemotherapy
Comments: a mean decrease in tumour size of 35% (SD 14) was estimated at follow-up after chemoembolisation,
so allowing follow-up with laser ablation
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190ResultsOutcomes Chemoembolisation + laser ablation (n = 82)
Cumulative survival after ﬁrst treatment 24.9 months (median, 26.2; 95% CI 20.3 to 32.9)
Comments: paper also reports survival rates by categories of tumour load (umber of lesions, vascularisation, and diameter)
but unclear whether this is for the total group or the combined group
Complications No to few symptoms Moderate to marked symptoms
Abdominal pain 57.1% 42.9%
Nausea 82.2% 17.8%
Fevera 89.3% 10.7%
Fevera 86.4% 13.6%
Lethargy 38.4% 61.6%
Comments: no major complications such as bleeding or abscess were observed immediately after chemoembolisation, no
major complications occurred during and immediately after laser treatment. In seven (8.5%) minor complications such as
pain, pleural effusion or subcapsular haematoma were noted
One major complication (1.2%) was observed within 30 days of the laser treatment; a 73-year-old patient died, most likely
as a result of sepsis
a Fever was indicated with a temperature of > 38.5 °C
General comments
l Generalisability: minimal baseline characteristics presented
l Outcome measures: appear reasonable, unclear what follow-up period was
l Inter-centre variability: not applicable
l Conﬂict of interests: unknownQuality assessment for case series studies (answer yes/no/not reported/unclear)1. Were the patient selection criteria speciﬁed a priori? Yes
2. Was the participant blinded to the research question? Not reported
3. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
4. Were withdrawals and dropouts completely described? Not reported
5. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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Grey et al., 200185Study details Participants Outcome measures
Country: Australia
Design: RCT
Number of centres: one
Funding: not stated
Intervention
(1) radioembolisation (SIRT)
and hepatic artery
chemotherapy; (2) hepatic
artery chemotherapy
See below for intervention
details
Indication for treatment: non-
resectable liver metastases
from primary adenocarcinoma
of the colon
Intention of treatment: not
stated
Number of participants:
(1) radioembolisation, n = 36;
(2) hepatic artery
chemotherapy (HAC), n = 34.
Total n = 74 but n = 70
eligible for trial entry
Sample attrition/dropout: four
participants deemed ineligible
due to the presence of
unconﬁrmed disseminated
cancer at the time of
randomisation. One
participant in the SIRT group
died before any protocol
treatment could be
administered
Inclusion criteria: non-resectable
metastases limited to the liver
and lymph nodes in the porta
hepatis, WHO performance
status 0–2, adequate
haematological and hepatic
function (not deﬁned). Previous
systemic chemotherapy for
metastases eligible
All participants underwent a
full laparotomy to conﬁrm the
non-resectable status of the
metastases, ensure no
intra-abdominal spread of the
tumour, and to insert a hepatic
artery catheter and port.
Catheter positioned to ensure
perfusion of the whole liver
Exclusion criteria: distant
metastases, previous
radiotherapy to the liver,
evidence of cirrhosis or ascites,
those in whom the liver
metastases could be treated by
local ablation (surgical
resection or cryotherapy)
Primary outcomes: initially median survival,
changed subsequently to time to disease
progression and treatment response when
regulator changed their criteria
Secondary outcomes: quality of life, toxicity
Method of assessing outcomes: deﬁnitions of
outcomes reported here
Partial response (PR): objectively measured
decrease in tumour size (area and volume, see
below), by 50% or more on two successive CT
scans not less than 3 months apart after
randomisation and before evidence of progressive
disease in the liver and before any non-protocol
treatments had been given
Complete response (CR): the disappearance of all
tumour on two successive CT scans not less than
3 months apart after randomisation and before
evidence of progressive disease in the liver and
before any non-protocol treatments had been given
Progressive disease in the liver (PD): same three
objective measures that determine response to
treatment and deﬁned as (i) an increase on any
occasion in cross-sectional tumour area, or tumour
volume, by 25% or more over the nadir as measured
on serial CT scans, (ii) the development of new
lesions in the liver or (iii) an increase in the serum
CEA (details not extracted, see below)
No change (NC): either a decrease in tumour area,
volume, CEA that is less than that required for a PR,
or an increase that is less than that required for PD
Not assessable (NA): for any of the response criteria
was attributed to those who had either (i) no
follow-up CT scans due to rapid deterioration after
randomisation, or (ii) unmeasureable index lesions
for estimating cross-sectional tumour areas
Deﬁnitions of response based on CEA
(carcinoembryonic antigen) were also provided and
used in the study but have not been data extracted
Quality of life was recorded at 3-monthly intervals
using a validated 13-point linear analogue Self
Assessment Scale (recommended by cited reference),
11 measures in the questionnaire but no further
details
Toxicity was recorded using standard UICC (Union
for International Cancer Control) criteria
Survival time from randomisation to death or last
follow-up if still alive
Length of follow-up: minimum of 3.5 years from
randomisation
continued
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Participant characteristics
Radioembolisation +HAC
(n = 36) HAC (n = 34) p-value
Age (years), mean 59 62 Not reported
Male/female 28/8 26/8 Not reported
Primary cancer site Not reported
Colon/rectum 29/7 31/3
Involved lymph nodes 24 24
Poorly differentiated 5 5
Number of liver metastases Not reported Not reported
Distribution of liver
metastases
Bi-lobar Bi-lobar
Size of metastases Not reported
< 25% 24 24
25%–50% 9 8
> 50% 3 2
Previous treatments for primary cancer
Complete surgical
resection, n
36 34
Systemic chemotherapy n not reported n not reported
Time from primary
treatment, mean/median
days
137/56 (therefore
≤ 12 months)
135/57 (therefore ≤ 12months)
Previous treatment for liver
metastases, n participants
5 (14%) 5 (15%) Not reported
Time from previous liver
mets treatment
Not reported Not reported
Comorbidities (including
other metastases)
Not reported Not reported
Comments: only 35/36 radioembolisation and HAC participants received treatment as one died before any treatment could
be started
HAC, hepatic artery chemotherapy.
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Radioembolisation + HAC
(n = 36) HAC (n = 34) p-value
Response measured by
Tumour area CR = 2 CR = 0 Difference between
groups p = 0.01
PR = 14 PR = 6
NC = 13 NC = 13
PD = 3 PD = 8
NA = 4 NA = 7
CR or PR: 44% CR or PR: 18% p = 0.01
Tumour volume CR = 2 CR = 1 Difference between
groups p = 0.03
PR = 16 PR = 7
NC = 10 NC = 12
PD = 5 PD = 9
NA = 3 NA = 5
CR or PR: 50% CR or PR: 24% p = 0.03
Comments: states one participant in each arm had disease reduced to such an extent that they were subsequently deemed
surgically resectable and underwent surgical excision of metastases
Also states that by all measures of response (volumes, areas and CEA) more participants in the HAC-alone arm had
Progressive Disease as their best response to treatment. Response measured by CEA not data extracted
Median time to progression in
the liver
Radioembolisation + HAC
(n = 36) HAC (n = 34) p-value
By tumour area 15.9 months 9.7 months p = 0.001
By tumour volume 12.0 months 7.6 months p = 0.04
Comments: time to progression presented in graphical form, only data are available in the abstract. Time to progression by
CEA not data extracted
Survival rates per year
Radioembolisation + HAC
(n not reported)
HAC
(n not reported) p-value
Median overall survival, months
(mean OS also reported but
not extracted)
17 15.9 HR 1.41, 95%
CI 0.86 to 2.34,
p = 0.18
1 year 72% 68% NS (see comment)
2 years 39% 29%
3 years 17% 6%
5 years 3.5% 0%
Comments: states shows a non-signiﬁcant trend towards increased survival for those treated with SIRT compared with
those treated with HAC alone. The hazard ratios suggest those receiving HAC alone have approximately a 40% higher
death rate than those receiving SIRT
Cox regression suggests those treated with SIRT who survive more than 15 months experience a survival advantage
compared with those treated with HAC alone (p = 0.06). This is not evident for those surviving less than 15 months
continuedCR, complete response; HAC, hepatic artery chemotherapy; NA, not assessable; NC, no change; NS, not signiﬁcant;
PD, progressive disease in liver; PR, partial response.
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Radioembolisation + HAC
(n = 36) HAC (n = 34) p-value
Mortality n = 32 deaths n = 33 deaths
States 65 participants have died, four remain alive, three in radioembolisation and one in HAC groups. Reviewers assume
that the one participant who died prior to treatment starting is not counted here as n = 69
Also reports the cause of death speciﬁcally related to disease progression of the liver metastases. Not reported here, as no
details as to how this was ascertained. Extrahepatic metastases caused or contributed to some deaths
Radioembolisation + HAC
(n not reported)
HAC
(n not reported) p-value
Complications 1 (pancreatitis)
Toxicities
Haemoglobin grade 3 – 1
Bilirubin grade 3 1 –
Aspartate aminotransferase grade 3 5 12
Aspartate aminotransferase grade 4 2 2
Alkaline phosphatase grade 3 14 5
Nausea/vomiting grade 3 1 2
Diarrhoea grade 3 – 1
Total number grade 3 and 4 events 23 23
Comments: states there was no difference in rates of any grade 3 and 4 toxicity events between the two treatment arms
(based on total number of toxicity events being 23 in each arm)
States there were more grade 1 and 2 toxicity events for those receiving SIRT for assessments of liver function tests
(300 vs. 207 events) and nausea and diarrhoea (16 vs. 11 events)
Quality of life
Radioembolisation + HAC
(n = 36) HAC (n = 34) p-value
Comments: no data presented, states that only sexual interest/ability deteriorated over the 18-month period during which the
protocol treatments were delivered. For all other measures, there were trends towards improvement in QoL scores over the
ﬁrst 18 months for both treatment groups. There were no signiﬁcant differences between the treatment groups
Mean dose (SD) of yttrium-90
received (GBq)
2.156 (0.324) Not applicable
Comments: states ﬁve participants received less and one participant more than the designated protocol amount of
ytttrium-90 activity, but all received within 90% of the 2–3GBq required by the protocol. The three ineligible patients in
this treatment arm received a mean of 2.276 (SD 0.231) of GBq of yttrium-90 activity
Mean (SD) dose of ﬂoxuridine received (mg),
per patient,
1863 (1735) 1822 (1323)
Mean (SD) number of cycles of ﬂoxuridine 8.7 (5.6) 8.0 (5.0)
Intervention details
1) Radioembolisation and hepatic artery chemotherapy group
Hepatic artery chemotherapy with ﬂoxuridine (dose as noted below for group 2) plus single injection of SIR-Spheres® (Sirtex
Medical Ltd), radioactive yttrium-90 microspheres administered as SIRT. SIR-Spheres® administered within 4 weeks of the
insertion of the access port (except in one where it was administered at the same time as the placement of the access port)
Nuclear medicine scan to determine the amount of SIR-Spheres® that would pass through the liver and lodge in the lungs
(required to be < 10% lung break through) otherwise dose reduction required
50 μg angiotensin-2 injected over 30-second period, then 30 seconds later the SIR-Spheres® were injected over a period of
several minutes. The quantity of SIR-Spheres® varied depending on the size of the tumour: < 25%= 2GBq, 25–50%=
2.5 GBq, > 50%= 3GBq of yttrium-90 activity. Per protocol this would be reduced if the lung–liver break through
percentage was > 10% (by 2% for each 1% over) but no participant required this adjustment
HAC, hepatic artery chemotherapy.
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2) Hepatic artery chemotherapy group
Hepatic artery chemotherapy with ﬂoxuridine only. Twelve-day cycles of continuous infusion at 0.3 mg/kg body weight per
day, repeated at 4-weekly intervals, for 18 cycles or until there was evidence of either tumour progression in the liver, the
development of extrahepatic metastases necessitation a change to systemic treatment, unacceptable toxicity, port failure, or
at a participant’s request
Details of post-intervention treatments: many participants received non-protocol chemotherapy (mainly 5-ﬂurouracil plus
folinic acid and mitomycin-C systemically or via the port, or ﬂoxuridine into the port). The total amount used was higher for
those in the HAC-only arm (5-FU, 36% more, ﬂoxuridine 59% more)
Methodological comments
l Allocation to treatment groups: randomised using a blinded envelope batch method controlled by an independent
person. Participants were stratiﬁed before randomisation into three groups depending on the percentage of liver
involved with tumour (< 25%, 25–50%, > 50%). Participants were randomised after the insertion of the hepatic
artery catheter and port
l Blinding: response to treatment measured by tumour volume and tumour area on CT scan calculated from serial slices
of and compared with pre-treatment CT scan. Two medical practitioners not associated with the trial independently
and blindly evaluated all CT scans. The outline of all tumours were traced and a third independent operator then
digitised these tracings and transferred data to data-handling software that calculated the total tumour and liver
volumes. Where one observer’s record of tumour volume varied by more than 10% from the mean of the two
observers’ measurements, then the scans were independently traced by the third observer. The ‘average tumour
volume’ was then taken as the mean of the two closest values. A third observer also independently evaluated changes
in tumour areas. Tumour response was also calculated from changes in serum CEA (in those where it had been
assessed at baseline) but not data extracted
l Comparability of treatment groups: states no signiﬁcant differences between the two treatment groups at baseline on
patient or tumour characteristics
l Method of data analysis: states outcomes were analysed on an intention-to-treat basis, and that outcome analyses
were preformed both with and without the inclusion of the four patients who were ineligible, but that as there were
no signiﬁcant differences results presented in the paper are for eligible participants only. States source data
independently monitored and audited before being subject to analysis and interpretation. Conditional binomial
exact test used to compare outcomes expressed as proportions. Log-rank tests were used to compare time to event
data in the presence of censored observations. Hazard ratio modelling used Cox modelling methodology and a
‘time-dependent’ adaptation of Cox modelling was performed. Time-to-event curves were constructed using
Kaplan–Meier methodology. Time-to-event curves from time-dependent analyses were derived from the appropriate
Cox models as a postiche exploratory analysis. An exploratory Cox regression analysis was performed for patients
surviving either less than, or more than, 15 months (time chosen based on divergence in the survival curves at this
time). Responses were compared using Kruskal–Wallis test. Mean quality-of-life scores were compared for each time
interval using independent t-tests. All p-values used 2-tailed tests of signiﬁcance
l Sample size/power calculation: trial power calculation based on median survival of 30% of intervention arm over the
control arm, with 90% power and 95% conﬁdence. Trial originally designed to enter 95 participants, but closed after
74 patients due to increasing reluctance of patients and referring clinicians to randomise, no ongoing funding for the
trial, changes in outcomes required by regulator to register the technology in the USA (treatment response and time to
disease progression rather than survival). Therefore, total of 74 participants was deemed to still allow the detection of
an increase in response from 20% to 55% with 80% power and 95% conﬁdence, and an increase in median time to
disease progression for control group patients of 4.5 months by 32% with 80% power and 95% conﬁdence. Based on
this (post-hoc) power analysis, a sample size of 74 participants led to a power to detect an absolute 30% increase in
survival at 6 months from 50% to 80% was 70%, with a 95% conﬁdence level
l Attrition/dropout: no discussion of any dropouts other than the one who died before treatments commenced
General comments
l Generalisability: minimal baseline characteristics make it difﬁcult to establish whether or not these are typical
participants
l Outcome measures: appear to be reliably assessed, unclear of validity given the broad range of categories for response.
States follow-up CT scans were performed only 3-monthly rather than 4-weekly and this increased the severity of the
deﬁnitions for response
l Inter-centre variability: not applicable
l Conﬂict of interests: not stated; text suggests that the manufacturer of SIR-Spheres® (Sirtex Medical Ltd) may have
funded the study, as discussed market application to the FDA in the text
HAC, hepatic artery chemotherapy.
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196Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors,
e.g. severity of disease, size, number of tumours, performance status, extrahepatic disease?
Yes
4. Were outcome assessors blinded to the treatment allocation? Yes
5. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned? Yes
No
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Not reported
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Country: Belgium
Design: RCT
Number of centres: three
Funding: support from 2 of the
authors and Sirtex Medical Ltd.
provided the microspheres
Intervention: (1) radioembolisation
plus systemic chemotherapy;
(2) systemic chemotherapy only
See below for intervention details
Indication for treatment: metastases of
colorectal cancer (mCRC) limited to liver, all
other evidence-based treatments failed
Intention of treatment: not stated
Number of participants: n = 46.
(1) radioembolisation plus systemic
chemotherapy, n = 23 but two not treated
(see below); (2) systemic chemotherapy
only, n = 23
Sample attrition/dropout: two patients in
the radioembolisation plus systemic
chemotherapy arm were found to be
ineligible
Inclusion criteria: histologically proven
adenocarcinoma of colon or rectum,
metastases in liver only, not amenable to
curative surgery or local ablation and
resistant or intolerant to standard
chemotherapy [ﬂuorouracil (FU), oxaliplatin,
and irinotecan]. If chemotherapy stopped
due to intolerance, documented progressive
disease was required. ECOG performance
status of 0 to 2, ≥ 18 years of age.
Adequate bone marrow function (absolute
neutrophil count ≥ 1000/µL, platelet count
≥ 100,000/µL), renal function [creatinine
< 1.5 × upper limit of normal limit (ULN) or
creatinine clearance > 50ml per minute],
and liver function [deﬁned by direct
bilirubin < 1.0 × ULN; aspartate
aminotransferase (AST), alanine
aminotransferase (ALT) and alkaline
phosphatase levels each < 5 × ULN]. Able to
give informed consent
Exclusion criteria: pre-existing hepatic
disease (cirrhosis > Child–Pugh B, liver
abscess, hepatic sarcoidosis or tuberculosis,
sclerosing cholangitis); extrahepatic disease;
clinically signiﬁcant ascites; > 20%
arteriovenous shunting from liver to lungs
observed on the technetium-99m-labelled
macroaggregated albumin (99mTc-MAA)
scan; hepatic arterial anatomy that would
not allow safe administration of yttrium-90
(90Y) microspheres, partial or total
thrombosis or hepatic artery or main
portal vein, prior hepatic arterial infusion
with FU, ﬂoxuridine (FUDR), or other
chemotherapeutic agent(s) or transarterial
embolisation procedures; prior external-
beam irradiation of the liver; severe chronic
or acute disease, concomitant or previous
malignancies within 5 years other than
basal cell or squamous cell carcinoma of the
skin or cervix; pregnant or breastfeeding
women, women refusing to take adequate
pregnancy prevention measures
Primary outcomes: time to liver
progression (TTLP)
Secondary outcomes: overall
survival, time to progression
overall (TTP), adverse events
Method of assessing outcomes:
physical examination and blood
tests every 3 weeks, CT scans of
chest, abdomen and pelvis
repeated every 6 weeks until
disease progression
Disease progression in the liver
and objective tumour response
based on Response Evaluation
Criteria in Solid Tumours (RECIST,
version 1.0) and documented by
CT or MRI. Radiologic tumour
assessment could be repeated
early on the basis of clinical need
or suspicion of disease
progression at the investigators’
discretion
TTLP and time to tumour
progression (TTP) were calculated
as time elapsed between
randomisation and ﬁrst
documented progression in the
liver or ﬁrst documented
progression at any site, death or
date of last observation (in
patients lost to follow-up)
Overall survival deﬁned as time
elapsed between randomisation
and death from any cause
Adverse events classiﬁed and
coded for severity using Common
Terminology Criteria for Adverse
Events (CTCAE, version 3.0)
Length of follow-up: median
(range) 24.8 (2 to 41) months at
time of database closure (for the
seven patients still alive, median
follow-up was 10 months)
continued
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Participant characteristics
Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Age (years), median (range) 62 (46–91) 62 (45–80)
Male/female, n (%) 18/5 (78/22) 10/11 (48/52)
Primary cancer site Colorectal Colorectal
Primary cancer type, n (%)
Adenocarcinoma 21 (100) 22 (96)
Adenocarcinoma mucinous 0 1 (4)
Number of liver metastases measured, n (%)
1 lesion 2 (10) 1 (4)
2–4 lesions 10 (48) 10 (44)
≥ 5 lesions 8 (38) 10 (44)
Not measurable 1 (5) 2 (9)
Distribution of liver metastases Not reported Not reported
Size of metastases
Sum of lesions diameters (mm),
median (range)
176.5 (31–324), 1 missing value 216 (51–416), two
missing values
Previous treatments for primary
cancer
Not reported, see below for chemotherapy Not reported, see
below for
chemotherapy
Time from primary treatment Not reported Not reported
Time since diagnosis, months,
median (range)
22 (7–52), 1 missing value 22 (12–44), no
missing values
Previous treatment for liver
metastases
Not reported Not reported
Time from previous liver mets
treatment
Not reported, but see detail re chemo
below which assumed to be for metastases
Not reported, but see
detail re
chemotherapy below
which is assumed to
be for metastases
Time since last chemotherapy
(weeks), median (range)
8 (2–57), 2 missing values 14 (2–60), no missing
values
Last chemotherapy regimen received before study entry, n (%)
Irinotecan based 13 (62) 20 (87)
Oxaliplatin based 4 (19) 2 (9)
Other based 4 (19) 1 (4)
Comorbidities
Presence of non-target lesions,
n (%)
5 (24), 1 missing value 6 (26), one missing
value
ECOG performance status, n (%)
0 15 (71) 17 (74)
1 5 (24) 5 (22)
2 1 (5) 1 (4)
Comments: the two participants in the radioembolisation plus chemotherapy group who were found to be ineligible are
not included, hence, n = 21. If lesions were not measurable this was mainly due to extensive and conﬂuent lesions
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Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Partial response, n (%) 2 (10) 0 (0) 0.22 (95% CI for
difference between
arms  0.10 to 0.32)
Stable disease, n (%) 16 (76) 8 (35) Not reported
Progressive disease,
n (%)
2 (10) 14 (61) Not reported
Non-evaluable, n (%) 1 (5) 1 (4) Not reported
Disease control rates
(partial response + stable
disease), n/N (%)
18/21 (86) 8/23 (35) 0.001 (95% CI for
difference between
arms 0.19 to 0.71)
Comments: data are the best response for target lesions according to RECIST criteria. Overall response rates are equivalent
to the partial response rates as no complete responses occurred
Outcomes
Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Liver progression
documented, n
18 23
TTLP (months), median
All progressions
considered as events
5.5 2.1 HR 0.38; 95% CI 0.20
to 0.72; p = 0.003
Patients with treatment
change censored at the
time of change
5.6 (15 events) 2.1 (22 events) HR 0.35; 95% CI 0.18
to 0.69; p = 0.002
TTP (months), median 4.5 2.1 HR 0.51; 95% CI 0.28
to 0.94; p = 0.03
Overall survival (months),
median
10.0 (ﬁve patients alive at time of
analysis)
7.3 (two patients alive
at time of analysis)
HR 0.92; 95% CI 0.47
to 1.78; p = 0.80
Comments: all patients in the chemotherapy-only arm experienced disease progression ﬁrst in the liver. For these patients,
TTLP equals TTP. Three patients in the radioembolisation arm were without documented progression and were censored at
4.3, 6.6, and 26 months. A Kaplan–Meier plot of TTLP and TTP is presented in the paper. Local progression was
documented in four patients (three radioembolisation + chemo; one chemotherapy-only arm) after an unjustiﬁed change in
the treatment allocated by randomisation (not further described). Censoring these four patients does not change the
median TTLP. One patient in the radioembolisation + chemotherapy arm had sufﬁcient downsizing of their liver metastasis
to receive a right hepatectomy. The rapid cross-over of 70% of patients in the chemotherapy-only arm to receive further
therapy (see below) may have confounded the survival data
Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Received further therapy n = 9 n = 16
Crossed over to
radioembolisation
monotherapy
Not applicable n = 10
Cetuximab combined
with chemotherapy
n = 3 n = 5
Chemotherapy alone n = 4 n = 1
Palliative brain
radiotherapy
n = 1
Unspeciﬁed treatment n = 1
Comments: chemotherapy received as further therapy is not described
continuedTTLP, time to liver progression; TTP, time to tumour progression.
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Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Toxicity analysis n = 21 n = 22, see below
Grade 3 or 4 toxicity
recorded
n = 1 n = 6 0.10
Gastrointestinal
Stomatitis n = 1 Grade 1 n = 1 Grade 1
n = 1 Grade 2 n = 1 Grade 3
Diarrhoea n = 1 Grade 1
Nausea n = 4 Grade 1
n = 1 Grade 2
Vomiting n = 2 Grade 2 n = 2 Grade 2
Constipation n = 3 Grade 1
Anorexia n = 4 Grade 1 n = 4 Grade 1
n = 1 Grade 2 n = 2 Grade 2
n = 1 Grade 3
Gastrointestinal n = 1 Grade 2
Pain
Abdominal pain n = 3 Grade 1 n = 2 Grade 1
n = 1 Grade 2 n = 1 Grade 2
Myalgia n = 2 Grade 1 n = 1 Grade 1
Other pain n = 1 Grade 1
Constitutional
Fatigue n = 4 Grade 1 n = 2 Grade 1
n = 4 Grade 2 n = 4 Grade 2
n = 5 Grade 3
Fever n = 2 Grade 1 n = 1 Grade 1
n = 1 Grade 2 n = 2 Grade 2
Dermatology/skin
Skin n = 2 Grade 2
Hand–foot syndrome n = 1 Grade 3 n = 2 Grade 2
Pulmonary
Dyspnoea n = 1 Grade 2
n = 1 Grade 3
Pulmonary n = 1 Grade 3
Neurology
Neurosensorial n = 2 Grade 1
Cognitive disturbance n = 1 Grade 2 n = 1 Grade 2
Cardiac arrhythmia n = 1 Grade 1
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Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23) p-value
Allergy/immunology
Allergy n = 1 Grade 3
Other toxicity n = 1 Grade 1 thrombocytopenia n = 1 Grade 2 ascites
n = 1 Grade 2 stomach ulcer, ascites
Comments: states two participants in the chemotherapy arm were never treated and so were not evaluated for toxicity;
however, gives n = 22 for the chemotherapy arm whereas n = 21 would be expected if two patients were excluded from
this analysis
Events listed by CTCAE (version 3.0) grade. Discussion notes that the probable reason for more patients in the
chemotherapy arm experiencing grade 3 toxicities was the lower efﬁcacy and more rapidly progressive disease in this
arm – with adverse events essentially indistinguishable from those due to disease progression. Also the FU dose intensity
was not signiﬁcantly higher in the chemotherapy-only arm which may partly explain some differences
Treatment received
Radioembolisation + chemotherapy
(n = 21)
Chemotherapy only
(n = 23)
90Y activity administered
(GBq), median (range)
1.79 (1.32–2.15), 3 (14%) missing
values
Not applicable
FU dose per patient (mg),
median (range)
14,588 (4740–97,612), 1 missing
value
17,700
(3240–119,700),
3 (13%) missing values
Intervention details
Radioembolisation plus systemic chemotherapy: radioembolisation (dose details below) plus intravenous FU 225mg/m2 for
14 days followed by 1 week of rest. Thereafter protracted intravenous (PIV) FU 300mg/m2 for 14 days every 3 weeks until
documented hepatic progression. Therapy was organised within 14 days of excluding lung shunting. All patients were
treated only once
Administered activity of 90Y-microspheres for radioembolisation: described as stepwise administration. Dose calculated
according to manufacturer’s instructions based on body surface area (BSA) and extent of tumour involvement using the
equation below:
Activity injected ðGBqÞ ¼ ðBSA−0.2Þ þ tumour volume
total liver volume
 
For hepatopulmonary shunting of 10% to 15% activity was decreased by 20%, for shunting of 15% to 20% activity
decreased by 40%. Radioembolisation contraindicated if shunting > 20%
Systemic chemotherapy: PIV infusion of FU 300mg/m2 for days 1 to 14 every 3 weeks until progression. For ethical reasons,
patients with documented progression were permitted to cross-over to receive radioembolisation at the investigators’ discretion
Chemotherapy (presumably in both study arms) continued until disease progression, unacceptable toxicity, or withdrawal
of consent
Methodological comments
l Allocation to treatment groups: randomisation used a minimisation technique. Institution and type of progression
before enrolment (progression while still receiving chemotherapy or delayed within 6 months after cessation of
chemotherapy) were stratiﬁcation factors. No further details provided
l Blinding: open label
l Comparability of treatment groups: states that arms were well balanced for clinical criteria
l Method of data analysis: states that for efﬁcacy analysis, all eligible patients were considered but numbers reported
suggest otherwise because two are missing. For safety analysis, eligible patients not treated were excluded. Distribution
of time-to-event variables estimated by the non-parametric Kaplan–Meier method. Comparison made using the
log-rank test; treatment effect reported by the estimation of a hazard ration (HR) obtained with Cox regression models.
Point estimates are reported with 95% CIs and p-values are two-sided. Response rates compared using Fisher’s exact
test. p-value signiﬁcant if < 0.05
continuedFU, ﬂuorouracil.
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Methodological comments
l Sample size/power calculation: the objective was to detect an impact of radioembolisation on TTLP using a two-sided
log-rank test with a signiﬁcance level of 0.05. On the basis of previous studies a TTLP of 6 weeks was anticipated in the
chemotherapy arm. With an estimated 90% power, 35 progressions were required to demonstrate an increase in
median TTLP from 6 to 18 weeks in the radioembolisation plus chemotherapy arm. Assuming a minimum follow-up
time of 30 weeks, it was estimated that 26 patients would be required per treatment arm to observe these
progressions. However, with an estimated 10% death rate without progression, it was planned to enrol 58 patients.
Actual accrual was lower and follow-up was longer than planned, so the trial was closed with the number of enrolled
patients lower than foreseen, but with the required number of progressions
l Attrition/dropout: two patients in the radioembolisation plus systemic chemotherapy arm were found to be ineligible
due to bone metastases (n = 1) and technical issues which impaired administration of 90Y-microspheres (n = 1). These
patients are not included in the analyses as noted above (i.e. analyses are not ITT). No loss to follow-up is reported
among those who received treatment
General comments
l Generalisability: anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor therapies
were routinely not available in Belgium during the trial recruitment period
l Outcome measures: appear appropriate for the stated objectives
l Inter-centre variability: states procedures were standardised at all centres but not further details
l Conﬂict of interests: one author declared honoraria from Sirtex Medical which is the company producing and supplying
the 90Y-microspheres
TTLP, time to liver progression; TTP, time to tumour progression.
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202Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Not reported
3. Were the groups similar at the outset of the study in terms of prognostic factors, e.g. severity of
disease/size, number of tumours, performance status, extrahepatic disease
Yes
4. Were outcome assessors blinded to the treatment allocation? No
5. (i) Were there any unexpected imbalances in dropouts between groups? (ii) If so, were they
explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more outcomes than they reported? Unclear
7. (i) Did the analysis include an intention-to-treat analysis? (ii) If so, was this deﬁned? No
8. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? No
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Country: Australia
Design: RCT
Number of centres: three
Funding: not stated
Intervention:
(1) radioembolisation
(SIRT) + systemic
chemotherapy;
(2) systemic chemotherapy
See below for intervention
details
Indication for treatment: multiple
bilobar colorectal liver metastases
with or without extrahepatic
metastases
Intention of treatment:
not stated
Number of participants:
(1) SIRT + chemotherapy n = 11;
(2) chemotherapy only n = 10
Sample attrition/dropout: two
deaths in the chemotherapy-
only arm occurred before any
protocol treatment could
be given
Inclusion criteria:
adenocarcinoma of the
colorectum (histologically
proven). Age 18 or over.
Unequivocal CT scan evidence of
liver metastases not treatable by
resection or any locally ablative
technique. Adequate
haematological, hepatic and
renal function (no deﬁnitions
provided). WHO performance
status < 3
Exclusion criteria: receipt of
chemotherapy or radiotherapy
for the liver metastases. Central
nervous system metastases.
Evidence of cirrhosis, ascites or
portal hypertension
Primary outcomes: response rate and toxicity
Secondary outcomes: time to progressive
disease, survival, quality of life
Method of assessing outcomes:
three-monthly clinical evaluation and
quality-of-life assessment, 3-monthly
CT scans of the abdomen and either chest
radiography or CT scan of the chest.
Monthly serological tests of haematological,
liver and renal function and CEA
Patients lost to follow-up or dying before any
follow up scans had been performed were
regarded as having progressed in the liver at
the time of death
Response: determined using Response
Evaluation Criteria In Solid Tumours (RECIST)
criteria (reference provided)
Patients with complete response or partial
response on CT scan had a second
conﬁrmatory CT scan at not less than
4 weeks after the initial scan that showed
the response. Progressive disease is a
measure that treatment is no longer effective
Toxicity: recorded on all patients using
standard Union for International Cancer
Control recommendations (no reference
provided) for grading of acute and subacute
toxicity criteria
Quality of life: measured at randomisation
and then 3-monthly using the validated
23-point Functional Living Index – Cancer
questionnaire (reference provided). Clinicians
completed an assessment of patients’
well-being at the same intervals using the
Spitzer index (reference provided)
Length of follow-up: not stated
Participant characteristics
SIRT + systemic
chemotherapy (n=11)
Systemic chemotherapy
only (n=10) p-value
Age (years) 64 65
Male/female 10/1 8/2
Primary cancer site Adenocarcinoma of colorectum Adenocarcinoma of colorectum
Number of liver metastases Multiple (no number reported) Multiple (no number reported)
Distribution of liver metastases Multiple bilobar Multiple bilobar
continued
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Participant characteristics
SIRT + systemic
chemotherapy (n=11)
Systemic chemotherapy
only (n=10) p-value
Size of metastases
< 25% 8 7
> 25% 3 3
Previous treatments for primary
cancer
Not reported Not reported
Time from primary treatment Not reported Not reported
Previous treatment for liver
metastases
None None
Time from previous liver mets
treatment
NA NA
Comorbidities – extrahepatic
metastases
2 (2 lung) (18%) 3 (2 lung, 1 peritoneal cavity)
(30%)
Histological differentiation of
primary bowel cancer
Poor (n = 1) Poor (n = 2)
Moderate (n = 10) Moderate (n = 6)
Well (n = 0) Well (n = 2)
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SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Mortality (time interval not speciﬁed) 10 10
First integrated response p< 0.001
Complete response 0 0
Partial response 10 0
Stable disease 1 6
Progressive disease 0 4
Best conﬁrmed response p< 0.001
Complete response 0 0
Partial response 8 0
Stable disease 3 6
Progressive disease 0 4
Comments: states p< 0.001 for comparison between groups below the table containing these data but not clear exactly
what the comparison(s) is (are). There was no difference in response rate between patients receiving the standard 2.5-GBq
yttrium-90 activity or the individualised doseNIHR Journals Library www.journalslibrary.nihr.ac.uk
(continued )
Outcomes
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Median time to progressive disease (PD),
months
18.6 3.6 < 0.0005
Site of ﬁrst disease progression
Liver 8 8
Liver and peritoneum combined
1
Bone
1
Liver and lung 1
Lung 1
Died from chemotherapy-related sepsis
without progression
1
Outcomes
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Median survival, months 29.4 12.8 HR 0.33; 95%
CI 0.12 to 0.91;
p = 0.025
Median survival excluding two patients in
the chemotherapy group who did not
receive treatment, months
29.4 14.1 HR 0.39; 95%
CI 0.14 to 1.13;
p = 0.07
Comments: at the time of analysis one SIRT + chemotherapy patient remained alive; all others had died. Kaplan–Meier
survival curve is available in the paper
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Treatment related death 1 (sepsis, due to
chemotherapy induced
neutropenia)
Liver abscess 1
Radiation induced liver cirrhosis 1
Transient abdominal pain at time of
injection
4
Number of grade 3 and 4 toxicity
events experienced during protocol
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Granulocytopenia 3 0
Nausea, vomiting 1 1
Mucositis 4 1
Gastritis 1 1
Diarrhoea 2 1
Anorexia 0 1
Cirrhosis 1a 0
Liver abscess 1a 0
Liver function tests 0 0
Total number of events 13 5
Comments:
a It is assumed that these events are the same as those mentioned in the section above
continued
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Quality of life
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Comments: no numerical outcome data reported. However, paper states that changes from baseline patient-rated quality
of life for the ﬁrst 3 months of treatment were almost identical in both arms (p = 0.96). This was also the case for physician-
rated quality of life (p = 0.98). After 3 months the number of quality-of-life assessments in the chemotherapy-only arm
diminished due to disease progression. The lack of variation from baseline during the ﬁrst 3 months may have been
because most patients were still receiving chemotherapy during this time. Abstract88 states that at 3 months the SIRT group
showed statistically signiﬁcant improvement in HRQoL compared with the chemotherapy-only group (p = 0.03,
95% CI 1.4 to 27.6), but was not statistically signiﬁcantly different thereafter. This appears to be different from the
information provided in the main publication
SIRT + systemic
chemotherapy (n = 11)
Systemic chemotherapy
only (n = 10) p-value
Total number of chemotherapy cycles 89 38
Fluorouracil dose intensity (%) 85.4 92
Mean SIR-Spheres dose 2.25 GBq NA
Comments: apart from the two early deaths in the chemotherapy-only arm (received no chemotherapy) the reason number
of chemotherapy cycles was greater in the SIRT + chemotherapy group was because most patients had a prolonged
response and therefore continued to receive on-going treatment. The slightly higher dose intensity in the chemotherapy
only group indicates that the lower response rate for patients in the control arm was not due to less intensive
chemotherapy. The latter six patients whose yttrium-90 dose was individualised to BSA received from 1.5 to 2.1 GBq; the
initial ﬁve received a standard amount of 2.5 GBq yttrium-90 activity
Intervention details
Single treatment with SIRT using SIR-spheres + standard regimen of systemic ﬂuorouracil/folinic acid chemotherapy
Arterial anatomy of liver was assessed by transfemoral hepatic angiogram to plan subsequent administration of SIR-Spheres.
Technetium-99 labelled macro-aggregated albumin was injected into the hepatic artery during the angiogram to estimate
‘percentage lung breakthrough’. If lung breakthrough was > 13% yttrium-90 activity administered was reduced
Single dose of SIR-Spheres administered on the third or fourth day of the second cycle of chemotherapy. If more than one
hepatic artery supplied blood to the liver the total dose of SIR-Spheres was divided into separate aliquots depending on the
estimated volume of tumour being supplied by each feeding artery
A single bolus of 25 µg Antiotensin-2 was pulsed into the hepatic artery 30 seconds before administering the SIR-Spheres
First ﬁve patients received 2.5 GBq of yttrium-90 activity
Subsequent six patients dose was calculated as: Dose of SIR Spheres in GBq ¼ ðBSAa− 0.2Þ þ% tumor involvement
100
(a, BSA = body surface area measured in square metres)
Change in dosing due to evidence of radiation hepatitis in one of the ﬁrst ﬁve patients who was very small
Patients treated with SIRT were generally kept in hospital overnight and discharged home the following day
Chemotherapy received by participants in both trial arms: ﬂuorouracil/folinic acid
5-ﬂuorouracil 425mg/m2 per day plus folinic acid 20mg/m2 per day for 5 consecutive days and repeated at 4-weekly
intervals. Chemotherapy cycles continued until evidence of unacceptable toxicity, patient request or disease progression
Details of post-intervention treatments: cancer speciﬁc treatment could include non-protocol chemotherapy. All
non-protocol cancer speciﬁc treatment recorded for all patients. Other supportive, but not cancer speciﬁc treatment was
allowed for patient management
Methodological comments
l Allocation to treatment groups: patients from three hospitals stratiﬁed prior to randomisation by institution, presence or
absence of extrahepatic metastases, and extent of liver involvement (> or< 25%) by tumour. Tumour and liver volumes
calculated from serial slices of pre-randomisation CT scan, recorded as a tumour-to-total liver volume ratio (reference
provided for this method). Patient registration and randomisation made by telephoning the independent Australian
National Health & Medical Research Council Clinical Trials Centre, which used a computer-based program to
randomise patients
l Blinding: all serial CT scans were read by an independent person not associated with the trial, who was blinded to the
treatment group of patients and who is experienced in reporting CT scans of the liver
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Methodological comments
l Comparability of treatment groups: states there is no signiﬁcant difference in any of the tumour or patient
characteristics between the two groups
l Method of data analysis: all trial source data was monitored and audited before analysis and interpretation. Analysed
by intention to treat and all tests were two-tailed. Also states that as the number of patients was small, an additional
analysis was performed to compare survival for only those patients who received protocol treatment. Patients who died
without follow-up scans, or in whom progressive disease (PD) was not logged on CT scans were recorded as having PD
at the time of death. Chemotherapy dose intensity deﬁned as the average amount of chemotherapy of each cycle
expressed as a percentage of the amount given in the ﬁrst cycle. Time to disease progression and survival curves used
the Kaplan–Meier method and were compared using the log-rank test. Response comparisons were performed using
the Kruskal–Wallis test. Difference in quality-of-life measures was compared with the t-test
l Sample size/power calculation: does not appear that this was done. However, does state that trial was designed to
enter 18 patients so that, based on an expected grade 4 toxicity event rate of 20%, if the rate in the combination
treatment exceeded ﬁve randomised patients continuation of the trial would be reviewed. The trial actually accrued
21 patients
l Attrition/dropout: two patients in the chemotherapy arm did not received protocol treatment, deteriorated rapidly and
died at 30 days and 45 days after trial entry. All patients in the SIRT + chemotherapy arm received SIRT and at least one
cycle of chemotherapy
General comments
l Generalisability: this study includes a small number of participants and some baseline information is not reported,
e.g. number of metastases, previous treatments received. It is difﬁcult therefore to know how generalisable the results
are to other patients with liver metastases
l Outcome measures: the response criteria are cited (RECIST criteria) but not deﬁned. Site and time to progressive disease
are reported but it is not clear whether this is progression in existing metastases or whether development of new
metastases has also been captured. No numerical data from quality-of-life assessment reported
l Intercentre variability: three different hospitals used but no comment made regarding any intercentre variability.
As patients were stratiﬁed by institution prior to randomisation, this should even out any differences by centre;
however, the small numbers could have led to imbalances
l Conﬂict of interests: not statement made and funding not reported
l Other: discussion states this was a small phase 2 trial designed to presage a large phase 3 trial. However, the larger trial
was not undertaken because newer chemotherapy drugs had shown superiority to FU/LU alone
RFA, radiofrequency ablation.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Quality assessment for randomised controlled trials (answer yes/no/not
reported/unclear)1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic
factors, e.g. severity of disease/size, number of tumours, performance
status, extrahepatic disease
Yes
4. Were outcome assessors blinded to the treatment allocation? Yes for outcomes reliant on CT scan data,
e.g. response. Not reported for toxicity
or quality of life
5. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
6. Is there any evidence to suggest that the authors measured more
outcomes than they reported?
Unclear
7. (i) Did the analysis include an intention-to-treat analysis? Yes
(ii) If so, was this deﬁned? Yes (can be inferred)
8. (i) Did the analysis account for missing data? Yes
(ii) If so, were the methods appropriate? Yes
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Eur Radiol 2010;20:173–80.Studies that remain unclear on whether prospective or
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clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for
metastatic liver cancer.] Gan to Kagaku Ryoho 1995:22:1807–11.
2. Shibata T, Shimano T, Kitada M, Niinobu T, Fukushima T, Hata S, et al. [Assessment of colorectal cancer
patients exhibiting bilobular multiple hepatic metastases.] Gan to Kagaku Ryoho 2000;27:1842–5.
3. Vogl T, Mack M, Straub R, Zangos S, Woitaschek D, Eichler K, et al. [Thermal ablation of liver
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Reference© Que
Health
provid
addres
Park, SAbramson, 2000115Health technologyHACEInterventions and comparators
What interventions/strategies were included?HACE and palliative careWas a no treatment/supportive care strategy included?Palliative care – symptom controlDescribe interventions/strategiesHACE – 5-FU, mitomycin, and ethiodised oil followed by embolisation with use of absorbable gelatin sponge
(Gelfoam; Pharmacia & Upjohn, Peapack, NJ)
For patients with metastatic lesions conﬁned to one hepatic lobe, a single embolisation procedure was
planned. All patients were eligible for re-embolisation if the original lesion or lesions grew or if new lesions
developed. The only contraindication for re-embolisation was portal venous thrombosis. In patients with
metastatic lesions in both the right and left hepatic lobes, the lobe with the greatest metastatic burden was
embolised ﬁrst. If the portal vein remained patent, lesions in the alternate lobe were embolised during a
second session. Speciﬁc lesions were considered for re-embolisation only if they failed to respond to the initial
treatment. Survival times were noted from the date of ﬁrst chemoembolisation
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APPENDIX 8
236Research questionWhat are the stated objectives of the evaluation?NIHRTo calculate the cost-effectiveness of HACE for the treatment of colorectal liver metastases (CLM) that are
refractory to systemic chemotherapyStudy type: cost-effectiveness/cost–utility/cost–benefit analysis?Cost-effectiveness analysisStudy population
What deﬁnition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?All patients had a diagnosis of colorectal carcinoma that was metastatic to the liver, as conﬁrmed at surgery
and/or biopsy, and that had been deemed to be unresponsive to systemic chemotherapy
A series of 21 patients who underwent HACE at the teaching hospital of Harvard Medical School from April
1996 to December 1998Institutional setting: where is/are the intervention(s) being evaluated
usually provided?HospitalCountry/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?USA, 1998 US dollars ($)Funding sourceHarvard Medical School (Department of Radiology, Beth Israel Deaconess Medical Center)Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services,
third-party payer, societal (i.e. including costs borne by individuals and lost productivity)?© Que
Health
provid
addres
Park, SOnly direct costs to the payer are consideredEffectiveness
Were the effectiveness data derived from a single study, a review/synthesis of previous studies or expert
opinion? Give the deﬁnition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.Survival for the HACE strategy was estimated from the authors’ 21 case series; however, these data were not used
in the CEA. Moreover, the authors found no RCT of HACE for the treatment of CLM, i.e. no data on the survival
beneﬁt of HACE compared with palliative care
A baseline survival expectation of 12 months was used for the palliative care strategy. Stangl et al.’sa observed that
patients with CLM who are treated with chemotherapy have a median survival time of 11.1 months
Moreover, survival beneﬁt of HACE was deﬁned as additional survival beyond the expected baseline survival for
patients receiving only palliative care. To calculate cost-effectiveness over a range of potential survival beneﬁts, the
denominator was maintained as an independent variable and varied from 0 to 24 months
Of the 21 patients in the authors’ series, seven died and 14 were still alive as of March 1999. The seven patients
who died each underwent a mean of 1.57 additional re-embolisation procedure. Survival times from the ﬁrst
chemoembolisation procedure ranged from 83 to 1097 days (2.8–36.6 months; mean, 17.4 months; median,
21.1 months)
As Stangl and colleagues’ median survival time overstates the survival time of patients who have already failed
systemic chemotherapy, the authors conducted sensitivity analyses with baseline survival expectations of 6
and 3 months
a Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors inﬂuencing the natural history of colorectal
liver metastases. Lancet 1994;343:1405–10.237
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APPENDIX 8
238Intervention costs
Were the cost data derived from a single (observational) study, a review/synthesis of previous studies or expert
opinion? Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? List the direct intervention costs and other direct costs used in the evaluation – include
resource estimates (and sources for these estimates, if appropriate) as well as sources for unit costs used.Input parameters derived from one of the following three sources: the authors’ internal data series, abstraction
from referenced sources, or reasonable assumption
Unit costs:
Direct costs to the payer were calculated by using 1998 Medicare reimbursementa as a proxy for inpatient
hospitalisation, procedural, and outpatient visit costs
Health Care Financing Administration (HCFA) Federal Upper Limit prices in 1998b were used for outpatient drug
costs; if HCFA prices were unavailable, average wholesale prices for generic equivalents were substituted
Resource use:
Probabilities of re-embolisation were estimated by using the mean from our patient series. Schedules for
follow-up visits and dosing regimens for analgesic medications were both modelled on assumption
a Drug Topics Red Book. Montvale, NJ: Medical Economics; 1998.
b National Heritage Insurance Company. Medicare B bulletin. Health Care Financing Administration Web site.
URL: www.hcfa.gov (accessed March 1999).Indicate the source for individual cost values (if appropriate).Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
Were indirect costs included?NIHRIndirect costs were not includedHealth state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?Not applicableList the utility values used in the evaluation.Not applicableIndicate the source for individual utility values (if appropriate).Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7ModellingIf a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.© Que
Health
provid
addres
Park, SA computer spreadsheet (Excel 97; Microsoft Corporation, Redmond, WA, USA) was constructed to calculate
the marginal direct cost of HACE compared with palliative care. Marginal cost-effectiveness was calculated
from marginal direct cost by varying the survival beneﬁt of HACE compared with palliative care from 0 to
24 months
A break-even analysis was performed to determine the survival beneﬁt at which HACE would be considered
to be cost-effective according to benchmarks obtained from the authors’ literature reviewExtract transition probabilities for [natural history/disease progression] model and show sources (or refer to
table in text).Not applicableWhat is the model time horizon?24 monthsWhat, if any, discount rates have been applied in the model? Same rate for costs and outcomes?Discounting was not performed due to the short time horizonResults/analysisWhat measure(s) of beneﬁt were reported in the evaluation?Life-years239
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240Provide a summary of the clinical outcome/beneﬁts estimated for each intervention/strategy assessed in
the evaluation.NIHRBaseline mean survival for palliative care – 12 months
Speculative incremental survival for the intervention arm ranging from 0 to 24 monthsProvide a summary of the costs estimated for each intervention/strategy assessed in the evaluation.Abramson et al. table 1: Parameters for calculation of marginal direct cost of HACE vs. palliative careSynthesis of costs and beneﬁts – are the costs and outcomes reported together (e.g. as cost-effectiveness
ratios)? If so, provide a summary of the results.Abramson et al. table 3: Marginal cost and cost-effectiveness of HACE vs. palliative care as a function of
survival beneﬁt
The authors also state that a cost-effectiveness standard of $50,000 per life-year gained requires a survival beneﬁt
of nearly 5 months more than baselineGive results of any statistical analysis of the results of the evaluation.Not reportedWas any sensitivity analysis performed – if yes, what type(s) [i.e. deterministic (one-way, two-way, etc.)
or probabilistic]?Deterministic one-way sensitivity analyses to the estimates of beneﬁt, resource use and unit costs of several
components of the strategiesWhat scenarios were tested in the sensitivity analysis? How do these relate to structural uncertainty
(testing assumptions over model structure such as relationships between health states), methodological
uncertainty (such as choices of discount rate or inclusion of indirect costs) or parameter uncertainty
(assumptions over values of parameters in the model, such as costs, quality of life or disease
progression rates)?The sensitivity analyses carried out tested the model robustness to parameter uncertaintyJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Give a summary of the results of the sensitivity analysis – did they differ substantially from the base-case
analysis? If so, what were the suggested causes?© Que
Health
provid
addres
Park, SThe authors stated that results of the sensitivity analyses performed show the robustness of the model
results to variation in key input parameters. The results of the model did not change substantially with 25%
increases or decreases in the cost of non-enhanced CT examination and the cost of measuring the CEA level.
Neither an increase or decrease in the post-chemoembolisation medication regimen nor a decrease the
baseline survival expectation (i.e. survival for patients receiving palliative care only) to 6 and 3 months
substantially alter the results of the model. The results of the model were somewhat inﬂuenced by changes
in the cost of chemoembolisation, the mean number of re-embolisation procedures per patient and the
schedule of follow-up visits after HACE
The authors report the range of marginal cost of HACE vs. palliative care and the survival beneﬁt for three
different thresholds of CE (US$20,000, US$50,000 and US$100,000) as shown in Abramson et al. table 4:
Sensitivity analysesConclusions/implicationsGive a brief summary of the author’s conclusions from their analysis.The authors state that their results demonstrate that the cost-effectiveness of HACE varies considerably with
expected survival beneﬁtWhat are the implications of the evaluation for practice?The authors state that practitioners and payers can generate preliminary CE estimates by using their own
empirical assessments of the survival beneﬁt of HACE
The authors acknowledge that one of their study limitations is the lack of adjustment for quality of life.
Though HACE may affect patients’ HRQoL positively due to the palliation of symptoms, there is potential for
negative impact on QoL due to its morbidity and potential for complicationsrySouthampton Health Technology Assessments Centre
commentary
commentaSelection of comparators:Appropriate241
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APPENDIX 8
242Validity of estimate of measure of beneﬁt:Measure of effectiveness of HACE estimated from a 21-case series. However, it was not included in the CEA due
to lack of comparator group. An estimate of incremental beneﬁt was not found by the authors. HRQoL was not
included in the analysisValidity of estimate of costsNIHRThe authors did not ﬁnd an estimate of incremental beneﬁt costs, thus unlikely to reﬂect the current UK
clinical practiceAPPENDIX 8B: DATA EXTRACTION FROM GAZELLE,116 2004Study characteristics
ReferenceGazelle et al. 2004116Health technologyPercutaneous Radiofrequency Ablation (RFA); hepatic metastasectomyInterventions and comparators
What interventions/strategies were included?No treatment, percutaneous radiofrequency ablation, surgical resection (metastasectomy) and laparotomyWas a no-treatment/supportive care strategy included?YesJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Describe interventions/strategies© Que
Health
provid
addres
Park, SNo details were provided regarding the no-treatment strategy (e.g. whether any monitoring is performed,
chemotherapy or other palliative care)
Strategies for radiofrequency ablation differed in the maximum number of lesions that could be treated, the
maximum number of repeat ablations allowed, and the frequency of follow-up imaging
Resection strategies differed in approach (surgical resection/metastasectomy or laparotomy), maximum
number of lesions or segments removed, and frequency of follow-up imaging. According to Gazelle et al.
(2003), surgical therapy may consist of resection (or metastasectomy) for resectable metastases or laparotomy
for unresectable metastases found at surgeryResearch questionWhat are the stated objectives of the evaluation?To evaluate the relative cost-effectiveness of radiofrequency ablation and hepatic resection and compare the
outcomes, cost, and cost-effectiveness of a variety of treatment and follow-up strategiesStudy type: cost-effectiveness/cost–utility/cost–benefit analysis?Cost–utility analysisStudy population
What deﬁnition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?Patients with metachronous liver metastases from colorectal carcinoma (CRC)Institutional setting: Where is/are the intervention(s) being evaluated
usually provided?Secondary care243
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APPENDIX 8
244Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?NIHRUSA/1998 US dollars ($)Funding sourceInstitute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard
Medical School; Centre for Risk Analysis and Department of Health Policy and Management, Harvard School
of Public Health; the National Cancer Institute; and the US Department of the ArmyAnalytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services,
third-party payer, societal (i.e. including costs borne by individuals and lost productivity)?Societal perspective (restricted to productivity and direct medical costs and beneﬁts). Costs from the
Medicare and Medicaid health care subsystemsEffectiveness
Were the effectiveness data derived from a single study, a review/synthesis of previous studies or expert
opinion? Give the deﬁnition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.Journals Library www.journalslibrary.nihr.ac.uk
Effectiveness data were derived from a comprehensive review of the English-language literature,
by using PubMed and reviewing the bibliographies of the articles identiﬁed, or from expert opinion
The study assessed the impact of the intervention on mortality, morbidity, length of stay, quality of life,
and probability of complete tumour necrosis (with RFA)
Mortality: 5% (resection),a 1% (laparotomy),b 0.3% (RFA)c
Morbidity: 20% (resection),a 4% (laparotomy),b 2% (RFA)c
Length of hospital stay: 12 days (resection), 5 days (laparotomy)d
Additional LoS due to complications: 3 days (resection, laparotomy, RFA)d
Probability of complete tumour necrosis with RFA: 0.784 (tumour size ≤ 2.5 cm), 0.472 (> 2.5–4 cm),
0.316 (> 4–10 cm)e
RFA, radiofrequency ablation.
a Derived from Adson et al. (1984), Foster et al. (1978), Cobourn et al. (1987), Nordlinger et al. (1987),
Scheele et al. (1991), Petrelli et al. (1997), Iwatsuki et al. (1986), Holm et al. (1989), Nakamura et al. (1997),
Fegiz et al. (1991).
b Expert opinion.
c Livraghi et al. (2003).
d Centers for Medicare and Medicaid Services.
e Solbiati et al. (2001).
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Intervention costs
Were the cost data derived from a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.Cost data were derived from a review of the literature and the methods for their derivation were adequately
described. Cost data for tests and procedures were estimated from the Medicare payment schedule, and the costs
of patient care per year according to the LVRT were derived from Taplin and colleagues’ study (1995)
The authors assumed that up to three liver metastases could be treated with ablation on 1 day and that two
treatment sessions would be required for patients undergoing treatment for 4–6 metastases. The costs were
adjusted accordingly assuming the cost of repeat radiofrequency ablation to be the same as the cost of
initial therapy
Morbidity costs were derived from per diem routine care (non-intensive care unit) costs among patients undergoing
hepatic resection at their institution (Massachusetts General Hospital) in the ﬁscal year of 1998. Complications
from radiofrequency ablation were assumed to require a 1-day hospitalisation and the resource use involved would
be similar to laparotomy-related complications
Gazelle et al. 2004, table 2: Direct costsIndicate the source for individual cost values (if appropriate).245
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APPENDIX 8
246Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
Were indirect costs included?Productivity costs were based on the daily wage rate of the US Bureau of Labor Statistics
TABLE 87 Indirect costs (Gazelle et al. 2004, table 2)
Test or procedure Base-case estimate
(year 1998 dollars)
Values used in
sensitivity analysis
Source
Daily wage ratec 96 NA US BLS
BLS, Bureau of Labor Statistics; NA, not applicable.
c The daily wage rate is calculated by multiplying the average hourly wage rate by 7.5 hours.Health state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
Were the utility data derived from a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?NIHRUtility data were derived from a review of the literature and based on expert opinion. There is limited detail
on the methods for deriving these data. Age- and sex-adjusted population values to survival without liver
metastases were derived from Fryback et al. (1993)List the utility values used in the evaluationQoL after ablation = 0.95 preablation value for 1 month (Solbiati et al. 2001)
QoL after surgery = 0.7 presurgical value for 1 month
QoL one month prior to death = 0.6 presurgical/ablation value
[Assumptions based on Earlam et al (1996) who had used Rotterdam Symptom Checklist (RSC), Hospital Anxiety
and Depression Scale (HADS), and Sickness Impact Proﬁle (SIP) in 50 patients with colorectal liver metastases (CLM)]Indicate the source for individual cost values (if appropriate).ModellingIf a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within
a Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.Journals Library www.journalslibrary.nihr.ac.uk
Markov state transition model adapted from previously published model to evaluate the cost-effectiveness of
surgical removal of metastases in patients with liver metastases from CRC (Gazelle et al. 2003). The main health
states are ‘alive_treat’, ‘alive_notreat’, and ‘dead’, where patients on ‘alive_treat’ are potential candidates to
intervention who move to the ‘alive_notreat’ when found untreatable (to have more metastases than the
threshold for treatment) or reached the maximum allowed number of interventions for the strategy under
consideration. The model simulates cohorts of 10,000 hypothetical patients, one at a time, from initial presentation
until death, while tracking disease progression, diagnostic tests, procedures, complications, survival, and costs
Structural assumptions
l The model includes only one generic imaging and treatment strategy, which is deﬁned using speciﬁc
parameters (e.g. treatment threshold, image/treatment interval, test sensitivity)
l For both RFA and hepatic resection, all possible combinations of follow-up interval (4, 6, or 12 months)
and treatment threshold (≤ 1, 2, 3, 4, 5 or 6 metastases seen) were simulated
l The model tracks up to 15 individual hepatic metastases in each patient, specifying and updating tumour
location, size, rate of growth, detection, and removal or ablation
l One-month cycle length
Number of metastases
l For each hypothetical patient, the number of metastases present is drawn at random from a
population distribution
Distribution of metastases
l Metastases are then distributed throughout the liver. The authors assume that each metastasis has
an independent, equal probability of being located in each of the eight liver segments
Size of metastases
The size of each metastasis is similarly drawn at random from a population distribution. Over time,
metastases that are present grow, may be detected with imaging tests, and may be removed
during resection
l Growth in tumour volume is assumed to be exponential, at rates determined from Finlay (1988)
Growth of metastases
l The authors assume that no new liver metastases develop over time, as all patients are assumed to
have undergone removal of their primary tumours
Detection of metastases
Metastases can be missed at initial diagnosis but can later be detected with repeat imaging tests
[Nordlinger (1994), Hughes (1986), Ekberg (1987)]
l Each time a patient undergoes a diagnostic imaging test, metastases may be (independently) detected
or missed. Tumour detection is based on test sensitivity, although it is assumed that below a certain
(deﬁnable) size threshold, all metastases are missed
l Helical contrast material-enhanced computed tomographic (CT) scanning is assumed to be used in
all patients
Removal of metastases
Decision on the candidacy of each patient for treatment (or for repeat treatment, in the event of newly
detected metastases or local treatment failure) is based on the CT results. The possibility of different
criteria for determining treatment candidacy is allowed, depending on the number of metastases identified
(≤ 1, 2, 3, 4, 5 or 6) and the number of hepatic segments involvedIn patients undergoing surgical removal
of metastases, additional metastases may be found at the time of surgery, either by palpation of the liver or
by using intraoperative ultrasonography. The detection of these additional metastases could influence the
decision to proceed with surgical removal of metastases and/or modify the plan for resection. As a result of
treatment, patients are either free of metastatic disease or have residual metastases, depending on
the number and location of metastases detected, the location of metastases not detected and
procedure performed
continued
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l The model allows treatment of speciﬁc lesions (i.e., rather than removal of entire liver segments), and
incomplete treatment of individual lesions because ablation may fail to achieve complete tumour necrosis.
In the event that incomplete tumour necrosis was detected (i.e., at a follow-up imaging examination), repeat
treatment with RFA was permitted, up to a maximum (deﬁnable) number of treatment sessions
Morbidity and mortality
Patients may also suffer operative morbidity or mortality. Each of these events is explicitly modelled
l The same estimates for the probability of morbidity and mortality for all instances of hepatic metastasectomy
and ablation were used
l According to the authors, based on their literature review, the single most important determinant of
survival appears to be the extent of LVRT. Hence, the authors assigned to patients with less than 25% LVRT
a median survival of 11.5 months, and to patients with at least 25%
LVRT a median survival of 6.3 months, based on a weighted average of the studies reporting survival as a function
of per cent of LVRT
l Transition probabilities for patients with liver metastases were calculated from the corresponding estimated
median survivals assuming constant hazard rates (i.e., exponential survival curves)
APPENDIX 8
248NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Extract transition probabilities for [natural history/disease progression] model and show sources (or refer to
table in text).The authors refer to several reports that had described the natural history of patients with untreated metastases
and have consistently identiﬁed the extent of liver replacement by the tumour as the single most important
determinant of survival – Bengtsson et al. (1981), Finan et al. (1985), Goslin et al. (1982), Lahr et al. (1983),
Wagner et al. (1984), Wood et al. (1976), Boey et al. (1981), Stangl et al. (1994) and Scheele et al. (1990)
The authors also report that as the number, size, and growth of all metastases were explicitly modelled, it was
possible to calculate percentage LVRT in each patient and to revise it with each cycle of the model. State-to-state
transition probabilities for patients with liver metastases were calculated from the corresponding estimated median
survivals assuming constant hazard rates
TABLE 88 Parameter estimates used to calculate transition probabilities (from Gazelle et al. 2004, table 1)
Parameter Base-case estimate
Values used in
sensitivity analysis Source
No. of metastases
per patient
∼ Poisson [6] ∼ Poisson [10] See materials and methods
Size of metastases (cm) ∼ Gamma [0.8333,3]a NA See materials and methods
Tumour volume doubling
time (days)
155 78 and 233 Finan et al. (1985)
Normal liver volume (cm3) 1225 NA Urata et al. (1995)
Sensitivity of CT 0.85 0.75 See materials and methods
and Wernecke et al. (1991),
Knol et al. (1993),
Valls et al. (1998),
Matsui et al. (1987),
Clarke et al. (1989),
Heiken et al. (1989),
Zerhouni et al. (1996)
and Parker et al. (1989)
Detection threshold
at CT (cm)
0.5 1.0
Detection threshold at
intraoperative US (cm)
0.3 0.5 Machi et al. (1987) and
Onik et al. (1986)
Hazard rate when
no metastases
2 that of population
(age and sex speciﬁc)
1.5 and 2 that of
base-case estimate
1988 US life tables
Hazard rate when
< 25% LVRT
0.7427 0.5 and 1.5 that of
base-case estimate
Bengtsson et al. (1981),
Finan et al. (1985)
and Stangl et al. (1994)
Hazard rate when
≥ 25% LVRT
1.3203 NA
Median survival when
< 25% LVRT (months)
11.5 nr
Median survival when
≥ 25% LVRT(months)
6.3 nr
NA, not applicable; nr, not reported.249
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APPENDIX 8
250What is the model time horizon?NIHRLifetimeWhat, if any, discount rates have been applied in the model? Same rate for costs and outcomes?Costs and QALYs were discounted at a real annual rate of 3%. Discount rates of 0% and 5% were
considered in sensitivity analysesResults/analysisWhat measure(s) of beneﬁt were reported in the evaluation?Quality-adjusted life-years (QALYs)Provide a summary of the clinical outcome/beneﬁts estimated for each intervention/strategy assessed in
the evaluation.The expected beneﬁts of the dominant strategies from the base-case analysis are presented in Table 89 below.
TABLE 89 Results of base-case analysis: resection vs. ablation – beneﬁts (from Gazelle et al. 2004, table 3)
Treatment Interval for follow-up testing
and treatment (months)
Maximum no. of
metastases treated
Effectiveness per
patient (QALY)
RFA 12 3 1.1327
RFA 12 5 1.3255
RFA 12 6 1.3575
Resection 12 6 3.2634
Resection 4 6 3.3923
RFA, radiofrequency ablation.
Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Provide a summary of the costs estimated for each intervention/strategy assessed in the evaluation.The estimated costs for the dominant strategies from the base-case analysis are presented in Table 90 below.
TABLE 90 Results of base-case analysis: resection vs. ablation – costs (from Gazelle et al. 2004, table 3)
Treatment
Interval for follow-up testing
and treatment (months)
Maximum no. of
metastases treated
Cost per patient
(year 1998 dollars)a
RFA 12 3 24,700
RFA 12 5 24,800
RFA 12 6 24,800
Resection 12 6 57,000
Resection 4 6 61,000
RFA, radiofrequency ablation.
a Rounded to nearest $100.Synthesis of costs and beneﬁts – are the costs and outcomes reported together (e.g. as cost-effectiveness
ratios)? If so, provide a summary of the results.The estimated ICER for the dominant strategies from the base-case analysis are presented in Table 91 below.
TABLE 91 Results of base-case analysis: resection versus ablation – ICER (from Gazelle et al. 2004, table 3)
Treatment
Interval for follow-up testing
and treatment (months)
Maximum no. of
metastases treated
ICER
(dollars per QALY)a
RFA 12 3 . . .
RFA 12 5 300
RFA 12 6 1,300
Resection 12 6 16,900
Resection 4 6 31,200
RFA, radiofrequency ablation.
a Rounded to nearest $100; ICERs may not equal the ratios of costs per QALY owing to rounding.
The ICER of a resection strategy of a 4-month follow-up interval and resection of six or fewer metastases
relative to the most effective non-dominated ablation strategy (i.e. ablation of up to six metastases with
12-month follow-up) was $17,800 per QALYGive results of any statistical analysis of the results of the evaluation.© Que
Health
provid
addres
Park, SNot reported251
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252Was any sensitivity analysis performed – if yes, what type(s) [i.e. deterministic (one-way, two-way, etc.)
or probabilistic]?Yes, deterministic one-way and two-way sensitivity analyses were performed
In all comparisons, RFA refers to a strategy of treating up to ﬁve metastases with a 4-month follow-up interval, and
resection refers to a strategy of resection of up to four metastases with a 6-month follow-up interval
For the base-case analysis, patients with one or more tumours larger than 5 cm in diameter were not considered
candidates for ablation. Different thresholds for treatment candidacy were evaluated in sensitivity analyses
Model assumptions tested: women aged 65 years, RFA for tumours ≤ 7 cm and ≤ 10 cm, CT sensitivity of 0.75, CT
sensitivity of 0.75 and RFA for tumours ≤ 10 cm, intraoperative US sensitivity of 0.90, number of metastases = 8
and = 10, mortality hazard (with no metastases) decreased by 50%, tumour doubling time doubled to 310 days and
halved to 78 days, cost of RF ablation doubled and halved, cost of care halved, discount rate of 5% and 0%What scenarios were tested in the sensitivity analysis? How do these relate to structural uncertainty
(testing assumptions over model structure such as relationships between health states), methodological
uncertainty (such as choices of discount rate or inclusion of indirect costs) or parameter uncertainty
(assumptions over values of parameters in the model, such as costs, quality of life or disease
progression rates)?Yes, the above-mentioned assumptions over parameter values and methodological choices were tested under three
scenarios of local control rates for RFA were considered: base case, improved RFA and perfect RFA
In the ‘perfect RF’ scenario, complete tumour necrosis was achieved in all treated tumours, whereas in the
‘improved RF’ one complete tumour necrosis was achieved in 100%, 75%, and 50% of treated tumours 2.5 cm
or smaller, larger than 2.5 cm but smaller than or equal to 4 cm, and larger than 4 cm but smaller than or equal to
10 cm, respectivelyGive a summary of the results of the sensitivity analysis – did they differ substantially from the base-case
analysis. If so, what were the suggested causes?The results were sensitive to changes in the number of metastases present (i.e., the assumed population distribution),
the size threshold above which lesions were considered untreatable with RFA, and the cost of RFA. More generally,
any changes in model parameters that increased the effectiveness of RF resulted in an increase in the ICER for
resection relative to RFA
In all cases, the ICER of RFA (up to ﬁve metastases with 4-month follow-up interval) versus the no-treat strategy
was less than $5000 per QALY, and, with very few exceptions, the ICER of resection (up to 4 metastases with
6-month follow-up interval) versus RFA was less than $30,000 per QALY
For the base-case scenario, the ICER of resection vs. RFA ranged from $21,200 to $88,300 per QALY (from
non-discounting costs or QALYs to performing RFA for tumours smaller than or equal to 10 cm). The authors
state that these results suggest that RFA of larger lesions should be encouraged, even though local control rates
diminish as the size of the target tumour increases
Across all scenarios, when all possible RFA and resection strategies were considered (results not shown), more
aggressive surgical strategies were superior (i.e. resulted in more QALYs gained) to RFA. In most cases, the ICERs of
even the most aggressive surgical strategies were less than $35,000 per QALY. An additional ﬁnding was that
some of the less aggressive RFA strategies (e.g. treatment of one to two metastases) were both less expensive and
more effective than the no-treat strategy
Further results are reported in Gazelle et al. 2004 table 4
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Give a brief summary of the authors’ conclusions from their analysis.© Que
Health
provid
addres
Park, SThe authors conclude that both RFA and hepatic resection are relatively cost-effective management
strategies for patients with limited hepatic metastases from CRC. In some instances, particularly with more
restrictive selective criteria for treatment candidacy (i.e. those based on the number of lesions detected),
ablation was found to be cost-saving relative to no treatment. However, throughout the analysis, more
aggressive strategies (i.e. the treatment of patients with more tumours, more frequent post-treatment
follow-up regimens, and surgery rather than ablation) were superior to more conservative strategiesWhat are the implications of the evaluation for practice?The authors suggest that physicians performing ablation and resection should be encouraged to select
patients for therapy on the basis of technical feasibility rather than numerical thresholds and to pursue
repeat treatment when new lesions are identiﬁed after initial therapySHTAC commentary
Selection of comparators:AppropriateValidity of estimate of measure of beneﬁt:Unclear; non-compliant with NICE Reference CaseValidity of estimate of costs:Appropriate; non-compliant with NICE Reference Case253
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DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Appendix 9 Search strategy for review of
quality-of-life studies© Que
Health
provid
addres
Park, SMEDLINE (Ovid)1. *quality of life/2. value of life/
3. quality adjusted life year/
4. quality adjusted life.ti,ab.
5. (qaly$ or qald$ or qale$ or qtime$).ti,ab.
6. disability adjusted life.ti,ab.
7. daly*.ti,ab.
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab.
9. (sf6 or sf 6 or SF 6D or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab.
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form
twelve).ti,ab.
11. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab.
12. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short
form twenty).ti,ab.
13. (euroqol or "euro qol" or "eq5d" or "eq 5d").ti,ab.
14. (hql or hqol or "h qol" or hrqol or "hr qol").ti,ab.
15. ("hye" or "hyes").ti,ab.
16. health* year* equivalent*.ti,ab.
17. (hui or hui1 or hui2 or hui3).ti,ab.
18. disutil*.ti,ab.
19. rosser.ti,ab.
20. quality of well being.ti,ab.
21. quality of wellbeing.ti,ab.
22. qwb.ti,ab.
23. willingness to pay.ti,ab.
24. standard gamble*.ti,ab.
25. time trade off.ti,ab.
26. time tradeoff.ti,ab.
27. tto.ti,ab.
28. (index adj2 well being).mp.
29. (quality adj2 well being).mp.
30. qwb.tw.
31. (health adj3 util* adj ind*).mp.
32. ((multiattribute* or multi attribute) adj3 (health ind* or theor* or health state* or util* or analys*)).mp.
33. quality adjusted life year*.mp.
34. qualy.tw.
35. health status indicator*.ti,ab.
36. "health related quality of living".ti,ab.en’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State
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NIHR37. "health related quality of life".ti,ab.
38. (patient* adj2 (preference* or satisfaction or acceptance)).ti,ab.
39. (health adj ("state" or "status" or "states")).ti,ab.
40. rating scale*.mp.
41. linear scale*.mp.
42. visual analog*.mp.
43. (categor* adj scale*).mp.
44. (FACT-G or "EORTC QLQ-C-30" or FLIC or QLI-CV).tw.
45. "functional assessment of cancer therapy".tw.
46. ("model of end stage liver disease" or MELD).tw.
47. "functional living index cancer".tw.
48. (LDQOL or "liver disease quality of life").tw.
49. or/1-48
50. exp Liver Neoplasms/sc
51. exp Neoplasm Metastasis/
52. exp Liver Neoplasms/
53. 51 and 52
54. (liver adj5 (secondar* or metasta* or micro-metasta* or micrometasta*)).tw.
55. (hepat* adj5 (secondar* or metasta* or micro-metasta* or micrometasta*)).tw.
56. 50 or 53 or 54 or 55
57. 49 and 56Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Appendix 10 Further details and results from
studies included in review of quality-of-life studies257
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258Allen-Mersh et al.,120 1994; Earlam et al.,121 1996;
Earlam et al.,140,152 1997; Durand-Zaleski et al.,142 1998Country
Study design
Study type/
purpose
Intervention(s), n
Study population
Indication
Age
Gender
Comparator population
QoL instrument(s) used
Methodology of
collecting QoL data
Time period where
HRQoL instruments
administered Results
UK
RCT and cost-
effectiveness
study (participants
in group 2 were
taken from a
separate RCT)
To assess efﬁcacy
including QoL and
to compare costs
and beneﬁts of
treatments
1. Hepatic artery infusion
chemotherapy (HAC),
n = 51
2. Systemic chemotherapy,
n = 34 (stated as n = 35 in
Earlam et al.)167
3. Symptom control, n = 49
(stated as n = 50 in
Earlam et al.)121
l Colorectal carcinoma
with unresectable liver
metastases occupying
up to 60% of the liver,
no evidence of
extrahepatic disease
l Mean (SD) age:
¢ Group 1:
55 (10) years
¢ Group 2:
63 (13) years
¢ Group 3:
59 (8) years
l Gender (male/female):
¢ Group 1: 34/17
¢ Group 3: 29/20
¢ Gender not
reported for
group 2
NB: some minor
discrepancies between the
four publications on n and
baseline characteristics;
however, dates of study and
treatments appear to be the
same so assume these are
the same participants
Physical symptoms were
assessed by the Rotterdam
Symptom Checklist (RSC)
and the Sickness Impact
Proﬁle (SIP)
Mood assessed by Hospital
Anxiety and Depression
Scale (HADS) and the RSC
Completed monthly for a
median of 91% (74–100)
of months between
randomisation and death
(for groups 1 and 3,
unclear for group 2)
Limited data presented on
quality-of-life results
QoL scores for a typical control
patient presented graphically in
Allen-Mersh,120 but no mean
score provided
Earlam et al.121 report
correlations between quality of
life and survival, and QoL and
tumour growth but no data
provided for overall scores only
individual questions/domains
Earlam et al.152 state no
signiﬁcant differences were seen
on QoL scores between
symptom control patients and
HAC or chemotherapy patients
(some short-term differences in
HAD observed). No data
presented. A signiﬁcant increase
in RSC physical score was seen
in the chemotherapy versus
symptom control group
(p < 0.05). No data presented
Earlam et al.152 also report
statistically signiﬁcant differences
between individual items on the
RSC physical scale (not extracted
here), and changes over time
(not extracted here)
Survival with normal QoL scores
(median, IQR, days) were:
l Group 1: 318 (162–630)
l Group 2: 127 (84–280)
l Group 3: 62 (31–124)
Health care costs (£) per normal
QoL life-year gained were:
l Group 1: 24,218
l Group 2: 24,280
l Group 3: 23,705
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7Blair et al.,137 2003USA
Prospective cohort
study including
qualitative analysis
To examine QoL after
regionally delivered
chemotherapy and
develop a speciﬁc
quality-of-life
questionnaire
1. Intrahepatic
chemotherapy via the
portal vein or hepatic
artery, n = 16
l Colorectal metastases,
following liver resection
l Colorectal metastases,
following liver resection
l Median age, 59 years
(range 43–75 years)
l Gender (male/female):
10/6
In-depth semi-structured
interviews to identify speciﬁc
concerns related to 6
domains of QoL
The City of Hope QoL Scale/
Cancer Patient scale
Self-report scale consisting
of 40 items, each on a
scale of 0 (worse) to
10 (best), with items
representing 4 domains of
physical, social, spiritual and
psychological well-being
Administered at
baseline only
Compared with 169 non-
patient norms (volunteers)
Overall QoL score was
decreased, 6.25 ± 2.44 in
patients (overall score in
volunteers not presented)
Physical well-being scores
were similar between patients
and volunteers (7.74 ± 1.77 vs.
7.63 ± 2.33)
Psychological, social and
spiritual well-being scores
were statistically signiﬁcantly
lower in the patient sample
(mean ± SD):
l Psychological: 5.21 ± 1.68
vs. 7.90 ± 1.81, p < 0.025
l Social: 6.45 ± 1.97 vs.
7.64 ± 2.09, p < 0.025
l Spiritual: 6.13 ± 2.00 vs.
7.54 ± 2.02, p < 0.025
Results also presented for the
individual items within the
domains for the patient
group only. Also the
general themes emerging
from the qualitative
interviews presentedBlazeby et al.,138 2009UK, Germany,
France
Prospective
cohort study
Validation study
(for the HRQoL
instrument)
1. Hepatic resection,
n = 263
2. Palliative treatment,
n = 93
l Colorectal liver
metastases with an
expected survival time of
at least 4 weeks
l Mean (SD) age:
¢ Resection:
63.3 (10.1)
¢ Palliative:
65.6 (10.1)
l Gender (male/female):
¢ Resection: 175/88
¢ Palliative: 62/31
EORTC QLQ-C30 (a generic
questionnaire assessing aspects
of health)
EORTC QLQ-LMC21 (a 21-item
questionnaire speciﬁcally
developed for patients with
colorectal liver metastases)
Self-report questionnaire.
Completed before and 3 months
after treatment
The 21 items are grouped into
ﬁve scales: fatigue, nutrition,
pain, social and emotional
problems
Adherence 100% at baseline
and 88.5% at follow-up
Results relate to the reliability
and validity of the instrument,
and subsequent remodelling
of the questionnaire itself
Some statistically signiﬁcant
differences were observed on
individual items between the
two groups, and in all
participants before and
after treatment
No overall score of QoL
was provided
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260Bruns et al.,139 2010Germany
Prospective
cohort study
To assess QoL
1. Liver resection group with
curative intent (deﬁned as
the absence of recurrent
disease at time of
assessment), n = 183
(96 completed all
assessments)
Various indications for liver
resection, 21% had benign
lesions, 21.9% had liver
primaries and 57.3% had liver
metastases (38 from colorectal
carcinoma, 17 from other
primary cancers)
Median age 63.4
(IQR 54.5–70.5) years
Gender (male/female): 48/48
Compared with general
German population norms
(n, demographics unknown)
and subgroups of indication
for surgery (metastases,
primary liver cancer,
benign liver disease)
SF-12 health survey, an
abbreviated version of the
SF-36, which has summary
measures of physical and
mental health status, derived
from subscales for physical
function, physical role, pain,
general health, vitality, social
function, emotional role and
mental health
Self-report questionnaire
completed post surgery, at
least 3 months after discharge
(range 3–36 months)
Also conducted pain
assessment on a 0–10 scale
and a liver-speciﬁc symptom
score (including fever,
dyspepsia, heartburn, lack of
appetite, nausea, vomiting,
night sweat and exhaustion)
68% (128 patients) response
rate or which 75% (96) were
complete
Median overall SF-12 scores for
the physical health status and
mental health status, stratiﬁed
for demographic items, type of
resection, indication and overall
morbidity: physical: 46.7 (IQR
34.2–53.9); mental: 54.1 (IQR
42.8–58.2) (all indications)
SF-12 data on the mental health
scale was signiﬁcantly higher
(p< 0.05) for the subgroup who
had liver resection for metastases
[55.9 (47.5–58.8)] compared
with primary liver cancer [49.6
(36.5–55.1)] or benign liver
disease [49.2 (37.7–56.3)]. On
the SF-12 physical health scale
the scores for the three
subgroups were: 43.5 (33.4–
54.9) for benign liver disease;
41.6 (32.9–53.1) for primary liver
cancer; and 50.6 (39.0–54.2) for
liver metastases
Also reports data on the SF-12
by type of resection (major,
minor), age, and gender, but not
extracted here
Also reports data on the
relationship between subjective
impairment and QoL score, and
the distribution of liver-speciﬁc
symptom scores, not
extracted here
SF-12 scores vs. the general
population presented by age.
Patients younger than 40–51
years who underwent liver
resection showed signiﬁcantly
lower SF-12 scores (physical and
mental health status) compared
with their age-matched normal
group (p< 0.05) (all indications)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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RCT
RCT to assess
effectiveness of
treatments, including
QoL. This particular
study aimed to assess
the use of QOL to
predict survival
1. Sunitinib, n = 375
2. Interferon alfa, n = 375
l Metastatic renal cell
carcinoma
l Median age, years:
¢ Group 1: 62;
¢ Group 2: 59
l Gender (male/female), %:
¢ Group 1: 71/29
¢ Group 2: 72/28
Functional Assessment of
Cancer Therapy-General
scale (FACT-G), a 27-item
scale ranging from 0
(worse) to 108 (best) QoL;
Functional Assessment of
Cancer Therapy-Kidney
Symptom Index-Disease-
Related Symptoms
subscale
(FKSI-DRS), a 9 item
scale ranging from 0
(most severe) to 36
(no symptoms; EQ-VAS
(0–100; worse to best)
Self-reported
questionnaires completed
at day 1 and 28 of each
cycle of treatment, and at
the end of treatment
or on withdrawal
from the study. Only
baseline data presented in
the publication
FACT-G:
l Group 1: 82.30 (SD 15.2)
l Group 2: 81.25 (SD 16.04)
FKSI-DRS:
l Group 1: 29.74 (SD 5.24)
l Group 2: 29.55 (SD 5.03)
EQ-VAS:
l Group 1: 73.80 (SD 18.5)
l Group 2: 71.43 (SD 19.51)
The predictive value of
baseline QoL for
progression-free survival
reported, not extracted here
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RCT
To assess efﬁcacy of
hepatic artery infusion
chemotherapy,
including QoL
1. Hepatic artery infusion
chemotherapy (HAC),
n = 68
2. Systemic chemotherapy,
n = 67
l Colorectal carcinoma with
unresectable liver
metastases occupying
< 70% of the liver
and no evidence of
extrahepatic disease
l Median age:
¢ Group 1: 57 years
¢ Group 2: 61 years;
overall 59
(range 21–86)
l Gender (male/female):
¢ Group 1: 41/27
¢ Group 2: 38/29
¢ Overall: 79/56
Rand 36-item Health
Status Proﬁle; Memorial
Symptom Assessment
Scale; Medical Outcomes
Study Social Support
Questionnaire; Medical
Outcomes Study Sexual
Functioning Scale
Self-report measures
administered before
treatment and every
3 months until
18 months
63 (47%) completed the
entire study QoL
assessments (baseline,
3, 6, 9, 12, 15 and
18 months)
Limited data presented
on QoL
The physical functioning of
the HAC group was better
than the systemic
chemotherapy group at
3 months (p< 0.038) and
6 months (p< 0.024)
No differences between
treatments were found in
social functioning, role
functioning-emotional, or
general health perceptions
Across the rest of the
follow-up period, treatment
arm differences among the
four QoL outcomes were
not evident, except for
physical functioning at the
12-month assessment.
The relationship between
treatment and time varied
signiﬁcantly as a function
of the time of dropout
(shown graphically for
the RAND-36)Knox et al.,145 2004USA
Retrospective cohort
study
To review clinical and
functional QoL
outcomes following
resection of liver
metastases
1. Liver resection, n = 13
l Hepatic carcinoid metastases
l Mean age: 47 ± 2.3 years
(range 33–65 years)
l Gender (male/female): 4/9
Functional performance
assessed by the
Karnofsky function score
which the authors state
measures functional
QoL. This ranges from 0
to 100 (higher scores
relate to better function)
and was assigned by
study investigators
preoperatively,
3 and 6 months
postoperatively and
annually thereafter
Average functional QOL
improved by the postoperative
month 3 from 75 ± 5 to
88 ± 5 (p< 0.01)
Assessed by subgroup
(amount of tumour resected
≥ 90% vs. < 90%) but this
did not reach a statistically
signiﬁcant group time
interaction effect (p = 0.26)
Overall longitudinal functional
QoL in 10 participants who
survived until at least month
54 presented graphically. This
showed a statistically
signiﬁcant improvement
(p< 0.05) by month 3, which
was sustained through to
month 54263
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APPENDIX 10
264Krabbe et al.,146 2004Netherlands
Prospective cohort
study
To compare generic
HRQoL measure with
disease-speciﬁc
measure
NB: possible overlap of
participants with
Langerhoff et al.
Exploratory laparotomy were
split into three groups:
1. Hepatic resection with or
without ablation by
cryoablation or
radiofrequency ablation,
n = 48
2. Ablation only, n = 11
3. No treatment (unresectable
disease), n = 16
l Colorectal liver metastases
l No baseline characteristics
presented
EQ-5D VAS and index;
EORTC QLQ C-30
Self-report questionnaires
administered at baseline
(1 day before
intervention), 2 weeks
post intervention, 3 and
6 months post intervention
Mean scores on the
EQ-5D index, EQ-5D
VAS and EORTC QLQ
C-30 are presented
graphically by time
and subgroup
Mean scores of total
EQ-5D index and EQ-5D
VAS are presented for
the four data collection
points for all participants
(not expressed by group)
Mean scores of the
individual items and
domains of the EQ-5D
are presented for each
time point for all
participants (not
expressed by group)
Mean scores of the
individual domains of
the EORTC QLQ C-30
are presented for the
four data collection
points for all participants
(not expressed by group)
Effect sizes (calculated
as baseline value –
post-assessment value/
standard deviation of
the baseline value) for
the EQ-5D domains,
EQ-5D index, EQ-5D
VAS compared with
EORTC QLQ C-30
presented (to test the
measures against one
another) for all
participants (not
by group)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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APPENDIX 10
266Pistevou-Gombaki et al.,148 2003Greece
Prospective cohort
study
To investigate QoL
after chemotherapy
for liver metastases.
1. Octreotide chemotherapy
monthly, n = 16
l Symptomatic liver
metastases from various
primary cancers (non-small
cell lung, colon, pancreas,
prostate, stomach)
l Age range, 43–69 years
l Gender (male/female): 11/5
EORTC QLQ C-30
Self-report questionnaire
administered at baseline,
at time of octreotide
administration, 1 week
later, and monthly
thereafter (up to
7 months)
Mean scores of the individual
items and domains of the
EORTC QLQ C-30 are presented
for baseline and 1 month post
chemotherapy. All the
functioning scales and pain,
fatigue, insomnia, appetite loss
were statistically signiﬁcantly
improved (p< 0.05)
Mean score for global QoL at
baseline and 1 month also
statistically signiﬁcant
improvement: 4.2 (SD 8.0) vs.
23.9 (SD 11.7) respectively,
p = 0.001
Results also presented for
individual items of the EORTC
QLQ C-30
Results also presented for
subgroups according to primary
site (not extracted here)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Prospective cohort study
To assess survival and
HRQoL in a consecutive
cohort of patients selected
for laparotomy
1. Laparotomy for surgical
treatment, where three
groups were identiﬁed:
resection, n = 117;
ablation (cryosurgery or
radiofrequency) alone or
in combination with
resection, n = 45;
chemotherapy only,
n = 39
Not all participants were
recruited into the HRQoL
study. Resection, n = 53;
ablation/resection, n = 29;
chemotherapy, n = 27.
Baseline characteristics
were presented for the total
group only
l Colorectal liver
metastases with no
extrahepatic
metastases
l Median (range) age:
¢ Resection:
61 (24–80)
¢ Ablation/resection:
61 (45–84)
¢ Chemotherapy:
61 (35–85)
l Gender (male/female):
¢ Resection: 66/51
¢ Ablation/resection:
29/16
¢ Chemotherapy:
22/17
NB: ablation was by radio
frequency ablation or
cryotherapy, results not
presented separately
EQ-5D VAS; EORTC QLQ
C-30 physical functioning
scale
EQ-5D scores used to
compute QALYs
QALYs expressed as
quality-adjusted days
Self-report questionnaires
administered
preoperatively, 2–3 weeks
post laparotomy, and then
every 3 months until
1 year post laparotomy
Baseline HRQoL scores on
both measures were similar
All groups showed a decline
in HRQoL 3 weeks post
laparotomy
At 3 months those in the
resection and ablation/
resection groups returned
to baseline
During the ﬁrst year QALYs
(days in full health) were:
l Resection: 283
l Ablation/resection 317
l Chemotherapy: 165
[signiﬁcantly lower in
comparison with the
other two groups
(p< 0.01)].
Data presented in graphically
for each time period for the
three groups
267
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APPENDIX 10
268Wiering et al.,149,151 2010 and 2011Netherlands
RCT leading to a
prospective cohort study of
the total population
To assess the added value
of positron emission
tomography imaging
including HRQoL in those
undergoing hepatic
resection
NB: some minor
discrepancies between
these two publications;
however, likely to be the
same participants as the
dates of study and
treatments appear to be
the same
1. Hepatic resection with
PET imaging, n = 70
(ﬁve excluded prior
to surgery)
2. Hepatic resection
without PET imaging,
n = 75
l Colorectal liver
metastases (up to four
resectable metastases,
no extrahepatic
metastases); n = 150
(145 in reference 150
as excludes the ﬁve
noted above)
l Additional 24 excluded
at laparotomy as either
no liver metastases at
ﬁnal histology (states
seven in reference 150)
or signiﬁcant
metastases precluding
surgical treatment)
l Mean age150 63 years
(range 33–80):
¢ Group 1:151 61.8
(32.8–78.1)
¢ Group 2: 62.9
(37.9–79.9)
l 94 males/44 females:150
¢ Group 1:151 45/25
¢ Group 2: 56/19
Wiering et al.149,151 states
that two subgroups
emerged: a curative surgery
group (n = 117) and a
non-curative surgery group
(n = 19) where complete
resection was not possible.
Some had chemotherapy
(results also provided by this
as a subgroup).
No pre-operative
chemotherapy.
Chemotherapy started only
in the event of unresectable
disease or tumour
recurrence that was
not amenable to
surgical reintervention
EQ-5D index (society
based) and visual analogue
scale (patient perspective)
Q-TWIST – an expression of
HRQoL for four distinct
clinical health states: death,
disease free, non-curative,
recurrence, based on the
EQ-5D measure
Self-reported questionnaire
(EQ-5D) completed at
baseline, at week 3 and
week 6 post surgery and
then every 3 months for
the next 3 years
Overall response rate was
90.8% after 3 years
Wiering et al.151
HRQoL, mean (SD), max/
min, EQ-5D index values at:
l Death: 0 (0);
l Disease free:
0.78 (0.23), 0.92/–0.59
l Non-curative:
0.67 (0.31), 0.92/–0.59
l Recurrence:
0.74 (0.25), 0.92/–0.59
l Recurrence without
chemotherapy (surgical
reintervention):
0.82 (0.17), 0.92/–0.43
l Recurrence with
chemotherapy:
0.68 (0.28), 0.92/–0.59
EQ-5D VAS scores showed
a pattern for all clinical
groups similar to that of the
society-based EQ-5D values
(data not shown)
Statistically significant
effects were observed
between the disease-free
and non-curative groups
from week 12 onwards
(p< 0.05), and the
disease-free and
recurrence groups at the
end of follow-up
(144 weeks, p = 0.024)
Results by time presented
graphically
Wiering et al.149
Results of EQ-5D by time
and intervention group
presented graphically
based on intention to
treat population except
two participants who
did not return their
questionnaires in the
control group
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Prospective cohort
study
To investigate
clinical outcomes
and quality of life
after laser ablation
for liver metastases
1. Laser interstitial thermo-therapy
(also known as laser ablation),
n = 45
l Colorectal liver metastases
(palliative – LITT was performed
only in palliative situations in
patients with progressive
disease undergoing second-line
or third-line chemotherapies)
l Median (range) age: 61.6
(38–79 years)
l Gender (male/female): 30/15
EORTC QLQ C-30
Self-report questionnaire
administered at baseline,
1 week post intervention,
1 month and 6 months
post intervention
Mean scores of general
symptoms for the
18 patients who survived
until 6 months presented
for each data collection
point graphically
The variable pain before
and 1 week after laser
ablation was seen to be
statistically signiﬁcantly
different (p< 0.05), and
before and 6 months after
treatment (p< 0.05).
Authors suggest this may
not be clinically relevant,
however
For general symptoms,
only constipation reached
statistical signiﬁcance
(p< 0.05) in a
multivariate analysis
Mean scores for
functioning scales and
global QoL presented
graphically. No statistically
signiﬁcant changes were
observed in any of these
domains before and after
laser ablation
IQR, interquartile range; LITT, laser interstitial thermo-therapy; QoL, quality of life; SF-12, Short Form questionnaire-12
items; SF-36, Short Form questionnaire-36 items.
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sensitivity analysis, sampling distributions and
parameterisation of sampling distributionsOverall survivalCorrelation between parameters in the overall survival regression is handled using the Cholesky
decomposition method.168 The Cholesky decomposition of the variance–covariance matrix for the
regression used to ﬁt the Weibull survival function would be:ln(t) treat ln(λ)
ln(t) C [1,1]
treat C [2,1] C [2,2]
ln(λ) C [3,1] C [3,2] C [3,3]In each simulation three draws are taken from standard normal distributions (mean = 0, SD = 1), labelled
here as z1, z2, z3. Three new variables (Tz1, Tz2 and Tz3) are deﬁned by multiplying elements of the
Cholesky decomposition matrix (C) by the values draw from standard normal distributions (z1, z2, z3).
Identifying elements of the Cholesky decomposition as C [i,j], as above, then:
Tz1 ¼ z1 C ½1,1
Tz2 ¼ z1 C ½2,1 þ z2C ½2,2
Tz3 ¼ z1 C ½3,1 þ z2C ½3,2 þ z3C ½3,3
ð3Þ
For each simulation the sampled values of the parameter estimates are therefore:
Tz1 þ lnðtÞ
Tz2 þ treat
Tz3 þ lnðλÞ
ð4Þ
The same approach was used to handle correlation between parameters in the model used to estimate
time to progression.271
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APPENDIX 11
272Variables included in probabilistic sensitivity analysis,
sampling distributions and parameterisation of
sampling distributionsMean
Standard
error Distribution Parameters
Health state utility
Stable disease 0.82 0.01 Beta α = 1209.50, β = 265.50
Stable disease – up to 6 months post surgery 0.65 0.01 Beta α = 1478.10, β = 795.90
Stable disease – up to 3 months post ablation 0.74 0.01 Beta α = 1423.02, β = 499.98
Proportionate reduction due to disease
progression
0.75 0.08 Beta α = 23.26, β = 7.75
Procedure costs
Microwave ablation 8302 847.16 Gamma α = 96.0365, β = 86.4463
Surgical resection 11,937 1218.08 Gamma α = 96.0365, β = 124.2965
Microwave ablation with adverse event 9550 974.51 Gamma α = 96.0365, β = 99.4414
Surgical resection with adverse event 13,240 1351.05 Gamma α = 96.0365, β = 137.8643
Radiofrequency ablation 3391 346.03 Gamma α = 96.0365, β = 35.3095
Surgical resection 8747 892.57 Gamma α = 96.0365, β = 91.0800
Radiofrequency ablation with adverse event 3900 397.97 Gamma α = 96.0365, β = 40.6096
Surgical resection with adverse event 9930 1013.28 Gamma α = 96.0365, β = 103.3982
Radioembolisation consumables 10,911 1113.39 Gamma α = 96.0365, β = 113.6131
Radioembolisation procedure 3305 337.25 Gamma α = 96.0365, β = 34.4140
On-treatment monitoring – HACE 203 20.75 Gamma α = 96.0365, β = 2.1173
Follow-up costs
Post-discharge follow-up 237 24.16 Gamma α = 96.0365, β = 2.4658
Post-treatment follow-up 231 23.61 Gamma α = 96.0365, β = 2.4095
Adverse events
Microwave ablation complications 14.3% 0.0935 Beta α = 1.8571, β = 11.1429
Surgical resection 18.8% 0.0976 Beta α = 2.8125, β = 12.1875
Radiofrequency ablation complications 6.2% 0.0181 Beta α = 10.9379, β = 165.0621
Surgical resection complications 21.2% 0.0245 Beta α = 58.7878, β = 218.2122
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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As described in the main body of the text, the survival models adopted for this report were developedusing linear regression to estimate the parameters of linear transformations of the observed
Kaplan–Meier estimates for overall survival and progression-free survival reported in included studies.
Three parametric survival functions were estimated – exponential, Weibull and log-logistic survival
functions – which were compared for goodness of ﬁt with the observed overall survival and
progression-free survival functions by visual inspection.
For an exponential distribution the survival function is given by
SðtÞ ¼ expð−λ tÞ ð5Þ
Taking the log of both sides gives
logðSðtÞÞ ¼ −λ t ð6Þ
which is a linear function and can be ﬁt using least squares methods to estimate λ.
For a Weibull distribution the survival function is given by
SðtÞ ¼ expð−λ tγÞ ð7Þ
with scale parameter λ and shape γ. Taking the log of both sides gives
logðSðtÞÞ ¼ −λtγ ð8Þ
Taking the log of both sides again gives
logð−logðSðtÞÞÞ ¼ logðλÞ þ γ logðtÞ ð9Þ
which is a linear function and can be ﬁt using least squares methods to provide estimates of log(λ) and γ.
Similarly, the log-logistic survival function, given by
SðtÞ ¼ ½1þ λtβ−1 ð10Þ
can be transformed to the linear function
log
1−SðtÞ
SðtÞ
 
¼ logðλÞ þ β logðtÞ ð11Þ
This can be ﬁt using least squares methods to provide estimates of log(λ) and β.273
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APPENDIX 12
274General method for extracting data from published
survival curvesFigures presenting overall and survival and progression-free survival curves were scanned from the original
publications and imported into Engauge software. The process of extracting data from a chart usually
begins with the user identifying key reference points on the chart (e.g. indicating the location of the origin
and maximum points for the x- and y-axes). Engauge software will indicate what appear to be data points
in the imported image (shown in green in the ﬁgure below, using the example of the overall survival chart
from Shibata and colleagues)72 or the user can select individual data points to be extracted using the
mouse. Points along the Kaplan–Meier were selected by hand as shown in the ﬁgure below, and the raw
data (without any interpolation) were extracted to a text ﬁle and imported into Microsoft Excel.
Overall survival
The following tables report the parameter estimates for linear regressions for the exponential, Weibull and
log-logistic survival functions. In each of these an additional parameter (treat) was included in the
regression – this was a dummy (0,1) variable that indicated whether the observed survival data were for
the intervention (treat = 1) or the comparator (treat = 0).TABLE 92 Microwave ablation compared with surgery
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.05409 ln(λ) –6.70614 ln(λ) –8.78953
treat –0.00821 γ 2.05724 γ 2.98013
treat –0.11424 treat 0.09976
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FIGURE 22 Extracting survival data from scanned images using Engauge.
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TABLE 94 Radiofrequency ablation compared with surgery for large (≥ 3 cm) liver metastases
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.01270 ln(λ) –5.57716 ln(λ) –6.33878
treat –0.01397 γ 1.32759 γ 1.62057
treat 0.67780 treat 0.94135
TABLE 93 Radiofrequency ablation compared with surgery for small (< 3 cm) liver metastases
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.01133 ln(λ) –7.19176 ln(λ) –7.84791
treat 0.00044 γ 1.71996 γ 1.96272
treat –0.00010 treat 0.02289
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7TABLE 95 Radioembolisation plus hepatic artery chemotherapy compared with hepatic artery chemotherapy alone
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.04441 ln(λ) –4.56813 ln(λ) –6.22661
treat Not estimateda γ 1.39754 γ 2.14318
treat Not estimateda treat 0.45931
Note: the published hazard ratio of 1.41 was used in the model for overall survival
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FIGURE 23 Transformed Kaplan–Meier overall survival curves for microwave ablation and surgical resection derived
from Shibata and colleagues72 plus linear fit. (a) Exponential model; (b) Weibull model; and (c) log-logistic model.
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FIGURE 24 Transformed Kaplan–Meier overall survival curves for radiofrequency ablation and surgery, for small
(< 3 cm) metastases, derived from Kim and colleagues73 plus linear fit. (a) Exponential model; (b) Weibull model;
and (c) log-logistic model.
DOI: 10.3310/hta18070 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 7
277
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
0
– 2
In
[S
(t
)]
0
– 1
10 20 30
t
Exponential
40 50 60 8070
Surgery
Surgery - fit
RFA
RFA - fit
(a)
0
– 4
In
{–
In
[S
(t
)]
}
– 2
2
0
1 2
In(t)
Weibull
3 4
Surgery
Surgery - fit
RFA
RFA - fit
(b)
0
– 4
– 2
0
In
{[
1–
S(
t)
/S
(t
)]
}
2
1 2
In(t)
Log-logistic
3 4
Surgery
Surgery - fit
RFA
RFA - fit
(c)
FIGURE 25 Transformed Kaplan–Meier overall survival curves for radiofrequency ablation and surgery, for large
(≥ 3 cm) metastases, derived from Kim and colleagues73 plus linear fit. (a) Exponential model; (b) Weibull model;
and (c) log-logistic model.
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FIGURE 26 Transformed Kaplan–Meier overall survival curves for radioembolisation plus hepatic artery
chemotherapy and hepatic artery chemotherapy alone derived from Grey and colleagues85 plus linear fit.
(a) Exponential model; (b) Weibull model; and (c) log-logistic model.
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APPENDIX 12
280Progression-free survival
The following tables report the parameter estimates for linear regressions for the exponential, Weibull and
log-logistic survival functions. As before an additional parameter (treat) was included in the regression –
this was a dummy (0,1) variable that indicated whether the observed survival data were for the
intervention (treat = 1) or the comparator (treat = 0).TABLE 97 Radiofrequency ablation compared with surgery for large (≥ 3 cm) liver metastases
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.01915 ln(λ) –2.81730 ln(λ) –3.09404
treat –0.01085 γ 0.70733 γ 0.91478
treat 0.89781 treat 1.22393
TABLE 98 Radioembolisation plus hepatic artery chemotherapy compared with hepatic artery chemotherapy alone
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.04640 ln(λ) –4.32603 ln(λ) –5.16223
treat –0.07796 γ 1.44306 γ 1.92574
treat 0.85427 treat 1.40902
TABLE 96 Radiofrequency ablation compared with surgery for small (< 3 cm) liver metastases
Exponential Weibull Log-logistic
Parameter Coefﬁcient Parameter Coefﬁcient Parameter Coefﬁcient
λ –0.02394 ln(λ) –3.22771 ln(λ) –3.43363
treat –0.00281 γ 0.92444 γ 1.14061
treat 0.05773 treat 0.03730
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FIGURE 27 Transformed progression-free survival curves for radiofrequency ablation and surgery, for small (< 3 cm)
metastases, derived from Kim and colleagues73 plus linear fit. (a) Exponential model; (b) Weibull model; and
(c) log-logistic model.
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FIGURE 28 Transformed progression-free survival curves for radiofrequency ablation and surgery, for large (≥ 3 cm)
metastases, derived from Kim and colleagues73 plus linear fit. (a) Exponential model; (b) Weibull model; and
(c) log-logistic model.
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FIGURE 29 Transformed progression-free survival curves for radioembolisation plus hepatic artery chemotherapy and
hepatic artery chemotherapy alone derived from Grey and colleagues85 plus linear fit. (a) Exponential model;
(b) Weibull model; and (c) log-logistic model.
283
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.

Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
